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Black South African (SA) women are disproportionally affected by obesity and insulin 
resistance, which have been associated with depot-specific alterations in adipose tissue 
function. This thesis aimed to evaluate the differences in fatty acid (FA) composition and gene 
expression between abdominal (aSAT) and gluteal subcutaneous adipose tissue (gSAT), and 
the changes in response to exercise training in relation to body composition, hepatic fat, 
inflammatory and oxidative stress markers, and insulin sensitivity (SI) in obese black SA 
women. 
This research evaluated the i) FA composition of aSAT and gSAT, and red blood cell 
total phospholipids (RBC-TPL) and their associations with body composition, hepatic fat and 
SI, ii) changes in these FA profiles in response to exercise training and the relationship with 
changes in systemic inflammation, hepatic fat and SI; iii) effects of exercise training on 
systemic markers and SAT gene expression of inflammation and oxidative stress; and iv) 
regional differences in transcriptome profiles of aSAT and gSAT pre- and post-exercise 
training.  
Forty-five IsiXhosa women (30-40kg/m2, 20-35 years) were randomized into control 
(n=22) or exercise groups (n=23; 12-week aerobic-resistance training, 40-60 min/session, 4 
days/week). Pre- and post-intervention measurements included: anthropometry, body 
composition, cardiorespiratory fitness, dietary intake, SI, hepatic fat, systemic markers and 
SAT gene expression of adipokines, inflammation and oxidative stress, RBC-TPL and SAT 
fatty acids profiles, and untargeted SAT gene expression analyses. 
The main findings showed differences in the circulating (RBC-TPL) and stored (SAT) 
FA composition, also reflected in different associations between these FA profiles, 
centralization of body fat and SI. Moreover, the changes in FA composition in response to 
exercise training were depot-specific, with the changes in RBC-TPL correlating with a decrease 
in systemic inflammation and hepatic fat. Exercise training alleviated systemic oxidative stress 
and induced increased gSAT inflammatory genes, reflecting SAT remodeling. These changes 
coincided with a reduction in gynoid fat and were not associated with increased SI. 
Furthermore, there were unique depot-specific gene expression signatures relating to 
embryonic development at baseline and more diverse functional-related processes at post-
training. This generated novel candidate genes potentially implicated in the relationship 








1.1.NON-COMMUNICABLE DISEASES AND DETERMINANTS 
1.1.1. Prevalence of NCDs, T2D and metabolic risk factors 
Non-communicable diseases (NCDs) refer to chronic “non-transmissible” diseases, 
contrary to infectious diseases, and are currently causing more deaths than all other causes 
combined worldwide (1). In 2012, the four major NCDs (cardiovascular diseases (CVD), 
cancers, chronic respiratory disease, and diabetes) caused more than 82% of deaths in the world, 
with nearly three-quarters of these deaths occurring in low- and middle-income countries (1). 
Among NCDs, type 2 diabetes (T2D) is the 4th leading cause of death and was estimated in 
2017 to affect 451 million adults worldwide, with projections of 693 million cases by 2045 (2). 
T2D disproportionately affects low- and middle-income countries (3). Although sub-Saharan 
Africa (SSA) currently has the smallest number of people with T2D globally, this region has 
the highest projected rate of increase in the T2D population over the next 25 years (2). Indeed, 
the prevalence of T2D is estimated to increase from 14.2 million in 2015 to 34.2 million by 
2040 (2). Within SSA, South Africa (SA) has the highest prevalence of T2D in adults (estimated 
at 5.5 (3.2-10.6)%; age-standardized) (2), which has significantly increased over the past 20 
years, especially in black African population (4). Moreover, high rates of T2D in SA are 
reported in women, with 14.7% compared to 11.3% in men (4). This high prevalence of T2D 
in African women is compounded by an increasing prevalence of obesity and low levels of 
physical activity (PA) (1, 5). Indeed, the prevalence of obesity within SA is high and is 
associated with NDCs, in particular, accounting for 87 % of all T2D attributable risks (6).  
1.1.2. Prevalence of obesity  
Overweight and obesity are mostly defined by body mass index (BMI) values between 
25 and 29.9 kg/m2, and ≥30 kg/m2, respectively (7). Although BMI does not directly measure 
the amount of adiposity, it has been associated with reduced life expectancy, mainly due to 
increased risk for NCDs including T2D, hypertension, dyslipidemia, CVD and many types of 
cancer (7, 8). Obesity is causing approximately 3.4 million deaths per year with a global 
prevalence of 9% (1). Obesity is the major attributable risk factor for T2D and is increasing in 
developing countries, with women having higher estimates than men (9, 10). Indeed, in Africa, 
the number of women affected by obesity is estimated at 15% compared to 6% of men (1, 4). 
Southern Africa is most affected by obesity (37%) (9), with a prevalence continuously 
increasing over the years (11), followed by the Western (11.9%), Eastern (8.8%) and Central 
regions (8.5%) (9). Moreover, SA women have the highest prevalence of overweight (25%) and 
obesity (40%) in SSA (11), with the highest prevalence among black SA women (42%) (9). 
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This is concerning, considering that the global burden of disease study estimated obesity to be 
the second leading risk factor for early death and disability in SA (12).  
The high prevalence of obesity in black SA women, who are historically disadvantaged, 
has been associated with low socio-economic status (SES) (13). Low socio-economic 
communities in SA have insufficient economic and community resources, poor health care 
systems and education (14). However, SA is undergoing rapid socio-economic transition and 
urbanisation, which affects nutritional and lifestyles behaviours (5, 14-16). These changes are 
key driving factors for the increasing prevalence of obesity and are a major concern for 
governments in the prevention and management of the rising burden of metabolic diseases.  
The prevalence of NCDs in developing countries has been increasing and is largely 
attributed to changes in lifestyles associated with globalisation and urbanisation (1). 
Urbanisation is the process of shifting from rural to urban life and the lifestyle changes this 
enforces. Although it has improved access to health care and the control of infectious diseases, 
urbanisation has also introduced several unexpected negative impacts on the health status of 
populations in low/middle-income countries (17). Indeed, urbanisation is strongly related to 
increased obesity rates, which is mediated by unhealthy diets and physical inactivity (Figure 
1.1) (18). Still under rapid industrialisation and economic transition, SA is the scene of major 
demographic changes with rural-to-urban area migration, resulting in modifications in dietary 
and lifestyle behaviours (17).  
The shift from manual labour to industrialised agriculture has resulted in increased 
production of processed and energy-dense foods. This is followed by an increase in energy 
intake, one of the main risk factors for obesity in both children and adults (1). Indeed, within 
SA the nutrition transition is characterized by a high total and saturated fat intake, high refined 
carbohydrate and added sugar intake, and low intake of fibre, fruits, vegetables, and 
micronutrients (19). The resultant poor access to healthy foods and high intakes of unhealthy 
food has been associated with the greater risk for obesity, T2D and other NCDs (11, 18).  
Together with the nutritional transition, physical inactivity strongly increases the burden 
of obesity (1, 20). Indeed, urban development increased the rate of occupation-related physical 
inactivity (e.g. administrative and services jobs sectors) (21). Urbanisation has also led to a 
reduction of green spaces, progressively replaced with densely populated buildings and 
infrastructure, reducing available outdoor spaces and recreational lands appropriate for leisure 
and physical activities (22). Furthermore, proximity and connectivity resulting from developed 
transport networks encourage sedentary life (18). In SA and particularly among black African 
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women, the lack of access to affordable healthy food choices, together with decreased 
opportunities of PA in urban areas is the main factor implicated in the increased prevalence of 
obesity (Figure 1.1) (23). 
1.1.3. Obesity as a major determinant for T2D risk 
Obesity is the major determinant of T2D. Indeed, the risk of T2D increases with the extent 
and duration of obesity, and in SA, 87% of T2D incidence is attributable to elevated BMI (6). 
However, it is well established that it is not merely the increase in total adiposity that drives the 
increased risk for T2D, but rather, the distribution of body fat is more closely associated with 
insulin resistance (IR) and T2D. The level of IR varies with ethnicity, with black African 
women, irrespective of the geographic location, being more insulin resistant than their white 
European counterparts (24-26). In black African women, IR is associated with 
hyperinsulinemia due to a greater insulin response, as well as reduced hepatic insulin clearance 
than their white European counterparts (24, 26). Notably, ethnic differences in insulin 
sensitivity and response between women of African ancestry and European women were 
independent of total body fat accumulation (24, 27), but the relationship with regional fat 
distribution differed by ethnicity. In European women, centralization of body fat specifically 
increased visceral adipose tissue (VAT) has been identified as the major determinant of reduced 
insulin sensitivity (28); while greater peripheral (gluteal-femoral) subcutaneous adipose tissue 
(SAT) deposition was associated with improved insulin sensitivity in these women (29). 
Despite lower insulin sensitivity, black African women have less VAT and more abdominal 
and gluteo-femoral SAT than European women (30-34). Both abdominal (28) and gluteal SAT 
(35) has been negatively associated with insulin sensitivity in black SA women, and have been 




Figure 1.1. Representation of the relationships between urbanisation, lifestyle changes, 
obesity and type 2 diabetes (T2D) in a South African context.  
In summary, obesity and its co-morbidities negatively affect the lives of many South 
Africans and represent a major health burden, contributing to the increasing cost of health care. 
This epidemic disproportionately affects women and individuals from lower SES communities. 
Environmental and lifestyle modifications resulting from modernisation and urbanisation have 
contributed to an exponential increase in obesity prevalence, with more than 65% of black SA 
women classified as overweight or obese (11). Concomitantly, T2D prevalence has 
significantly increased within SA over the past 20 years, particularly in black African urban-
dwelling populations, with higher prevalence among women compared to men (4, 11). Black 
African women present with a phenotype of low insulin sensitivity and hyperinsulinemia, 
despite relatively low levels of VAT and high abdominal and gluteal SAT depots (27, 36, 37). 
However, the mechanisms underlying the increased risk for IR and T2D in women of African 
ancestry are not known. Therefore, this thesis focused on obesity and body fat distribution in 
the development of IR, as the major risk factors of T2D in black SA women.  
1.2. DETERMINANTS OF ADIPOSE TISSUE DISTRIBUTION  
1.2.1. Adipose tissue biology and distribution 
Obesity is characterized by an excessive accumulation of triglycerides (TG) in adipose 
tissue (AT) from a continuous positive energy balance exceeding energy expenditure. Although 
obesity is a risk factor for IR, T2D, and CVD, obesity itself does not always lead to these 
comorbidities (38). The distribution of AT throughout the human body is an independent 
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contributor to the development of obesity-associated metabolic disorders (39, 40). AT is 
categorised in two major types, white AT (WAT) and brown AT (BAT), which are 
differentiated by their location, cellular composition and structure, vascularization and 
metabolic function.  
BAT is composed of brown adipocytes with highly enriched mitochondria and 
multilocular lipids droplets. It is functionally characterized by its ability to uncouple 
mitochondrial respiration from ATP synthesis via uncoupling protein 1, allowing for enhanced 
free fatty acid (FFA) oxidation and heat production (41). Although BAT has been mostly 
described in rodents, this tissue has now been proven to exist and to be metabolically active in 
adult humans (42, 43). These have led to the concept that targeting an increased activity of BAT 
might provide a therapeutic strategy to improve insulin sensitivity in humans, given that BAT 
mass and activity is reduced in obese and diabetic patients (44, 45). However, although few 
studies have described BAT  characteristics in humans, the molecular mechanisms 
demonstrating the beneficial effects of this tissue in adults, especially during obesity, has not 
been elucidated. Therefore, the relevance of this tissue in human obesity and related metabolic 
complications remains questionable. Contrary to BAT, WAT is quantitatively the most 
important fat pad in the human body (46). Because WAT is the main tissue involved in obesity-
associated metabolic disorders, it will be the focus of this thesis, and the term AT will refer to 
WAT throughout.  
AT mass varies across individuals and can represent 5-60% of total body weight or more 
in morbid obesity (46). This endocrine organ is further divided into several sub-types, mainly 
grouped by their location in different sites of the human body. SAT represents 80-90% of total 
fat tissue (46). SAT is principally distributed in the abdominal, subscapular (upper back), 
gluteal and femoral regions (46-48). Another significant sub-type of AT, VAT is distributed in 
the abdominal cavity around internal organs. VAT represents 10-20% of total body fat in men 
and 5-10% in women and includes the omental depot, the mesenteric depot around the 
intestines, and retroperitoneal depot around the kidney (46). WAT also infiltrates some organs 
including the liver, skeletal muscles (intramyocellular and intermuscular fat), heart (epicardial 
fat), and pancreas where it is termed ectopic fat and may serve specialized functions related to 
these neighbouring tissues (49, 50). AT heterogeneity is not only reflected by its differential 
location, but also by its cellular composition.  
 AT is composed of different cell types including endothelial cells, pericytes, immune 
cells such as macrophages, neutrophils, lymphocytes and T-cells, pluripotent stem cells, 
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preadipocytes, and mature adipocytes (51). Adipocytes constitute approximately 90% of AT 
total volume (46). These cells contain unilocular lipid droplets where TG are stored, occupying 
about 95% of their volume and determining their size (20-200 µm) (46). In addition to their 
principal role in TG storage, adipocytes can secrete bioactive molecules (adipokines or 
adipocytokines) (52). These adipokines may act as a signal via autocrine, paracrine or endocrine 
pathways to exert different metabolic effects on other cells and organs (e.g. brain, liver, 
muscle), making AT a highly active endocrine organ (38). However, the endocrine function of 
AT is not only exerted via the production of adipokines by adipocytes. Rather, more than 90% 
of adipocytokines released from AT are produced by non-adipose cells (53). Immune cells play 
a central role in AT biology, especially during AT expansion and/or reduction (54). Amongst 
AT immune cells, macrophages are the most abundant (up to 50%) and functionally dominant 
cell type. These cells accumulate during AT expansion and predominantly secrete inflammatory 
cytokines in obesity (52). Notably, the phenotype of macrophages varies with the physiological 
state of AT. Activated M2 macrophages can release anti-inflammatory cytokines, contributing 
to tissue homeostasis and repair (55). Conversely, M1 macrophages, differentiated from blood 
monocytes, predominantly release pro-inflammatory cytokines and sustain a chronic low-grade 
inflammatory state and impair insulin signalling. While M1 macrophages are highly expressed 
in obesity, M2 macrophages are predominantly found in AT of lean individuals (56). 
Macrophages are also involved in preadipocyte differentiation, adipogenesis, and angiogenesis, 
which are all necessary for “healthy” expansion of AT (52, 57).  
AT depots differ in their cellular composition (cell types and abundance) and function 
and are known to be independently associated with metabolic diseases in obesity (46). Gynoid 
or “pear-shape” obesity refers to AT accumulation in the lower-body, preferentially in the 
gluteo-femoral region. Gynoid obesity is typically found in women, in contrast to android or 
“apple-shape” obesity, characterized by the accumulation of AT in upper-body areas 
(abdominal subcutaneous and visceral), mostly found in men (52). While android or central fat 
accumulation has been associated with greater risk for developing metabolic diseases, lower-
body fat (gluteo-femoral) appears to have positive effects on metabolic health (39, 58, 59). The 
mechanisms underlying these depot-specific associations with metabolic risk are not fully 
understood. However, several factors such as age, gender, total body fat content, energy 
balance, ethnicity, and genetic factors have been proposed to play a role in the fat distribution 





1.2.2. Determinants of body fat distribution 
Body fat distribution is a major contributor to the development of obesity-associated 
metabolic risks, independently of total fat mass (38-40). Women generally possess higher total 
adiposity that is predominantly distributed subcutaneously in the gluteo-femoral area in pre-
menopausal women, while men accumulate more fat in the abdominal regions (39, 46, 62). This 
difference in fat distribution between men and women has been principally attributed to the 
difference in sex hormones, shown to modulate AT depot-specific accumulation (39). 
Oestrogens can be produced locally from AT, mediated by aromatase (63). Oestrogen regulates 
depot-specific AT accumulation preferentially in gluteo-femoral, rather than visceral regions 
by modulating lipolysis and lipogenesis through oestrogen receptors (ERα) (39). In contrast, 
testosterone was shown to inhibit fat storage in the gluteo-femoral area  (64, 65). 
Alterations in endocrine signalling may also contribute to changes in fat distribution 
pattern, as observed in hyperandrogenism (66) or patients with Cushing’s syndrome (60). These 
observations underline the significant role of gender-associated to sex hormones and age in 
body composition and fat distribution patterns in humans.  
Obesity status and regional fat distribution vary by ethnicity (67). Europeans generally 
present with lower obesity rates than other ethnic groups, while Africans have a higher total 
body fat percentage (68, 69) mostly distributed in SAT, with relatively lower VAT than other 
groups (34, 70, 71). Interestingly, SA black women have also been shown with higher gluteal 
SAT (gSAT) and less VAT compared to their white counterparts (32, 33). These ethnic-
differences in fat distribution have been attributed to differences in anthropometric, metabolic 
and behavioural mechanisms between ethnicities (69). Further, the interplay between genetic 
and environmental factors most likely determine these ethnic-specific differences in obesity 
rates and body fat distribution (32).  
Obesity is a complex condition that is determined by genetic and environmental factors. 
The heritability of BMI, based on families and twin genetic studies, showed a large range of 
variability, estimated to be between 40-70 % (39). One of the pioneering studies exploring the 
influence of genetic predisposition to fat distribution comes from the study by Bouchard et al. 
on identical twins (72). They showed that within-pair similarity was particularly evident for 
differences in regional fat distribution and VAT accumulation, with significantly greater 
variance between pairs than within pairs (72). This study and others suggested that fat 
distribution is strongly controlled by both genetic and environmental factors (72-74). Moreover, 
recent genome-wide transcriptional analyses comparing SAT and VAT identified hundreds of 
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genes as differentially expressed between these depots (39, 52, 61, 75). Further evidence 
supports the role of genetic background in fat distribution. These studies demonstrated that 
waist-hip ratio (WHR), a surrogate measure that differentiates gluteo-femoral from central fat 
distribution, is a heritable trait estimated to contribute to up to 60% of inter-individual variation 
in body fat distribution, independent of BMI (76, 77). Based on these findings, the genetic 
architecture underlying fat distribution has been suggested to influence mechanisms related to 
AT development and metabolism (39). Therefore, AT accumulation follows a specific 
individual pattern during modifications of fat mass quantity, with preferential subcutaneous or 
visceral depot expansion/reduction largely determined by their heritable potential  (39, 52).  
Notably, gene expression studies showed that developmental genes are differentially 
expressed in various fat compartments and might also be involved in the regulation of fat 
distribution and obesity-related metabolic traits (52, 61, 78, 79). In the same line, in vitro 
experiments showed unique gene expression signatures in adipocytes from different depots, 
which were conserved after numerous cell differentiation cycles, suggesting that the depot-
specific metabolic phenotype is intrinsic and programmed in the developmental/early life stage 
(80-82). Despite extensive research on the genetic influence of obesity and fat distribution, there 
seems to have no consensus on the exact mechanisms by which this influence occurs. Besides, 
although genome-wide association studies (GWAS) approach has identified more than 50 loci 
associated with BMI, WHR, body fat percentage and extreme obesity (83), most of these studies 
were conducted primarily in cohorts of European ancestry populations, with very few studies 
investigating the genetics of body fat distribution in individuals of African ancestry. One of the 
largest studies on Africans used a meta-analysis of GWAS of waist circumference (WC) and 
WHR, adjusted and unadjusted for BMI, in up to 33,591 and 27,350 individuals, respectively 
(84). This study has identified two loci associated with body fat distribution independently of 
generalized adiposity in African ancestry individuals, in addition to confirming 6 loci 
previously identified in populations of European ancestry (84). Ancestral genetic background, 
therefore, contributes to ethnic differences in body composition, total fat accumulation, and 
distribution above and beyond the effects of ethnic classification (85). However, no genetic 
studies on body fat distribution have been conducted on populations from Southern Africa, 
except for a recent study in n=1926 black South Africans assessing whether European body 
composition-associated gene loci (11 loci evaluated) played a similar role in this population  
(86). Although single nucleotide polymorphism (SNPs) in several gene loci were similarly 
associated with phenotypes linked to fat mass percentage and WHR in this African cohort, in-
depth genomic studies in larger African cohorts is needed. Such studies may reveal novel SNPs 
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for body composition and adiposity, which will provide greater insight into the etiology of 
obesity in populations from Southern Africa (86). 
1.3. ADIPOSE TISSUE METABOLISM AND FUNCTION 
AT is a heterogeneous tissue with a complex structure (47). This heterogeneity is not only 
reflected by the different locations of this tissue, but also in its metabolism and function. Indeed, 
AT depots differ in their cellular composition, micro-vasculature, innervation, metabolism, 
extracellular matrix (ECM) composition, as well as secretory profile (46). This section firstly 
provides an overview of the general AT metabolism and function under normal physiological 
conditions, followed by the mechanisms underlying the impairment of AT function in the obese 
state and finally describes depot-specific AT metabolism and function, as well as the depot-
specific associations with metabolic risk factors. 
 
1.3.1. Adipose tissue metabolism and function under normal physiological conditions  
The primary function of AT is the storage of TG during calorie intake and the release of 
fatty acid (FA) in periods of energy demand. SAT is the largest adipose depot and the most 
important in terms of its quantitative contribution to lipid storage/release and endocrine function 
(87). The principal contributors to lipid storage/release from AT are adipocytes, although they 
only represent one-third of the tissue cells, in addition to fibroblasts, macrophages, monocytes, 
stromal cells and preadipocytes (51).  
1.3.1.1. Adipogenesis 
Mature adipocytes are formed from precursor cells and preadipocytes through 
adipogenesis. This process is required for healthy AT development and function. AT 
development and expansion can occur via the increase in adipocytes number referred to as 
hyperplasia, the increase in cell size named as adipocytes hypertrophy,  or both (88). Adipocyte 
hypertrophy is characterized by the presence of large, lipid-laden adipocytes in AT (89, 90). Of 
note,  this increase in adipocyte size might simply be the response to the need to sequester 
available excess lipid, rather than a dysfunctional mechanism per se.  
Adipogenesis is mediated by several hormones and transcriptional factors and is 
dependent on body energy status and storage needs (91). The inability of an individual to 




During adipogenesis, precursor cells are first committed to the adipocyte lineage and this 
is controlled by the expression of the bone morphogenic protein (BMP)-4 (93). Subsequently, 
pre-adipocytes undergo clonal expansion, multiplication, and early and terminal differentiation 
to mature adipocytes. These steps are controlled by CCAAT enhancer-binding protein 
(C/EBP)-β/δ, followed by the activation and expression of C/EBPα and peroxisome 
proliferator-activated receptor-gamma (PPARγ) (94, 95). PPARγ is one of the most important 
transcription factors for the maturation of preadipocytes to adipocytes. Low or dysregulated 
expression of PPARγ has been associated with impaired mitochondrial function and abnormal 
fat accumulation in non-AT organs (96, 97). Conversely, increased expression of PPARγ 
enhances AT storage capacity by inducing the recruitment of new adipocytes, which has been 
associated with an improvement in whole-body insulin sensitivity (98, 99). The release of FFAs 
from large adipocytes can also stimulate the differentiation of nearby preadipocytes to increase 
the lipid storage capacity of AT (100).  
1.3.1.2. Adipose tissue lipogenesis 
 Lipid accumulation or storage in AT is governed by lipogenesis and incorporates the 
process of uptake, synthesis and storage of TG from non-esterified fatty acids (NEFA; also 
called FFAs), carbohydrates and/or other energy sources (94). This process, as well as lipolysis 
(the mobilization of this energy source as FFA), is highly regulated by genetic, nutritional, 
hormonal, and paracrine factors (101). 
In the postprandial state, the majority of FFAs are delivered to adipocytes either through 
the breakdown of circulating TG (from chylomicrons or VLDL), via direct uptake of circulating 
FFAs or after endogenous synthesis (Figure 1.2). Fatty acid synthesis or de novo lipogenesis 
(DNL) in the adipocyte plays a minor role in fat deposition in human AT under normal 
physiological conditions (101, 102). However, adipocyte DNL may also be an important source 
of endogenous FAs, playing a key role in maintaining systemic metabolic homeostasis (103).  
Chylomicron- or VLDL-containing TGs are hydrolysed into FFAs by insulin-stimulated 
action of LPL within vascular endothelium in AT (104). Released FFAs enter adipocytes 
through FA transporters such as CD36 and FA transport protein-1 (FATP1) (105, 106). 
Meanwhile, insulin also stimulates adipocyte glucose uptake, which drives DNL in the 
cytoplasm (Figure 1.2). FAs from these two sources are esterified using glycerol 3-phosphate 
derived from glucose to form TG that is stored in lipid droplets (103). The esterification of FAs 
is mainly controlled by acyl-coenzyme A diacylglycerol acyltransferase (DGAT) catalysing the 
final step of TG synthesis (101, 107) and thereby playing a crucial role in lipid deposition in 
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adipocytes (108, 109). DGAT also catalyses the synthesis of TGs from diacylglycerides in 
adipocytes (107). DGAT2 is widely expressed in hepatocytes and adipocytes and over-
expression results in large TG droplets (110).  
The rate of glucose uptake into adipocytes is essential for TG storage (46). Moreover, 
glucose molecules provide glycerol for esterifying FA directly taken up from the circulation 
(111). The transport of glucose into adipocytes is exerted via the glucose-transporter protein 4 
(GLUT4), expressed under the stimulation and signalling cascades consecutive to the reaction 
of insulin and its receptor (IRS). Glucose derived from dietary carbohydrates stimulates the 
release of insulin from the pancreas, which in turn stimulates glucose uptake into adipocytes 
(Figure 1.2). Subsequently, glucose undergoes glycolysis and enters the tricarboxylic acid 
(TCA) cycle in the mitochondria to produce citrate. Citrate is subsequently transported into the 
cytosol and releases acetyl-CoA by ATP-citrate lyase (ACLY). Acetyl-CoA (substrate for 
DNL) is successively converted to malonyl-CoA by acetyl-CoA carboxylases 1 (ACC1) and 
palmitate by fatty acid synthase (FASN) (103, 111). Palmitate further undergoes elongation and 
desaturation reactions to generate FAs such as stearic acid, palmitoleic acid, and oleic acid 
(103). Insulin also promotes FA esterification through multiple mechanisms including 
activation of LPL, induction of translocation of FATP and upregulation of related gene 
expression in adipocytes (111). Moreover, insulin stimulates the expression of the lipogenic 
gene sterol regulatory element-binding protein 1 (SREBP1) that controls the expression of 
genes required for FA, TG and phospholipid synthesis (112). In addition to SREBP1, 
carbohydrate response element-binding protein (ChREBP), promotes DNL gene expression and 
has been shown to modulate both lipid and glucose metabolism in AT and consequently 
influence whole-body insulin sensitivity (113, 114). Taken together, AT is a fuel reservoir that 
plays a vital role in buffering FA fluxes and regulating clearance of plasma TGs to protect 
peripheral organs from lipotoxicity and therefore, prevent ectopic fat accumulation, IR and 
metabolic syndrome (115). This concept of lipotoxicity arose from observations of an impaired 
AT function in insulin-resistant states, in the excess fat accumulation with an impaired buffering 
FA flux, or in the pathological reduction/loss of AT mass as observed in lipodystrophy (115). 
In either case, a dysregulated ability of AT to buffer excessive FA flux will inevitably lead to 
increased lipid exposure and deposition in other tissues, providing a well-accepted link between 
obesity and cardiometabolic complications. AT lipid storage capacity is therefore essential for 
the maintenance of whole-body insulin sensitivity (103).  
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1.3.1.3. Adipose tissue lipolysis 
Contrary to lipogenesis, lipolysis is the catabolic process involving the breakdown of TGs 
stored in adipocytes to release FFAs and glycerol for energy metabolism or re-esterification in 
the AT (116-118). In periods of energy demand, such as during fasting or physical exercise, 
adipocytes mobilize stored fat to fulfil the energy needs of other organs (Figure 1.2). Each 
molecule of TG is broken down into three molecules of FA and one molecule of glycerol. 
Glycerol and FA molecules are subsequently transported in the blood and can infiltrate into 
muscle, liver and other organs, thereby modulating whole-body energy balance (Figure 1.2) 
(115). Glycerol can be used for hepatic gluconeogenesis and FAs can be oxidized in muscles 
and liver or used for TG in the liver, according to energy needs (46, 103, 111, 119). FFAs are 
important sources of energy in peripheral tissues (87). The availability of FFAs and TG in non-
adipose tissues is dependent on the lipolytic activity of the AT (87). Adipose triglyceride lipase 
(ATGL) is the first enzyme implicated in the hydrolysis of the stored TG into diacylglyceride 
(DAG). Hormone-sensitive lipase (HSL) cleaves DAG into monoacylglycerol (MAG), 
followed by the conversion of MAG to glycerol and FA. This last step is catalysed by the 
monoacylglyceride lipase (MGL) (103, 111). While ATGL mostly acts in the basal or non-
stimulated lipolysis, HSL is necessary for maximal catecholamine-stimulated lipolysis (64, 
120). 
In the basal/non-stimulated state, adipocytes are protected from lipases by coating 
proteins surrounding the lipid droplet on the cytosolic surface (121). In humans, the most 
expressed lipid droplet-coating protein is perilipin 1 (PLIN1), the major substrate for cAMP-
dependent protein kinase A (PKA) (122). PLIN1 promotes TG storage during basal conditions 
by restricting access of cytosolic lipases to the lipid droplet. On another hand, this protein 
facilitates maximal lipolysis during increased energy demand by its phosphorylation via PKA 
and stimulation of HSL (122). Therefore, perilipin regulates both basal and stimulated lipolysis. 
AT lipolysis can be stimulated by glucagon or catecholamines (effect on β-adrenergic receptor) 
and via the cAMP pathways, leading to PKA phosphorylation and phosphorylation of PLIN1 
(123). Of note, PLIN1 can also be phosphorylated via cGMP-dependent pathways by the 
activation of protein kinase G, stimulated by natriuretic peptides (124). PLIN1 sequesters 
ATGL co-activator, comparative gene identification-58 (CGI-58) in basal conditions. This key 
regulatory protein (CGI-58) is very important for the activation of ATGL.  Upon PLIN1 
phosphorylation, CGI-58 is released and interacts with ATGL to allow full activation of this 
lipase (123). Also, PLIN1 phosphorylation is responsible for the activation, translocation and 
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docking of HSL to the adipocyte lipid droplet, inducing lipolysis (123). Conversely, the reaction 
of insulin with its receptor in insulin sensitive AT is followed by consecutive activations of 
phosphoinositol-3-kinase (PiP3k), PKB/Akt and phosphodiesterase 3B (PDE3B), which  
converts cAMP (necessary for PKA phosphorylation) into 5’-AMP and inhibits lipolysis (123). 
 
 
Figure 1.2. Adipose tissue lipogenesis and lipolysis.  
Lipogenic and lipolytic pathways are inter-related and the maintenance of a regulatory balance between 
these pathways is essential for energy homeostasis and insulin sensitivity. Disruption in the equilibrium 
between fat storage and mobilization can lead to pathological AT expansion, function, and development 
of insulin resistance. AR: adrenergic receptor; cAMP: cyclic adenosine monophosphate; IR: insulin 
receptor; PKA: protein kinase A (111). 
 
In addition to cell requirements in periods of nutrient scarcity and high energy 
expenditure, adipocytes can undergo lipolysis when their storage capacity is exceeded (124, 
125). Under normal physiological conditions, lipogenesis and lipolysis are tightly co-ordinated 
and regulated by signals or endogenous stimuli (e.g. hormones, neurotransmitters…) from 
peripheral tissues and the central nervous system consecutive to the energy status (126). The 
lipid content in AT is controlled by a dynamic balance between these pathways, which is critical 
to maintaining systemic energy homeostasis and insulin sensitivity. Progressive and continuous 
energy surplus deposited in AT through the lipogenic pathway results in increased lipid droplet 
size and enlarged adipocytes (111), AT expansion and subsequent obesity (127). This can 
disrupt the balance between lipogenesis and lipolysis as observed under pathological conditions 
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such as during the early stages of IR (101). The following increase in unrestrained lipolysis 
results in excessive FFA spillover into the circulation. Consequently, this contributes to higher 
postprandial FFA plasma concentrations reaching peripheral tissues (128), leading to 
lipotoxicity and IR (129). Therefore, positive energy balance and dysregulated equilibrium 
between fat storage and mobilization are central factors in the pathogenesis of several metabolic 
characteristics of obesity-associated IR (101). 
1.3.1.4. Adipose tissue endocrine function and adipokine production 
In addition to its role in the maintenance of energy homeostasis as a passive fuel reservoir, 
AT is an active secretory organ known to produce and secrete hundreds of molecules acting via 
autocrine, paracrine or endocrine signalling (46, 103, 111). although the function of many of 
these active biomolecules is not yet fully understood, they can modulate systemic metabolism 
and inflammation (130). Indeed, these bioactive factors secreted from AT into the circulation 
relay information to other metabolically active organs such as muscle, liver, pancreas, and brain 
via endocrine mechanisms (131-133). These molecules are grouped in different categories 
depending on their origin (or secretory cells) and secretory pathways. Adipokines are secreted 
by adipocytes and include, among others, leptin, adiponectin, resistin, chemerin, serum amyloid 
A (SAA) and retinol-binding protein 4 (RBP-4) (111, 134). Leptin (135) and adiponectin (136) 
are the main adipocyte hormones and play a central role in the regulation of energy homeostasis 
(137). Cytokines such as omentin, visfatin, resistin, apelin, plasminogen activator inhibitor 1 
(PAI-1), monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor-alpha (TNFα), 
macrophage migration inhibitory factor (MIF) and interleukins (e.g IL-1, IL-6, IL-8) are 
secreted mainly by adipose-resident immune and endothelial cells of the stromal vascular 
fraction (SVF) (134). Moreover, AT secretes lipokines such as palmitoleate and fatty acid esters 
of hydroxyl fatty acids (FAHFAs) that regulate systemic glucose and lipid metabolism (103).  
Adipokines or adipocytokines are involved in numerous metabolic pathways, 
contributing to the regulation of appetite control, energy expenditure and activity, fat 
distribution, adipocyte metabolism and function, regulation of adipogenesis, migration of 
immune cell into AT and inflammation (tissue and systemic) (Figure 1.3) (88). Importantly, 
adipocytokines influence β-cell function and insulin sensitivity by regulating energy 
metabolism in insulin-sensitive tissues (e.g. liver, muscle and AT) (Figure 1.3) (88, 89). 
Adipocytokines are mainly mediated by binding to their receptors on the membrane of target 
cells and trigger intracellular signaling pathways (134). These molecules are relevant clinical 
biomarkers in obesity and associated metabolic dysfunction such as detrimental fat distribution 
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and function, ectopic fat deposition, impairment of insulin sensitivity, systemic and tissue 





Figure 1.3. Example of physiological effects of adipocytokines  
Adipocytokines (and lipokines) act on peripheral tissues via autocrine, paracrine and endocrine 
signaling pathways by regulation of adipogenesis, adipocyte metabolism, inflammation, insulin 
sensitivity, energy expenditure and activity, cardiovascular function, behaviour and cell growth. IL-6, 
interleukin 6; MCP1, monocyte chemoattractant protein 1; PAI-1, plasminogen activator inhibitor 1; 
TNFα, tumor necrosis factor-alpha; FAHFA: fatty acid esters of hydroxyl fatty acids; RBP-4: retinol-
binding protein 4. Adapted from (89, 111). 
 
1.3.2. Adipose tissue metabolism and function in the obese state  
Obesity is characterized by an increased volume of AT, which is the major supplier of 
FFA to other organs in the post-absorptive state. Excess lipid storage in adipocytes  during 
positive energy intake and the consequent increased basal lipolysis results in higher levels of 
circulating FFAs, involved in the development of low-grade inflammation and IR (134). The 
adaptation of AT to different physiologic conditions is therefore susceptible to alter whole-body 
metabolism (138).  
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1.3.2.1. Adipose tissue expandability 
Although SAT is the largest adipose depot for lipid storage, this tissue has a limited 
expansion capacity (the so-called “tipping point”), depending on the ability of cells to enlarge 
and/or to recruit new cells (139). AT expansion limit varies between individuals and is 
dependent on the level of total body adiposity and AT depot (139). Consequently, this threshold 
limit may be reached in a non-obese range in certain individuals and may not be reached at all 
even during morbid obesity in other individuals (139). Once the tipping point is reached, the 
SAT is now unable to efficiently expand to serve as an energy buffer. The continuous calorie 
intake is followed by the redirection of excess lipids to VAT and ectopic fat depots (134). This 
pathological expansion, referred to as the AT expandability, is one of the most accepted 
hypotheses in the development of obesity-associated IR.  
SAT has been referred to as a metabolic reservoir where lipids are sequestrated, thereby 
protecting other tissues against excess lipids or ectopic fat deposition (127). The impairment of 
SAT function and the metabolic disorders associated with obesity may result from AT impaired 
storage ability (127). In this condition, continuous calorie/energy intake favours the 
accumulation of fat ectopically (e.g. liver, heart, muscle) and contributes to hepatic and 
peripheral IR (140, 141). This is mostly observed in metabolically unhealthy obese (MUO) 
individuals (127). In contrast, a subcategory of morbidly obese individuals has been shown with 
a functional SAT expansion resulting in the maintenance of insulin-sensitive, healthy obese 
phenotype referred to as metabolically healthy obesity (MHO), although this term has been 
heavily debated and remains questionable (142, 143). VAT accumulation has been associated 
with the impairment of SAT function in healthy individuals in response to lipid overfeeding 
(141). This supports the hypothesis that the incapacity of SAT to further expand contributes to 
VAT accumulation and its adverse metabolic effects. The main described events characterizing 
the occurrence of AT dysfunction after an impaired expansion capacity have been proposed to 
consist of impaired adipogenesis, adipocyte hypertrophy, increased hypoxia, changes in the 
ECM resulting in fibrosis, increased immune cell infiltration into AT and inflammation, AT 
stresses, altered lipid metabolism, ectopic fat accumulation and modifications in AT 







Figure 1.4. Adipose tissue expandability hypothesis: proposed mechanisms whereby 
hypertrophic AT expansion is linked to IR.  
The most accepted factors implicated in the impairment of AT function during excess fat accumulation 
are the impairment of adipogenesis and adipocyte hypertrophy, followed by increased FFA release and 
ectopic fat deposition, dysregulation of adipocytokine secretion, increased cellular hypoxia and AT 
stresses such as ER and oxidative stress. These mechanisms all contribute to the establishment of a pro-
inflammatory state in AT, interfering with the insulin signalling pathway and leading to peripheral and 
systemic insulin resistance. ER: endoplasmic reticulum; FFA: free fatty acids; UPR: unfolded protein 
response; JNK: Jun N-terminal kinase; NFkB: nuclear factor-kappa B. 
 
1.3.2.2. Impaired adipogenesis, adipocytes hypertrophy and angiogenesis in the 
obese state 
While the expansion of AT through hyperplasia has been shown in insulin-sensitive AT, 
an increase in cell size has mostly been associated with detrimental or pathologic development 
as described in insulin-resistant AT. An impaired ability of precursor cells to enter adipogenesis 
or adipocyte development process may be the upstream factor leading to AT dysfunction and 
involved in the development of obesity-related systemic IR and inflammation in humans (61, 
134, 144) (Figure 1.4). Indeed, decreased levels of adipogenic genes have been associated with 
systemic IR in obese individuals (131, 145) and related to AT inflammation (146). However, 
pro-inflammatory signals released from enlarging adipocytes have been proposed to favour 
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excess fat storage by stimulating adipogenesis and/or terminal differentiation of preadipocytes 
(147). Therefore, besides restricting accommodation of excess fat in the mature adipocytes, 
impaired adipogenesis may build up the inflammatory response of the hypertrophic adipocytes 
(61). Consistently, defective adipogenic potential has been positively associated with adipose 
secretion of IL-6 and IR in obese individuals (148). Impaired adipogenesis, therefore, restrains 
AT expansion and favours adipocyte hypertrophy and adipose/systemic inflammation, inducing 
abnormal glucose regulation and IR (61, 139). 
A study evaluating the relationship between adipocytes size and insulin sensitivity 
showed that hypertrophic adipocytes were found in patients with T2D and prediabetic 
individuals and were an independent marker of IR in SAT from prediabetic patients (149). 
Furthermore, increased adipocyte volume in obese individuals correlated with impairment in 
whole-body insulin sensitivity and higher systemic inflammatory and oxidative stress status 
and increased AT macrophage number (143). Decreased adipogenesis along with adipocyte 
hypertrophy might not be followed by adequate angiogenesis, setting up a local hypoxic 
environment, which might cause adipocyte apoptosis and necrosis. Indeed, AT expansion 
requires suitable vascularization and angiogenesis (150, 151). For instance, SAT angiogenic 
capacity decreases with increasing BMI and is associated with IR, suggesting that impaired 
angiogenesis in SAT contributes to obesity-related metabolic complications (144). During AT 
hypertrophy, oxygen level supply may decrease, possibly due to a decreased or insufficient 
angiogenesis for the level of lipogenesis, and a decreased blood flow, creating a hypoxic state 
in AT and macrophage infiltration (Figure 1.4) (152). 
1.3.2.3. Adipose tissue hypoxia 
Hypoxia in expanding AT is a suggested factor triggering stresses and inflammatory 
processes within the tissue and subsequently impaired AT function, although the mechanisms 
are not yet well established (88). It has been proposed that, if AT expansion occurs with 
insufficient angiogenesis, groups of adipocytes can become distant from the vasculature 
creating an insufficient amount of oxygen in the AT micro-environment (88, 153). The 
impairment of AT function could therefore be a specific consequence of relative hypoxia 
observed in obese individuals (152, 153). For instance, it has been shown that hypoxia 
(experimental) can stimulate adipocytokines secretion (e.g. angiopoietin-like protein 4, IL-6, 
leptin and macrophage migration inhibitory factor (MIF-1)) and induce oxidative and 
endoplasmic reticulum (ER) stress, potential additional pathways of impairment of AT function 
by low O2 tension in the tissue (153). 
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1.3.2.4. Immune cell infiltration and adipose tissue inflammation 
Several efforts have been made to identify triggers of AT inflammation subsequently 
involved in obesity-associated development of IR. The expansion of AT is associated with 
increased infiltration of pro-inflammatory immune cells initiating chronic low-grade 
inflammation (steady, low-level inflammation throughout the body) (154). Indeed, during 
adipocyte hypertrophy, higher amounts of pro-inflammatory adipocytokines and FFAs and are 
released from AT (52, 139). Saturated FAs serve as ligands for toll-like receptor 4 (TLR4), 
thereby inducing inflammatory reactions in AT through activation of nuclear factor-kappa B 
(NFkB) pathways (52, 139, 155). For instance, palmitate induces increases in TNFα production 
from macrophages (156). On another hand, elevated production of pro-inflammatory cytokines 
induces lipolysis, increases the release of more FFAs and inflammatory changes in adipocytes, 
creating a vicious circle between lipolysis and inflammation (156). Therefore, FFAs are 
significant adipocyte-derived paracrine mediators of inflammation in AT (156). The resultant 
effects could be the downregulation of cellular insulin signalling, activation and migration of 
monocytes, recruitment of additional macrophages through MCP1, propagation of 
inflammation by interleukins and TNFα, and impairment of tissue matrix remodelling through 
matrix metalloproteinase-9 (MMP-9) (139). These inflammatory mediators and metabolic 
pathways may further limit the recruitment and maturation of new adipocytes resulting in the 
impairment of AT function or AT dysfunction (88), playing a critical role in the development 
of obesity-associated IR (134, 157-159). Moreover, macrophages-derived cytokines influence 
local and systemic inflammation (88, 154). Obesity and inflammation are therefore tightly 
interconnected in the pathogenesis of IR and T2D (160).  
Both animal and human studies showed that in the obese state, AT is the target of immune 
cell infiltration, especially macrophages (161). The number of macrophages infiltrating into AT 
has been shown to increase with BMI, body fat mass and adipocyte hypertrophy, and decrease 
upon weight loss (162, 163). The death of hypertrophic adipocytes may also induce the 
infiltration and activation of macrophages into AT where they aggregate in ‘crown-like 
structures’ around the damaged cells (164). These immune cells may be attracted from the 
circulation by chemoattractant proteins such as MCP-1, chemerin, progranulin and colony-
stimulating factor-1 (CSF-1) (88, 162, 163). Once infiltrated into AT, macrophages are 
activated by FFAs released from hypertrophic adipocytes and produce elevated amounts of 
inflammatory cytokines (156). The infiltrated macrophages therefore contribute to increase 
inflammatory state in AT and enhance circulating levels of pro-inflammatory cytokines (88).  
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Dysregulation in the production or secretion of adipocytokines may cause AT 
dysfunction, due to their inflammatory properties, proposed as the mechanism by which 
adipocytokines induce IR in obese state (134, 165). A large number of AT-derived bioactive 
factors has been recently identified, although their specific function, molecular targets, 
intracellular signal transduction, and potential clinical relevance in the treatment of obesity and 
metabolic diseases remain to be elucidated (134). Nevertheless, the majority of adipocytokines 
(mostly pro-inflammatory) are elevated in obesity and correlate with total fat mass, body fat 
distribution and insulin sensitivity (88). Conversely, the production of anti-inflammatory 
adipocytokines decreases in the obese state, consecutive to the shift in macrophages population, 
from M2-type (anti-inflammatory) to M1-type (pro-inflammatory) and increase of M1/M2 ratio 
(89). Therefore, via their significant endocrine effects on target tissues like brain, liver, muscle, 
blood vessels, heart, and pancreatic β-cells, adipocytokines represent important determinant in 
metabolic dysfunction associated with excessive during fat accumulation (89, 134). 
1.3.2.5. Adipose Tissue stresses 
Overfeeding and obesity can cause a variety of stresses on AT such as metabolic (from 
increased metabolic fluxes and availability of glucose and lipids), oxidative and ER stress (88, 
89, 166). Indeed, adipocyte hypertrophy and impaired subcutaneous expandability may induce 
AT stresses by the activation of stress sensing pathways leading to failure in cellular function 
and contributing to obesity-associated metabolic disorders (134). Among obesity-related stress 
pathways, kinases are committed in the transmission of stress responses, including  the stress-
activated protein kinases p38 mitogen-activated protein kinase (MAPK) and Jun N-terminal 
kinase (JNK) (88). JNK has been involved in the establishment of obesity-induced IR and 
inflammation (88). Indeed, JNK1-dependent secretion of the inflammatory cytokine IL-6 by 
AT causes increased expression of liver SOCS3, a protein that induces hepatic IR (167). This 
suggests that activation of stress signalling pathways in AT may also cause a shift toward the 
secretion of proinflammatory adipocytokines.  
Obesity is also associated with ER stress, reflecting functional overload of ER in response 
to increased protein synthesis or secretion requirements and/or reduced elimination of 
misfolded proteins (88, 166). Proteins are folded and assembled by chaperones in the ER under 
normal conditions (88). However, in a hypoxic environment or with the over-supply of 
nutrients, the unfolded protein response (UPR) cascade can be activated (166, 168). Activation 
of the UPR in AT leads to transcriptional induction of genes involved in the assembly, folding, 
modification, and degradation of proteins to relieve ER stress (168), increase JNK, IKKβ 
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activity and pro-inflammatory cytokine expression (such as IL-6, TNFα and MCP1) (168). 
Notably, FFAs can trigger ER stress in adipocytes (Figure 1.4) (168), supporting that with 
increasing nutrient flux – including increased serum concentrations of FFAs and fat 
accumulation, AT is exposed to several stresses capable of generating a pro-inflammatory state 
and impairment of AT function in obesity. Besides the kinase-induced stress responses, and 
nutrient overflow causing ER stress, oxidative stress also occurs in AT. This has been evidenced 
by increased levels of oxidized proteins in AT of obese mice (169). Moreover, AT of insulin-
resistant and insulin-sensitive morbidly obese individuals could be differentiated by increased 
oxidative stress in the former (143, 170).  
1.3.2.6. Oxidative stress 
The increase in cell size following progressive fat accumulation in AT, the impaired 
angiogenesis and resulting decreased vasculature, as well as the lack of appropriate ECM 
remodelling may result in the reduction of oxygen supply to adipocytes. These events proposed 
to set up local hypoxia may contribute to inflammation and oxidative stress within AT (Figure 
1.4) (134). Oxidative stress has been demonstrated in obese individuals with elevated markers 
of reactive oxygen species (ROS) such as urinary 8-isoprostanes, thiobarbituric reactive acid 
substances (TBARS), and lipid hydroperoxides, as well as reduced antioxidant defence system 
(171). Oxidative stress is associated with systemic inflammation (171), impairment of glucose 
uptake in adipocytes (172), and decreased insulin secretion from pancreatic β-cells (173), 
supporting its critical role in the pathogenesis of IR. Increased oxidative stress in accumulated 
fat has also been associated with dysregulation of adipocytokines secretion and IR observed in 
obese individuals (174). Moreover, obesity-induced inflammation is associated with increased 
systemic and AT oxidative stress (171, 174). It is therefore valuable to understand the 
mechanism underlying the association between obesity-induced oxidative stress and IR.  
Oxidative stress generally refers to an imbalance between the production of pro-oxidant 
substances (ROS) and antioxidant defences (such as superoxide dismutase (SOD), glutathione 
peroxidase (GPx) and catalase (CAT)), resulting in cellular damage (171). ROS is generated 
during cellular metabolism when the chemical reduction of oxygen forms unstable free radicals, 
characterized by an unpaired electron (e.g. including superoxide (O2−), hydrogen peroxide 
(H2O2), and hydroxyl radical (OH
−)) (175). Under normal conditions, these oxidizing agents 
are essential for physiological functions such as gene expression, cellular growth and infection 
defence (171, 175). Their physiological levels in cells are conserved by the action of 
antioxidants from enzymatic (e.g. SOD, GPx and reductase, CAT) or non-enzymatic sources 
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(ascorbate, carotenoids, phenolic compounds, proline, polyamines) (171). Through the 
inhibition of ROS formation and action, or by repairing ROS-damaged cells, antioxidants are 
important to prevent oxidizing damage of ROS (171). However, long-term exposure to elevated 
ROS reduces insulin sensitivity and impairs glucose and lipid metabolism (174).   
Systemic oxidative stress has been closely associated with excess fat accumulation and  
BMI (176). AT is the major source of elevated circulating ROS in the obese state. Indeed, lipid 
accumulation in adipocytes leads to the generation of ROS, principally through the activation 
of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (174, 177). Leptin, which 
plays a key role in mediating pro-inflammatory state in obese individuals, has been proposed 
to induce oxidative stress by stimulation of mitochondrial oxidation of FAs (178). Leptin can 
also induce AT oxidative stress through increasing pro-inflammatory cytokines secretion (179). 
High levels of leptin have been associated with increased production of pro-inflammatory 
cytokines such as TNF-α, a potent activator for activation of NADPH oxidase, resulting in the 
formation of ROS (180).  
As previously reported in several studies, macrophages infiltrate obese AT and play a 
vital role in regulating obese AT inflammation by the ability to shift adipocyte secretory profile 
to a pro-inflammatory condition (T-helper 1 subtype) (181). Macrophages can produce ROS 
(e.g. O2
−, H2O2 and OH
−), which also provides positive feedback to upregulate T-helper 1 cell 
activation and further sustain a pro-inflammatory state (182). Moreover, macrophage-induced 
ROS production increases the activity of NADPH oxidase in obese AT, which subsequently 
induces a dysregulated expression of inflammatory adipocytokines, including adiponectin, PAI-
1, IL-6, and MCP1 and the decreased production of antioxidant enzymes (174, 177). On another 
hand, elevated ROS can upregulate the mRNA expression of NADPH oxidase, creating a 
vicious circle and resulting in increased oxidative stress in AT and the circulation (174). Indeed, 
ROS and by-products of lipid peroxidation such as TBARS have also shown to increase the 
expression of MCP-1, resulting in attraction, infiltration and activation of macrophages into AT 
and inflammation (174). Moreover, prolonged exposure of adipocytes to ROS results in 
impairment of insulin-induced activation of PI3-kinase and Akt, insulin-stimulated lipogenesis, 
glucose uptake, and GLUT4 translocation to the plasma membrane (172, 183). ROS also 
suppressed the mRNA expression of lipogenic genes, such as FASN and SREBP-1c (174). 
Oxidative stress was further shown to suppress PPARγ mRNA expression in adipocytes 
(174), and consequently, is implicated in the impairment of adipogenesis and AT expansion. 
Furthermore, PPARγ positively regulates the transcription of the adiponectin gene via PPARγ-
24 
 
responsive element in the promoter (184). Therefore, downregulation of adiponectin expression 
in obese subjects may be partially attributed to the decreased gene expression and a smaller 
amount of nuclear PPARγ under conditions of oxidative stress (174). Additionally, elevated 
FFAs resulting from impaired lipolysis and lipogenesis in hypertrophic adipocytes can activate 
NADPH oxidase and induce ROS production in AT (174). These findings suggest that increased 
ROS production during lipid accumulation may dysregulate adipocytokine production, impair 
further lipid storage and favour ectopic lipid deposition, ultimately leading to IR.  
In summary, increased pro-inflammatory response and immune cell infiltration in obese 
AT promote the formation of ROS and increase oxidative stress. This may lead to dysregulated 
production of adipocytokines, which exacerbates AT inflammation. Further, increased ROS 
production in AT leads to elevated systemic oxidative stress and potentially instigates whole-
body IR by affecting other peripheral organs’ function. Therefore, oxidative stress could be a 
useful target in the development of therapies to reduce obesity-associated metabolic 
dysfunction. The increase in endogenous activity of antioxidant enzymes can reduce the 
incidence of oxidative stress and associated metabolic disorders by regulating or delaying the 
production of ROS (185, 186). In this regard, antioxidant treatment improves insulin function 
in people living with diabetes (187). The inhibition of NADPH oxidase has also been proposed 
to improve the dysregulation of adipocytokines and insulin sensitivity via restoration of normal 
ROS production in obese adipocytes (174).  
1.3.2.7. Ectopic fat deposition 
Ectopic fat deposition contributes to low-grade inflammation and IR. Indeed, ectopic 
deposition of lipids may result in polarization of macrophages, stimulate changes in adipokine 
secretion and induce inflammation (87). Lipid accumulation in non-adipose organs is indicative 
of an oversupply of FFAs more than what can be oxidised (e.g. skeletal muscle) and/or secreted 
(e.g. liver, visceral area) (Figure 1.4). An increase in the delivery and storage of FFAs in 
skeletal muscle impairs the activity of glucose transporter (GLUT 4) and decreased glucose 
uptake, resulting in a decrease of peripheral insulin sensitivity (46, 188). Accumulation of TGs 
in the liver promotes steatohepatitis and non-alcoholic fatty liver disease. This results in hepatic 
IR by decreasing glucose uptake and increased glucose production (188). Furthermore, while 
FFA accumulation in the heart can result in diastolic dysfunction (188), FFAs increase 
pancreatic insulin secretion and systemic basal insulin concentrations leading to 




1.3.3. Genetic factors implicated in AT dysfunction 
The failure of appropriate AT expansion and fat storage leading to overflow of lipids as 
ectopic fat has been associated with the absence of “favourable adiposity alleles”, predisposing 
these individuals to poor AT expandability and leading to obesity-related complications. This 
is usually the case in obese individuals characterized by greater VAT and lower SAT, contrary 
to carriers of the “favourable adiposity alleles” characterized by a fat distribution directed 
towards subcutaneous, rather than VAT expansion (189). 
Genetically programmed developmental differences in adipocytes and their precursors in 
different regions of the body are thought to have a fundamental role in obesity and fat 
distribution (134). Genetic variants of several previously unknown genes associated with fat 
distribution have been reported from GWAS (76). However, the function of these genes and 
the mechanisms underlying their association with detrimental fat distribution and impairment 
of AT function are not fully understood (88). GWAS suggested that body fat distribution is 
associated with variations in genes involved in pattern formation during embryonic 
development (190). To understand the mechanisms implicated in the impairment of AT in the 
course of obesity, the specificity in metabolism and function of each AT depot, and the depot-
specific gene expression signatures need to be considered. Indeed, pre-adipocytes from SAT 
and VAT are thought to be derived from different precursors programmed through epigenetic 
modulation (81, 82). In addition, different precursors seem to be responsible for specific adipose 
depot development, which confers distinctive biological features and may participate in 
determining differences in function and gene expression (e.g. VAT and SAT (reviewed in (46) 
and/or between aSAT and gSAT (reviewed in (78, 79)). The next section provides some 
differences in adipose-depots biology, metabolism and function as well as the causal factors of 
differential associations with obesity-related metabolic risk factors.  
1.3.4. Depot-specific differences in adipose tissue function and associated metabolic risk 
factors 
Adipose depots present differences in several metabolic and functional pathways, which 
may explain their differential associations with metabolic risk in the obese state. AT 
development is preceded by capillary network growth. Endothelial cells contribute to the 
stimulation of preadipocyte differentiation (191). SAT has a higher capacity to expand its 
capillary network, and higher angiogenic growth capacity compared to VAT (144). 
Preadipocyte proportion and subtypes with different proliferative capacities also differ between 
fat depots (192). The predominant adipogenesis type (hypertrophy vs hyperplasia) determines 
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the size and number of fat cells in different depots and contributes to the predisposition to 
obesity-related metabolic disorders (52). VAT contains fewer adipogenic precursors, with 
lower proliferation and differentiation capacities (193), smaller adipocytes (46), lower number 
of pre-adipocytes (192) and a higher number of stromal cells compared to SAT (194). However, 
in obese individuals, stromal cells from the SAT region proliferated faster than those from VAT 
depots (194).  
Differences in secretory profiles have also been shown between VAT and SAT, with a 
higher expression of pro-inflammatory cytokines in the former (including TNF-α and PAI-1) 
while levels of adiponectin, leptin and IL-10 are higher in SAT (46, 195). Moreover, it has been 
reported by several research groups that VAT is a major contributor to metabolic risk (139, 
196), whereas SAT may have a protective role (195, 197). The first proposed explanation of 
the association of VAT with metabolic disorders was the portal vein hypothesis, based on the 
anatomical position of this depot in proximity to the liver. Hypertrophic adipocytes in VAT are 
less sensitive to the anabolic action of insulin and are characterized by a hyperlipolytic state, 
thus producing larger amounts of circulating FFAs (61). According to the portal vein 
hypothesis, these high levels of FFAs, directly enter the liver through the portal circulation and 
lead to increased lipid synthesis and gluconeogenesis (198). This can result in impaired hepatic 
insulin sensitivity, increased hepatic glucose production, fasting hyperglycemia and 
hyperlipidemia, hepatic steatosis and ultimately IR (46, 196). Further, excess FFAs deposition 
in skeletal muscle can inhibit glucose uptake and lead to peripheral IR (46, 188). However, if 
VAT was the sole contributor to metabolic risk, it should be the major source of systemic FFA 
pool. In contrast, only a small portion of total body fat (7%-8% in women) is located in the 
intra-abdominal region and contributes to only 15% of the total systemic FFAs, whereas the 
majority of FFA is stored in SAT (199). This observation raised doubts on the exclusive 
contribution of VAT to the development of IR. Therefore, although VAT is considered a unique 
pathogenic depot that confers risk beyond its contribution to overall adiposity, SAT volume and 
quality also seem to be involved in the incidence of metabolic risk factors (200).  
The adverse effects of excessive upper-body adiposity have often been attributed to VAT, 
and the role of aSAT in the regulation of metabolic health has been less acknowledged until 
recently (128). Abdominal SAT shares some morphological and functional similarities to VAT 
(201). The expansion of this depot may therefore have a negative impact on effective fat storage 
(128). Abdominal SAT volume is approximately five times larger than VAT volume at the same 
level (L4-L5 level) (139) and this depot (aSAT) is the major source of systemic FFA flux, 
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greater than the VAT depot and the lower-body SAT (190). Moreover, aSAT inflammation has 
been associated with the partitioning of fat towards the VAT and liver and altered β-cell 
function, independent of total adiposity (202). Therefore, both SAT and VAT may contribute 
to ectopic lipid deposition and associated complications. Each AT depot has a unique pattern 
of FA storage, suggesting distinctive regulation and intracellular processing of FA (107). 
Abdominal adiposity (including aSAT and VAT depots) is the primary site for immediate 
storage of diet-derived fat (128). The differences in the rate of lipid accumulation between AT 
depots been proposed to be influenced by DGAT activity. This enzyme can create a favourable 
gradient for uptake and storage of circulating FAs by modulating adipocyte size (107). 
Furthermore, regional differences in direct FFA storage is dependent on LPL activity and was 
shown to be more elevated in VAT compared to aSAT in women (46, 203). Moreover, although 
VAT and aSAT have a high lipid turnover rate, VAT is more metabolically active (fat storage 
and release) compared to aSAT (46, 195).  
In contrast to VAT and aSAT, gSAT is characterized by reduced lipid turnover, and a 
high capacity to accommodate lipids undergoing redistribution, consisting of recirculated FAs 
from VLDL or directly from the FFA pool (204). The uptake of diet-derived FAs occurs less 
efficiently in gSAT than in aSAT, which is balanced by fewer FA release from gSAT in the 
post-absorptive state or during adrenergic lipolytic stimuli (128). Indeed, evidence showed that 
gSAT adipocytes are less sensitive to factors stimulating lipolysis and have a lower rate of 
lipolysis than in aSAT (205). Indeed, adipocytes from aSAT are more sensitive to β-adrenergic 
agonists and gSAT adipocytes are more responsive to the anti-lipolytic effect of α-2 adrenergic 
agonist, with lower lipolytic responses to mixed agonist (46). In vivo studies also showed 
greater lipolytic activity in aSAT with higher that FFA delivery to the periphery compared to 
gSAT (46). Moreover, during weight loss, the reduction of gSAT occurs slower than aSAT, 
suggesting and elevated retention capacity of FA in gSAT (128). Besides FFA levels, the 
expression of pro-inflammatory cytokines in aSAT like in VAT, as well as the number of 
infiltrated macrophages, was shown to be higher than in gSAT (206). Furthermore, a 
population-based study found that aSAT is negatively and gSAT is positively correlated with 
serum adiponectin concentrations (207). Adiponectin is critical for AT expansion and its 
dominant secretion also corresponds with the adipogenic potential of gSAT (52). Indeed, upper 
and lower-body AT respond differently to increasing demands for fat storage, underlying 
differences in expansion capacity between aSAT and gSAT. Whilst aSAT expands through a 
hypertrophic response (more fat in each adipocyte), gSAT shows a proliferative or hyperplastic 
response (new fat deposited in new adipocytes) (208).  
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Oxidative stress also seems to play a role in the high cardio-metabolic risk associated 
with VAT accumulation. This adipose depot has been strongly associated with urinary 8-
isoprostanes (a marker of oxidative stress) and MCP-1 compared to SAT (209). In addition, 
higher android rather than gynoid fat correlates positively with systemic oxidative stress, 
independent of cardiovascular risk factors and inflammation (177). Further, a reduction in 
android fat mass, but not gynoid fat or BMI was associated with decreases in oxidative stress 
after 1 year of follow-up (177). A recent study on SAT depot-specific proteome in overweight 
and obese women showed a higher expression of the antioxidant enzyme SOD1 and lower 
expression of nitric oxide production related enzymes in gSAT compared to aSAT, supporting 
differences in the level of oxidative stress in SAT depots, with higher oxidative stress profile in 
aSAT (210). 
Taken together, AT depots have distinct influences on metabolic health, with central fat 
accumulation (VAT and aSAT) associated with a detrimental metabolic profile, mostly 
attributed to VAT, which has been associated with metabolic syndrome even in non-obese 
individuals (211). Conversely, individuals with greater gSAT mass have been found with a 
more favourable metabolic profile (52, 139). In addition to their functional differences and 
distinctive associations with metabolic risk, epigenetic differences between fat depots (SAT vs 
VAT and aSAT vs gSAT) have been shown (46, 78). These data are mainly derived from 
European studies and may not be directly attributed to depot-specific SAT associations with 
metabolic risks in Africans. Indeed, different ethnic groups have distinct patterns of body fat 
distribution, conferring differential associations with metabolic risks (36, 37). Therefore,  the 
metabolic effects of AT depots in the development of IR and T2D may vary in women of 
different ethnicities (32).  
1.3.5. Ethnic-specific differences in metabolic risk factors 
Different ethnic groups are distinctively susceptible to metabolic diseases, which may be 
partly explained by differential patterns of body fat distribution. For instance, African 
Americans have a higher risk for abdominal fat-related chronic conditions such as CVD and IR 
than non-Hispanic white women (69). Conversely, leg fat indices tend to negatively correlate 
with the risk of IR, regardless of ethnicity (195). Contrary to Europeans, fat accumulates mostly 
in SAT with relatively less VAT in African women (34, 70, 71). These last have a weaker 
association between VAT and parameters of metabolic syndrome (e.g. blood pressure, TG, 
high-density lipoprotein cholesterol and total cholesterol concentrations) than European 
descendants (212). In contrast, aSAT was negatively correlated with insulin sensitivity in 
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African-American women, but not in European women (25). Interestingly, black and white SA 
women present with different patterns of body fat distribution which have been associated, at 
least in part, with differences in cardio-metabolic risks between these ethnic groups (33). In this 
regard, centralization of body fat, including an increase in both VAT and aSAT are important 
risk factors for IR and T2D in both black and white (25, 32, 37).  
 Paradoxically, although black SA women have shown greater SAT accumulation in the 
gluteo-femoral region and less VAT for a similar BMI (31-33), they have higher levels of IR 
than their white counterparts (24). Only a few studies have investigated the AT biology and 
function in black SA women, despite their higher metabolic risks. Impairment in SAT function, 
especially in the gSAT, has been proposed as a possible mechanism explaining the higher 
incidence of IR in obese black SA women (35). Indeed, gSAT in obese black SA women is 
characterized by reduced expandability capacity with decreased adipogenic and lipogenic gene 
expression, associated with decreased insulin sensitivity (35). Further, black African women 
had larger adipocyte size compared to their white counterparts (213), which has been shown to 
correlate with insulin levels in postmenopausal African American women, but not white 
American women (36). Moreover, larger median gluteal adipocyte size and a greater proportion 
of large gluteal adipocytes were shown in black SA women, while white women had a greater 
proportion of small cells (36). 
Furthermore, elevated expression of genes involved in hypoxia and ECM remodelling 
(HIF-1, collagen type V a1 and collagen VI a1) and reduced vascular endothelial growth factor-
a expression have been shown in gSAT of black SA women, which correlated with decreased 
insulin sensitivity (214). The association between SAT mass and lower insulin sensitivity in 
black women may therefore be driven by increased hypoxia, which in turn induces a fibrotic 
and inflammatory response, leading to IR. To address the implication of SAT inflammation in 
this association, it was further shown that pre-menopausal black SA women had higher 
expression of the chemokine C–C motif ligand and its receptor; higher expression of the 
macrophage marker CD68, and greater expression of the cytokines TNFα, MIF and CSF-1 
compared to their white counterparts, independent of VAT, adiposity and age (213). Strikingly, 
the higher SAT inflammatory gene expression profile of African women only explained 20% 
of the variation in insulin sensitivity, in comparison to 56% in white women (213). This 
suggested that despite the Africans displaying a higher gSAT inflammatory response (213), and 
carrying genetic variants associated with higher inflammation (215), factors other than SAT 
inflammation might be stronger contributors to insulin sensitivity in these women.  
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Ethnic differences in insulin sensitivity may also be related to increased oxidative stress. 
Indeed, high levels of hypoxia may increase oxidative stress in African women (36), which has 
been associated with increased FFAs and reduced insulin sensitivity in African Americans, but 
not European or Americans (216). However, there is a lack of studies examining the association 
between oxidative stress in AT and IR in black SA women. More studies are required to 
understand the mechanisms implicating obesity-induced oxidative stress in the development of 
IR in black SA women.  
Another important mediator of obesity-related IR may be the increased release of FFAs 
from SAT, resulting in the accumulation of lipids and their intermediates in ectopic sites, which 
disrupt metabolic processes and reduce insulin sensitivity in these tissues (188). Although black 
African women have lower hepatic lipid deposition compared to their white counterparts (217, 
218), there is evidence to suggest that obese African women are more sensitive to the effects of 
ectopic lipid deposition and VAT on hepatic insulin sensitivity than white SA women (32, 37, 
217). In addition, it has been shown that the activity of the lipogenic enzyme stearoyl-CoA 
desaturase 1 (SCD1), the principal enzyme involved in the desaturation of palmitic acid (16:0) 
to palmitoleic acid (16:1n-7), is reduced in obese African American women compared to their 
white counterparts (219). Therefore, lipid and FA metabolism in AT may be implicated in the 
higher metabolic risk in African women, but it is not known whether SAT FA metabolism and 
FA profile can explain the impairment in insulin sensitivity in obese black SA women. 
Mechanistic studies are required to explore the differential function and metabolism of aSAT 
and gSAT in obese black African women, where both SAT depots have been associated with 
risk for IR and T2D (32, 35, 37).  
1.4. FATTY ACID METABOLISM IN OBESITY 
FA composition of stored TG during positive energy balance may exert positive and/or 
detrimental metabolic effects on insulin signalling pathways within AT tissue and peripheral 
organs (220, 221). Indeed, FAs are important receptor agonists that can regulate AT function 
by modulating gene expression (222), lipid metabolism (155), trigger transcriptional profiles 
associated with adipogenesis and inflammation (223), potentially contributing to IR in 
individuals with obesity (156, 224). Moreover, changes in FA profiles in the circulation or AT 
has been reported in obese individuals and proposed to significantly affect their metabolism 
and the risk of IR and T2D (225). The implication of biologically active FAs stored and released 
by AT in the development of metabolic control underlies the need to give special attention on 
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these molecules in a context of metabolic control and prevention of comorbidities in obese 
individuals.  
1.4.1. Fatty acid classes and metabolism 
FAs are essential components of almost all lipids and constitute structural elements of 
phospholipids (PHLs) and glycolipids building biological membranes. These molecules are also 
the principal component of TGs, which accumulate in AT and serve as an energy source (226). 
FAs are a diverse group of compounds differing in chain length, degree of saturation and 
metabolic effects. They may originate from dietary intake, from endogenous synthesis during 
DNL or from AT release (225). According to their degree of unsaturation (presence, number 
and position of carbon-carbon double bonds), FAs are generally grouped into three main 
classes.  
Saturated fatty acids (SFA) are mainly derived from animal and dairy products and can 
also be synthesized endogenously (225). This class is generally considered to exert 
unfavourable effects and to induce numerous diseases, principally related to inflammation 
(225). High dietary intake of SFAs results in increased concentration of their metabolites, which 
have been shown to stimulate the synthesis of inflammatory cytokines in various tissues (227). 
The dietary influence on the concentration of FAs has been shown by a strong correlation 
between dietary intake of SFAs and the degree of PHL saturation and the proportion of SFAs 
within serum PHLs (228). However, some studies have suggested that membrane PHLs and 
circulating SFA contents derive from endogenous synthesis (229).  
Mono-unsaturated fatty acids (MUFA) are an FA class defined by the presence of one 
double bond in the carbon chain. These FAs are abundant in vegetable oils and can be actively 
synthesized in human liver and AT from their SFA precursors (e.g. palmitic and stearic acids) 
by desaturation (mainly regulated by SCD1). MUFAs form the main substrates for TGs, PHLs 
and cholesteryl ester synthesis and are the major FAs in VAT and SAT, and consequently play 
a role in the pathogenesis of obesity and associated T2D (230). 
Poly-unsaturated fatty acids (PUFA), are characterized by the presence of more than one 
double bonds in the carbon chain, and mainly derived from vegetable oils and marine products 
(231). This FA class is further subdivided into two groups according to the position of the final 
double bond, that is, n-3 and n-6 PUFAs (231). Long-chain PUFAs (LC-PUFAs) derived from 
a series of desaturations, elongations and β-oxidation of their main precursor, i.e. alpha-
linolenic acid (ALA; 18:3 n-3) and linoleic acid (LA; (18:2 n-6) respectively, referred as 
essential fatty acids. Essentials FAs are FAs that cannot be synthesised from DNL and can only 
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be obtained from the diet. N-3 PUFAs and n-6 PUFAs compete for the same desaturase 
enzymes in their respective metabolic pathways. However, they generally exert opposite 
metabolic effects, with n-3 PUFAs considered to exhibit anti-inflammatory properties, whereas 
n-6 PUFAs are thought to promote inflammation (225). Elevated n-6 PUFAs and a high ratio 
of n-6/n-3 have also been associated with the development of inflammatory diseases and obesity 
(232, 233). Conversely, n-3 PUFAs have been shown to contribute to the improvement of 
metabolic profile such as an improvement in lipid metabolism in obese humans (234) and 
bodyweight reduction in mice (235). 
Apart from their dietary origin, FAs are synthesized endogenously principally in human 
liver and AT. Although endogenous synthesis of FAs is minor under normal physiological 
conditions (such as in lean individuals), it represents a major determinant of circulating lipid 
profiles in obesity, and especially in individuals with high-carbohydrate diets (236). Glucose is 
the main substrate in this pathway and is metabolized via glycolysis to produce pyruvate and 
acetyl-CoA, forming substrates for FA synthesis. FASN is the principal enzyme involved in the 
synthesis of FAs and its main product is palmitic acid (225). Palmitic acid can be subsequently 
activated by acyl-CoA synthase and can also subject to desaturation and elongation. In human 
AT (and liver), the main enzyme responsible for desaturation of FAs is delta-9 desaturase 
(D9D) or SCD1(225). This enzyme mainly desaturates palmitic (16:0) and stearic acids (18:0) 
to produce palmitoleic acid (16:1n-7) and oleic acid (18:1n-7), which have been identified as 
the major constituents of FAs in stored adipose TGs (237). Therefore, the activity of SCD1 is 
a determinant of MUFAs content in blood and AT (237, 238). SCD1 has been proposed to 
contribute to the development of obesity and IR. Indeed, pharmacological inhibition of this 
enzyme may attenuate the course of obesity-related disorders (236-238). Moreover, SCD1-
knockout mice exhibited an enhanced muscular uptake of glucose and increased FAs oxidation 
in the liver, showing that SCD1 deficiency may prevent the development of diabetes and obesity 
(239, 240). 
In addition to SCD1, other desaturases, delta-6 desaturase (D6D) and delta-5 desaturase 
(D5D), are involved in the metabolism of FA, essentially in the PUFAs synthesis pathways. 
Together with elongases, D5D and D6D convert the essential dietary FAs ALA and LA into 
their corresponding LC-PUFA products eicosapentaenoic acid (EPA; 20:5n-3) and arachidonic 
acid (AA; 20:4n-6) (241). Dysregulation in the activities of these enzymes, specifically an 
increase of D6D and decrease of D5D are independent predictors of metabolic syndrome (242). 
Moreover, a higher BMI correlates with lower D5D activity (243) and enhanced activity of 
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D6D has been associated with dysregulations in PUFAs metabolism in obese individuals (244). 
Notably, PUFAs released from membrane PHLs can also be metabolized by cyclooxygenases, 
lipoxygenases and cytochromes, forming oxylipins (including prostaglandins, thromboxane and 
resolvins) (245), which can be transformed to various peroxidation products, if exposed to 
elevated oxidative stress (246). 
1.4.2. Fatty acid profile in blood and adipose tissue in obesity  
FA metabolism in AT is central to the maintenance of lipid homeostasis, particularly in 
obese individuals that are characterised by excessive AT accumulation. However, if the AT 
tipping point is reached or exceeded, one of the early malfunctions occurring is the 
dysregulation of lipid metabolism characterized by elevated lipolysis (basal and/or stimulated), 
as well as a reduction of lipogenesis, consecutive to impaired adipogenesis (134). The 
immediate effect of this incapacity to sequester more lipids into adipocytes is the increase of 
circulating saturated FFAs, the alteration of blood FA profiles, the lipotoxicity and the 
impairment of whole-body metabolism (247). The composition of FAs in the blood is reflective 
of both dietary fat intake and their endogenous synthesis/AT release. However, it is difficult to 
unravel the source of FA composition in the circulation without having information on dietary 
fat intake. This information can only be obtained if accurate and precise measurements of usual 
dietary fat intake are available. Dietary fat intake from self-reported data has shown to be highly 
biased due to the under-reporting of food consumption (especially in overweight individuals), 
alteration of usual diet during the recording period (influenced by the intervention), interviewer 
bias, incorrect portion size estimations, coding and computational errors (248). Additionally, 
the unavailability of exact food match and incomplete food composition in databases (especially 
regarding the exact values for individual FAs) have been described as limitations of self-
reported dietary intake (248). Therefore, there is great interest in using tissue and blood FA 
composition as biological markers of fat intake to improve dietary assessments and understand 
the relationships between diet, metabolism and diseases.  
FA in plasma (or serum) and erythrocyte or red blood cell (RBC) membranes are used as 
biomarkers of dietary fat intake. While the FA composition of plasma and serum reflects fat 
intake over the past weeks, RBC PHLs FA profile reflects the dietary intake over 2-3 months 
and has therefore been proposed as the preferential indicator of an individual’s dietary FA 
intake (231, 249). These cells can preserve their membrane FA composition with lower diet-
induced fluctuations than plasma or serum FA profile (80, 250, 251). Furthermore, the FA 
profile of AT is considered the gold standard for the representation of dietary FA in the context 
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of obesity research, due to its slow lipid turnover in weight stable individuals (225, 248), with 
a half-life (t1/2) of lipids estimated to be 1-2 years (248). Moreover, the total FA composition 
of AT is typically measured in TG, which constitutes 99% of TG in adult humans (252). The 
FA composition of SAT depots has been shown to differ between gSAT and aSAT, with higher 
contents of SFA and lower MUFA in aSAT than gSAT (252, 253). These differences have also 
been shown between SAT and VAT with higher proportions of MUFA and lower SFA in SAT 
compared to VAT, while no obvious differences were reported for PUFA between these depots 
or within SAT depots (253, 254). The correlation between serum FFA profile and FA 
composition of AT (255) supports the major contribution of AT-FA to circulating FFA pools, 
consecutive to higher TG hydrolysis. Therefore, alterations of lipid metabolism pathways in 
obese AT can be reflected by substantial modification in circulating lipid profile and increased 
risk for oxidative stress, inflammation, diabetes and CVD in obese subjects. 
Obesity has been associated with substantial quantitative and qualitative alterations in the 
serum/plasma FA profile (232, 243). Moreover, greater circulating saturated FFA 
concentrations result in FA incorporation into membranes PHLs (225). Therefore, not only the 
FA composition of plasma/serum but also FA profiles of RBC total phospholipids (RBC-TPL) 
are altered in obesity (225). These alterations are characterized by increased SFA and n-6 PUFA 
(e.g. 20:3n-6, 20:4n-6, 22:4n-6 and 22:5n-6) contents with lower proportions of MUFA and n-
3 PUFAs (225). The FA composition of PHLs membranes determines not only their physical 
properties but also their biochemical properties (248). For instance, FAs of membrane PHLs 
are implicated in several fundamental regulatory processes (e.g. gene expression, signal 
transduction and synthesis of lipid or lipid-derived messengers) (138, 256) and were 
demonstrated to be involved in the development of IR and metabolic syndrome (225). PHLs 
are also precursors of intracellular messenger molecules and are very sensitive or susceptible 
to the detrimental effects of ROS generated in excessive amounts by cells in an obese micro-
environment (257). The FA profile of RBC-TPL has also been strongly associated with the liver 
FA profile and therefore is proposed as a marker of dysfunctional lipid metabolism in the liver 
of obese patients, due to the restricted accessibility of human liver as a biological sample in 
research (258). Alterations in circulating and tissue FA profile in obesity could also result from 
dysregulation of desaturase enzyme activity. For instance, the increased activity of D6D may 
be responsible for the impairment of LC-PUFAs metabolism in serum, RBC and AT (244). The 
changes in desaturases activities and their association with the incidence of T2D may derive 
from genetic variation in the expression of genes regulating these enzymes (259). 
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1.4.3. Genetic background and ethnicity: Implications in the relationship between fatty 
acids and metabolic disorders  
The influence of genotype and ethnicity on FA composition in AT and blood has not been 
extensively studied. However, differences in AT FA composition have been shown between 
black and white men, with lower MUFA (16:1n-7) and higher SFA (18:0) in gSAT and VAT 
of black African compared to white men (260). These differences were suggested to result from 
higher elongase activity in black Africans, as opposed to higher desaturase activity in their white 
counterparts (260). However, ethnic-specific differences in FA composition could also be 
explained by differences in the dietary intake between ethnic groups (261, 262). For instance, 
black African women consume higher proportions of n-6 PUFA and lower SFA compared to 
their white counterparts (32, 263). Genetic factors may also mediate the ethnic differences in 
FA metabolism. A strong genetic influence on food choices, post-absorptive metabolic 
processes and FA incorporation in cell membranes, independently of diet have been reported 
(264). Besides, differences in AA levels and fatty acid desaturase (FADS) gene variants have 
been found between African Americans and European Americans (265). The genotype G-allele 
(rs174537) associated with higher circulating levels of AA was higher in African Americans 
compared to their Europeans counterparts, resulting from an increased D5D enzymatic 
conversion of dihomo-γ-linolenic acid (DGLA) to AA in individuals of African ancestry (265, 
266). Therefore, apart from differences in the pattern of dietary intake, differences in FA 
metabolism may also be attributed to genetic mechanisms, which may contribute to health 
disparities between ethnic groups with greater risk observed in black African populations. The 
regulation of FA metabolism and composition represents a valuable aspect to consider in the 
development of multidisciplinary strategies of treatment of obesity. Obesity and its associated 
metabolic complications currently constitute a tangible challenge for future generations, 
especially with the continuous urbanization-related development in African countries. 
Therefore, lifestyle modifications (or “re-modification” aiming to “regain” the habits before the 
emergence of metabolic era associated with urbanisation and civilisation) represent a 




1.5. MANAGEMENT OF OBESITY AND METABOLIC RISKS 
Obesity is now considered a disease entity, with multi-factorial etiology, including the 
involvement of genetic, epigenetic, environmental, social and behavioural components (267). 
Most cases of obesity result from the interaction between these factors, rather than due to a 
single causal factor, and the progression and severity of this condition varies over time and 
among individuals (268). Consequently, the management of obesity and related comorbidities 
is extremely challenging among societies. The increasing burden of obesity and the 
consequences at individual and government level has led to the development of numerous 
weight-loss therapies ranging from behavioural, pharmacological, and surgical, to lifestyle 
interventions aiming to prevent and slow down its exponential progression. 
1.5.1. Pharmacological, surgical and dietary interventions 
1.5.1.1. Pharmacological treatment 
Pharmacotherapy is generally indicated for patients with BMI ≥ 30 kg/m2 and those with 
a BMI ≥ 27 kg/m2 with at least one obesity-related comorbidity (e.g. T2D, hypertension, 
hyperlipidemia), and mostly as an adjunct to behavioural counselling (269). The five 
medications currently approved by the Federal Drug Administration (FDA) for long-term 
obesity treatment include orlistat, Lorcaserin (Belviq), Phentermine-topiramate extended-
release (Qsymia), Naltrexone-bupropion extended-release (Contrave) and higher dose 
liraglutide 3.0 mg (Saxenda) (270, 271). However, the benefits of medication may be lost if the 
treatment is discontinued. Patients responding to the treatment (defined as at least 5% weight 
loss after 3 months of treatment), should therefore continue the medication, with goals of 
continuous weight loss and maintenance of lost weight (269). Although many intermediate 
cardiovascular risk factors are improved by the use of these medications, long-term 
cardiovascular and neuro-cognitive safety has not yet been established (270, 271).  
1.5.1.2. Surgical treatment 
Bariatric surgery is indicated for patients with morbid obesity (BMI ≥ 40 kg/m2) or those 
with a BMI ≥35 kg/m2 with at least one obesity-related comorbidity, and who have failed 
conservative treatment (269, 272). The most common bariatric surgeries are vertical sleeve 
gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB)(270). Surgical treatment of obesity 
seems the most effective long-term weight reduction therapy (271). This method has provided 
notable data of weight reduction of up to 30% accompanied with the improvement of several 
parameters of the metabolic syndrome (T2D, hypertension, hyperlipidemia), as well as 
improvements of long-term mortality (270). However, most of the weight loss after surgery 
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occurs in the first-year post-surgery, follow by a weight plateau or regain (271). Moreover, 
bariatric surgery comprises the most adverse safety profile, primarily because of perioperative 
morbidity and mortality (271). Notably, this method is also limited, especially in low- and 
middle-income countries by the lack of accessibility in public hospital system, the lack of well 
experienced medical teams and equipped structures, the high costs related to this procedure as 
well as lack of long-term follow-up systems. Nevertheless, bariatric surgery and to a lesser 
extent pharmacological treatment, overall seem to be promising long term intervention 
strategies by both resulting in weight reduction and improvement of obesity-associated cardio-
metabolic risks (270). It is, however, important to consider the cost-effectiveness of these 
therapies given the global obesity epidemic, and the fact that obesity is a chronic disease 
requiring long‐term management, especially in low-middle income countries characterized by 
a low socio-economic status. Therefore, lifestyle interventions and counselling, which are also 
critical during pharmacotherapy and post-surgery remain the basis of treatment of obesity and 
prevention of metabolic alterations. 
1.5.1.3. Dietary intervention 
Lifestyle factors such as ‘unhealthy’ and/or excess food intake and increased sedentary 
lifestyle and physical inactivity are particularly important factors to consider in weight 
maintenance. Globalisation has increased the availability of food, including food of high energy 
but low nutritional value, high in unhealthy fats, sugar and salt, which are usually affordable 
and easily accessible even in impoverished communities (11). The creation of an energy deficit 
by addressing caloric intake and energy expenditure is among the more efficient alternatives to 
manage obesity (273). Dietary interventions such as calorie restriction aim for an energy deficit 
of 2-4 MJ per day (approximately 500-1000 Kcal) to achieve a steady rate of weight loss of 0.5-
1 kg per week (271). This moderate and progressive weight loss has been shown to improve 
metabolic function in different tissues and contributes to dose-dependent changes in the main 
AT biological pathways (268). Very-low calories diets (VLCD) are the most intensive dietary 
intervention in obesity management, with the replacement of usual dietary intake with 
nutritionally complete commercial products, providing a total of 450-800 Kcal (1855-3297 kJ) 
per day (271). Although this may result in a weight loss of approximately 10-15% over 3 
months, a substantial weight regain is envisaged, particularly in the absence of a maintenance 
program (272). Several studies have examined the effects of dietary interventions on cardio-
metabolic risks (e.g. reviewed in (274-276)) in obese individuals. However, this is out of the 
scope of this thesis. The hierarchical approach to the treatment of obesity does not only 
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emphasise the importance of sustained dietary interventions but also importantly address energy 
expenditure by increasing PA as a central aspect in obesity management. 
1.5.2. Physical activity and exercise training in the management of obesity and insulin 
resistance 
Physical inactivity is one of the 10 leading risk factors for mortality worldwide and a 
major contributor to the rising prevalence of obesity, although other factors such as excess 
energy intake, genetic predisposition and environmental factors are also involved (1). Physical 
inactivity and low cardiorespiratory fitness have been suggested to be higher risks factor than 
obesity itself in the development of NCDs (277). The global prevalence of physical inactivity 
is about 23% in adults, with women being less active (27%) than men (20%) (1). Among 
populations of African ancestry, particularly in women, the lack of PA is a leading cause of the 
rapid increase in obesity rates (278). Therefore, PA is one of the prevailing strategies against 
the progression of obesity. In SA, approximately 40% of men and more than 50% of women 
are considered insufficiently physically active based on WHO guidelines (1). However, these 
guidelines are questionable in developing countries, where most women meet the guidelines 
but have very poor cardiorespiratory fitness, are obese and at high risk of metabolic syndrome 
(279). Low cardiorespiratory fitness is a risk factor for all-cause mortality (280).  
PA is defined as “any bodily movement produced by skeletal muscles that require energy 
expenditure” (1). Regular PA is a key determinant of energy expenditure and is fundamental 
for energy balance and weight control during excess calories supply (278), influencing body 
composition and substrate oxidation and metabolism (281). Interestingly, the use of PA in the 
prevention or treatment of obesity is not only adequate for adults but is also beneficial for 
children. Accordingly, an inverse association between PA levels and fat mass has been reported 
in SA children (281). PA may, therefore, benefit from early-life which is a critical period for 
both the prevention and the elimination of cardio-metabolic risk factors (282).  
Moderate aerobic PA with at least 30 minutes brisk walking five times a week (≥150 
minutes/week) has been shown to achieve an energy deficit and reduce T2D risk (273). 
Furthermore, higher levels of activity (200-300 minutes/week) are recommended over the long 
term in order to prevent weight regain (273). Strength and resistance exercise training involving 
major muscle groups 2–3 times per week may prevent chronic disease, extend healthy lifespan 
in adults, and improve metabolism by stimulating muscle mass development (270, 283). It is 
proposed that 1-2 sets of 8 to 12 repetitions per set, with an intensity greater than 80% of 1-
repetition maximum (1RM; the maximum load that can be lifted once only throughout a 
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complete range of motion), with 8 to 10 exercises per session and 2-3 sessions per week, are 
optimal for maximising the beneficial health effects of increased strength and muscle mass 
(284, 285).  
Exercise training is a principal component of PA and has been shown to exert positive 
effects on several organs and tissues by the accumulative response from each training bouts 
(286). Aerobic and resistance exercise training increases cardiorespiratory fitness, and reduce 
fasting blood glucose, Hb1Ac and increase insulin sensitivity in obese individuals (287-289). 
Indeed, the exercise-induced improvements in whole-body glucose metabolism and insulin 
sensitivity have been well established to be exerted via its predominant action on skeletal 
muscle (290-292). However, long-term exercise training may also induce beneficial changes in 
metabolic status, such as improvement of systemic glucose homeostasis, via modifications in 
AT metabolism and function, above and beyond the exercise-induced reduction in fat mass 
(292, 293). Indeed, it has been extensively shown that exercise training from as little as 8 weeks 
up to 9 months is effective in improving body composition by decreasing of body weight, WC, 
BMI and body fat mass in obese women of different ethnicities (283, 294-299). Besides, 
reductions in abdominal and visceral fat percentages were observed in obese women after 12 
weeks of moderate-intensity combined aerobic and resistance training, and these changes were 
greater than those observed in response to resistance or aerobic training alone (295, 299). 
Although aerobic and resistance exercises interact to have a greater effect than either type alone, 
the mechanisms involved are unclear and further investigations are necessary. Nevertheless, 
executed alone or in combination, these types of exercise training result in increased maximum 
oxygen uptake (VO2max) (299, 300). Improved cardiorespiratory fitness has been associated 
with decreased risk of disease and death (299). Furthermore, obese individuals with higher 
levels of cardiorespiratory fitness have reduced mortality rates compared to their sedentary 
normal-weight counterparts (300). Interventions targeting the improvement of cardiorespiratory 
fitness are therefore of high relevance, especially in the context of black SA women in which 
low cardiorespiratory fitness has been identified as a significant determinant of IR (301).  
Exercise training-related reductions in SAT mass have also been shown to be higher in 
combined (aerobic and resistance) exercise training than in aerobic training alone in obese 
women of different ethnicities (287-289, 302). Although exercise-induced weight loss is 
relatively lower than the other methods of weight reduction, as little as 3% sustained 
bodyweight loss may result in improvements in glycemic control, lipid profile, blood pressure, 
IR and risk of T2D (267, 273). This highlights the role of AT changes in the improvement of 
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metabolic health in obese individuals. Indeed, exercise training modulates lipids metabolism by 
stimulating AT lipolysis and decreasing lipogenesis. This results in FFA release into the 
circulation and their oxidation in muscle or utilisation by other tissues (303-305). The increase 
in AT lipolysis has been shown in humans and animal models by increasing ATGL, as well as 
HSL and MGL activities (303, 304). Exercise-induced AT lipolysis has been proposed to be 
regulated by epinephrine, signalling PKA activation via cAMP, followed by the 
phosphorylation of PLIN1 and activation of ATGL to initiate lipolysis (306). Moreover, upon 
PLIN1phosphorylation HSL translocates to the lipid droplet and degrades DAG to MAG with 
the subsequent production of FA and glycerol by MGL (306). Therefore, exercise training may 
stimulate lipolytic activity within AT, contributing to the more efficient reduction of AT mass 
and/or prevent accumulation thereof. In contrast, prolonged exercise training may reduce 
lipogenesis by decreasing the activity of LPL and FA uptake (305). The changes in adipocyte 
metabolism in response to exercise training are therefore associated with modifications of FA 
metabolism and composition in AT (305). Indeed, the reduction of FA uptake results in the 
improvement of mitochondrial function, upregulation of enzymes involved in the metabolism 
of PUFA such as FADS1 and elongase 5 (138, 305, 307), and may consequently alter circulating 
FA composition (138, 225, 308). Moreover, exercise training has been shown to decrease AT 
synthesis of MUFA (especially 18:1) by decreasing FA desaturase SCD1 activity (138). 
Although these findings demonstrated that exercise training induces changes in the expression 
of enzymes involved in lipid metabolism, data on the exercise-induced changes in the activity 
of other lipogenic enzymes are inconclusive (305). Additionally, studies investigating the 
effects of exercise training on FA composition in human AT and circulating FA profiles are 
limited, especially in African populations.  
Another notable effect of exercise training on AT mass is the reduction of adipocytes size 
(298). Hypertrophy of adipocytes is known to influence adipokines expression in the obese state 
(309). Therefore, the effect of exercise training on dysregulated expression of adipokines and 
AT inflammation has been suggested to largely depend on a decrease in adipocyte size (298). 
The resultant decreased expression of pro-inflammatory cytokines from the AT contributes to 
the attenuation of systemic inflammation (310). Indeed, exercise training (aerobic, resistance 
and combined types) has been extensively shown to mitigate inflammation in human and animal 
models, with or without a significant change in body composition (reviewed in (298)). For 
instance, exercise training has been shown to reduce circulating levels of CRP, leptin, TNFα, 
IL-6, IFN-γ (311-314); and increase adiponectin levels in circulation and in AT of obese 
humans (reviewed in (298)). The upregulation of adiponectin expression in AT was associated 
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with downregulation of TNF-α gene expression (298, 315). Recent studies in rats also showed 
decreased expression and circulating concentrations of adipocytokines such as apelin and 
resistin in response to exercise training, resulting in improvements in IR (305). Altogether, these 
findings suggest that long-term exercise training may improve the profile of adipokines released 
from the AT, systemic inflammation and thus, may be beneficial for health. However, data on 
the improvement of the pro-inflammatory state in AT remain conflicting (305, 315). For 
example, a study in obese women showed no effect of 12 weeks of exercise training on SAT 
adiponectin expression (316), and the expression of IL-6 in the AT did not change in another 
study after 3 months of dynamic strength training in obese men (317). These disparities could 
be due to the differences in experimental design, participants, exercise intensity, or exercise 
duration (298). Therefore, the effects of exercise training on AT function may vary depending 
on the participants, highlighting the importance of selecting the adequate exercise type/intensity 
for each population. Studies of the effects of exercise training on obese individuals in African 
regions are rare and more investigations in this population are needed.  
Exercise training has also been reported to improve oxidative stress in obese individuals, 
characterised by the reduction of urinary markers of oxidative stress (e.g. 8-hydroxy-2-
deoxyguanosine and 8-isoprostanes) (318) and the reduction of circulating ROS (294). Besides, 
the reduction of oxidative stress in AT has been described as one of the unique effects of 
exercise training in addition to fat mass reduction (315). Given that oxidative stress is closely 
related to the dysregulation of adipocytokines expression in AT, reducing AT oxidative stress 
may be essential in the prevention of obesity and related metabolic conditions. In animal 
models, a decrease in lipid peroxidation in AT was shown concomitantly with a reduction of 
TNFα and MPC1 after exercise training (315, 319). Also, the phosphorylation of ERK, which 
is activated by oxidative stress and is involved in the expression of MCP1, is diminished after 
exercise training (319). The improvement of AT oxidative stress has been proposed to be 
exerted by the antioxidative effect of long-term exercise training (315). Indeed, SOD and 
catalase (content, expression and activity) increased in AT of mice and rats after exercise 
training, at the expense of NADPH oxidase and MCP1 (315, 319). Notably, this evidence 
derives from animal studies, and further research to confirm these changes in obese humans is 
warranted. Yet, the reduction of AT oxidative stress is a proposed pathway in the exercise-
incused improvement of inflammation (319). Altogether, these different effects of exercise 
training on AT function might contribute to the reported exercise-induced improvement of 
whole-body insulin sensitivity (320). 
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It is important to note that exercise-induced metabolic effects are dependent upon many 
factors including the model or type of exercise (e.g. cycling, jogging, swimming), the intensity 
(percentage of VO2max), and the duration (total time exercising at a given percentage of VO2max) 
of the exercise training program (171). The characteristics of the individuals involved (e.g. 
fitness or training levels, gender, and clinical disease status) constitute another major 
determinant of the response to exercise training (171). The effect of exercise training therefore 
differs between ethnicities (278). In addition to higher disease risk, African women have lower 
rates of exercise training and structured leisure time PA compared to women from European 
ancestry (278, 321). Moreover, resting energy expenditure and fat oxidation and VO2max are 
lower in women of African ancestry than European women (278). These differences may partly 
explain the higher risk of metabolic diseases in the former, as aerobic fitness is inversely 
associated with AT accumulation and body fatness (322, 323).  
The South African National Health and Nutrition Examination Survey (SANHANES) 
data from 2013 show that 66% of males and only 38% of females (18 to 24 years old) were 
considered fit (11). SA women have a very poor cardiorespiratory fitness (301) and high 
prevalence of obesity and metabolic syndrome despite meeting the PA guidelines from the 
WHO (279). Indeed, meeting these guidelines is not associated with reduced obesity or body 
fat, or improved cardio-metabolic outcomes in these women (279). This could be explained by 
the low intensity of PA in black SA women, who mostly participate in light-intensity PA 
(mainly by walking for transport), with almost no vigorous/high-intensity PA (301, 324). Low 
cardiorespiratory fitness has been associated with greater adiposity (325), higher VAT and with 
lower insulin sensitivity, independent of fat mass and PA in a cohort of young black SA women 
(301). Another study showed that increase cardiorespiratory fitness over 1 year was associated 
with reduced levels of fasting plasma glucose and fasting serum insulin at follow-up (326). Low 
cardiorespiratory fitness levels strongly predict the incidence cardio-metabolic syndrome, 
independent of BMI (327). 
Moreover, the rate of sedentary behaviour is very high in young black SA women with 
up to 8-9h of sedentary time per day (>50% waking hours) (324). Further, sedentary behaviour 
inversely correlated with cardiorespiratory fitness (301). Indeed, independent of PA, the greater 
the amount of time spent in sedentary behaviours, the higher the BMI and greater the risk of 
cardio-metabolic disease (328, 329). High levels of sedentary behaviour and low fitness may 
therefore result in excess adiposity and increased BMI, which in turn further increases sedentary 
time (324). This high sedentary time and low amounts of vigorous-intensity activity, in 
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combination with a high prevalence of overweight and obesity; and the relationships with 
fitness levels have been proposed as the principal factors responsible for the high risk of cardio-
metabolic diseases in young black SA women (324). Therefore, it is essential to promote 
increased moderate-to-high intensity PA and exercise training programs among this population, 
to reduce obesity-associated metabolic risk. Such interventions may allow improvements in 
cardiorespiratory fitness, and therefore have positive health benefits by maintaining favourable 
adiposity levels and reducing VAT (279). However, few to no studies have investigated the 
effects of a structured exercise training program on obesity-associated metabolic risks in 
women from Southern Africa. The implementation of these programs is necessary and essential 
to reduce this high metabolic risk among SA women. 
1.6. SUMMARY AND RATIONALE FOR THE THESIS 
Modernisation and urbanisation have led to environmental and lifestyle changes, 
contributing to increasing obesity prevalence within SA over the past 20 years, particularly in 
populations of African ancestry, with higher prevalence among women compared to men (1, 
4). The high and rising prevalence of obesity in black SA women is associated with increased 
risks for T2D and other NCDs (1, 4, 9). Black SA women present with greater IR than their 
white counterparts for the same level of adiposity, underlying ethnic-specific associations 
between obesity and cardio-metabolic risks in populations living in the same country, but 
compounded with a high difference in SES (24, 27). Furthermore, body fat distribution is more 
important than total body adiposity in the development of obesity-associated complications. In 
this regards, central fat accumulation (VAT and aSAT) is associated with increased risk of 
metabolic diseases, whereas peripheral fat, especially distributed in gSAT is beneficial, exerting 
a protective role against the development of obesity-associated disorders (28, 29, 35, 36). 
Strikingly, black and white SA women also differ in body fat distribution patterns, which could 
explain their distinct cardio-metabolic risks. Unexpectedly, black SA women are at higher risk 
for metabolic diseases although they have less VAT and more gSAT than white SA women. 
Adipose depot-specific associations with IR and T2D risks therefore vary with ethnicity. In 
obese black SA women, specific changes in SAT function during progressive fat accumulation 
are proposed to explain the positive associations between this fat depot and impairment of 
insulin sensitivity (36, 37). However, the specific pathways driving these associations between 
SAT function and increased metabolic risk in black SA women are not know and need to be 
investigated. This will enable early identification of the risks and progression of these metabolic 
conditions in young women of African ancestry.  
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The increased body fat mass characterizing obese state negatively affects whole-body 
metabolism. These metabolic effects of fat accumulation vary with AT location independently 
of the size of the depot and are exerted partly via increased FFA release and the production of 
adipocytokines (132, 134). According to AT expandability hypothesis, the pathological 
expansion of AT is characterised by adipocyte hypertrophy, resulting from impairment of 
adipogenesis, followed by the reduction/insufficient angiogenesis to compensate for the AT 
expansion, hypoxia, macrophage infiltration and activation, and inflammation (134). Moreover, 
adipogenic and lipogenic capacities are further down-regulated by mechanisms mediated by 
higher levels of inflammation (148). This originates a vicious circle between inflammation and 
lipolysis, ultimately leading to ectopic fat deposition, systemic low-grade inflammation and 
peripheral IR (134, 139, 155, 157-159). A small study in SA has shown decreased adipogenic 
genes and higher expression of genes involved in hypoxia and inflammation in gSAT of black 
SA women (213, 214), suggesting that SAT function might be impaired in these women. Higher 
hypoxia may equally increase the levels of oxidative stress (36, 134). Indeed, not only high 
rates of lipolysis but also oxidative stress in obese AT is associated with the increased release 
and circulating concentrations of FFAs, contributing to impairment of insulin sensitivity in 
Africans (183). However, the association between oxidative stress in AT and IR has not been 
extensively studied in black SA women. FFA concentrations are also dependent on dietary fat 
intake which differs between ethnicities, with high intake of SFA and n-6 PUFAs in black 
women (32, 263). Concomitantly, high conversion rates of DGLA to AA have been shown in 
African, proposed to be mediated by genetic factors (265, 266). Therefore, FA metabolism and 
composition in AT and in the circulation is another potential pathway linking obesity to IR and 
T2D in black women. 
Obesity and its associated metabolic diseases represent a significant economic burden for 
individuals and government due to its related comorbidities and costs (1). Lifestyle 
interventions, particularly an increase in PA remains the cornerstone amongst the management 
strategies for obesity and its associated cardio-metabolic risks (278, 281). Exercise training as 
a structured intervention method is therefore advantageous, especially in low- and middle-
income countries and low socio-economic communities, as it requires less economic resources 
(than other methods such as pharmacotherapy or bariatric surgery) and can be used in younger 
groups (children and adolescents). Moreover, this type of intervention may improve health-
related quality of life by improving physical fitness (330), which is associated with all-cause 
mortality worldwide (277, 280). Exercise training has been demonstrated to reduce IR and T2D 
risk (331-333) and prevent the progression from impaired glucose tolerance to T2D (334). 
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These beneficial effects of exercise training may be exerted via changes in the metabolism of 
AT (292, 293). Sustained exercise training is currently proposed as one of the most effective 
methods to improve body composition and correct obesity-associated IR by increasing energy 
expenditure (270). Moreover, an appropriate combination of aerobic and resistance exercise has 
been shown as most effective for obese women with a high risk of disease (283). However, 
given the low PA levels, poor cardiorespiratory fitness and high rates of overweight and obesity 
in black SA women, intervention should target to increase the intensity of PA (from light to 
moderate-high intensity) and reduce sedentary behaviour (324). In addition to increasing the 
level and intensities of PA in black SA women, structured exercise training interventions should 
most importantly focus on increasing cardiorespiratory fitness, which has been shown to reduce 
the obesity-associated risk for IR and T2D (301). Intriguingly, the effects of such interventions 
on the cardio-metabolic status of black SA women have not been investigated. Specifically, no 
studies have examined the effects of exercise training on SAT FA metabolism, oxidative stress 
and inflammation and consequently on whole-body insulin sensitivity in black SA women who 
have low cardiorespiratory fitness, high levels of obesity and a very distinctive phenotype. 
1.7. AIMS AND OBJECTIVES 
The overall aim of this thesis was to: i) investigate the relationship between depot-specific 
SAT lipid metabolism and the circulating FA profile and body composition and insulin 
sensitivity in sedentary obese black SA women; ii) examine the depot-specific changes in SAT 
metabolism and function in response to 12 weeks of supervised combined aerobic and 
resistance training; and iii) explore the relationship between these changes and improvements 
in metabolic status. This aim was achieved by completing four studies presented as separate 
chapters and described below: 
Chapter 3: Circulating and subcutaneous adipose tissue fatty acid composition in obese black 
South African women: relationship with body composition and insulin sensitivity 
Aim: Evaluate the circulating and SAT FA composition in obese black SA women and explore 
the relationships with body composition and insulin sensitivity. 
Objectives: 
1. Compare the FA composition of RBC-TPL, aSAT and gSAT, 
2. Examine the relationship between the FA composition of each depot and VAT/SAT ratio (as 
a measure of centralisation of body fat) and insulin sensitivity in these women. 
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Hypothesis: FA profile of RBC membrane may reflect the FA metabolism in  SAT depots and 
the relationship between FAs and central fat distribution and insulin sensitivity does not variate 
according to their storage site and/or the blood compartment or fraction where they occur. 
 
Chapter 4: Exercise training alters red blood cell fatty acid desaturase activity and adipose 
tissue fatty acid composition in obese black South African women 
Aim: Evaluate the effect of 12-week combined resistance and aerobic exercise training without 
dietary modification on RBC-TPL and SAT FA composition and desaturase activity in obese 
and previously sedentary black SA women, and explore the relationships with changes in 
insulin sensitivity. 
Objectives: 
1. Evaluate the changes in cardiorespiratory fitness, body composition and insulin sensitivity in 
response to exercise training. 
2. Evaluate the changes in RBC-TPL, aSAT and gSAT FA composition and desaturase 
activities in response to exercise training. 
3. Assess the changes in the expression of genes involved in adipogenesis, lipid metabolism 
and insulin signalling in aSAT and gSAT after the 12-week exercise training. 
4. Examine the association between these changes in RBC-TPL and SAT depots and changes 
in systemic inflammatory markers, liver fat and insulin sensitivity. 
Hypothesis: Twelve-weeks of supervised exercise training will alter the FA profile of RBC-
TPL, and SAT FA and lipid metabolism and these changes will contribute to the improvement 
in insulin sensitivity in obese black SA women.  
 
Chapter 5: Changes in systemic and subcutaneous adipose tissue inflammation and oxidative 
stress in response to exercise training in obese black South African women 
Aim: Assess the effects of 12-week exercise training on systemic and SAT depot-specific 
inflammatory and oxidative stress status, and explore the relationship with the exercise-induced 
improvement of insulin sensitivity in obese black SA women. 
Objectives: 
1. Compare baseline’s inflammatory and oxidative stress profiles between aSAT and gSAT. 
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2. Examine the changes in systemic oxidative stress markers in response to the 12-week 
intervention. 
3. Evaluate the effects of exercise training on SAT depot-specific gene (inflammatory and 
oxidative stress markers) and protein expression (inflammatory markers). 
4. Study the associations between the changes in systemic and SAT depot-specific 
inflammatory and oxidative stress status and changes in body composition and insulin 
sensitivity. 
Hypothesis: Abdominal SAT will have higher inflammatory and oxidative stress profiles than 
gSAT and exercise training will induce depot-specific changes in the expression of genes and 
proteins involved in these pathways. Moreover, exercise training will reduce systemic oxidative 
stress in obese black SA women, and these systemic and depot-specific changes in 
inflammation and oxidative stress will contribute to the improvement in insulin sensitivity in 
these women. 
 
Chapter 6: Distinct abdominal and gluteal adipose tissue transcriptome signatures are altered 
by exercise training in obese black South African women 
Aim: Evaluate the regional differences in gene expression profiles between aSAT and gSAT in 
obese black SA women at baseline and after the exercise training intervention. 
Objectives: 
1. Compare whole-genome profiles between aSAT and gSAT pre- and post-exercise training. 
2. Evaluate the changes in transcriptomic profiles within each depot (aSAT vs gSAT) in 
response to the 12-week exercise training program. 
3. Identify the biological pathways represented by the differentially expressed genes between 
and within SAT depots. 
Hypothesis: SAT depots have different developmental origins, and therefore possess distinct 
transcriptome signatures, driving their distinctive functional responses to external stimuli such 










2.1. Ethical Approval 
Approval was obtained from the Human Research Ethics Committee of the Faculty of 
Health Sciences at the University of Cape Town (HREC REF: 827/2016) and registered to the 
Pan African Clinical Trial Registry (trial registration: PACTR201711002789113). The study 
was performed following the principles of the Declaration of Helsinki (1964, amended last in 
Fortaleza Brazil, 2013), ICH Good Clinical Practice (GCP), and the laws of South Africa. All 
participants provided verbal and written informed consent before their involvement in any 
aspect of the study. 
2.2. Participants and Study design  
Participants were recruited from universities, churches and community groups in Cape 
Town, SA. Participants were included in the study if they were i) of isiXhosa ancestry (both 
parents); ii) weight stable (i.e. <5% change from maximum weight for the last 6 months); iii) 
sedentary (i.e. not participating in exercise training (>1 session of >20 min per week) within 
the last 12 months); iv) not having known metabolic or inflammatory diseases (e.g. HIV, 
tuberculosis, active hepatitis, or rheumatoid arthritis); v) not taking any medications; vi) non-
smoker; vii) not pregnant or lactating; viii) on injectable contraception (depot 
medroxyprogesterone acetate, 400 mg); ix) no orthopedic or medical problems that may prevent 
the participation in exercise training program; x) no surgical procedures within the last 6 
months.  
Before their inclusion in the study, the volunteers completed screening which included 
measurements of weight and height for the calculation of BMI, blood pressure measurements 3 
times at 1-min intervals using an automated blood pressure monitor (Omron 711, Omron Health 
Care, Hamburg, Germany). In addition, the screening procedure included the determination of 
glucose, hemoglobin, HbA1c as well as HIV screening from venous blood samples. 
Counselling was provided pre- and post-HIV test by a trained counsellor and a referral was 
made to appropriate HIV clinics for participants diagnosed HIV-positive. Moreover, 
participants completed a physical activity readiness questionnaire (PARQ) and a questionnaire 
about their PA habits, contraception method, ancestry origin, smoking status and history, 
current medication and clinical condition.  
Forty-five obese black SA women (based on the Xhosa ancestry of both parents) aged 
between 20-35 years, with a BMI of 30-40 kg/m2 were randomized into control (n=22) and 
experimental (exercise n=23) groups. Ten participants did not complete the intervention 
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(dropout: n=7 in control and n=3 in exercise group) due to time commitments or loss to follow-
up. Consequently, the final number of participants was 15 in control and 20 in the exercise 
group (Figure 2.1). Specific numbers are given in each chapter, were different to the number 
indicated in Figure 2.1. The detailed design of the study and the participants’ baseline 





Figure 2.1. Diagram representing participants’ enrolment, randomization and analysis.  
As reported in (335). 
2.3. Study Intervention 
The exercise training intervention consisted of 12 weeks of supervised combined aerobic 
and resistance training progressing from 40 to 60 min, 4 days per week by a trained facilitator. 
This training type was based on previous studies showing that combined aerobic and resistance 
training affected AT mass, glucose metabolism, insulin sensitivity and cardiorespiratory 
capacity to a greater extent than aerobic training alone (287, 288, 301). The frequency, duration 
and intensity of the exercise intervention were based on the recommendations from the British 
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Association of Sport and Exercise Sciences (BASES) (336). BASES recommends that ‘those 
with increased risk for T2D may benefit in particular from going beyond the levels of activity 
recommended for “all healthy adults”, to around 300 min or more of moderate-intensity aerobic 
activity per week, or around 150 min or more of vigorous-intensity aerobic activity per week, 
or equivalent combinations of moderate- and vigorous-intensity activity’ (336). Using 
accelerometry, it was previously shown that black women from the same community perform 
on average 31 min of moderate-intensity exercise per day, but do not perform a vigorous-
intensity activity (301). Most of the activity was performed as walking for travel with very little 
leisure time activity, and the women accumulated on average 10,459 steps per day (301). 
Therefore the exercise intervention aimed to increase moderate and vigorous-intensity exercise 
to achieve improvements in cardiorespiratory fitness. 
Aerobic exercises included dance, running, skipping, and stepping that were performed 
at a moderate-vigorous intensity (75%-80% peak heart rate, HRpeak). Resistance exercises 
consisted of participants using their body weight and progressed to the use of equipment (e.g. 
bands and light free weights). These exercises mainly included squats, lunges, bicep curls, push-
ups and shoulder press with a prescribed intensity of 60% to 70% HRpeak. Attendance was 
recorded at each training session, and a heart rate monitor (Polar A300, Kempele, Finland) was 
worn by participants to ensure the prescribed exercise intensity was maintained throughout the 
12 weeks. 
The control group was instructed to maintain their normal daily physical activity patterns, 
and not start any exercise training program which was verified through monthly monitoring 
using accelerometry (ActivPAL3c, PAL Technologies Ltd, Glasgow, UK). Accelerometry 
provides an accurate assessment of the intensity of activity. Both groups were instructed to 
maintain their usual dietary intake, which was evaluated every four weeks by a food frequency 
questionnaire, as previously described (337), to monitor any changes in dietary patterns. Before 
and after the 12-week intervention, anthropometry, body composition, liver fat content and 
cardiorespiratory fitness were measured. Blood and SAT samples were collected for the 
evaluation of insulin sensitivity and the analyses of FA composition, inflammatory and 
oxidative stress markers as well as gene and protein expression, as described below. 
2.4. Pre and post-intervention testing procedures  
2.4.1. Body composition, body fat distribution and liver fat content 
Basic measures of anthropometry included weight (in light-weight clothing without 
shoes), height, waist circumference (WC; at the level of umbilicus) and hip circumference (HC; 
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largest gluteal area). The whole-body composition was measured by dual-energy x-ray 
absorptiometry (DXA; Discovery-W, software version 12.7.3.7; Hologic, Bedford, MA) 
according to standard procedures. Regional body fat distribution (gynoid and android fat mass, 
VAT and SAT) was characterized as previously described (338, 339). The DXA measure of 
VAT has been shown to perform as well as a clinical read of VAT from a computerized 
tomography scan (340). 
After a standardized meal (Energy: 2553 kJ), magnetic resonance imaging (MRI) was 
used to determine VAT and SAT volumes and liver fat content using a 3 Tesla whole-body 
human MRI scanner (MAGNETOM Skyra, Siemens Medical Solutions, Erlangen, Germany). 
A MATLAB algorithm separated the water and fat signals to create a fat fraction map calculated 
as the fat signal over the sum of the water and fat signals. A region of interest (ROI) was drawn 
on 7 consecutive slices in the right lobe of the liver using the following software OsiriX 
software (Pixmeo SARL, Geneva, Switzerland). Methods were adapted from (341). 
2.4.2. Cardiorespiratory Fitness 
Cardiorespiratory fitness was determined by measuring peak oxygen consumption 
(VO2peak) using a walking treadmill-based (C, Quasar LE500CE, HP Cosmos, Nussdorf-
Traunstein, Germany) graded exercise test with an increasing gradient (2% every minute until 
16%), followed by alternate increased speed (0.5 km/h) and gradient (1%) until volitional 
exhaustion. Walking was chosen because the participants of the study were not accustomed to 
cycling or treadmill running exercise. Pulmonary gas exchange was measured to calculate 
VO2peak using a metabolic gas analysis system (CPET, Cosmed, Rome Italy). 
2.4.3. Fasting blood samples and frequently sampled intravenous glucose tolerance 
Before and following the 12-week intervention, blood samples were collected after an 
overnight fast (10-12 h) and at least 72 h after the last exercise training session for subsequent 
biochemical analysis. Participants stayed overnight at the laboratory and were given a 
standardized evening meal at 8 PM and then fasted overnight. The standardized meal contained 
2,456 kJ energy (E), 21 g protein (14% E), 49 g carbohydrate (33% E), and 32 g fat (48% E). 
At 7 AM, fasting blood samples were collected for the determination of adipocytokines, 
inflammatory and oxidative stress markers, and RBC-TPL FA composition. 
After fasting blood collection, participants underwent a frequently sampled intravenous 
glucose tolerance test (FSIGT) to measure insulin sensitivity (SI) calculated using Bergman’s 
minimal model of glucose kinetics (335, 342). Baseline blood samples were collected (at -5 and 
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-1 min) prior to intravenous administration of glucose (50% dextrose; 11.4 g/m2 body surface 
area) over 60 seconds. After 20 min, human insulin (0.02 U/kg; NovoRapid, Novo Nordisk) 
was infused over 5 min (HK400 Hawkmed Syringe Pump, Shenzhen Hawk Medical Instrument 
Co., Shenzhen, China) and samples were subsequently collected for the determination of 
plasma glucose and serum insulin concentrations (serial blood collection at 2, 3, 4, 5, 6, 8, 10, 
12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 
220, and 240 min) (335). Fasting IR was estimated using the homeostasis model assessment of 
IR (HOMA-IR) (343).  
Although the gold standard measurement of insulin sensitivity is the euglycemic 
hyperinsulinemic clamp, insulin secretion cannot be directly evaluated from this technique 
(344). The FSIGT method was chosen for this study as it provides a measure of both insulin 
sensitivity and secretion. Black SA women hyper-secrete insulin and it is not clear whether this 
is a cause or a consequence of insulin resistance. FSIGT allows the measurement of glucose, 
insulin and more often also C-peptide during the highly dynamic phase that immediately 
follows the glucose injection. Therefore, this technique quantifies the ability of insulin to 
enhance glucose uptake by insulin-dependent tissues and to inhibit liver glucose production 
(344). 
2.4.4. Diet intake monitoring  
Participants completed a self-reported 7-day food frequency questionnaire (FFQ) before 
and after the exercise training program for the estimation of their dietary intake. No dietary 
recommendations were given to the participants and they were instructed to maintain their 
habitual dietary intake. Energy and macronutrient intake were analyzed as previously described 
(337).  
2.4.5. Biochemical analyses 
Plasma glucose concentrations were determined using a colorimetric assay (Randox, 
Gauteng, South Africa) and serum insulin and high-sensitivity C-reactive protein (CRP) were 
measured using immunochemiluminometric assays (IMMULITE 1000 immunoassay system, 
Siemens Healthcare, Midrand, South Africa). Inflammatory cytokines (IL-6, IL1-Rα, IL-8, IL-
10, IL-15, MCP-1, IFNγ, TNFα were measured using Milliplex MAP MAG Human Cytokine 
kit (Merck, Johannesburg, South Africa) and xMAP technology (Luminex, Austin, Texas) 
according to the manufacturer’s instruction. The serum concentration of IL-1Rα, IL-6, IL-10 
and IL-15 were below the detectable range and were excluded from the analysis. This resulted 
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from purely technical reason due to the low sensitivity of the Milliplex kit available from the 
manufacturer at the time of the study. Serum concentrations of leptin and high molecular weight 
(HMW) adiponectin were analysed using commercially available ELISA kits according to the 
manufacturer’s instructions (EMD Millipore Corporation, St Charles, Missouri, USA). 
Systemic oxidative stress was evaluated in the serum by measuring concentrations of TBARS, 
the total antioxidant capacity of serum samples (oxygen radical capacity absorbance; ORAC), 
SOD and CAT activities via enzymatic assays (345) using a microplate data acquisition 
program (Synergy HT, Gen5 2.01; Biotek Instruments, Inc; Vermont, USA) (see detailed 
protocol in appendix). 
2.4.6. Adipose Tissue Gene and Protein Expressions 
Adipose Tissue collection 
Participants underwent fat biopsies for SAT sample collection after 4-6 h of fasting and 
at least 72 h after the last exercise training session for the subsequent determination of fatty 
acid composition, gene and protein expression.  
Abdominal samples were collected from the area around the umbilicus and gluteal 
samples were obtained from the right upper outer quadrant by mini-liposuction (213). After 
local anaesthesia with Lignocaine hydrochloride (2%, Intramed, Port Elizabeth, South Africa), 
200 mL of normal saline with 20 mL 2% Lignocaine was infused using an infiltration cannula 
(Lamis 14 ga x 15 cm, Byron Medical Inc., Tucson, AZ, USA). An aspiration cannula 
(Coleman, 12 ga x 15 cm, Byron Medical Inc.) attached to a 10 mL syringe was used to aspirate 
fat. Approximately 2 - 3 cm3 of fat was extracted from each site, washed with normal saline 
until no blood was visible, immediately frozen in liquid nitrogen (N2) and stored at −80°C until 
further analyses. 
Determination of RBC-TPL and adipose tissue fatty acid composition 
RBC-TPL FA composition in gluteal and abdominal SAT samples was evaluated using 
pairwise analyses that ensured samples of a participant were analyzed in the same batch on the 
same day. Aliquots (300 µL) of saline (0.9% NaCl in distilled water) washed RBCs and 100 
mg portions of saline washed adipose tissue (335) were subjected to total lipid extraction with 
chloroform (amylene stabilised):methanol (2:1; vol:vol; containing 0.01% butylated 
hydroxytoluene) by using a modification of the method of Folch et al (346, 347). Thin-layer 
chromatography (TLC) was applied to isolate the TPL fraction in the RBC total lipid extract 
(347). The TLC-isolated RBC-TPL fractions and a small aliquot of the AT total lipid extracts 
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were trans-methylated using methanol:sulphuric acid (95:5; vol:vol) at 70 °C for 2 h to yield 
fatty acid methyl esters (FAMEs) which, after cooling, were extracted with water and n-hexane. 
The organic layer containing the FAMEs was evaporated, redissolved in a small volume of n-
hexane and analysed by gas-liquid chromatography on a Finnigan Focus Gas Chromatograph 
equipped with flame ionisation detector (Thermo Electron Corporation, Austin, TX, USA) and 
a 30m capillary column of 0.32 mm internal diameter; BPX70 0.25 µm (SGE International Pty 
Ltd, Victoria, Australia) as described (347). The sample FAMEs were identified by comparison 
of the retention times with those of a standard FAME mixture (27 FAMEs; Nu-Chek Prep Inc., 
MN, USA). The relative percentage of a FAME was calculated by taking the area under the 
curve (AUC) of a given FAME as a percentage of the total area count of all the FAMEs 
identified in the sample (%, wt:wt). The mixed standard contained saturated (12:0, 14:0, 16:0, 
17:0, 18:0, 20:0, 22:0, 24:0) mono-unsaturated (16:1n-7, 18:1n-7, 18:1n-9, 20:1n-9, 22:1n-9, 
24:1n-9) and poly-unsaturated (18:2n-6, 18:3n-6, 20:2n-6, 20:3n-6, 20:4n-6, 22:2n-6, 22:4n-6, 
22:5n-6, 18:3n-3, 20:3n-3, 20:5n-3, 22:5n-3, 22:6n-3) FAMEs. Product-to-precursor FA ratios 
of the samples were used as a proxy to reflect enzyme activity: 18:3n-6/18:2n-6 (GLA/LA) and 
20:4n-6/20:3n-6 (AA/DGLA) ratios were used to estimate D6D and D5D activities, 
respectively (348, 349). SCD1 activity was estimated by the ratios of 16:1n-7/16:0 (for SCD1-
16) and 18:1n-9/18:0 (for SCD1-18) (350). 
 
RNA extraction and Real-Time PCR 
 Total RNA was extracted from SAT samples using RNeasy Mini lipid kit (Qiagen Ltd, 
Germantown, MD, USA). The yield and purity were determined spectrophotometrically using 
a microplate data acquisition program (Synergy HT, Gen5 2.01; Biotek Instruments, Inc; 
Vermont, USA) and the RNA integrity was checked using 1% agarose gel electrophoresis. The 
extracted RNA (1.2 µg) was reverse transcribed to cDNA using High-Capacity cDNA Reverse 
Transcription Kit with RNase inhibitors (Applied Biosystems Foster City, CA, USA). Real-
Time PCR (RT-PCR) was performed in triplicate for each sample using Applied Biosystems 
QuantStudioTM3 Real-Time PCR system with predesigned Taqman assays from Applied 
Biosystems (Warrington, UK). A standard curve was constructed for each primer-probe set 
using a serial dilution of cDNA pooled from all samples. The evaluated genes were selected 
based on the physiological pathways involved in adipogenesis (PPARγ), lipid metabolism (LPL, 
DGAT2, PLIN1, ATGL), insulin signalling (IRS1, GLUT4, serine/threonine-protein kinase; 
SMG1), inflammation (adiponectin, leptin, MIF, MCP1, IL-10, TLR4, NFκB1 and TNFα) and 
oxidative stress (nitric oxide synthase 3 (NOS3), CAT, SOD1). The amplification plots showing 
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the level of expression of each gene (with cycle threshold (Ct) values) are presented in the 
appendix section.  These genes were specifically chosen because of their extensive documented 
association with alteration of AT function and IR during obesity and were therefore quantified 
in both aSAT and gSAT (TaqMan gene IDs in Supplementary Table 2.1).  
Endogenous (“housekeeping”) genes were evaluated by comparing ribosomal protein 
lateral stalk subunit PO (RPLPo) and low-density lipoprotein receptor-related protein 10 
(LRP10) against the full study cohort using the NormFinder algorithm (v0.953, Denmark). 
RPLPo was identified as the most stable gene and its mRNA level did not differ within and 
between aSAT and gSAT, and pre- vs post-training. The expression levels of the target genes 
were therefore normalized to RPLPo as the endogenous control and presented as the ratio of 
abundance of the gene of interest: abundance of RPLPo.  
Protein extraction and western blot analysis 
The evaluation of protein expression was determined in both SAT depots on a sub-sample 
of participants (n=10). Within the exercise group, five participants with the greatest 
responsiveness to the exercise training, based on a slightly decreased BMI, and increased 
VO2peak and SI were selected. In contrast, five participants with slightly increased BMI over the 
intervention period were selected in the control group. SAT samples (100 mg) were 
homogenized in 200 µl RIPA buffer with protease inhibitor cocktail 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride (Roche Diagnostic GmbH, Germany) and centrifuged 
at 9500 g, 4°C for 15 min. The protein concentration was determined in the supernatant using 
a Bradford protein assay kit. The lysate (20 µg of total protein per lane) was separated using 
precast gels (4-15%, Mini-PROTEAN®TGXTM, BIORAD, USA) and transferred to a 
polyvinylidene fluoride membrane (Millipore) for semi-dry transfer blotting (Biometra 
FastblotTM, Germany). The expression of adiponectin (AF1065, R&D Systems), leptin 
(Ab16227, abcam), IL-10 (PA1354, Booster Biological), TNFα (TNF706+p/T2, enquire 
Bioreagents), MIF (AF-289-PB, R&D Systems), MCP1 (MA5-17040, ThermoFisher 
scientific), TLR4 (76B357.1, ThermoFisher scientific), and NFkBp65 (#8242, Cell Signaling, 
most abundant protein and transcriptional activators of NFkB1 signalling pathway) were 
measured and normalized to beta-actin (A5060, Sigma). The expression of beta-actin was not 
different between depots and was not affected by the exercise training. These proteins were 
selected to correspond to the evaluated inflammatory genes described above. Integrated optical 
densities of the immune-reactive protein bands were measured and quantified using G: Box 
Chemi-XX9 GeneSys® version 1.6.4.0 and GeneTool® version 4.3.9.0, respectively. The 
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images were captured within the linear range and signal exposure was automatically corrected 
to ensure appropriate analysis and quantification of the generated data. The background was 
equally subtracted from the bands before normalization and plotting. 
Array data extraction and analysis  
Another set of purified RNA samples (from aSAT and gSAT) were analyzed before and 
after exercise training using Illumina Expression BeadChip (Epicentre Biotechnologies, 
Madison, WI, USA) on a total number of 12 participants. These participants’ samples were 
selected and included in this analysis, based on their greatest response, in terms of improvement 
of body composition after the exercise training intervention. Although the weight loss was not 
the main outcome of this study, these participants were specifically selected to maximize the 
responses within SAT depots to exercise training. One array per tissue sample, for each SAT 
depot and for each time point (i.e. 4 arrays per participant x 12 participants) was used for the 
gene expression profiling (total of 24 arrays for gSAT samples and 24 arrays for aSAT 
samples). Each total RNA aliquot of 250 ng was ethanol precipitated with GlycoBlue 
(Invitrogen) as the carrier and dissolved at a concentration of 100-150 ng/µl before probe 
synthesis using the TargetAmp™- Nano Labeling Kit for Illumina Expression BeadChip. 750 
ng of cRNA were hybridized to Human HT-12 v4 Expression BeadChips (Illumina, San Diego, 
CA, USA) and scanned on the Illumina iScan instrument according to the manufacturer’s 
specifications. Raw expression intensities of 47,323 probes were extracted using Illumina 
GenomeStudio (Version 1.9.0) and the normalization, background correction and analysis were 
executed using R statistic software (version 3.6.1). 
2.4.7. Statistical analyses 
All data were expressed as mean ± standard deviation (SD) or median interquartile range 
(25th-75th percentile) depending on the normality of quantitative variables. Normality was tested 
using Shapiro-Wilks test and skewed data were transformed before analysis. The data were 
transformed if p values from the normality test were lower than 0.05 and transformations were 
performed after checking the best-normalized option, which was mostly log-transformation. 
The equality of variance of the groups was checked using Levene’s test and there was 
homogeneity of variances. Subsequently, the following statistical analyses specific to each 
chapter were performed:  
 
Chapter 3: Circulating and subcutaneous adipose tissue fatty acid composition in obese black 
South African women: relationship with body composition and insulin sensitivity 
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The comparison of FA composition between RBC, aSAT and gSAT was performed using 
a one-way repeated measures ANOVA. The relationship between the FA profiles in each tissue 
type and VAT/SAT ratio and SI were explored using multivariate analysis. Firstly, the data set 
was inspected by a principal component analysis (PCA) to detect groupings, trends and outliers. 
Secondly, the associations between tissue-specific FA profiles and VAT/SAT ratio and SI were 
explored using orthogonal partial least squares of analyses (OPLS). All models were validated 
based on ANOVA of the cross-validated OPLS scores (CV-ANOVA) for significance testing 
(351).  All OPLS-analyses were performed using SIMCA v.16. Metabolites were considered 
significant when fulfilling the statistical significance criteria using post-hoc linear regression 
on loadings calculated from the validated OPLS-models on a 95% confidence level (352). 
 
Chapter 4: Exercise training alters red blood cells fatty acid desaturase activity and adipose 
tissue fatty acid composition in obese black South African women 
Changes in cardiorespiratory fitness, body composition, insulin sensitivity (including 
fasting insulin, fasting glucose and HOMA2-IR), FA composition and gene expression between 
the groups over time were analyzed using two-way ANOVA with repeated measures, followed 
by a post-hoc analysis when p<0.1 for interaction effect or p<0.05 for time or group effects. 
Pearson´s correlations were used to evaluate the associations between the changes in RBC-TPL 
and SAT FA composition and SAT gene expression, systemic inflammatory markers, liver fat 
and SI. Analyses were performed using STATA statistical software 13.1 (StataCorp, College 
Station, Texas 77845 USA) and significance levels were set at p<0.05.  
 
Chapter 5: Changes in systemic and subcutaneous adipose tissue inflammation and oxidative 
stress in response to exercise training in obese black South African women 
The difference between the groups in response to exercise training (for inflammatory and 
oxidative stress markers at systemic, gene and protein expression levels) was analyzed using a 
two-way analysis of variance (ANOVA) with repeated measures on transformed data, and post-
hoc analysis was conducted when p<0.1 for interaction effect or p<0.05 for time or group 
effects. A paired t-test was used to compare gene and protein expression between the two depots 
at baseline. Pearson´s correlations were used to evaluate the association between the changes 
in systemic and SAT inflammatory and oxidative stress markers, body composition, SI and 
HOMA-IR. Significance levels were set at p<0.05 and the analyses were performed using Stata 




Chapter 6: Distinct abdominal and gluteal adipose tissue transcriptome signatures are altered 
by exercise training in obese black South African women 
Changes in cardiorespiratory fitness and body composition in response to exercise 
training were analyzed using a paired t-test. Significance levels were set at p<0.05 and the 
analyses were performed using Stata Software version 13.1 (StataCorp, College Station, Texas 
77845 USA).  
Data quality control and differential gene expression analysis were subsequently 
performed. For these analyses, gene expression profiles of aSAT and gSAT were processed 
from the raw data obtained from Illumina GenomeStudio following the protocol of Ritchie at 
al. (353). After background correction, normalization, and log2 transformation (with neqc 
function), the probes annotated as “No match” or “Bad” were removed from the analysis. 
However, before removing, the 53 genes annotated as 'Bad" but with high average expression 
intensities (>12) were further investigated. Forty-five were repetitive Alu-elements, and the 
remaining were ribosomal proteins, EEF1A1 (eukaryotic translation elongation factor), and 
FTH1 (Ferritin heavy chain) all of which were encoded at multiple genomic loci, making further 
analysis questionable. 
The filtered expression data were then used for differential expression analysis of the 
genes across the two depots, separately for each time points. A linear model was fitted, and the 
moderated t-statistics, moderated F-statistics, and log-odds were computed for the pairwise 
contrasts by empirical Bayes from the limma package. This comprised correction for multiple 
testing (false discovery rate; FDR). Differential expression was investigated between aSAT and 
gSAT at baseline and post-training as well as comparison within each fat depot before and after 
exercise training. Genes were identified as differentially expressed when differences in the 
expression intensities were equal or higher than 33% (i.e. fold change (FC) ≤ 0.67 for 
lower/downregulated genes and FC ≥ 1.5 for higher/upregulated genes) or an absolute log2 fold 
change (|LFC|) ≥ 0.58, with a p-value ≤ 0.05.  
A Gene Set Enrichment Analysis (GSEA) was performed to determine the enriched 
biological processes and functional pathways represented by the identified differentially 
expressed genes (DEGs) using STRING (354). Afterwards, the number of expected genes in a 
random set of the same size was compared to the number of observed DEGs assigned to a 




2.5. Ethical aspects of the study  
There were no appreciable risks associated with the methods chosen for this study other 
than those associated with routine blood sampling for the measure of insulin sensitivity. In this 
test, the procedures were supervised and carried out by a medical doctor and appropriately 
trained medical personnel using sterile techniques to minimise any risks of infection. A 
maximum of 200 ml of blood was drawn during the entire study, which is less than half that 
drawn during standard blood donation.    
The methods used to measure body composition and fat distribution (DXA and MRI 
scans) were not associated with any significant or harmful risk. Although the fat biopsies were 
performed under local anaesthetic, this procedure represented a challenge for the participants 
due to the discomfort during and after the biopsies (e.g. local stinging after the anaesthetic, 
small bruising, temporary loss of feeling in the area around the biopsy site, itching). However, 
these were generally resolved after a short while and there were no adverse events reported.  
The training program was designed for exercise progression to ensure minimal physical 
discomfort and associated soreness. This was supervised by a trained biokineticist, who 
monitored each participant’s progress (using heart rate data) and adjusted the sessions 
accordingly to ensure adequate improvement in cardiorespiratory fitness throughout the 12-
week program. All efforts were made to ensure a suitable training environment, including safe 
setting up and provision of equipment, sufficient lighting, suitable temperature, suitable 
ventilation, and convenient access to toilets etc, and necessary assistance in case of need was 
provided during and after the training sessions. The participants assigned to the control group 
were offered the opportunity to undergo the same 12-week exercise training program as the 
exercise group, and participation was totally voluntary. 
The participants of this study received their individual results after completion, including 
body composition (weight, height, waist circumference and fat mass), blood pressure, risk for 
diabetes, physical fitness and dietary analysis, with some recommendations made by a dietician 
on how to adapt their dietary intake to improve their health. Additionally, the participants were 





CIRCULATING AND SUBCUTANEOUS ADIPOSE TISSUE FATTY ACID 
COMPOSITION IN OBESE BLACK SOUTH AFRICAN WOMEN: RELATIONSHIP 





During positive energy balance, adipocyte number and/or size increase to accommodate 
the accumulation of TGs into adipocytes, expanding the AT mass (102). This has been 
described as a physiological mechanism protecting other tissues against lipotoxicity (355). 
However, excess TG storage in SAT may cause the impairment of tissue metabolism and 
function (134). The impairment in SAT lipid metabolism may critically influence systemic FFA 
concentrations (356). Indeed, increased basal and/or stimulated lipolysis characterizing obese 
SAT elevates circulating concentrations of FFA, which may interfere with glucose 
transport/uptake and phosphorylation activity, contributing to the weakening of peripheral 
insulin sensitivity (250, 357). Moreover, alterations of the composition of cell membrane PHLs 
in insulin-sensitive tissues (e.g. AT, liver and muscle), as observed in obesity, may change 
membrane fluidity and consequently, impair insulin signalling pathways, resulting in IR (358). 
On the other hand, FFAs released from SAT are redirected to ectopic regions including VAT 
(134, 247). Therefore, VAT accumulation, an independent risk factor for obesity-associated 
metabolic disorders, may be influenced by SAT lipid metabolism and circulating FA profiles 
(224). 
High concentrations of FFA may not only derive from AT but also dietary fat intake. 
Plasma or serum FA composition is subject to great diet-FA-induced variations compared to 
the RBC membrane. RBCs can maintain their membrane FA composition for several weeks 
and are therefore a good biological material to study the implication of FA (both from dietary 
intake and/or AT lipid metabolism) in obesity-associated metabolic risk (250). In this regard, 
alterations RBC-TPL FA composition have been associated with IR (358). These changes in 
membrane composition could either derive from changes in dietary FA intake or changes in the 
endogenous synthesis of long-chain FA by desaturase enzymes (358). Δ9-desaturase or SCD1 
desaturates palmitic (16:0) and stearic (18:0) acids into MUFAs palmitoleic (16:1n-7) and oleic 
(18:1n-9) acids, respectively (102). Additionally, D6D and D5D together with elongases 
convert the two essential dietary FAs, ALA (18:3n-3) and LA (18:2n-6), into their 
corresponding LC-PUFA products, EPA (20:5n-3) and AA (20:4n-6) (241). Dysregulation in 
the activity of these enzymes specifically increases of SCD1 and D6D, and a reduction of D5D 
as assessed in plasma, serum (242, 349, 359), RBC (360, 361) and AT (220, 349, 362) have 
been associated with obesity and related impairment of insulin sensitivity (358). 
The mechanisms involved in the regulation of FA metabolism are specific to each tissue. 
Indeed, the rates of FA synthesis, uptake and release differ between gSAT and aSAT (47, 78, 
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79). These differences have been suggested to contribute to variations in FA composition (221, 
305) and the differential associations of gSAT and aSAT with metabolic status (79). 
Additionally, desaturase activity and FA composition vary among different ethnicities, which 
may be explained by differences in lifestyle factors such as dietary intake (261, 262). When 
compared to their white counterparts, black African women have lower SFA intake and higher 
intake of n-6 PUFA, corresponding to their serum FA composition (32, 263). Genetic factors 
may also mediate these ethnic differences. African Americans carry the genotype associated 
with higher D5D activity and are consequently more efficient in the conversion of DGLA to 
AA than their white counterparts (265, 266). Further, the susceptibility to develop metabolic 
diseases varies in different ethnicities with African descendants at higher risk than European 
descendants (261). Notably, the differences in dietary intake between these ethnicities have also 
been associated with differences in basal insulin sensitivity and secretion (262), suggesting that 
the relationship between FA and markers of IR is ethnic-specific.  Therefore, focusing on 
women of African ancestry, this study aimed to assess the FA composition of RBC-TPL, aSAT 
and gSAT, and their relationship with the centralisation of body fat (VAT/SAT ratio) and 
insulin sensitivity (SI). The hypothesis was that the FA profile of RBC membranes which is 
affected by direct exchange with plasma FFA pools may reflect FA metabolism in AT, as 
circulating FFAs are mainly derived from SAT in individuals with obesity. Therefore, the 
relationship between FA composition and central fat distribution and insulin sensitivity would 
not variate according to the storage site and/or the blood compartment or fraction where they 
occur.  
3.2. RESULTS 
3.2.1. Participant characteristics and dietary macronutrient intake 
Basic characteristics of the participants in this cross-sectional study are presented in 
Table 3.1. Self-reported daily dietary fat intake (Table 3.2) comprised 34 % of total energy 








Table 3.1. Basic characteristics of participants  
Variables Values (n=41) 
Age (year) 23 (21 - 27) 
Body composition 
 
BMI (kg/m²) 33.9 ± 2.8 
Waist circumference (cm) 103.8 ± 8.0 
Hip circumference (cm) 116 (114 – 121) 
WHR 0.9 (0.8 – 0.9) 
Body FM (%) 50.4 ± 12.0 
Android FM (%) 8.1 ± 1.1 
Gynoid FM (%) 18.6 ± 2.0 
VAT (cm
3
) 900 ± 345 
SAT (cm
3
) 5454 ± 1547 
VAT/SAT 0.2 ± 0.2 





 2.5 ± 1.4 
Fasting glucose (mmol/L) 5.3 (4.5 – 5.8) 
Fasting Insulin (µIU/mL) 13.1 (8.4 – 16.7) 
Values are expressed as mean ± SD or median (25th – 75th percentile). BMI: body mass index; FM: fat-


















Data presented as median (25th and 75th percentiles). kJ: kilojoules; CHO: carbohydrate; SFA: 







Energy (kJ) 12507 ( 9330-15374)  
Total protein (g) 96.1 (67.5-119.9) 
Protein (%E) 13.2 (12.2-14.1) 
Total CHO (g) 372.7 (295.1-464.7) 
CHO (%E) 53.1 (49.0-54.8) 
Total Fat (g) 113.0 (71.5-131.4) 
Fat (% E) 33.4 (30.1-36.5) 
SFA (g) 31.4 (18.7-42.3) 
SFA (%E) 9.5 (7.9-11.6) 
MUFA (g) 36.0 (24.1-44.6) 
MUFA (%E) 11.4 (10.1-12.5) 
PUFA (g) 25.8 (18.0-32.5) 
PUFA (%E) 7.9 (7.2-9.8) 
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3.2.2. Tissue-specific fatty acid composition  
The FA composition of RBC-TPL was 44% SFA, 16% MUFA and 40% PUFA, while 
gSAT was composed of 31% SFA, 43% MUFA and 26% PUFA and aSAT comprised 32% 
SFA, 42% MUFA and 26% PUFA (Table 3.3). Accordingly, total SFA and PUFA were higher, 
while total MUFA was lower in RBC-TPL compared to SAT depots (p<0.001). When 
comparing these FA classes between SAT depots, total SFA was higher and total MUFA was 
lower in aSAT than in gSAT (p<0.01), with no difference in total PUFA content (p>0.05).  
When comparing individual FAs in RBC-TPL and SAT depots (Table 3.3), long-chain 
SFAs (18:0, 20:0, 22:0 and 24:0) were higher and the medium-chain SFA 14:0 was lower in 
RBC-TPL than in SAT depots (p<0.001). Notably, 16:0 and 18:0 were higher in aSAT 
compared to gSAT (p<0.05). Individual MUFAs (16:1n-7, 18:1n-7, 18:1n-9, 20:1n-9) were 
lower in RBC-TPL compared to SAT depots (p<0.001), and 16:1n-7 and 18:1n-7 were higher 
in gSAT than in aSAT (p<0.01). In contrast, n-3 PUFAs EPA (20:5n-3), DPA n-3 (22:5n-3), 
DHA (22:6n-3) and total n-3 FAs were higher in RBC-TPL than in SAT depots (p<0.001), with 
no significant difference between aSAT and gSAT (p>0.05). Likewise, n-6 PUFAs DGLA 
(20:3n-6), AA (20:4n-6), adrenic acid (22:4n-6), DPA n-6 (22:5n-6) and total n-6 PUFA were 
higher in RBC-TPL than in SAT depots (p<0.001), and only DGLA was higher in gSAT 
compared to aSAT (p<0.05). Conversely, LA (18:2n-6) and eicosadienoic acid (20:2n.6) were 
lower in RBC-TPL compared to SAT depots (p<0.001) but were not different between gSAT 
and aSAT (p>0.05). The estimated activities of D5D (20:4n-6/20:3n-6), D6D (18:3n-6/18:2n-
6) and SCD1-18 (18:1n-9/18:0) were higher (p<0.001), and SCD1-16 (16:1n-7/16:0) was lower 
in RBC-TPL compared to SAT depots (p<0.001). Notably, both SCD1-16 and SCD1-18 were 




Table 3.3. Comparison of fatty acid composition (percentage) between red blood cell total 
phospholipids, gluteal and abdominal subcutaneous adipose tissue depots 
 RBC-TPL gSAT aSAT P VALUES  
Saturated fatty acids (SFAs) 
14:0 (Myristic acid) 0.24 ± 0.06 
a,b
 2.77 ± 0.62 2.89 ± 0.59
 
 <0.001 
16:0 (Palmitic acid) 21.88 ± 2.06 21.70 ± 1.12 22.52 ± 1.11 
c
 0.024 
18:0 (Stearic acid) 16.31 ± 0.78
 a,b
 5.25 ± 1.53 5.75 ± 1.49
c
 <0.001 
20:0 (Arachidic acid) 0.35 ± 0.04 
 a,b
 0.16 ± 0.06 0.16 ± 0.05 <0.001 
22:0 (Behenic acid) 1.39 ± 0.20 
a,b
 0.06 ±0.03 0.05 ± 0.01 <0.001 
24:0 (Lignoceric acid) 3.99 ± 0.64 
a,b
 0.05 ± 0.02 0.04 ± 0.01 <0.001 
Total SFAs 44.16 ± 1.68 
a,b
 30.76 ± 2.88  32.23 ± 2.46 
c
 <0.001 
Mono-unsaturated fatty acids (MUFAs) 
16:1n-7 (Palmitoleic acid) 0.24 ± 0.07 
a,b
 6.61 ± 2.09
 c
 5.93 ± 1.68
 
 <0.001 
18:1n-7 (cis-Vaccenic acid) 1.11 ± 0.22 
a,b
 3.00 ± 0.49
 c
 2.79 ± 0.43 <0.001 
18:1n-9 (Oleic acid) 10.70 ± 0.87 
a,b
 32.56 ± 0.92 32.49 ± 1.01 <0.001 
20:1n-9 (Eicosenoic acid) 0.18 ± 0.02 
a,b
 0.71 ± 0.10 0.69 ± 0.11 <0.001 
Total n-7 MUFAs 1.34 ± 0.27 
a,b
 9.61 ± 2.50 
c
 8.71 ± 2.02 <0.001 
Total n-9 MUFAs 14.23 ± 0.89 
a,b
 33.31 ± 0.94 33.22 ± 1.04 <0.001 
Total MUFAs 15.57 ± 0.97 
a,b
 42.92 ± 2.64 
c
 41.93 ± 2.25 <0.001 
Poly-unsaturated fatty acids (PUFAs) 
20:5n-3 (EPA) 0.47 ± 0.23 
a,b
 0.09 ± 0.04 0.08 ± 0.04 <0.001 
22:5n-3 (DPA n-3) 1.96 ± 0.31 
a,b
 0.27 ± 0.09 0.24 ± 0.08< <0.001 
22:6n-3 (DHA) 4.45 ± 0.81 
a,b
 0.24 ± 0.08 0.21 ± 0.08< <0.001 
18:2n-6 (LA) 11.71 ± 1.31 
a,b
 22.33 ± 1.64 22.15 ± 1.55 <0.001 
20:2n-6 (Eicosadienoic acid) 0.35 ± 0.04 
a,b
 0.50 ± 0.10 0.48 ± 0.12 <0.001 




 0.37 ± 0.12 <0.001 
20:4n-6 (AA) 15.74 ± 1.19 
a,b
 0.73 ±0.18 0.67 ± 0.17 <0.001 
22:4n-6 (Adrenic acid) 3.37 ± 0.59 
a,b
 0.30 ± 0.09 0.27± 0.09 <0.001 
22:5n-6 (DPA-n-6) 0.68 ± 0.16 
a,b
 0.08 ± 0.04 0.08 ± 0.03 <0.001 
Total n-3  6.90 ± 1.87 
a,b
 1.76 ± 0.33 1.66 ± 0.32 <0.001 
Total n-6  33.38 ± 1.87 
a,b
 24.56 ± 1.73 24.18 ± 1.64 <0.001 
Total PUFAs 40.27 ± 1.77 
a,b
 26.32 ± 1.95 25.84 ± 1.80 <0.001 
Estimated enzyme activities 
D5D  10.57 ± 1.95 
a,b
 1.79 ± 0.43 1.90 ± 0.37 <0.001 
D6D 0.13 ± 0.02 
a,b
 0.019 ± 0.01 0.016 ± 0.01 <0.001 
SCD1-16 0.01 ± 0.00 
a,b
 0.31 ± 0.11 c 0.27 ± 0.08 <0.001 
SCD1-18 0.68 ± 0.01 
a,b
 0.65 ± 0.30 
c
 0.53 ± 0.21  <0.001 
Fatty acids (FA) presented as relative percentages of total FAs (%, wt:wt) and mean ± SD (n=41). P 
values represent the differences in FA composition between the sites using one-way repeated measures 
ANOVA as follows: a: RBC vs gSAT; b: RBC vs aSAT and c: gSAT vs aSAT. LA: linoleic acid; EPA: 
eicosapentaenoic acid; DPA: docosapentaenoic acid; DHA: docosahexaenoic acid; DGLA: dihomo-
gamma-linolenic acid; AA: arachidonic acid; SFA: saturated fatty acid; MUFA: monounsaturated fatty 
acid; PUFA: polyunsaturated fatty acid; D5D: delta-5-desaturase index (20:4n-6/20:3n-6); D6D: 
delta-6-desaturase index (18:3n-6/18:2n-6); SCD1: stearoyl-CoA desaturase-1 (SCD1-16: 16:1n-




3.2.3.  Relationship between fatty acid profiles and VAT/SAT ratio 
 The relationships between site-specific FA profiles and the VAT/SAT ratio were 
evaluated using multivariate analysis (Figure 3.1). In RBC-TPL, MUFAs (16:1n-7 and 18:1n-
7, n-7 MUFA) and SCD1-16 were positively associated with the VAT/SAT ratio, while DGLA 
was negatively associated with the VAT/SAT ratio. Both SAT depots showed a similar pattern 
of association with the VAT/SAT ratio for SFA and PUFA. Indeed, lower SFAs (12:0, 14:0, 
18:0, 20:0 and total SFA) and higher PUFAs (ALA, AA, DPA n-3, total PUFA, total n-6, total 
n-3) and SCD1-18 were associated with higher VAT/SAT ratio in both SAT depots. However, 
while vaccenic acid (18:1n-7), positively associated with VAT/SAT ratio in gSAT, oleic acid 
(18:1n-9) and total n-9 MUFA in aSAT inversely correlated with the VAT/SAT ratio.  
3.2.4. Relationship between fatty acid profiles and insulin sensitivity 
The relationships between site-specific FA profiles and SI (Figure 3.2) were evaluated 
using multivariate analysis. Higher RBC-TPL total SFA and 20:2n-6, and lower 22:4n-6 were 
associated with lower SI. In gSAT, PUFAs (LA, DGLA, DPA n-3, total n-6, total PUFA), 
SCD1-18 and D6D were inversely correlated with SI, while MUFAs (16:1n-7, total n-7 and 
total MUFA) were positively associated with SI. Likewise, total MUFA in aSAT were 
positively associated with SI, while individual PUFA (LA, eicosadienoic acid, DGLA, adrenic 
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Figure 3.1. Associations between tissue-specific fatty acid composition and VAT/SAT 
ratio from multivariate models 
Data represent the individual and grouped FA and FA ratios in each tissue type which significantly 
contributing to the multivariate model (CV-ANOVA P=0.02), with a 95% confidence interval (error 
bars). T-SFA: total saturated fatty acid; T-MUFA: total monounsaturated fatty acid; T-PUFA: total 
polyunsaturated fatty acid; LA: linoleic acid; ALA: alpha-linolenic acid; SCD1: stearoyl-CoA 
desaturase-1 (SCD1-16: 16:1n-7/16:0; SCD1-18: 18:1n-9/18:0); gSAT: gluteal subcutaneous adipose 


















Figure 3.2. Associations between tissue-specific fatty acid composition and insulin 
sensitivity from multivariate models  
Data represent the individual and grouped FA and FA ratios in each tissue type which significantly 
contributing to the multivariate model (CV-ANOVA P=0.03), with a 95% confidence interval (error 
bars). T-SFA: total saturated fatty acid; T-MUFA: total monounsaturated fatty acid; T-PUFA: total 
polyunsaturated fatty acid; LA: linoleic acid; ALA: alpha-linolenic acid; D6D: delta-6-desaturase index 
(18:3n-6/18:2n-6); SCD1: stearoyl-CoA desaturase-1 (SCD1-16: 16:1n-7/16:0; SCD1-18: 18:1n-
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The novel finding of this study is that the FA composition of circulating phospholipids 
(RBC-TPL) and SAT are distinctly associated with the centralization of body fat and SI in black 
South African women with obesity. Notably,  the FA composition of RBC-TPL is different 
from TG FA profiles in SAT. Specifically, RBC-TPL contained higher proportions of SFAs 
and PUFAs and lower MUFAs than SAT. The higher content of SFA in RBC-TPL was not 
associated with the VAT/SAT ratio, but rather with lower SI.  Furthermore, the estimated 
activities of D5D, D6D and SCD1-18 were higher and SCD1-16 was lower in RBC-TPL 
compared to SAT depots. Interestingly, SAT depots had distinct FA composition, with higher 
SFAs (16:0, 18:0 and total SFA) and lower MUFAs (16:1n-7, 18:1n-7 and total MUFA), as 
well as lower SCD1-16 and SCD1-18 activity in aSAT compared to gSAT. Despite these 
differences, the associations with VAT/SAT ratio and SI did not differ by SAT depot. Indeed, 
in both SAT depots, lower SFAs and higher PUFAs (n-3 and n-6) correlated with higher 
VAT/SAT ratio. Further, lower PUFAs (n-3 and n-6) and higher total MUFA correlated with 
higher SI. Notably, SCD1-18 was positively associated with the VAT/SAT ratio and D6D 
inversely correlated with SI in both SAT depots. These findings show that the association of 
FAs with metabolic status is dependent on the FA class and the blood compartment/ fraction 
where they occur or tissue type where they are stored. 
The FA profile of cell membrane PHLs is modulated by the FA composition of dietary 
fat (363, 364). This is specifically true for PUFA intake (358). The present study showed high 
proportions of SFA and PUFA in RBC-TPL, which may indicate a high consumption of these 
FA types in obese black SA women. This is commensurate with previous research in this 
population (365). However, this was not supported by the self-reported dietary intake of the 
participants in this study, which reported lower SFA (9.5% of total energy intake, EI) and PUFA 
(8% EI) intake than MUFA intake (11% EI). It is important to note that under-reporting of 
dietary intake is well recognized, and may significantly influence investigations of nutrient 
pattern and association with disease (366). This makes the evaluation of FA profile in biological 
matrices a preferential method over self-reported dietary intake (248). Nevertheless, SFAs such 
as 16:0 can be synthesized endogenously from acetyl-CoA during DNL, which can be 
subsequently elongated (to 18:0) and desaturated to generate MUFAs (such as 16:1 and 18:1) 
(250, 358, 367). This pathway is elevated in obese individuals and under high-carbohydrate 
loads and excess energy intake (250), which is characteristic of the participants in the present 
study. Excess consumption of carbohydrates and high glycemic load results in increase 
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lipogenesis with the rapid synthesis of SFA, especially 16:0 and 18:0 in the circulation (232, 
368). Accordingly, these were the most abundant SFAs in RBC-TPL in the present study (16:0 
(22%) and 18:0 (16%)). However, RBC cannot undergo de novo PHL synthesis or FA 
desaturation, but rather renew their FA composition by direct exchange with plasma FFA pools 
(248). Therefore, high content of SFA and PUFA in RBC-TPL could derive from plasma FFAs, 
highly influenced by both dietary intake (especially for PUFA) and endogenous synthesis in 
other tissues such as AT and liver (especially for SFA). Further studies are required to elucidate 
the origin of these FA classes and proportions in RBC membranes in obese black SA women. 
This study further reported lower MUFA contents in RBC-TPL compared to SAT depots. 
Although no previous studies have compared the FA composition between RBC-TPL and SAT 
depots, previous data showed high SFA and PUFA and lower MUFA levels in RBC-TPL of 
obese compared to lean individuals (369, 370). Concomitantly with higher SFA and lower 
MUFA, the present study showed lower desaturation rate (SCD1-16 activity) in RBC-TPL than 
in SAT depots. SCD1-16 is involved in the endogenous synthesis of MUFA from SFA and is 
mainly active in AT were it is very important for de novo synthesis and storage of excess energy 
as TGs (349). In contrast, in circulating PHLs, SCD1-18 is mostly modulated by dietary intake 
of 18:1n-9 (371). This potentially explains the higher activity of SCD1-18 in RBC-TPL, as the 
FA composition in this fraction mostly represents the short-term (2-3 months) dietary intake 
than the FA profile in SAT representing FA intake over a much longer-term (248).  
MUFAs form the major class of FA in adipose TGs (372),  mainly consisting of long-
chain 16 and 18 carbons; and oleic acid has been reported as the major species in adipose TGs 
(225, 232, 248, 373, 374). Accordingly, oleic acid (18:1n-9) was the most abundant FA in SAT 
depots (32.5%) in the present study. Remarkably, MUFA content was lower in aSAT (with 
higher SFA) than gSAT in these women. This is similar to what has been previously found in 
European populations (248, 253). This difference in FA profiles might be attributed to the 
previously reported depot-specific differences in FA metabolism between SAT depots 
(including synthesis, uptake, release, deposition rate, mobilisation and endogenous synthesis) 
have been reported (47, 78, 79),  suggested being dependent on the energy balance (253). The 
higher saturation of aSAT has also been linked to the physical properties of this depot (semi-
solid) in relation to its anatomical role in the protection of abdominal organs (253). Conversely, 
the lower content of SFA in gSAT in the present study was complemented by the higher SCD1 
activity and a higher percentage of MUFA (16:1n-7, 18:1n-7 and total MUFA). This suggests 
a higher desaturation rate and therefore, a preferential FA species accumulation in gSAT in 
73 
 
these women. However, PUFA content was similar between aSAT and gSAT, which is 
supported by previous studies (232, 248, 253, 254, 375). These data support the notion that 
PUFA content in SAT depots is dependent on dietary intake (with 18:2 representing the major 
dietary PUFA in SAT); and LC-PUFAs are also synthesized from essential FAs (18:2n-6 and 
18:3n-3) that can only be obtained from food (232, 253). Collectively, these findings suggest 
comparable PUFA metabolism (deposition, mobilization and desaturation rates) between aSAT 
and gSAT, further supported by the similar estimated desaturase activities observed between 
these depots. 
The alteration of circulating and AT FA composition in obese individuals can influence 
the physical properties of membranes (e.g. fluidity and permeability) and increase the 
susceptibility to metabolic diseases (369). Importantly, the metabolic effects of individual FAs 
are dependent on their respective class (100, 231). For instance, high contents of SFAs and low 
MUFAs increased cell membrane rigidity resulting in a reduced number of insulin receptors 
and binding affinity in insulin-sensitive cells (250, 358). The opposite effects have been shown 
for high MUFA and PUFA, which increase membrane fluidity, thereby explaining, at least in 
part, the different associations of FA classes with metabolic risks (358). Henceforth, the 
relationships between the FA profiles in RBC-TPL and SAT depots, centralisation of body fat 
and SI were assessed in this study. Despite differential SFA and MUFA composition in SAT 
depots, there were no differences in the association of these FA classes with the centralisation 
of body fat and SI. Indeed, lower individual and total SFAs in both SAT depots correlated with 
a higher VAT/SAT ratio. In contrast, higher total SFA in RBC-TPL, and not the SAT depots, 
was associated with lower SI. These findings, similar to a previous study in black South 
Africans showing a positive association between plasma PHL SFAs and measures of adiposity 
and metabolic syndrome (374), add to the notion that circulating SFAs have an adverse effect 
on metabolic profile. Indeed, high intake of dietary SFA may significantly increase IR via 
alterations of desaturases activity (mainly D5D and D9D) of cell membrane PHLs and 
inhibition of insulin-stimulated Akt activation followed by the reduction in glucose uptake (358, 
376). 
In contrast to circulating SFA, the implication of PUFAs in the development of obesity-
associated metabolic disorders is controversial. Increase in membrane unsaturation has been 
associated with higher SI (358). For instance, Gunes et al. showed an association between 
membrane enrichment in n-3 PUFA and improvement of SI in obese adolescents (250). 
Moreover, rats fed with diets rich in n-6 PUFA exhibited an increased insulin-stimulated 
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glucose uptake in adipocytes (377). In addition, plasma total n-3 PUFA was negatively 
associated with markers of obesity and metabolic syndrome in obese individuals (378, 379). 
However, other studies reported positive associations between n-6 PUFAs intake, obesity and 
metabolic syndrome (380, 381), as well as inverse associations between RBC total n-6 PUFAs 
and metabolic syndrome (382, 383). These discrepancies in the association between circulating 
PUFAs and metabolic status were also observed in the present study where RBC-TPL adrenic 
acid (22:4n-6) was positively and eicosadienoic acid (20:2n-6) was negatively correlated with 
SI.  
Further, both n-6 and n-3 PUFAs in SAT depots were negatively associated with SI and 
positively correlated with VAT/SAT ratio in the present study. PUFAs regulate lipogenic gene 
expression during adipogenesis, hence increasing TG storage in SAT (384). However, n-6 and 
n-3 PUFAs are known to exert opposite effects on adipogenesis and lipid metabolism, with n-
6 PUFAs involved in the terminal differentiation of preadipocytes to mature adipocytes; 
processes reported to be inhibited by n-3 PUFAs (231). Furthermore, while n-6 PUFAs have 
been shown to induce an increase of cellular TG content (via increased membrane 
permeability), n-3 PUFAs may reduce fat deposition in AT by suppressing lipogenic enzymes 
and increasing beta-oxidation (231). The current diverse associations between PUFA (n-3 and 
n-6) and SFA content in SAT with the centralisation of body fat and SI accord with a previous 
study in a French population showing positive associations between n-6 PUFA content of SAT 
(abdominal) and central fat distribution (232). Moreover, studies in Swedish cohorts reported a 
positive association between individual n-3 PUFA (EPA and DHA) intake and body fat 
accumulation (385) and positive correlations between aSAT n-6 PUFA (20:3n-6 and 20:4n-6) 
content and HOMA-IR (386). Further, Iggman et al. showed strong positive correlations 
between that gSAT content of individual SFAs (12:0, 14:0 and 18:0) and LA with insulin 
sensitivity, while DHA negatively correlated with insulin sensitivity (387). Conversely, high 
SFA intake caused a higher deposition of VAT and total body fat, whereas increased dietary 
PUFA (mainly LA) reduced central fat accumulation (385). These data highlight the complexity 
in the relationship between FA classes (especially PUFAs) and obesity-associated metabolic 
diseases. The role of circulating and SAT FAs species in central fat accumulation and 
impairment of insulin sensitivity in different population therefore warrants further 
investigations. Nevertheless, the similar associations of n-6 and n-3 PUFAs and desaturases in 
both SAT depots suggest that the differential relationship between SAT depots and metabolic 
risks in obesity might not be driven by PUFA metabolism. Likewise, total MUFAs in both SAT 
depots were positively associated with SI, whereas RBC-TPL MUFA contents were positively 
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associated with central fat accumulation in the present study. These findings suggest that high 
circulating MUFA could exert negative metabolic effects, which are negated once MUFAs are 
sequestrated into adipose depots, thereby preventing lipotoxicity and associated IR in peripheral 
organs. Accordingly, MUFA content of AT has been suggested to be protective against cardio-
metabolic risks in overweight and obese individuals (232).  
Another novel aspect of this study is the multivariate models, most significant for FA 
composition of SAT depots. This highlights a stronger influence of SAT FA metabolism over 
dietary FA intake (reflected by RBC-TPL), on the metabolic status in obese individuals, 
represented in this study by centralisation of body fat and insulin sensitivity. These findings 
support the contribution of excess SAT accumulation in the incidence of metabolic disorders 
(200) both as a major source of systemic FFAs and as a determinant of ectopic lipid deposition 
and whole-body insulin sensitivity (250, 357).  
A limitation of this study is that the desaturase enzyme activities were estimated based 
on product to precursor FA ratios and may simply indicate a higher proportion of product than 
precursor in this tissue and not necessarily a higher desaturation level. Future studies should 
measure the direct activity of the main desaturases, as well as elongases involved in FA 
metabolism. In addition, the cross-sectional nature of these analyses prevents conclusions on 
cause and effect. The lack of detailed information on the dietary FA intake may also represent 
a limitation. Besides, only whole-body insulin sensitivity was measured using the FSIGT. 
Accordingly, changes in hepatic and muscle insulin sensitivity could not be determined, which 
would have been of particular interest. However, the strength of this research work is the robust 
measure of the FA composition of RBC-TPL and two main depots of SAT represent strengths 
of this research work. This method is regarded as more objective and accurate than estimations 
from dietary reporting in the investigation of the effects of these lipid molecules in the 
development of metabolic diseases (248, 366). Because this study only included obese SA 
women, prospective studies in a more representative population (including men, and normal-
weight individuals) are required to gain a better understanding of the associations between 
RBC-TPL and SAT FA composition and central fat accumulation and development IR. 
This was the first study that has comprehensively measured and compared the FA 
composition of RBC-TPL and two distinct SAT depots in humans with obesity; and evaluating 
the tissue-specific relationships between FA composition, desaturase activities and measures of 
central fat distribution and insulin sensitivity, making this research work original and novel. It 
was shown that the circulating (RBC-TPL) FA profile is distinctly different from the FA 
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composition of SAT, with higher SFAs and PUFAs and lower MUFAs in RBC-TPL compared 
to the SAT depots. Notably, differences were also observed within SAT depots with higher 
SFAs and lower MUFAs in aSAT compared to gSAT, but no differences in PUFA content. 
However, the differential SFA and MUFA contents between aSAT and gSAT was not reflected 
in the relationship with the VAT/SAT ratio and SI. SAT depots, rather than RBC-TPL, were 
the major contributors to the variance in central fat accumulation and insulin sensitivity. This 
study showed for the first time that the FA composition of RBC-TPL and SAT is associated 
with metabolic risk in black SA women with obesity, and these associations are not only 
dependent on their class, but also on the tissue type and blood compartment or fraction in which 
they are distributed. Intervention studies such as exercise training are known to alter AT lipid 
and FA metabolism as well as circulating FA composition, which might contribute to the 
improvement of insulin sensitivity in obese individuals. Such interventions are required to 
elucidate the causal relationship between FA composition and metabolic profile, as well as the 
specific roles of the individual FAs and total FA groups in mediating obesity-associated 




EXERCISE TRAINING ALTERS RED BLOOD CELLS FATTY ACID 
DESATURASE ACTIVITY AND ADIPOSE TISSUE FATTY ACID COMPOSITION 





The previous chapter of this thesis (Chapter 3) showed that SAT FA composition is the 
major contributor of the variance in central fat accumulation and insulin sensitivity in obese 
black SA women, rather than RBC-TPL FA profile. However, the differential FA content 
between aSAT and gSAT was not reflected in the relationship with the VAT/SAT ratio and SI. 
This study was limited by its cross-sectional nature and hence an understanding of the causative 
link between FA composition in SAT depots and RBC-TPL and whole-body insulin sensitivity 
could not be gained. This was further investigated in the present chapter using exercise training 
as an intervention model.  
Lifestyle interventions such as exercise training represent a key component in the 
management of obesity and related IR. Exercise training has been well established to improve 
whole-body glucose metabolism and insulin sensitivity via its predominant action on skeletal 
muscle (290-292). However, long term exercise training can induce beneficial adaptations in 
AT (292, 388). Indeed, exercise training can modify lipid metabolism and FA composition, 
independently of changes in nutrition (138). In this regard, exercise training can stimulate AT 
lipolysis, decrease lipogenesis and improve insulin sensitivity (290, 292, 303, 304). Exercise 
training can also alter FA synthesis, desaturation and elongation in AT (221, 305), as well as 
change the FA composition of RBC membranes (225). However, data on the effects of exercise 
training on FA metabolism in African populations are scarce. This is particularly relevant given 
the reported ethnic differences in desaturase activity and capacities of LC-PUFAs synthesis 
(265, 266). Evaluation of the impact of exercise training on these pathways and the association 
with insulin sensitivity can provide an understanding of the mechanisms linking FA metabolism 
to IR in specific ethnic groups. Indeed, obese black SA women are less insulin sensitive than 
their white counterparts despite having less VAT (30-34) and liver fat content (389). Moreover, 
reduced insulin sensitivity in obese state has been associated with systemic inflammation and 
partitioning of excess lipids to VAT and the liver due to elevated circulating FFA concentrations 
deriving from SAT impaired function (134, 139, 155). This study therefore represents a unique 
opportunity to investigate whether exercise-induced improvement in insulin sensitivity is 
associated with changes in SAT FA metabolism and therefore changes in circulating (reflected 
here in RBC-TPL) FA profile in obese black women. Specifically, the aim of this chapter was 
to evaluate i) the effect of exercise training, without dietary modification, on RBC-TPL and 
SAT FA composition and desaturase activity in obese and previously sedentary black SA 
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women; and ii) the associations with changes in SAT lipid metabolism, systemic inflammatory 
markers, liver fat and insulin sensitivity in respone to exercise training. 
4.2. RESULTS 
4.2.1. Compliance, participant characteristics and dietary macronutrient intake in 
response to the intervention 
A total of 48 exercise training sessions were conducted, in which participants attended 
79±13 (range: 52-100) % at a mean intensity of 79.7±4.0 (range: 71-85) % HRpeak.  
A summary of participant characteristics at baseline and in response to the intervention is 
presented in Table 4.1. At baseline, the cardio-respiratory fitness, body composition and SI did 
not differ between the groups. Following the intervention, VO2peak increased in the exercise 
group and was unchanged in the control group (p<0.01 for group x time interaction). There 
were small but significant decreases in body weight, BMI, WC and gynoid fat (% of total fat 
mass; FM) in the exercise group (p<0.01). In contrast, body weight, BMI and WC (p<0.01), 
and SAT (p<0.05) volume increased in the control group. Total body FM (%), android FM (%) 
and VAT did not change in either group. Liver fat tended to decrease in the exercise group 
(p=0.074), with no changes in the control group (p=0.356). SI increased in the exercise group 
and did not change in the control group (p<0.05 for group x time interaction). No changes in 
fasting glucose, insulin, HOMA2-IR and circulating inflammatory markers were observed in 
either group in response to the intervention.  
Dietary energy, macronutrient and FA intake were not significantly different between the 
groups at baseline and did not change in response to the intervention (Table 4.2).
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Table 4.1. Changes in anthropometry, cardiorespiratory fitness, insulin sensitivity and systemic inflammation in response to the 12-week 
exercise intervention in exercise and control groups 
Variables CONTROL (n=15) EXERCISE (n=20) P VALUES 
 Pre Post Pre Post Time Group Interaction 
Cardiorespiratory fitness 
VO2peak (ml/min) 2099 ± 282 2032 ± 196 2077 ± 211 2278 ± 231
#
 0.130 0.100 0.001 
VO2peak (ml/kg) 23.90 ± 2.97 22.98 ± 2.64 24.91 ± 2.24 27.58 ± 3.39
#
 0.078 0.003 <0.001 
Body composition   
Weight (kg) 87.8 ± 2.5 88.8 ± 2.5 ** 84.1 ± 2.2 83.3 ± 2.2** 0.787 0.187 0.003 
BMI (kg/m²) 33.4 ± 0.7 33.8 ± 0.7** 34.1 ± 0.6 33.8± 0.6** 0.898 0.695 0.003 
WC (cm) 103.4 ± 2.1 106.1 ± 2.1*** 103.6± 1.8 100.4 ± 1.8** 0.700 0.331 <0.001 
Body FM (%) 50.4 ± 0.9 50.6 ± 0.9 50.2 ± 0.8 50.1 ± 0.8 0.698 0.782 0.471 
Android FM (%) 8.0 ± 0.3 7.9 ± 0.30 8.3 ± 0.3 8.1 ± 0.3 0.033 0.608 0.860 
Gynoid FM (%) 19.4 ± 0.5 19.5 ± 0.5 18.5 ±0.4 18.2 ± 0.4
#
 0.139 0.095 0.002 
VAT (cm3) 931.1 ± 427.1 968.7 ±392.4 920.0 ±322.1 906.2 ± 346.9 0.266 0.619 0.196 
SAT (cm3) 5440.3 ± 1858.0 5532.8 ± 1890.0* 5489.3 ±1053.4 5444.7 ± 1260.7 0.640 0.823 0.026 
Ectopic fat     
   
Liver fat % 4.72 (4.33-5.41)  4.54 (4.21-5.29) 5.23 (4.47-6.47) 4.84 (3.93-5.52) 0.679 0.921 0.069 
Insulin sensitivity   
SIx10
-4(mU/L)-1min-1 2.01 (1.29-3.24) 1.83 (1.65-2.64) 2.04 (1.20-2.77) 2.17 (1.45-3.69)* 0.145 0.422 0.045 
Fasting glucose 
(mmol/L) 
5.0 (±0.7) 5.1 (±0.8) 5.5 (±0.8) 5.1 (±1.0) 0.169 0.645 0.217 
Fasting Insulin 
(µIU/mL) 
13.0 (9.6-14.2) 12.9 (7.7-19.6) 14.8 (6.4-19.1) 12.6 (10.5-17.1) 0.811 0.977 0.773 
HOMA-2IR 1.8 (1.4-2.2) 2.0 (1.1-2.9) 2.2 (1.0-2.9) 1.9 (1.4-2.6) 0.956 0.916 0.943 
Circulating inflammatory markers    
hsCRP (mg/L) 2.5 (1.9-8.0) 4.02 (2.8-9.6) 5.0 (2.1-11.5) 4.6 (2.8-9.0) 0.151 0.575 0.225 
TNFα (pg/mL) 7.0 (3.8-8.5) 6.4 (3.7-9.3) 4.1 (3.27-7.8) 4.6 (4.0-6.3) 0.816 0.461 0.515 
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Data presented as means ± SD for normally distributed variables and median (25th - 75th percentile) for skewed variables; *P<0.05, **P<0.01 and ***p<0.001 
represent the difference between the groups after the intervention and #P<0.01 and #P<0.001 represents the difference post vs pre in the exercise group. BMI: body 
mass index; WC: waist circumference; FM: fat-mass; VAT: visceral adipose tissue; SAT: subcutaneous adipose tissue; VO2max: maximal oxygen uptake, used as 
a measure of cardiorespiratory fitness; SI: insulin sensitivity; hsCRP: high-sensitive C-reactive protein; HOMA2IR: homeostatic model assessment of insulin 











0.206 0.042 0.358 
IL-8 (pg/mL) 3.0 (2.3-5.5) 4.0 (1.1-6.7) 2.3 (0.2-4.1) 2.3 (1.7-5.1) 0.859 0.382 0.377 
Leptin (ng/mL) 67.1 (57.2-79.3) 75.7 (53.7-80.2) 62.5 (47.3-81.5) 63.4 (46.7-79.1) 0.900 0.305 0.613 
Adiponectin (µg/mL) 3.9 (3.3-5.2) 3.6 (2.0-4.7) 3.3 (1.9-5.0) 2.1 (1.3-3.3) <0.001 0.060 0.793 
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Table 4.2. Daily energy, macronutrient and fat intake at baseline and after the 12-week 
exercise training intervention in both groups 
Data presented as median (25th - 75th percentiles). kJ: kilojoules; CHO: carbohydrate; SFA: saturated 
fatty acid; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid. 
  
Variables CONTROL (n=15) EXERCISE (n=20) P VALUE 
 
Pre Post Pre Post Interaction  









   Total protein (g) 74.8 (59.4-114-
2) 





Protein (%E) 13.8 (11.4-14.3) 13.6 (12.7-14.5) 13.2 (12.4-13.9) 12:8 (12:0-14:1) 0.346 









CHO (%E) 53.2 (49.1-56.4) 54.2 (49.2-55.9) 52.6 (49.8-54.2) 53.5 (50.4-56.1) 0.645 









Fat (% E) 34.0 (28.4-36.1) 32.2 (29.5-35.4) 33.3 (31.7-37.1) 31.5 (29.7-34.4) 0.288 
SFA (g) 29.1 (18.8-40.6) 25.1 (21.7-38.6) 34.4 (22.9-44.5) 29.6 (23.7-37.7) 0.237 
SFA (%E) 9.1 (4.1-11.8) 9.7 (8.2-11.3) 9.5 (7.9-11.3) 9.55 (8.0-10.2) 0.327 
MUFA (g) 35.7 (19.2-41.6) 29.9 (23.5-35.3) 40.7 (31.1-51.6) 34.4 (28.4-3.6) 0.324 
MUFA (%E) 11.2 (9.6-12.2) 11.5 (10.0-12.2) 11.1 (10.7-12.9) 11.2 (9.4-12.5) 0.172 
PUFA (g) 26.6 (15.5-34.5) 18.5 (15.6-22.5) 25.8 (0.7-36.2) 22.6 (18.2-29.8) 0.479 
PUFA (%E) 7.9 (7.2-10.1) 7.1 (6.4-8.4) 7.9 (7.2-9.6) 7.5 (6.6-8.2) 0.717 
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4.1.1.  Exercise training-induced changes in RBC-TPL fatty acid composition 
At baseline, RBC-TPL FA composition was not different between groups and constituted 
of 44% SFA, 16% MUFA and 40% PUFA. In response to exercise training (Table 4.3), RBC-
TPL total SFAs, individual and total MUFAs did not change and were not different between 
the groups. However, stearic acid (18:0) showed a significant group effect such that it was lower 
in the exercise group compared to the control group at post-training (p=0.028). Moreover, 
arachidic acid (20:0) decreased in the exercise group (p=0.040) and not in the control group 
(p=0.525) after the intervention period. In terms of PUFA, eicosadienoic acid (20:2n-6) 
decreased in both groups (p=0.002; time effect), whereas a trend was noted for an interaction 
effect (p=0.069) for DGLA (20:3n-6) such that it decreased in the exercise group (p=0.019) and 
not in the control group (p=0.726). Accordingly, the estimated enzyme activity of D5D 
(AA/DGLA) increased in the exercise group only (p=0.021), while D6D (GLA/LA) and SCD1-
16 activities tended to be lower in the exercise compared to the control group at post-
intervention (p=0.070 and p=0.048, respectively). 
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Table 4.3. RBC-TPL fatty acid composition (percentage) at baseline and in response to the 12-week exercise training intervention 
Variables CONTROL (n=15) EXERCISE (n=20) P VALUES 
 Pre  Post Pre Post Time Group Interaction 
Saturated fatty acids (SFAs) 
14:0 (Myristic acid) 0.21 (0.18-0.25) 0.24 (0.21-0.26) 0.23 (0.2-0.3) 0.25 (0.22-0.28) 0.807 0.354 0.333 
16:0 (Palmitic acid) 22.00 (20.45-23.21) 21.33 (20.73-22.52) 21.31 (20.35-22.36) 21.31 (20.61-22.93) 0.560 0.663 0.790 
18:0 (Stearic acid) 16.56 ± 0.91 16.82 ± 1.05 16.21 ± 0.75 16.11 ± 1.01 0.520 0.080 0.137 
20:0 (Arachidic acid) 0.34 ± 0.04 0.34 ± 0.04 0.36 ± 0.05 0.33 ± 0.04 0.069 0.747 0.369 
22:0 (Behenic acid) 1.33 ± 0.14 1.35 ± 0.18 1.42 ± 0.26 1.41 ± 0.18 0.897 0.219 0.594 
24:0 (Lignoceric acid) 3.87 ± 0.58 4.02 ± 0.55 4.11 ± 0.80 4.19 ± 0.62 0.346 0.299 0.778 
Total SFA 44.33 ± 1.82 44.38 ± 1.97 44.44 ± 1.81 44.21 ± 1.54 0.820 0.951 0.729 
Mono-unsaturated fatty acids (MUFAs) 
 
16:1n-7 (Palmitoleic acid) 0.22 (0.19-0.3) 0.26 (0.20-0.30) 0.21 (0.19-0.27) 0.22 (0.18-0.27) 0.639 0.289 0.132 
18:1n-7 (cis-Vaccenic 
acid) 
1.13 (0.95-1.28) 1.06 (0.97-1.38) 1.05 (0.92-1.25) 1.11 (1.00-1.23) 0.277 0.360 0.588 
18:1n-9 (Oleic acid) 10.84 (10.38-11.01) 10.95 (10.49-11.44) 10.31 (10.01-11.30) 10.59 (9.97-11.62) 0.765 0.539 0.777 
20:1n-9 (Eicosenoic acid) 0.18 ± 0.03 0.18 ± 0.03 0.17 ± 0.02 0.18 ± 0.02 0.734 0.974 0.130 
24:1n-9 (Nervonic acid) 3.27 (3.1-3.5) 3.53 (3.27-3.79) 3.63 (3.3-3.8) 3.68 (3.27-4.01) 0.068 0.423 0.987 
Total n-7 MUFA 1.43 ± 0.36 1.46 ± 0.41 1.30 ± 0.24 1.32 ± 0.19 0.418 0.247 0.936 
Total n-9 MUFA 14.39 (13.81-14.94) 14.53 (14.17-15.31) 14.23 (13.72-14.64) 14.47 (13.67-15.17) 0.091 0.768 0.818 
Total MUFA 15.57 (15.03-16.23) 15.91 (15.47-16.47) 15.44 (15.05-15.82) 15.66 (15.08-16.48) 0.036 0.542 0.872 
Poly-unsaturated fatty acids (PUFAs) 
 
20:5n-3 (EPA) 0.40 (0.32-0.47) 0.4 (0.33-0.50) 0.46 (0.36-0.53) 0.41 (0.37-0.44) 0.205 0.457 0.174 
22:5n-3 (DPA n-3) 1.81 (1.66-2.06) 1.83 (1.75-1.96) 2. 00 (1.75-2.12) 1.9 (1.82-2.05) 0.548 0.531 0.998 
22:6n-3 (DHA) 4.05 (3.78-4.56) 4.12 (3.80-4.50) 4.52 (3.98-507) 4.47 (4.16-4.96) 0.617 0.143 0.881 
18:2n-6 (LA) 11.57 ± 1.59 11.36 ± 1.50 11.76 ± 1.55 11.57 ± 1.16 0.119 0.654 0.913 
20:2n-6 (Eicosadienoic 
acid) 
0.35 ± 0.03 0.33 ± 0.04* 0.36 ± 0.05 0.34 ± 0.04* 0.002 0.651 0.824 
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20:3n-6 (DGLA) 1.55 ± 0.26 1.56 ± 0.25 1.54 ± 0.23 1.47 ± 0.18* 0.187 0.479 0.069 
20:4n-6 (AA) 15.73 ± 0.98 15.68 ± 1.41 15.43 ± 1.29 15.66 ± 1.24 0.580 0.687 0.392 
22:4n-6 (Adrenic acid) 3.44 ± 0.57 3.46 ± 0.64 3.24 ± 0.63 3.36 ± 0.42 0.282 0.408 0.455 
Total PUFA 39.87 (38.35-41.15) 39.35 (38.56-41.23) 39.82 (38.76-41.26) 39.58 (38.72-41.55) 0.754 0.581 0.716 
Total n-6  34.31 ± 1.71 33.06 ± 1.71 32.99 ± 2.09 33.07 ± 1.57 0.709 0.782 0.490 
Total n-3  6.15 (5.83-6.74) 6.29 (6.05-6.95) 6.93 (6.27-7.52) 6.93 (6.49-7.15) 0.973 0.164 0.717 
Estimated enzyme activities 
 
D5D  10.47 ± 2.04 10.34 ± 2.13 10.32 ± 2.11* 10.86 ± 1.83* 0.239 0.778 0.057 
D6D 0.136 ± 0.020 0.139 ± 0.019 0.133 ± 0.022 0.127 ± 0.017* 0.667 0.213 0.086 
(SCD1)-16 0.010 (0.010-0.014) 0.012 (0.010-0.014)
#
 0.010 (0.010-0.013) 0.010 (0.010-0.011)
#
 0.455 0.300 0.047 
(SCD1)-18 0.65 (0.65-0.65) 0.66 (0.64-0.66) 0.65 (0.64-0.68) 0.66 (0.64-0.68) 0.875 0.738 0.228 
Data presented as means ± SD for normally distributed variables and median (25th - 75th percentile) for skewed variables; *p<0.05 represents the difference 
between the groups in response to the intervention and #p<0.05 represents the difference between the groups at post-training. LA: linoleic acid; EPA: 
Eicosapentaenoic acid; DPA: Docosapentaenoic acid; DHA: Docosahexaenoic acid; DGLA: Dihomo-γ-linolenic acid; AA: Arachidonic acid; D5D: delta-5-





4.2.2. Changes in the fatty acid composition of SAT depots in response to exercise training  
The baseline FA composition of SAT depots was not different between the groups and 
consisted of 32% SFA, 42% MUFA and 26% PUFA in aSAT and 31% SFA, 43% MUFA and 
26% PUFA in gSAT. Table 4.4 and Tables 4.5 present the changes in FA composition in SAT 
following the exercise training. Within the aSAT depot (Table 4.4), lauric (12:0) and myristic 
(14:0) acids decreased in the exercise group (p=0.006 and p=0.001, respectively) with no 
change in the control group (p>0.05). In contrast, the mono-unsaturated eicosenoic acid (20:1n-
9) increased in the exercise group only (p=0.003), whereas oleic acid (18:1n-9) and total n-9 
MUFA content increased in the control group (p=0.035 and p=0.031, respectively) and not in 
the exercise group (p>0.05). In terms of PUFA, eicosadienoic (20:2n-6) and adrenic (22:4n-6) 
acids increased in the exercise (p=0.023 and p=0.018, respectively) and not in the control group 
(p>0.05). The estimated enzyme activities (D5D, D6D and SCD1-16 and 18) did not change in 
the aSAT of either group in response to the exercise training intervention (Table 4.4). 
Within the gSAT depot (Table 4.5), only GLA (18:3n-6) decreased in the exercise group 
(p=0.007) and not the control group (p>0.05). However, within the control group, total SFA 
increased (p=0.046), while palmitoleic acid (16:1n-7) and SCD1-16 decreased over the 12-




Table 4.4. Fatty acid composition (percentage) of abdominal subcutaneous adipose tissue at baseline and in response to the 12-week exercise 
training intervention 
Variables CONTROL (n=15) EXERCISE (n=20) P VALUES 
 Pre  Post Pre Post Time Group Interaction 
Saturated fatty acids (SFAs)  
12:0 (Lauric acid) 0.36 (0.32-0.46) 0.40 (0.33-0.46) 0.49 (0.38-0.62)** 0.45 (0.37-0.56)** 0.251 0.085 0.019 
14:0 (Myristic acid) 2.79 (2.44-3.17) 2.86 (2.51-3.07) 3.08 (2.70-3.37)** 2.94 (2.64-3.25)** 0.120 0.359 0.004 
16:0 (Palmitic acid) 22.43 ± 1.31 22.60 ± 1.21 22.77 ± 1.08 22.64 ± 0.74 0.794 0.535 0.448 
17:0 (Heptadecanoic acid) 0.38 (0.35-0.44) 0.36 (0.33-0.47) 0.39 (0.35-0.44) 0.40 (0.35-0.45) 0.989 0.742 0.965 
18:0 (Stearic acid) 5.72 ± 1.66 5.54 ± 1.46 5.60 ± 1.01 5.77 ± 1.20 0.829 0.935 0.257 
20:0 (Arachidic acid) 0.15 (0.12-0.18) 0.13 (0.11-0.18) 0.14 (0.13-0.18) 0.16 (0.13-0.18) 0.706 0.583 0.306 
22:0 (Behenic acid) 0.05 (0,04-0,05) 0.05 (0.04-0.05) 0.04 (0.04-0.05) 0.04 (0.04-0.05) 0.706 0.932 0.186 
Total SFA 31.94 ± 3.34 31.96 ± 2.95 32.52 ± 1.62 32.43 ± 1.63 0.742 0.538 0.683 
Mono-unsaturated fatty acids (MUFAs) 
 
16:1n-7 (Palmitoleic acid) 6.11 ± 2.13 6.00 ± 1.91 5.64 ± 1.34 5.48 ± 1.44 0.248 0.361 0.709 
18:1n-7 (cis-Vaccenic acid) 2.79 ± 0.57 2.84 ± 0.55 2.72 ± 0.35 2.84 ± 0.40 0.182 0.756 0.691 
18:1n-9 (Oleic acid) 32.66 (31.74-33.06)* 32.84 (32.04-33.51)* 32.39 (32.04-32.92) 32.78 (32.05-33.70) 0.012 0.772 0.504 
20:1n-9 (Eicosenoic acid) 0.67 ± 0.10 0.67 ± 0.12 0.70 ± 0.13 0.76 ± 0.10** 0.059 0.135 0.033 
Total n-7 MUFA 8.91 ± 7.65 8.84 ± 2.40 8.36 ± 1.55 8.32 ± 1.72 0.601 0.413 0.864 
Total n-9 MUFA 33.32 (32.46-33.78)* 33.58 (32.72-34.27)* 33.07 (32.81-33.45) 33.51 (32.71-33.50) 0.006 0.645 0.664 
Total MUFA 41.89 ± 3.05 42.27 ± 2.58 41.56 ± 1.47 41.85 ± 1.88 0.133 0.585 0.641 
Poly-unsaturated fatty acids (PUFAs) 
 
18:3n-3 (ALA) 1.16 ± 0.26 1.15 ± 0.26 1.07 ± 0.18 1.04 ± 0.21 0.234 0.219 0.541 
20:3n-3 (Eicosatrienoic acid) 0.05 (0.05-0.06) 0.05 (0.05-0.05) 0.04 (0.04-0.05) 0.05 (0.04-0.05) 0.804 0.513 0.217 
20:5n-3 (EPA) 0.07 (0.04-0.11) 0.07 (0.04-0.08) 0.07 (0.06-0.10) 0.08 (0.06-0.09) 0.349 0.261 0.816 
22:5n-3 (DPA n-3)  0.23 ± 0.09 0.23 ± 0.09 0.24 ± 0.08 0.26 ± 0.09 0.638 0.495 0.195 
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22:6n-3 (DHA) 0.20 ± 0.06 0.19 ± 0.06 0.23 ± 0.08 0.24 ± 0.08 0.822 0.215 0.436 
18:2n-6 (LA) 22.42 ± 2.00 22.62 ± 2.20 22.24 ± 1.38 21.91 ± 1.15 0.823 0.544 0.179 
18:3n-6 (GLA) 0.17 ± 0.03 0.16 ± 0.03 0.16 ± 0.03 0.15 ± 0.02 0.053 0.024 0.826 
20:2n-6 (Eicosadienoic acid) 0.47 (0.36-0.57) 0.50 (0.36-0.55) 0.44 (0.41-0.52)* 0.49 (0.45-0.57)* 0.178 0.355 0.090 
20:3n-6 (DGLA) 0.37 ± 0.16 0.37 ± 0.15 0.37 ± 0.10 0.39 ± 0.10 0.441 0.858 0.347 
20:4n-6 (AA) 0.68 ± 0.23 0.66 ± 0.21 0.67 ± 0.12 0.70 ± 0.16 0.844 0.831 0.364 
22:4n-6 (Adrenic acid) 0.27 ± 0.11 0.27 ± 0.11 0.27 ± 0.07* 0.30 ± 0.08* 0.262 0.745 0.042 
22:5n-6 (DPA n-6) 0.07 ± 0.03 0.07 ± 0.02 0.08 ± 0.03 0.08 ± 0.03 0.411 0.230 0.564 
Total PUFA 26.17 ± 2.45 26.28 ± 2.73 25.92 ± 1.46 25.71 ± 1.53 0.868 0.628 0.526 
Total n-6  24.46 ± 2.21 24.61 ± 2.39 24.26 ± 1.36 24.06 ± 1.31 0.679 0.635 0.431 
Total n-3  1.71 ± 0.37 1.67 ± 0.41 1.66 ± 0.29 1.65 ± 0.36 0.448 0.706 0.741 
Estimated enzyme activities 
 
D5D 1.92 ± 0.44 1.89 ± 0.37 1.90 ± 0.40 1.84 ± 0.37 0.600 0.890 0.802 
D6D 0.016 ± 0.006 0.016 ± 0.007 0.017 ± 0.005 0.018 ± 0.004 0.416 0.709 0.283 
(SCD1)-16 0.28 ± 0.10 0.27 ± 0.10 0.25 ± 0.06 0.24 ± 0.047 0.167 0.471 0.528 
(SCD1)-18 5.75 (4.93-7.51) 6.34 (4.75-7.89) 5.87 (5.28-6.69) 5.78 (4.78-6.40) 0.520 0.812 0.392 
Data presented as means ± SD for normally distributed variables and median (25th-75th percentile) for skewed variables; *p<0.05 and **p<0.01 represent the 
difference between the groups in response to the intervention. ALA: alpha-linolenic acid; LA: linoleic acid; EPA: Eicosapentaenoic acid; DPA: Docosapentaenoic 
acid; DHA: docosahexaenoic acid; GLA: γ-linolenic acid; DGLA: dihomo-γ-linolenic acid; AA: Arachidonic acid; D5D: delta-5-desaturase index (20:4n-6/20:3n-
6); D6D: delta-6-desaturase index (18:3n-6/18:2n-6); SCD1: stearoyl-CoA desaturase-1 (SCD1-16: 16:1n-7/16:0; SCD1-18: 18:1n-9/18:0). 
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Table 4.5. Fatty acid composition (percentage) of gluteal subcutaneous adipose tissue at baseline and in response to the 12-week exercise 
training intervention 
Variables CONTROL (n=15) EXERCISE (n=20) P VALUE 
 Pre  Post Pre Post Time Group Interaction 
Saturated fatty acids (SFAs)  
12:0 (Lauric acid) 0.38 (0.25-0.49) 0.33 (0.26-0.48) 0.47 (0.32-0.50) 0.44 (0.32-0.61) 0.443 0.141 0.946 
14:0 (Myristic acid) 2.56 ± 0.84 2.69 ± 0.47 2.86 ± 0.47 2.84 ± 0.42 0.921 0.346 0.347 
16:0 (Palmitic acid) 21.43 ± 1.35 21.80 ± 1.22 21.95 ± 1.07 22.18 ± 0.79 0.069 0.201 0.728 
17:0 (Heptadecanoic acid) 0.35 (0.32-0.44) 0.36 (0.31-0.44) 0.42 (0.36-0.44) 0.39 (0.34-0.47) 0.773 0.184 0.283 
18:0 (Stearic acid) 4.80 ± 1.59 5.15 ± 1.50 5.31 ± 1.23 5.48 ± 1.02 0.077 0.389 0.624 
20:0 (Arachidic acid) 0.13 (0.10-0.18) 0.14 (0.12-0.17) 0.15 (0.12-0.19) 0.16 (0.13-0.18) 0.479 0.431 0.714 
22:0 (Behenic acid) 0.05 (0.04-0.07) 0.04 (0.04-0.06) 0.05 (0.04-0.07) 0.05 (0.04-0.06) 0.236 0.661 0.357 
Total SFA 29.72 ± 3.55* 30.58 ± 2.86* 31.19 ± 2.22 31.55 ± 1.71 0.033 0.166 0.366 
Mono-unsaturated fatty acids (MUFAs) 
 
16:1n-7 (Palmitoleic acid) 7.27 ± 2.30* 6.64 ± 2.28*  6.20 ± 1.84 5.91 ± 1.45  0.010 0.175 0.533 
18:1n-7 (cis-Vaccenic acid) 3.06 ± 0.61 3.01 ± 0.62 2.96 ± 0.41 2.88 ± 0.21 0.131 0.428 0.688 
18:1n-9 (Oleic acid) 32.37 (32.02-33.25) 33.38 (32.54-33.31) 32.32 (31.70-33.01) 32.70 (32.28-33.28) 0.193 0.776 0.189 
20:1n-9 (Eicosenoic acid) 0.69 ± 0.11 0.71 ±0.11 0.72 ± 0.10 0.75 ± 0.11 0.098 0.324 0.782 
Total n-7 MUFA 10.34 ± 2.81 9.65 ± 2.82 9.16 ± 2.18 9.79 ± 1.67 0.015 0.181 0.677 
Total n-9 MUFA 33.13 (32.82-33.82) 33.27 (32.24-33.03) 33.11 (32.67-33.74) 33.50 (33.04-34.13) 0.100 0.667 0.140 
Total MUFA 43.59 ± 3.12 42.92 ± 3.19 42.41 ± 2.19 42.39 ± 1.75 0.101 0.282 0.310 
Poly-unsaturated fatty acids (PUFAs) 
 
18:3n-3 (ALA) 1.17 (1.00-1.37) 1.21 (0.89-1.26) 1.09 (0.94-1.25) 1.07 (0.93-1.17) 0.016 0.161 0.712 
20:3n-3 (Eicosatrienoic acid) 0.05 (0.04-0.05) 0.05 (0.05-0.06) 0.05 (0.04-0.06) 0.04 (0.04-0.05) 0.759 0.763 0.182 
20:5n-3 (EPA) 0.08 (0.05-0.1) 0.06 (0.04-0.10) 0.09 (0.08-0.12) 0.08 (0.06-0.10) 0.090 0.089 0.361 
22:5n-3 (DPA n-3)  0.26 ± 0.10 0.25 ± 0.10 0.27 ± 0.08 0.27 ± 0.08 0.308 0.705 0.916 
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22:6n-3 (DHA) 0.22 ± 0.08 0.21 ± 0.07 0.26 ± 0.08 0.24 ± 0.07 0.310 0.159 0.456 
18:2n-6 (Linoleic acid) 22.72 ± 2.08 22.56 ± 2.08 22.34 ± 1.48 22.14 ± 1.25 0.298 0.600 0.461 
18:3n-6 (GLA) 0.176 ± 0.035 0.170 ± 0.039 0.171 ± 0.030** 0.157 ± 0.028**  0.012 0.355 0.270 
20:2n-6 (Eicosadienoic acid) 0.49 ± 0.13 0.50 ± 0.12 0.51 ± 0.10 0.51 ± 0.09 0.356 0.445 0.712 
20:3n-6 (DGLA) 0.42 ± 0.16 0.43 ± 0.16 0.43 ± 0.11 0.43 ± 0.12 0.986 0.953 0.416 
20:4n-6 (AA) 0.70 ± 0.21 0.71 ± 0.25 0.76 ± 0.16 0.73 ± 0.14 0.569 0.591 0.275 
22:4n-6 (Adrenic acid) 0.29 ± 0.12 0.30 ± 0.12 0.31 ±0.07 0.30 ± 0.08 0.855 0.771 0.464 
22:5n-6 (DPA n-6) 0.06 (0.05-0.09) 0.07 (0.05-0.09) 0.08 (0.06-0.10) 0.08 (0.06-0.10) 0.368 0.326 0.161 
Total PUFA 26.68 ± 2.56 26.49 ± 2.53 26.41 ± 1.64 26.06 ± 1.45 0.074 0.690 0.999 
Total n-6  24.88 ± 2.23 24.75 ± 2.25 24.64 ± 1.50 24.38 ± 1.29 0.181 0.715 0.904 
Total n-3  1.80 ± 0.44 1.74 ± 0.39 1.76 ± 0.25 1.68 ± 0.29 0.053 0.661 0.771 
Estimated enzyme activities  
D5D  1.73 (1.50-1.98) 1.63 (1.58-1.93) 1.77 (1.43-2.02) 1.70 (1.55-1.87) 0.275 0.668 0.636 
D6D 0.019 ± 0.007 0.019 ± 0.007 0.019 ± 0.005 0.020 ± 0.005 0.856 0.807 0.432 
(SCD1)-16 0.36 (0.24-0.43)* 0.30 (0.30-0.41)* 0.27 (0.23-0.34) 0.27 (0.22-0.31) 0.012 0.207 0.343 
(SCD1)-18 7.12 (6.33-8.26) 6.83 (5.01-8.19) 6.21 (5.77-6.81) 6.00 (5.46-7.06) 0.074 0.235 0.509 
Data presented as means ± SD for normally distributed variables and median (25th-75th percentile) for skewed variables; *p<0.05 and **p<0.01 represent the 
difference between the groups in response to the intervention. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DPA: docosapentaenoic acid; DHA: 
docosahexaenoic acid; GLA: γ-linolenic acid; DGLA: dihomo-γ-linolenic acid; AA: arachidonic acid; D5D: delta-5-desaturase index (20:4n-6/20:3n-6); D6D: 
delta-6-desaturase index (18:3n-6/18:2n-6); SCD1: stearoyl-CoA desaturase-1 (SCD1-16: 16:1n-7/16:0; SCD1-18: 18:1n-9/18:0. 
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4.2.3. Effect of exercise training on SAT gene expression 
The expression of genes involved in SAT adipogenesis, lipid metabolism, insulin 
signalling and inflammation (Table 4.6) were evaluated in aSAT and gSAT before and after 
the 12-week intervention. ATGL mRNA content decreased in gSAT of both groups (p=0.009 in 
control and p=0.024 in exercise group) and in aSAT of the control group (p=0.044), whereas 
GLUT4 mRNA content increased in aSAT of both groups (p=0.047 in control and p=0.018 in 
exercise). Moreover, there was a time effect for adiponectin mRNA in both SAT depots such 
that it decreased in both groups (p<0.05) although this effect could not be attributed to the 
exercise training intervention. The remaining evaluated genes (IRS1, SCL2A4, SMG, LPL, 




Table 4.6. Depot-specific adipose tissue gene expression before and after the 12-week exercise training intervention 
 
Variables CONTROL (n=15) EXERCISE (n=20) P VALUE 
 Pre  Post Pre Post Time Group Interaction 
Abdominal subcutaneous adipose tissue (aSAT) 
Adipogenesis 
PPARγ mRNA (AU) 0.97 ± 0.40 0.93 ± 0.40 1.11 ± 0.55 0.88 ± 0.49 0.096 0.767 0.313 
Lipogenesis & lipolysis 
LPL mRNA (AU) 0.94 (0.71-1.24) 0.75 (0.61-0.89) 1.03 (0.80-1.31) 0.90 (0.58-1.16) 0.082 0.293 0.305 
PLIN1 mRNA (AU) 2.04 (1.28-3.03) 1.57 (1.15-2.20) 1.73 (1.07-2.47) 1.65 (1.44-2.56) 0.302 0.756 0.297 
ATGL mRNA (AU) 1.34 (0.82-1.76) 1.08 (0.84-1.37) 1.02 (0.78-1.74) 0.95 (0.59-1.15) 0.027
c
 0.594 0.414 




0.76 (0.53-0.98) 0.53 (0.49-0.66) 0.79 (0.44-1.01) 0.62 (0.42-0.78) 0.020 0.627 0.800 
GLUT4 mRNA (AU) 1.18 (1.01-1.77) 1.95 (1.46-2.43) 1.39 (0.71-2.43) 2.33 (1.33-3.13) 0.003
b
 0.535 0.915 
IRS1 mRNA (AU) 1.17 (0.93-1.86) 1.57 (0.87-1.80) 1.41 (0.96-2.10) 1.35 (1.01-1.98) 0.945 0.360 0.772 
SMG1 mRNA (AU) 1.35 (1.05-1.67) 1.23 (1.02-1.73) 1.30 (0.97-1.70) 1.36 (1.06-2.08) 0.849 0.953 0.151 
Gluteal subcutaneous adipose tissue (gSAT)  
Adipogenesis 
PPARγ mRNA (AU) 1.15 ± 0.46 0.99 ± 0.43 1.13 ± 0.41 1.13 ± 0.46 0.325 0.403 0.471 
Lipogenesis & lipolysis 
LPL mRNA (AU) 1.34 (0.83-1.45) 1.06 (0.74-1.35) 1.04 (0.80-1.34) 0.32 (0.69-1.51) 0.095 0.964 0.529 
PLIN1 mRNA (AU) 1.97 (1.32-2.37) 1.60 (1.32-2.42) 1.83 (1.44-2.39) 1.81 (1.04-2.48) 0.232 0.918 0.844 
ATGL mRNA (AU) 1.53 (1.04-2.35) 1.20 (0.93-1.49) 1.40 (1.05-1.70) 1.02 (0.87-1.46) 0.001
b
 0.542 0.577 






0.84 (0.50-1.10) 0.52 (0.47-0.69) 0.69 (0.58-0.82) 0.64 (0.50-0.80) 0.026
c
 0.530 0.166 
GLUT4 mRNA (AU) 1.41 (1.19-1.76) 1.62 (0.78-2.70) 1.42 (0.92-1.98) 1.92 (1.24-2.27) 0.258 0.996 0.772 
IRS1 mRNA (AU) 1.08 (0.94-1.62) 1.21 (1.02-1.73) 1.31 (0.92-1.86) 1.30 (1.07-1.78) 0.439 0.405 0.626 
SMG1 mRNA (AU) 1.63 (1.14-1.83) 1.23 (1.05-1.92) 1.37 (1.11-1.63) 1.48 (1.20-1.95) 0.895 0.836 0.322 
Data presented as means ± SD for normally distributed variables and median (25th-75th percentile) for skewed variables. cP<0.05: difference pre vs 
post in the control group; bP<0.01: difference pre vs post in both groups. PPARγ: peroxisome proliferator-activated receptor gamma; LPL: lipoprotein 
lipase; PLIN1: perilipin 1; ATGL: adipose triglyceride lipase; DGAT2: diacylglycerol acyltransferase 2; GLUT4, glucose transporter 4; IRS1, insulin 




4.2.4. Correlations between changes in fatty acid composition and changes in metabolic 
parameters 
The associations between the changes in individual FAs and estimated enzyme activities 
and the changes in systemic inflammatory markers are presented in Figure 4.1. As the 
associations between these changes did not differ by group (no interaction effect), the data for 
the exercise and control groups were combined. Lower RBC-TPL DGLA and higher D5D 
activity correlated with lower circulating leptin concentrations (r=0.445; p=0.006 and r=-0.388; 
p=0.021, respectively). In contrast, lower RBC-TPL D6D activity was associated with lower 
circulating TNFα concentrations (r=0.395; p=0.025). Notably, lower RBC-TPL SCD1-16 
correlated with decreased liver fat (r=0.439, p=0.009).  
There were no significant associations between the changes of the individual FA or 
estimated enzyme activities in both SAT depots and the changes in SAT lipid metabolism or 
insulin signalling genes. Moreover, the changes in FA composition in RBC-TPL and SAT were 
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Figure 4.1. Correlations between changes in RBC fatty acids/estimated enzyme activities and changes of systemic inflammatory markers and 
liver fat in response to the exercise training intervention. Pooled data from control (n=15) and exercise (n=20) presented as changes (∆) from pre- to 
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post-intervention. r and p values are from Pearson’s pairwise correlations. DGLA: dihomo-γ-linolenic acid; D5D: delta-5-desaturase index (20:4n-6/20:3n6); 




The novel findings of this randomized controlled trial were that 12 weeks of combined 
aerobic and resistance exercise training reduced RBC-TPL SCD1-16 and D6D (tendency), and 
increased D5D estimated activities, along with a reduction of DGLA (20:3n-6). These changes 
in estimated desaturase activities (and DGLA) were associated with decreased liver fat, as well 
as lower circulating leptin and TNFα concentrations. Within the SAT depots, exercise training 
induced a reduction of individual SFAs (12:0 and 14:0) and increased individual PUFAs (20:2n-
6 and 22:4n-6) in aSAT, while in gSAT, only GLA (18:3n-6) decreased. In contrast, the 
expression of the genes involved in lipid metabolism and insulin signalling in both SAT depots 
did not change following this exercise training intervention. 
The reduction in RBC-TPL SCD1-16 activity in response to the exercise intervention 
was accompanied by a reduction in individual RBC-TPL SFAs (18:0 and 20:0). The dietary 
intake of SFA and MUFA did not change in either group over the 12-week intervention period, 
suggesting that these changes were not mediated by dietary FA intake. Rather, SCD1 is a 
marker of DNL in the liver and AT, and is responsible for the conversion of SFA to MUFA 
as previously reported (390). Increased activity of this desaturase has been associated with 
obesity, inflammation, IR and metabolic syndrome (259, 362, 380). Conversely, SCD1-
knockout mice are protected against the development of obesity, hypertriglyceridemia and IR 
(237, 239, 391). Moreover, the pharmacological inhibition of SCD1 in mice attenuated obesity-
related hepatic steatosis (392). The reduction of SCD1-16 activity is therefore suggestive of a 
beneficial metabolic effect of exercise training on circulating FA metabolism. Notably, the 
reduction of SCD1-16 activity correlated with a reduction of liver fat in the present study. 
However, there was no association between the reduction of RBC-TPL SCD1-16 (or liver fat) 
and the improvement of SI in response to exercise training. A previous study in black African 
individuals showed an inverse association between liver fat and insulin sensitivity (217), while 
others did not find this relationship (393). Moreover, although black African women have lower 
SCD1 activity than their white counterparts (389), they are less insulin sensitive (24). Hence, 
the lower activity of SCD1 in these women might explain their lower liver fat content as 
suggested by Chung et al. (389) but not the improvement in insulin sensitivity after the 12-week 
exercise training intervention.  
In addition to the reduction of SCD1-16, there was a decrease of RBC-TPL DGLA and 
D6D (trend) and an increase of RBC-TPL D5D activity in response to this exercise training 
intervention, supporting our hypothesis of favourable changes in RBC FA metabolism induced 
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by exercise training. Plasma phospholipid D6D activity and DGLA content are higher in 
overweight and obese compared to lean individuals, which have been positively correlated 
with IR (244, 259, 359, 394). Moreover, circulating DGLA concentrations have consistently 
been shown to predict the risk of developing metabolic syndrome in obese individuals across 
four independent studies (reviewed in (390)) and identified as an independent determinant of 
IR in patients with T2D (394). In the present study, the decrease in RBC-TPL D6D activity 
and the consequent reduction in DGLA content were associated with lower systemic TNFα and 
leptin concentrations. DGLA can be metabolized by cyclooxygenases and lipoxygenases to 
produce 1-series prostaglandins (e.g. PGE1) and 15-HETrE (15-(S)-hydroxy-8,11,13-
eicosatrienoic acid), capable of suppressing inflammation (359, 395). Hence, in addition to the 
lower conversion rate of LA to DGLA from the reduced D6D activity, the decrease of DGLA 
could also stem from its use as a substrate for production of mild anti-inflammatory eicosanoids 
of the 1-series, to resolve the chronic low-grade pro-inflammatory state observed during 
obesity. On the other hand, the increased RBC-TPL D5D activity may also explain the reduction 
of DGLA by increased conversion rates of DGLA to AA. However, it is surprising that there 
was no increase in AA, especially given that African Americans are genetically predisposed for 
high conversion of medium-chain to long-chain PUFA (266), with stronger associations 
between FADS variants and increased AA compared to European Americans (265, 266). 
Nonetheless, the lack of increased AA after exercise training intuitively seems advantageous as 
this FA is a precursor of several potent bioactive eicosanoid products with pro-inflammatory 
properties (e.g. prostaglandins, thromboxane’s and leukotrienes) (266). Further, the increased 
RBC-TPL D5D activity and decreased DGLA content were associated with decreased leptin 
concentrations in response to exercise training. Decreasing in D5D activity has been associated 
with high BMI, body fat and IR (244, 259, 359, 394). The findings of the present study suggest 
that the inverse association between RBC-TPL D5D activity and leptin reflect a protective, 
anti-inflammatory action of D5D on obesity-associated inflammation since leptin is a pro-
inflammatory cytokine and an important regulator of body fatness (243). The lack of 
association between the changes in RBC-TPL desaturases and DGLA content and changes in 
SI following this exercise training intervention suggest that the improvement of whole-body 
insulin sensitivity after exercise training is not mediated by the changes in circulating RBC 
FA metabolism. 
Plasma FA composition can be modulated by AT lipid turnover, which is dependent on 
the lipolysis rate in response to exercise training (138). Moreover, exercise training can alter 
the exchange rate of phospholipid FA between plasma and RBC (396). The effects of exercise 
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training on SAT FA composition and gene expression were therefore investigated to clarify the 
mechanisms implicated in the alterations of RBC-TPL FA composition, and to ascertain 
whether the changes in SAT FA composition were associated with inflammatory markers, liver 
fat and/or insulin sensitivity. A reduction in individual SFAs (12:0 and 14:0) in aSAT was 
observed after exercise training, suggesting the use of these medium-chain FA as substrates for 
β-oxidation. Indeed, exercise training can activate the FA oxidation in adipocyte mitochondria 
to produce energy (305). The oxidation rate is determined by the FA chain type (saturated or 
unsaturated) and length, with the preferential oxidation of short to medium chains compared to 
long-chain FAs (397). Exercise training further increased percentages of individual 
polyunsaturated eicosadienoic (20:2n-6) and adrenic (22:4n-6) acids in aSAT, and decreased 
GLA (18:3n-6) in gSAT in the present study. These findings suggest an FA class- and tissue-
specific effect of exercise training, as previously shown in other studies (221, 305). N-6 LC-
PUFA content in the cell membrane has been reported to increase the number of insulin 
receptors, and enhances insulin binding and action, while SFAs decrease insulin binding and 
transport (398), and induce inflammation through NFĸB/TLR4 related pathways (155). 
Therefore, the present study reports beneficial effects of exercise training via the reduction of 
individual SFAs and the increase of individual PUFAs in aSAT. These changes were not 
reflective of the changes in RBC-TPL FA composition, highlighting the tissue-specific effect 
of exercise training.  
The modifications in SAT individual FAs could not be explained by changes in body fat 
mass, as there was only a small (but significant) change in body weight and no significant 
change in fat mass percentage or SAT volume in the exercise group. This suggests that the 
changes in SAT n-6 PUFA content are not mediated by the change in AT mass as previously 
shown by Sjögren et al. (221). These changes rather seem to reflect a direct effect of exercise 
training on SAT FA and lipid metabolism. However, there were no changes in the expression 
of selected genes involved in adipogenesis (PPARγ), lipogenesis (DGAT2, LPL, PLIN1, 
GLUT4), or lipolysis (ATGL), concomitantly with unaltered desaturase activities in both SAT 
depots after this intervention. The depot-specific changes of SAT FA composition were 
therefore unlikely due to alterations in the expression of these genes but could relate to changes 
in protein expression. It is also possible that these changes were the consequences of alterations 
in other pathways, as shown that lipolysis, inflammation and oxidative stress in AT are related 
and contributes to the impairment of AT function in obese state (52, 101, 111, 134, 139). This 
hypothesis requires further investigation. The participants of this study previously had a 
sedentary lifestyle, with very low cardiorespiratory fitness (VO2peak) before participation in the 
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exercise training intervention. Thus, a longer duration of exercise training and/or higher 
intensity might be required to induce more profound changes in lipid and FA metabolism in 
SAT depots (138, 221). The lack of association between the changes in individual FAs in SAT 
depots and SI suggests that the reported improvement in SI in response to this intervention 
could have derived from modifications in other tissues such as skeletal muscle. Indeed, the 
FA composition of skeletal muscle has been associated with fasting insulin concentration and 
insulin sensitivity in normoglycemic individuals (398). 
The strength of this randomised controlled exercise training study was the objective 
measurement of FA composition both in the blood (RBC) and in two major depots of SAT, in 
combination with detailed measures of systemic inflammatory markers, SAT gene expression, 
liver fat content and SI. Moreover, the exclusion of potential confounders such as inflammatory-
related diseases and medication during participant recruitment represent strengths of this 
research work. The reported dietary data were not sufficiently detailed for quantification of 
individual dietary FA composition, which may represent a limitation. However, it is unlikely 
that this would have influenced the outcomes as no dietary recommendations were given, but 
rather the participants were instructed to maintain their habitual dietary intake.  
In conclusion, 12 weeks of exercise training altered RBC-TPL estimated desaturase 
enzyme activities by decreasing SCD1-16 and increasing D5D activity, along with a reduction 
of DGLA content and a trend for a reduction in D6D activity. These changes correlated with 
decreased liver fat content and lower circulating TNFα and leptin concentrations but were not 
associated with the improvement in SI. Within the SAT depots, individual SFAs (lauric and 
myristic acids) decreased and individual n-6 PUFAs (eicosadienoic and adrenic acids) increased 
in aSAT, but these changes were not associated with changes in SAT lipid metabolism, liver 
fat or SI. The mechanisms underlying the relationship between circulating FA profiles, 
desaturase activities, liver fat and systemic inflammation, as well as the clinical relevance of 
the changes in SAT individual FAs requires further investigation. Furthermore, the contribution 
of exercise-induced changes in AT metabolism and function in the improvement of SI needs to 
be further elucidated. Of particular interest are the inflammatory and oxidative stress pathways, 
which have previously been associated with SI, and importantly, are also subject to change 
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Obesity is associated with IR and the risk for developing T2D (134). One of the most 
accepted mechanisms linking obesity and IR is the pathological expansion of AT (134). During 
continuous energy intake exceeding energy expenditure, adipocytes progressively store excess 
lipids in the form of TGs, increasing their size and/or number. However, the pathophysiological 
expansion of AT is mainly exerted via an increase in cell size, which has been associated with 
alteration of immune cell populations and increase of pro-inflammatory processes (399). 
Activation of pro-inflammatory pathways may not only inhibit adipogenesis (400) but also 
stimulate ROS production (401). For instance, TNF-α can activate NADPH oxidase resulting 
in ROS production, and IFNγ is one of the most potent activators of macrophage-induced ROS 
production (171). On the other hand, elevated ROS concentrations can lead to IR via activation 
of inflammatory pathways such as NFkB and inhibitory phosphorylation of the insulin receptor 
(402-404). Notably, hypoxia associated with AT hypertrophy also increases macrophage 
infiltration, fibrosis and oxidative stress (405), resulting in cell damage, activation of stress 
signalling pathways, inflammatory processes and IR (401). Inflammation and oxidative stress 
are hence interrelated during obesity and are both suggested to be independent contributors to 
the development of IR (171, 406). 
The distribution of AT is more important than total body fat mass to determine the 
individual obesity-related risk for cardio-metabolic diseases. Compared to SAT,  VAT has the 
highest expression and secretion of pro-inflammatory cytokines and has been closely associated 
with IR (407). Depending on its location, the SAT also contributes to the development of 
oxidative and inflammatory phenotype (87, 408). Indeed, compared to peripheral SAT, 
abdominal SAT has a higher inflammatory profile and is negatively associated with insulin 
sensitivity (32, 408). In contrast, gluteo-femoral SAT is proposed to be “protective” against 
obesity-associated complications in obese individuals (408). Importantly, these relationships 
are modified by ethnicity (406). Black African women have more gluteo-femoral SAT and less 
VAT compared to their BMI- and age-matched white counterparts (30) but are less insulin 
sensitive (24). Linked to this, the gluteal AT depot of black African women has been shown to 
contain larger adipocytes (409) and higher expression of genes involved in hypoxia, fibrosis 
and inflammation (214), compared to white women. These findings suggest that the regulatory 
pathways underlying depot-specific AT metabolism and function and the associations with 
whole-body metabolism need to be investigated within specific ethnic groups. Further, studies 
using animal models have shown that AT from trained mice transplanted in untrained mice 
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improved their peripheral insulin sensitivity (87, 292), and the knockout of the insulin receptor 
in AT of mice (FIRKO mice) protected these animals against obesity-related glucose 
intolerance (410). Therefore, gluteal AT function might be altered in black African populations 
during excessive fat accumulation, potentially representing a link between obesity and 
impairment of insulin sensitivity in this ethnic group. Understanding the mechanisms 
underlying the causal molecular links between depot-specific AT function and obesity-
associated  IR in black African women is fundamental. This will be useful for future research 
focusing on targeted prevention and/or treatment strategies for obesity-associated 
complications in this ethnic group who is at particularly high risk for cardio-metabolic diseases 
(278).  
In this chapter, exercise training was further used as a model to evaluate the link between 
inflammation and oxidative stress and insulin sensitivity in obese black SA women. Indeed, 
exercise training has been previously shown to attenuate AT inflammation by reducing the 
expression of pro-inflammatory adipocytokines (e.g. leptin, TNFα, IL-6, IFN-γ) and increasing 
adiponectin expression in AT (298). Moreover, although less extensively studied, exercise 
training has been reported to improve oxidative stress in the obese state by reducing circulating 
ROS levels (294), decreasing lipid peroxidation (315, 319) or by increasing antioxidant enzyme 
activity in AT (315).  Further, findings from the previous chapter of this thesis (Chapter 4) 
showed an improvement of SI in response to exercise training, but this was not associated with 
changes in circulating and SAT FA composition or SAT lipid metabolism. Whether the 
exercise-induced improvement in SI is associated with changes in systemic and/or AT 
inflammation and oxidative stress in black SA women has not yet been investigated. Therefore, 
this study aimed to i) assess the effects of 12-week exercise training on systemic and depot-
specific SAT (abdominal vs gluteal) inflammatory and oxidative stress status; and to ii) 
examine the relationship between these changes and the improvement of body composition and 
insulin sensitivity in obese black SA women. This study hypothesised that exercise training 
reduces systemic oxidative stress in obese black SA women and improves SAT inflammation 









5.2.1. Participant characteristics and dietary macronutrient intake 
The adherence to this exercise training program as well as the participants’ characteristics 
has been presented in Chapter 4 (Table 4.1). In brief, cardiorespiratory fitness and body 
composition were not different between the groups at baseline. Following the exercise training 
intervention, VO2peak (ml/kg/min) increased in the exercise group only (p<0.01). There were 
small but significant decreases in body weight, BMI, WC and gynoid FM (%) in the exercise 
group (p<0.01). In contrast, body weight, BMI, WC (p<0.01) and SAT volume (p<0.05) 
increased in the control group. Liver fat tended to decrease in the exercise group (p=0.074), 
with no changes in the control group (p=0.356). Notably, SI improved in the exercise compared 
to control group (median of 2.04 to 2.17 x10-4(mU/L)-1min-1 vs. 2.01 to 1.83 x10-4(mU/L)-1min-1, 
respectively; p<0.05 for interaction). No changes in circulating inflammatory markers were 
observed in both groups and dietary energy, macronutrient and FA intake were not significantly 
different between the groups and did not change in response to the intervention (as presented 
in Table 4.2 of Chapter 4). 
Protein expression in SAT depots was analysed in a sub-sample of participants in the 
present study. The characteristics of the sub-sample selected for this analysis are presented in 
Table 5.1. These participants had similar cardio-respiratory fitness, BMI and SI between the 
groups at baseline. Following the intervention period, VO2peak and SI increased in the exercise 
group (p<0.05) with no significant changes in the control group (p>0.05, Table 5.1). Moreover, 
weight, BMI and SAT volume decreased in the exercise group (p<0.01) and increased in the 
control group (p<0.05). Gynoid fat and WC decreased in the exercise group (p<0.05) and was 
unchanged in the control group (p>0.05; Table 5.1). Notably, the basic characteristics of the 










Table 5.1. Characteristics data (pre and post-exercise training) from the sub-sample 
selected for adipose tissue protein analysis.  
Values are means ± SD for normally distributed variables and median (25th - 75th percentile) for non-
normally distributed variables; *p<0.05 and **p<0.01 represent the difference post vs pre in each 
group. BMI: body mass index; WC: waist circumference; FM: fat-mass; VAT: visceral adipose tissue; 
SAT: subcutaneous adipose tissue; VO2peak: maximal oxygen uptake, used as a measure of 
cardiorespiratory fitness; SI: insulin sensitivity. 
  












Cardio-respiratory fitness  
  








0.398 0.122 0.521 
VO2peak (ml/kg) (26.3 ± 2.5) (28.9 ± 2.8)* (23.1 ± 2.9) (23.4 ± 3.0) 0.104 0.020 0.181 
Body composition 
  
Weight (kg) (79.3 ± 8.7) (77.7 ±9.1)** (88.1 ± 15.2) (90.4 ± 15.0)** 0.207 0.246 <0.001 
BMI (kg/m²) (33.1 ± 3.1) (32.4 ± 3.3)** (33.0 ± 3.0) (33.9 ±3.1)** 0.740 0.427 <0.001 
WC (cm) (98.4 ± 5.4) (95.6 ± 6.1)* (102.0 ± 7.5)  (106.8 ± 7.5) 0.097 0.535 0.043 
Body FM (%) (50.3 ± 1.6) (48.6 ± 1.8) (51.6 ± 4.2) (51.3 ± 4.2) 0.334 0.077 0.154 
Android FM 
(%) 
(8.3 ± 1.8) (8.1 ± 1.8) (7.9 ± 1.3) (7.9 ± 1.6) 0.811 0.368 0.356 
Gynoid FM (%) (17.8 ± 2.3) (17.4 ± 2.3)* (18.7 ± 2.8) (18.7 ± 2.8) 0.518 0.121 0.024 








0.952 0.362 0.084 








0.454 0.330 0.002 
Insulin sensitivity   
SIx10-4(mU/L)-
1min-1 
1.2 (0.9-1.3) 2.3 (1.4-2.6)* 2.0 (1.3-3.1) 1.8 (1.6-3.1) 0.040 0.092 0.158 
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5.2.2.  Systemic oxidative stress markers in response to the intervention 
Circulating markers of oxidative stress were altered in response to the exercise training 
and were unchanged in the control group (Table 5.2). Specifically, circulating TBARS 
concentrations decreased (p<0.01) while catalase activity increased (p<0.05) in the exercise 
group only. There was a tendency for SOD activity to increase (p<0.1) in the exercise group 
and there were no changes in total antioxidant capacity (ORAC) in both groups in response to 
the intervention.  
 
 
Table 5.2. Changes in systemic oxidative stress markers in response to the 12-week 
exercise intervention in exercise and control groups 
Values are presented as median (interquartile range); **P<0.01, *P <0.05 and #P<0.1 represent the 
difference between post vs pre in the exercise group after the intervention (post-hoc). TBARS: 
thiobarbituric acid reactive substances; SOD: superoxide dismutase; ORAC: oxygen radical 
absorbance capacity. 
  
Variables CONTROL (n=15) EXERCISE (n=20) P VALUES 
 




0.46 (0.42-0.49) 0.48 (0.44-0.51) 0.49 (0.44-0.52) 0.46 (0.43-0.49)* 0.797 0.168 0.003 
Catalase 
(UI/mg) 
0.67 (0.27-1.97) 1.21 (0.55-1.85) 0.80 (0.37-1.51) 1.04 (0.74-1.74)* 0.842 0.201 0.091 
SOD  
(UI/mg) 
0.17 (0.03-0.62) 0.21 (0.04-0.65) 0.21 (0.14-0.52) 0.32 (0.17-0.48)# 0.300 0.049 0.672 
ORAC 
(nmol/L/mg)  
823.3        
(769.2-1080.8) 






0.554 0.826 0.918 
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5.2.3. Gene and protein expression in subcutaneous adipose tissue  
The expression of selected genes and protein levels were compared between the depots 
at baseline to evaluate depot-specific inflammatory and oxidative profiles (Table 5.3). Leptin 
mRNA content was higher in gSAT compared to aSAT (p<0.01) with no difference in 
adiponectin mRNA content. In terms of protein levels, MIF, MCP1, NFĸBp65 and TNFα 
(detected at 12kDa, 25kDa, 65kDa and 25kDa respectively) were higher in aSAT than gSAT at 
baseline (p<0.05) without a difference in their mRNA content.  
 
Table 5.3. Comparison of gene and protein expression between the gluteal (gSAT) and 
abdominal (aSAT) subcutaneous adipose tissue depots at baseline 
 
gSAT aSAT P value 
  Gene ID and definition     
ADIPOQ Adiponectin 0.76 ± 0.31 0.79 ± 0.31 0.619 
MCP1 Monocyte chemoattractant protein 1 1.16 ± 1.02 1.37 ± 1.25  0.216 
IL-10 Interleukin 10 0.72 ± 0.43 0.73 ± 0.54 0.331 
LEP Leptin 1.57 ± 0.97  1.22 ± 0.79 0.008** 
MIF Macrophage migration inhibitory factor 0.73 ± 0.25  0.74 ± 0.30  0.880 
NFκB1 Nuclear factor kappa B 1.48 ± 0.53 1.56 ± 0.64 0.501 
TLR4 Toll like receptor 4 1.78 ± 1.03 1.94 ± 1.25 0.385 
TNFα Tumor necrosis factor alpha 1.10 ± 0.49 1.04 ± 0.56 0.277 
CAT Catalase 1.78 ± 0.54 1.82 ± 0.62 0.896 
NOS3 Nitric oxide synthase 1.49 ± 0.64 1.47 ± 0.86 0.243 
SOD Superoxide dismutase 2.01 ± 0.53 1.97 ± 0.84 0.337 
Protein ID and definition    
ADIP Adiponectin 3.46 ± 3.33 4.28 ± 2.82 0.536 
MCP1 Monocyte chemoattractant protein 1 0.87 ± 1.37 1.25 ± 1.06 0.019* 
IL-10 Interleukin 10 0.59 ± 0.48 1.20 ± 1.28 0.722 
LEP Leptin 1.22 ± 0.82 2.17 ± 2.73 0.076 
MIF Macrophage migration inhibitory factor 1.25 ± 0.84 2.83 ± 1.16 0.001* 
NFκBp65 Nuclear factor kappa B p65 0.50 ± 0.77 0.63 ± 0.51 0.018* 
TLR4 Toll like receptor 4 0.69 ± 1.11 0.86 ± 0.95 0.773 
TNFα Tumor necrosis factor alpha 1.03 ± 1.01 2.47 ± 2.13 0.001* 
Values are estimated means ± SD (n=41) and p values represent the t-test difference between the depots 




The changes in gene and protein expression in response to exercise training are presented 
in Figure 5.1. In gSAT, IL-10 mRNA increased in the exercise group (p<0.001) but remained 
unchanged in the control group (p=0.016 for group x time interaction) and IL-10 protein level 
(detected at 25 kDa) did not change in both groups. There was a significant group effect for 
gSAT NFĸB1 and TNFα mRNA (p=0.011 and p=0.025 respectively), such that the expression 
of these genes was significantly higher in the exercise compared to the control group at 12 
weeks (p<0.01). Of note, TNFα mRNA in aSAT tended to increase in both groups after the 
intervention (p<0.05 in control and p<0.1 in exercise group). In gSAT, the expression of none 
of the proteins changed following this intervention, whereas in aSAT, NFĸBp65 (detected at 
65kDa) and TLR4 (detected at 70kDa) proteins decreased in the exercise group (p<0.05, time 
effect), with no changes reported in the control group (Figure 5.1). Furthermore, gSAT MIF 
mRNA decreased in the control group only (p=0.037 for group x time interaction) and was 
significantly lower in this group compared to the exercise group at 12 weeks (p=0.001). MIF 
protein expression decreased in aSAT of both groups (p<0.05). MCP1 mRNA content did not 
change in both depot and groups, whereas aSAT MCP1 protein tended to decrease in the 
exercise group (p=0.087, for time effect), with no changes in the control group (Figure 5.1).  
Leptin protein (detected around 25kDa) and mRNA contents did not change in response 
to exercise training. Moreover, adiponectin mRNA (in both depots) tended to decrease in 
control group while the protein level (detected at 30 kDa) tended to decrease in aSAT of both 
groups (p<0.05 and p<0.1). The levels of NOS3, SOD and catalase mRNA were not different 
at baseline between the depots and did not change in response to the intervention 
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Figure 5.1. Effect of exercise training on gluteal (gSAT) and abdominal subcutaneous 
adipose tissue (aSAT) inflammatory gene (A-F) and protein (G-L) expression. 
°P<0.1; *P <0.05 and **P<0.01: pre vs post within groups following the intervention (time effect). δP<0.05: 
interaction between groups throughout the intervention. #P < 0.01: differences between groups at post-
intervention (ie. group effect at 12 weeks). Control group n=15, both depots and exercise group n=20 in aSAT 
and n=18 in gSAT at post-training due to biopsy interruption. IL-10: interleukin-10; MCP1: monocyte 
chemoattractant protein 1; MIF: Macrophage migration inhibitory factor; NFκB: nuclear factor kappa B; TLR4: 
toll-like receptor 4; TNFα: tumor necrosis factor-alpha. 
 
5.2.4. Correlations between changes of inflammatory markers and changes in body 
composition and insulin sensitivity/resistance over the intervention period 
As the relationship between the changes in inflammatory and oxidative stress markers 
and changes in body composition and insulin sensitivity/resistance over the 12 weeks did not 
differ between groups (no interaction effect), the data from both groups were combined for the 
correlation analyses. An increase in gSAT MCP1 and TNFα mRNA was associated with a 
decrease in BMI (p<0.01; Figure 5.2), while an increase of gSAT IL-10 and MIF mRNA 
correlated with the reduction in gynoid FM (%) (p<0.05 and p<0.001 respectively; Figure 5.2). 
No significant associations were found between changes in aSAT gene expression and changes 
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Figure 5.2. Correlations between changes in gluteal (gSAT) and abdominal (aSAT) 
subcutaneous mRNA expression and changes in body composition in response to the 
intervention. Pooled data from control (n=15, both depots) and exercise (gSAT n=18) presented as 
changes (∆) from pre- to post-intervention. R and P values are from Pearson’s pairwise correlations. 
 
In terms of protein levels, these data can only be regarded as a pilot study due to the small 
sample size. Nevertheless, there was a tendency for the decrease in gynoid to be associated with 
decrease in aSAT MCP1 (r=0.843, p=0.004), NFĸBp65 (r=0.616, p=0.077) and TLR4 (r=0.857, 
p=0.030).  
The changes in systemic and SAT inflammatory markers (genes and proteins) were not 
associated with changes in SI. However, the change of circulating TNFα and MCP1 
concentrations were positively associated with changes of HOMA2IR (Figure 5.3), and this 
remained significant when adjusting for changes in BMI or gynoid FM (%) (p<0.05). Besides, 
changes of aSAT IL-10 and TLR4 mRNA content were positively associated with changes of 
HOMA2-IR (Figure 5.3), even after adjusting for changes in BMI (p=0.018 and p=0.014) or 
in gynoid FM (%) (p=0.009, p=0.011), respectively. Notably, changes in gSAT inflammatory 
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Figure 5.3. Correlations between changes in systemic inflammatory markers and 
abdominal subcutaneous adipose tissue (aSAT) mRNA expression and changes in insulin 
resistance (HOMA2-IR). Pooled data from control (n=15) and exercise (n=20) presented as 
changes (∆) from pre- to post-intervention. R and P values are from Pearson’s pairwise correlations.  
 
5.2.5. Correlations between changes in oxidative stress and inflammatory genes 
When exploring the associations between transcript levels of oxidative stress markers and 
inflammatory markers in the SAT depots, we found that gSAT levels of MIF, NFĸB1 and TNFα 
mRNA were positively correlated with gSAT SOD1 (MIF r=0.289 p=0.114; NFκB1 r=0.459 
p=0.010; TNFα r=0.422 p=0.018) and catalase (MIF r=0.399 p=0.026; NFκB1 r=0.568 
p<0.001; TNFα r=0.537 p=0.002) mRNA content. There were no significant correlations 
between inflammatory and oxidative markers in aSAT, and no associations between SAT 
mRNA and circulating levels of systemic markers of inflammation and oxidative stress. 
5.3. DISCUSSION 
This is to the best of my knowledge, the first study in women of African ancestry that has 
evaluated changes in SAT depot-specific and systemic inflammatory and oxidative stress 
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markers in response to an exercise training intervention. As reported in the previous chapter on 
this thesis (Chapter 4), the 12 weeks of combined aerobic and resistance exercise training 
resulted in significant improvements in SI, cardiorespiratory fitness and body composition, but 
did not reduce circulating markers of inflammation. In contrast, the present study showed that 
circulating TBARS concentrations, a by-product of lipid peroxidation by ROS decreased with 
a concomitant increase in circulating antioxidant enzyme activity, mainly catalase. Notably, 
exercise training increased gSAT IL-10, TNFα, NFĸB1 and MIF mRNA contents with a trend 
for aSAT MCP1, NFĸBp65 and TLR4 protein levels to decrease. These changes did not 
correlate with the improvement in SI but were rather associated with the reduction of gynoid fat 
mass. Moreover, changes in aSAT IL-10 and TLR4 mRNA were positively associated with 
changes in HOMA2-IR in response to the intervention and these were independent of changes 
in body composition.  
The effect of exercise training on systemic inflammation in obese cohorts has been 
extensively studied but findings remain controversial. Some studies showed a reduction of 
systemic inflammatory markers after exercise training (311, 313), while others found no 
changes in these markers (411, 412). In the present study, there were no changes in circulating 
concentrations of leptin, adiponectin, CRP, TNFα, MCP1 and IL-8 after 12 weeks of exercise 
training. This may relate to the duration of the intervention and/or the limited effects that 
exercise training has on weight loss and body fat mass, with the small (≈1 kg) but significant 
decrease in body weight in the exercise group, whereas body weight, BMI and WC increased 
in the control group. Of note, the increased weight in the control group, although instructed to 
maintain their normal daily (physical activity and food intake) habits, is reflective of the typical 
changes in body weight expected in this group of young women (413). Contrary to the lack of 
changes in systemic inflammatory markers, Cordova et al. showed a reduction of cytokine 
levels (IFNγ, IL-6, TNFα) after 8 months of resistance training in obese women (311) and 
Trachta et al showed a decrease in circulating CRP with a decline in body fat of 4.1% after 3 
months of aerobic exercise training (313). The differences in exercise duration and total fat 
mass reduction between these interventions and the present study could explain these 
discrepancies in changes in systemic inflammation in response to exercise training. 
Inflammation and oxidative stress are interrelated during obesity, both contributing to the 
development of IR (171). While this study reported no changes in inflammatory markers, there 
was a decrease in TBARS and an increase in antioxidant enzyme activity, mainly catalase. 
Likewise, Oh et al. showed an increase of the glutathione peroxidase after 6 months of aerobic 
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training that was accompanied by a reduction of body weight (414). In contrast, 8 weeks of 
high-intensity exercise training without changes in body weight did not improve oxidative stress 
and inflammatory state in obese adolescents (415). Catalase and SOD represent the primary 
antioxidant protection against the harmful effects of ROS and contribute to lower oxidative 
stress and cell damage (416). The accumulation of modified “ROS-damaged” proteins can lead 
to IR by activating IĸB via p38 mitogen-activated protein kinase (MAPK), followed by the 
activation of NFĸB (403). Elevated ROS can also activate serine/threonine phosphorylation of 
insulin receptor substrate-1 (IRS1) leading to IR (403, 404). However, there were no 
associations between the changes in circulating TBARS levels, catalase and SOD activities and 
the improvement of SI. The maintenance of a balanced oxidative stress status seems to reflect 
the beneficial effect of exercise training on body fat, but not a direct mechanism in the 
improvement of SI in these women.  
The distribution of body fat (abdominal vs. gluteo-femoral) is distinctively associated 
with metabolic risks, due to the different biological properties and metabolism of SAT depots 
(61). When comparing the gene expression between aSAT and gSAT at baseline, leptin mRNA 
level was higher in gSAT. Gluteal SAT has been shown to have larger adipocytes compared to 
aSAT in this population (36) and a strong positive correlation between cell size and leptin 
mRNA have been reported (309). These findings support the role of leptin as a signal of fat 
mass (and its effect on adipocytes metabolism). In contrast, MIF, MCP1, NFĸBp65 and TNFα 
protein levels tended to be higher in aSAT compare to gSAT at baseline. This can be explained 
by the pronounced inflammatory profile previously reported in upper body fat compared to 
peripheral fat (61). Additionally, aSAT is a major source of FFA, which are a determinant link 
between obesity and adipose inflammation (190).  
Surprisingly, the gene expression of the inflammatory markers in gSAT at 12 weeks 
(post-intervention) increased in response to this exercise training intervention, and this was 
associated with the reduction in gynoid fat mass, but not with the improvement in SI. 
Noteworthy, the samples analysed in this study were collected 3 days after the last exercise 
training session to exclude the potential acute effects of the last bout of exercise training. The 
increase in inflammatory gene expression in the gSAT seems to be an adaptive response to fat 
mass reduction (417), potentially representing a remodelling process occurring within this 
tissue. Indeed, the AT inflammatory state is modulated during expansion and/or remodelling of 
this tissue (418). Additionally, recent evidence showed that inflammation in the adipocyte 
microenvironment is required for ECM remodelling and angiogenesis (147, 419). Fat mass 
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reduction, driven by an overall reduction of stored TGs consecutive to lipolysis,  requires 
extensive remodelling of the tissue (420, 421). Exercise training has been shown to increase 
basal and/or stimulated adipocyte lipolysis (422, 423). The FFA released from adipocytes (from 
both basal and exercise-induced stimulated lipolysis) activate monocytes and create a paracrine 
loop between lipolysis and local inflammation (156), increasing the inflammatory state in the 
fat depot. The increased IL-10 mRNA content in gSAT is supported by previous findings 
showing that the reduction of stored TGs in adipocytes is followed by an increased expression 
of lipolysis-associated M2 macrophage markers (424, 425). IL-10 activates M2 macrophages 
for tissue repair and may also be a compensatory mechanism to cope with the increased 
inflammation. Although there was no change in the genes involved in lipid metabolism 
presented in Chapter 4, it cannot be concluded that SAT lipolysis was not enhanced after this 
exercise training intervention, as only ATGL and PLIN1 mRNA expression were evaluated as 
markers of lipolysis. The changes could have therefore derived from the increase of other 
proteins such as HSL or MGL, and this is acknowledged as a limitation of this study. Increased 
inflammation can subsequently influence the oxidative stress state. Accordingly, there was a 
strong positive association between the expression of inflammatory genes (MIF, NFĸB1 and 
TNFα mRNA) and antioxidant enzymes (catalase and SOD1 mRNA) in gSAT. Inflammatory 
markers such as TNFα can trigger the activation of NADPH oxidase and the production of ROS 
(171), followed by increased expression of antioxidant enzymes to buffer and maintain a 
“healthy” oxidative stress balance  (426). 
In contrast to the response in gSAT, aSAT inflammatory genes did not change after this 
intervention potentially explained by the unchanged android fat mass in the present study. This 
is in accordance with data provided by Lakhdar et al. who also did not find changes in aSAT 
inflammatory markers in response to 12 weeks of moderate exercise training, despite the 
expected improvements in body composition (411). However, there was a reduction trend for 
NFĸBp65, TLR4 and MCP1 protein expression in the aSAT depot in response to exercise 
training, albeit in a sub-sample of participants. Khadir et al. also showed that 3 months of an 
aerobic exercise program decreased IL-6 and TNF-α protein expression in the aSAT of diabetic 
and non-diabetic obese patients (427) suggesting a beneficial effect of exercise training. In the 
present study, the decrease of inflammatory proteins in aSAT also tended to be associated with 
the reduction of gynoid fat, suggesting a favourable effect of lower-body fat loss following 
exercise training on abdominal inflammation. However, it is important to note that the protein 
analyses were undertaken in a small sub-sample of participants, which prevented me from 
making conclusive statements from these results. Nevertheless, I hypothesise that the reduction 
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in gynoid fat may reflect the “flexibility” of gSAT, providing additional storage space for future 
excess FFA in times of positive calorie balance. This would thereby limit redirection of excess 
FFA to upper-body central and ectopic depots and consequently, reduce inflammation 
associated with abdominal fat accumulation. 
Another important finding of this study was that although no improvements in HOMA-
2IR were observed, there was a positive association between changes in HOMA-2IR and 
changes in aSAT IL-10 and TLR4 mRNA content in response to the exercise training. In contrast 
to the whole-body SI, estimated using the FSIGT, HOMA-2IR is based on fasting measures of 
insulin and glucose and is more representative of hepatic IR (428). Hence, this study showed a 
linear relationship between abdominal inflammation and estimated hepatic IR. However, to 
show an improvement in hepatic IR following exercise training, a more profound and sustained 
alteration of aSAT inflammatory profile, which may only be achieved by a pronounced 
reduction in abdominal fat mass, may be required (411). Furthermore, the concomitant absence 
of association between aSAT inflammatory profile and SI is supported by a previous study 
where inflammation in this depot was weakly correlated with SI (201).  
The discrepancies found between mRNA and protein levels are supported by Wang’s 
findings showing a weak correlation between mRNA and protein abundance (429). Indeed, 
RNA and protein molecules represent different steps of the cellular genetic information and are 
dynamically produced and degraded. These differential changes could be the result of features 
of the gene expression machinery at the transcriptional and translational levels, the speed of 
transportation as well as the degradation (RNA and protein) processes (reviewed in (429)).  
This is the first study which robustly measured the effect of exercise training on systemic 
and depot-specific SAT inflammation and oxidative stress in obese women of African ancestry, 
which makes the findings unique, relevant and novel. However, some limitations should be 
mentioned. In addition to the analysis of protein content in only a sub-sample of participants 
(due to tissue availability and cost), NFkBp65 protein content and not the phosphorylation 
status was assessed, which is preferred measured as an indication of pro-inflammatory state. 
Moreover, the limited number of evaluated genes represents another limitation of this research 
work. Further studies exploring differences between SAT inflammatory markers at both the 
transcriptional and translational levels in response to exercise training in larger sample size is 
needed. This will help to gain a better understanding of the role of SAT inflammation and ROS 
in the exercise-induced changes in metabolic status. Notably, this study was restricted to young 
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black SA women and therefore, the findings cannot be directly translated to other groups of 
obese individuals with different phenotypes and/or age, sex, socioeconomic and health status.  
In conclusion, 12-weeks of aerobic and resistance exercise training program improved 
systemic oxidative stress markers, increased inflammatory mRNA levels in gSAT and reduced 
pro-inflammatory protein levels in aSAT. These changes were associated with the reduction of 
gynoid fat but were not correlated with the improvement in whole-body insulin sensitivity in 
obese black SA women. Further investigations are required to evaluate other regulatory 
pathways in AT that could determine the beneficial effects of exercise training on SI. This can 
be addressed by using a non-targeted analysis approach to explore the unrevealed pathways that 
may be affected by exercise training and that are associated with improved SAT function, as 








DISTINCT ABDOMINAL AND GLUTEAL ADIPOSE TISSUE TRANSCRIPTOME 





Body fat distribution is an independent contributor to the development of obesity-
associated metabolic diseases (38, 40). While central fat accumulation (both in visceral and 
abdominal subcutaneous areas) has been associated with greater risk for developing metabolic 
diseases, lower-body fat (gluteo-femoral) appears to have positive effects on metabolic health 
(39, 58, 59). The mechanisms underlying these depot-specific associations with metabolic risks 
are not fully understood. However, environmental and genetic factors could mediate differences 
in gene expression, metabolism and function between fat depots (430, 431).  
The accumulation of AT during positive energy balance follows a specific individual 
pattern, with the preferential expansion of subcutaneous vs. visceral depot, largely determined 
by heritable factors (38). This specific response to energy intake could also be influenced by 
site-specific sets of developmental genes (81, 432). Numerous studies have reported an 
extensive number of differentially expressed genes (DEGs) between VAT and SAT (both 
abdominal and gluteal) (39, 61, 432, 433). This suggests different developmental lineage, 
potentially explaining depot-specific adipose metabolism and association with metabolic risk. 
However, whether the difference in embryonic origin exists within SAT depots remains elusive. 
Indeed, in addition to their functional differences and their distinctive associations with 
metabolic risk, evidence showed epigenetic differences between aSAT and gSAT (59, 78, 79, 
432). However, these findings were mainly derived from studies in European populations and 
no data is available on the depot-specific SAT transcriptome profile exclusively in an African 
population. This highlights the need to study SAT signatures in Africans to understand the role 
of this tissue in the development of IR and T2D. Indeed, differential patterns of body fat 
distribution and association with IR have been found between obese black and white SA women 
(32, 34, 70). Moreover, there is evidence to suggest impaired adipogenesis and high hypoxic 
and fibrotic state in SAT of obese black SA women (214), suggesting that the gene expression 
profile of SAT depots is ethnic-specific and consequently, might play a role in the divergent 
metabolic profiles in African compared to European women.  
It is known that exercise training affects several metabolic pathways in AT, which directly 
or indirectly contribute to the improvement of glucose homeostasis and insulin sensitivity (293). 
Findings from the previous chapters of this thesis (Chapter 4 and Chapter 5) showed SAT depot-
specific adaptations to exercise training in obese black SA women. However, this was limited 
to a candidate gene approach, focusing on a small number of genes involved in inflammation, 
oxidative stress, lipid metabolism, adipogenesis and insulin signalling.  The extent of these 
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changes on SAT transcriptome has not been investigated in African populations. The 
microarray technology represents a great instrument to identify and explore other potential 
pathways in SAT function that might be influencing peripheral or whole-body insulin 
sensitivity in these women at rest and after chronic exercise training. Therefore, using an 
unbiased microarray analysis approach, this study aimed to evaluate the regional differences in 
gene expression profiles between aSAT and gSAT in obese black SA women and tested the 
hypothesis that the gene expression pattern is altered in a depot-specific manner in response to 
12-weeks of exercise training. These different transcriptome signatures might be driving their 
distinctive functional responses to external stimuli such as exercise training, potentially 




6.2.1. Participants’ characteristics 
The basic characteristics of the participants involved in this study are presented in Table 
6.1 below. The women were on average 23 ± 3 years of age and had a BMI of 33.8 ± 2.6 kg/m². 
In response to exercise training, cardiorespiratory fitness (VO2peak) increased (p<0.05), and 
weight, BMI, WC, waist/hip ratio (WHR) decreased. While total body fat (%) did not change, 
both android and gynoid fat mass (%) decreased (p<0.05), and there was a tendency for VAT 






























                                          
 
 
Data presented as means ± SD; p values represent the differences between baseline and post-training. 
VO2peak, peak oxygen consumption, used as a measure of cardiorespiratory fitness; BMI: body mass 
index; WC: waist circumference; WHR: waist and hip ratio; FM: fat-mass; VAT: visceral adipose 
tissue; SAT: subcutaneous adipose tissue. 
  
Variables  Pre (n=12) Post (n=12) P Value 
Cardiorespiratory fitness 
VO2peak (ml/min) 2121 ± 217 2245 ± 204 0.023 
VO2peak (ml/kg/min) 25.9 ± 2.2 28.0 ± 2.6 0.008 
Body composition    
Weight (kg) 82.2 ± 7.2 80.5 ± 7.5 0.004 
BMI (kg/m²) 33.8 ± 2.6 33.1 ± 2.8 0.004 
WC (cm) 102.0 ± 5.5 97.7 ± 5.42 0.002 
WHR 0.90 ± 0.09 0.88 ± 0.06 0.019 
Body FM (%) 49.7 ± 1.6 49.1 ± 1.5 0.205 
Android FM (%) 8.4 ± 1.1 8.2 ± 1.2 0.010 
Gynoid FM (%) 6.8 ± 1.0 6.6 ± 1.0 0.033 
VAT (cm3) 971 ± 330 909 ± 384 0.086 
SAT (cm3) 5451 ± 803 5266 ± 944 0.062 
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6.2.2. Differential gene expression profiles in subcutaneous adipose depots at baseline 
and in response to exercise training 
The differences in gene expression profiles between aSAT and gSAT at baseline and after 
exercise training are presented in Figure 6.1A and Figure 6.1B, respectively. At baseline, only 
15 genes were differentially expressed between aSAT and gSAT (|LFC|≥ 0.58; p ≤ 0.05) with 
the expression of 13 genes being higher and 2 genes were lower in aSAT vs. gSAT (Figure 
6.1A; Table 6.2). In contrast, a total of 318 DEGs were identified between the depots after 
exercise training (Figure 6.1B); with 166 genes higher and 152 genes lower in aSAT vs gSAT 
(Table 6.3 for the top 10 DEGs; Supplementary Table 6.1 for the complete list of DEGs). 
Notably, 11 of these genes overlapped between the SAT depots before and after exercise 
training (Figure 6.1C). The most prominent genes distinguishing the SAT depots at both time 
points (highlighted in bold in Tables 6.2 and Table 6.3) were DMRT2, DMRT3, and HOXA5, 
with higher expression levels in aSAT compared to gSAT; as well as CSN1S1, with lower 
expression in aSAT vs gSAT. Several homeobox (HOX) genes had higher expression levels in 
aSAT than in gSAT at baseline or after exercise training (HOXA3, HOXA5, HOXA9, HOXB5, 
HOXB8, HOPX, IRX2 and IRX5). The evaluation of the biological processes represented by the 
DEGs between the depots at both time points using STRING showed that they were mainly 
enriched for GO terms: embryonic development, anatomical structure and developmental 
processes at baseline (Figure 6.2), and more diverse functional-related processes at post-







    
Figure 6.1. Comparison of abdominal SAT vs gluteal SAT, before (A) and after (B) 
exercise training, respectively.  
The volcano plots highlight genes with p-value < 0.001 and fold change |LFC| > 0.58. Blue: higher 
gene expression in aSAT (LFC <-0.58); Red: lower gene expression in aSAT (LFC > 0.58); Orange: p-
value < 0.001. The horizontal line corresponds to p < 0.001 and the vertical lines mark a |LFC| > 0.58. 
A: aSAT vs gSAT at baseline. B: aSAT vs gSAT after exercise training. C: Overlap of genes with changed 
expression (|LFC|>0.58) between aSAT and gSAT. PRE: difference between aSAT and gSAT pre-







Table 6.2. List of all differentially expressed genes between SAT depots (up and down-
regulated) before exercise training based on log2 fold change > 0.58  
 
SYMBOL SEARCH_KEY logFC DEFINITION 
Higher in aSAT than gSAT 
DMRT2 NM_181872.1 -1.11 Homo sapiens doublesex and mab-3 related transcription 
factor 2 (DMRT2), transcript variant 1, mRNA. 
HOXA5 NM_019102.2 -1.11 Homo sapiens homeobox A5 (HOXA5), mRNA. 
DMRT3 NM_021240.2 -0.92 Homo sapiens doublesex and mab-3 related transcription 
factor 3 (DMRT3), mRNA. 
RSPO3 NM_032784.3 -0.86 Homo sapiens R-spondin 3 homolog (Xenopus laevis) (RSPO3), 
mRNA. 
IRX2 NM_033267.2 -0.85 Homo sapiens iroquois homeobox 2 (IRX2), mRNA. 
C6 NM_000065.1 -0.82 Homo sapiens complement component 6 (C6), mRNA. 
ALDH1A1 NM_000689.3 -0.81 Homo sapiens aldehyde dehydrogenase 1 family, member A1 
(ALDH1A1), mRNA. 
ALDH1A1 NM_000689.3 -0.66 Homo sapiens aldehyde dehydrogenase 1 family, member A1 
(ALDH1A1), mRNA. 
HOXB8 NM_024016.2 -0.63 Homo sapiens homeobox B8 (HOXB8), mRNA. 
FGFBP2 NM_031950.2 -0.62 Homo sapiens fibroblast growth factor binding protein 2 
(FGFBP2), mRNA. 
IRX5 NM_005853.4 -0.62 Homo sapiens iroquois homeobox protein 5 (IRX5), mRNA. 
LOC440928 XM_942885.1 -0.61 PREDICTED: Homo sapiens hypothetical LOC440928 
(LOC440928), mRNA. 
PPP1R1B NM_181505.1 -0.59 Homo sapiens protein phosphatase 1, regulatory (inhibitor) 
subunit 1B (dopamine and cAMP regulated phosphoprotein, 
DARPP-32) (PPP1R1B), transcript variant 2, mRNA. 
Lower in aSAT than gSAT 
CSN1S1 NM_001890.1 0.90 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 






Table 6.3. Top 10 differentially expressed genes between SAT depots (up and down-
regulated) after exercise training based on log2 fold change > 0.58  
SYMBOL SEARCH_KEY logFC DEFINITION 
Higher in aSAT than gSAT 
HOXA5 NM_019102.2 -1.44 Homo sapiens homeobox A5 (HOXA5), mRNA. 
DMRT2 NM_181872.1 -1.41 Homo sapiens doublesex and mab-3 related transcription factor 
2 (DMRT2), transcript variant 1, mRNA. 
DMRT3 NM_021240.2 -1.35 Homo sapiens doublesex and mab-3 related transcription factor 
3 (DMRT3), mRNA. 
MYL2 NM_000432.2 -1.15 Homo sapiens myosin, light chain 2, regulatory, cardiac, slow 
(MYL2), mRNA. 
CDKN1B NM_004064.2 -1.10 Homo sapiens cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
(CDKN1B), mRNA. 
MYH11 NM_002474.1 -1.07 Homo sapiens myosin, heavy chain 11, smooth muscle (MYH11), 
transcript variant SM1A, mRNA. 
ANGPT2 NM_001118888.1 -1.06 Homo sapiens angiopoietin 2 (ANGPT2), transcript variant 3, 
mRNA. 
LOC649841 XM_938906.1 -1.05 PREDICTED: Homo sapiens similar to protein immuno-reactive 
with anti-PTH polyclonal antibodies (LOC649841), mRNA. 
PARM1 NM_015393.2 -1.05 Homo sapiens prostate androgen-regulated mucin-like protein 1 
(PARM1), mRNA. 
MYH7 NM_000257.1 -1.05 Homo sapiens myosin, heavy chain 7, cardiac muscle, beta 
(MYH7), mRNA. 
Lower in aSAT than gSAT 
CSN1S1 NM_001025104.1 1.37 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 
SPP1 NM_001040058.1 1.25 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript variant 
1, mRNA. 
LOC644936 NR_004845.1 1.22 Homo sapiens cytoplasmic beta-actin pseudogene (LOC644936), 
non-coding RNA. 
IFI30 NM_006332.3 1.17 Homo sapiens interferon, gamma-inducible protein 30 (IFI30), 
mRNA. 
LAPTM5 NM_006762.1 1.17 Homo sapiens lysosomal multispanning membrane protein 5 
(LAPTM5), mRNA. 
SPP1 NM_000582.2 1.16 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript variant 
2, mRNA. 
FCGBP NM_003890.1 1.15 Homo sapiens Fc fragment of IgG binding protein (FCGBP), 
mRNA. 
TM4SF19 NM_138461.1 1.13 PREDICTED: Homo sapiens transmembrane 4 L six family 
member 19, transcript variant 2 (TM4SF19), mRNA. 
CSN1S1 NM_001890.1 1.12 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 






   
Figure 6.2. GO term enrichment of differentially expressed genes between abdominal and 




6.2.3. Depot-specific responses of gluteal and abdominal subcutaneous adipose tissue to 
exercise training 
To evaluate the depot-specific response to exercise training, the gene expression levels 
were compared in gSAT (Figure 6.3A) and aSAT (Figure 6.3B) pre and post-training, 
respectively.  
In gSAT, 61 DEGs were identified (|LFC|≥ 0.58; p ≤ 0.05) with 54 genes upregulated and 
7 genes downregulated in response to exercise training (Table 6.4; Supplementary Table 6.2). 
In addition, the biological processes most affected by exercise training (Figure 6.4) were 
immune and inflammatory responses (e.g. SPP1, CCL22, MMP9, CHI3L1, HP), regulation of 
lipid metabolism (e.g. APOE, PLTP, SPP1, C3, APOC1, SREBF1) and regulation of plasma 
lipoprotein particle levels and remodelling (e.g. APOC1, APOE, PLA2G7, PLTP, LIPA).  
Within aSAT, the expression of 77 genes changed in response to exercise training (|LFC|≥ 
0.58; p ≤ 0.05), with 55 genes upregulated and 22 genes downregulated (Table 6.5; 
Supplementary Table 6.3). Surprisingly, these genes mostly represented muscle-associated 
processes (e.g. ACTA1, MYH7, MYL2, TCAP, CKM) and immune response (e.g. HP, COL1A1, 
CD3D, IL7R) (Figure 6.5). However, TWIST1, a gene documented to play a role in obesity-
associated inflammation and IR was down-regulated in aSAT after the exercise training (Table 
6.5). Notably, only 3 genes had commonly altered expression levels in aSAT and gSAT after 






Figure 6.3. Comparison of gene expression changes induced by exercise training in gSAT 
(A) and aSAT (B), respectively. 
The volcano plots highlight genes with p-value < 0.001 and fold change |LFC| > 0.58. Red: gene 
expression upregulated after exercise training (LFC > 0.58); Blue: gene expression downregulated after 
exercise training (LFC < -0.58); Orange:  p-value < 0.001. The horizontal line corresponds to p < 
0.001 and the vertical lines mark a |LFC| > 0.58. A: expression changes in gSAT after exercise. B: Gene 
expression changes in aSAT after exercise training. C: Overlapping genes with changed expression 






Table 6.4. Differentially expressed genes in gluteal SAT in response to exercise training 
based on log2 fold change > 0.58 (Top 10 up-regulated genes and all down-regulated 
genes) 
SYMBOL SEARCH_KEY logFC DEFINITION 
Up-regulated genes in gSAT after exercise training 
MMP9 NM_004994.2 -1.44 Homo sapiens matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) (MMP9), mRNA. 
SPP1 NM_001040058.1 -1.24 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript 
variant 1, mRNA. 
SPP1 NM_000582.2 -1.20 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript 
variant 2, mRNA. 
APOC1 NM_001645.3 -1.14 Homo sapiens apolipoprotein C-I (APOC1), mRNA. 
ITGAX NM_000887.3 -1.04 Homo sapiens integrin, alpha X (complement component 3 
receptor 4 subunit) (ITGAX), mRNA. 
TM4SF19 NM_138461.2 -1.04 Homo sapiens transmembrane 4 L six family member 19 
(TM4SF19), mRNA. 
IFI30 NM_006332.3 -1.02 Homo sapiens interferon, gamma-inducible protein 30 (IFI30), 
mRNA. 
PLA2G7 NM_005084.2 -0.94 Homo sapiens phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma) (PLA2G7), mRNA. 
LAPTM5 NM_006762.1 -0.93 Homo sapiens lysosomal multispanning membrane protein 5 
(LAPTM5), mRNA. 
CISH NM_145071.1 -0.89 Homo sapiens cytokine-inducible SH2-containing protein 
(CISH), mRNA. 
Down-regulated genes in gSAT after exercise training 
LOC651309 XM_942586.1 0.64 PREDICTED: Homo sapiens hypothetical protein 
LOC651309 (LOC651309), mRNA. 
PCDH9 NM_020403.3 0.64 Homo sapiens protocadherin 9 (PCDH9), transcript variant 1, 
mRNA. 
NTM NM_016522.2 0.63 Homo sapiens neurotrimin (NTM), transcript variant 2, 
mRNA. 
SLIT2 NM_004787.1 0.62 Homo sapiens slit homolog 2 (Drosophila) (SLIT2), mRNA. 
NUTF2 NM_005796.1 0.61 Homo sapiens nuclear transport factor 2 (NUTF2), mRNA.  
Hs.99472 0.60 Homo sapiens mRNA; cDNA DKFZp564O0862 (from clone 
DKFZp564O0862) 
FAM13A NM_014883.2 0.59 Homo sapiens family with sequence similarity 13, member A 










Table 6.5. Top 10 differentially expressed genes in abdominal SAT in response to exercise 
training based on log2 fold change > 0.58 (up and down-regulated) 
SYMBOL SEARCH_KEY logFC DEFINITION 
Up-regulated genes in aSAT after exercise training 
ACTA1 NM_001100.3 -1.59 Homo sapiens actin, alpha 1, skeletal muscle (ACTA1), mRNA. 
FOLR3 NM_000804.2 -1.23 Homo sapiens folate receptor 3 (gamma) (FOLR3), mRNA. 
MYL2 NM_000432.2 -1.15 Homo sapiens myosin, light chain 2, regulatory, cardiac, slow 
(MYL2), mRNA. 
CHI3L2 NM_004000.2 -1.13 Homo sapiens chitinase 3-like 2 (CHI3L2), transcript variant 1, 
mRNA. 
MYH7 NM_000257.1 -1.09 Homo sapiens myosin, heavy chain 7, cardiac muscle, beta 
(MYH7), mRNA. 
COL1A1 NM_000088.2 -1.02 Homo sapiens collagen, type I, alpha 1 (COL1A1), mRNA. 
FLNC NM_001458.2 -0.98 Homo sapiens filamin C, gamma (actin-binding protein 280) 
(FLNC), mRNA. 
CKM NM_001824.2 -0.96 Homo sapiens creatine kinase, muscle (CKM), mRNA. 
LTB NM_002341.1 -0.93 Homo sapiens lymphotoxin beta (TNF superfamily, member 3) 
(LTB), transcript variant 1, mRNA. 
FNDC1 NM_032532.1 -0.90 Homo sapiens fibronectin type III domain containing 1 
(FNDC1), mRNA. 
Down-regulated genes in aSAT after exercise training 
FOS NM_005252.2 1.05 Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene 
homolog (FOS), mRNA. 
FOSB NM_006732.1 0.89 Homo sapiens FBJ murine osteosarcoma viral oncogene 
homolog B (FOSB), mRNA. 
CSN1S1 NM_001025104.1 0.87 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 
MYOC NM_000261.1 0.82 Homo sapiens myocilin, trabecular meshwork inducible 
glucocorticoid response (MYOC), mRNA. 
TWIST1 NM_000474.3 0.77 Homo sapiens twist homolog 1 (Drosophila) (TWIST1), mRNA. 
LOC643911 XR_042101.1 0.76 PREDICTED: Homo sapiens hCG1815491 (LOC643911), 
miscRNA. 
CSN1S1 NM_001890.1 0.76 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 
MYOC NM_000261.1 0.75 Homo sapiens myocilin, trabecular meshwork inducible 
glucocorticoid response (MYOC), mRNA. 
THBS4 NM_003248.3 0.75 Homo sapiens thrombospondin 4 (THBS4), mRNA. 














This is the first study that has investigated the regional differences in SAT transcriptome 
signatures in obese African women and showed differences in gene expression profiles between 
aSAT and gSAT at baseline and in response to exercise training. As a key result of this unbiased 
analysis, 15 DEGs were found between these fat depots at baseline, which were mainly 
associated with embryonic development (e.g. HOXA5, DMRT2, HOXB8, IRX5, IRX2) and 
regulation of anatomical structure morphogenesis (e.g. DMRT2, DMRT3, HOXA5, RSPO3). 
Depot-specific AT transcriptome signatures were strongly pronounced in response to the 12-
weeks structured exercise training program, such that 318 genes were differentially expressed 
between the depots, with only three genes commonly changed in aSAT and gSAT. Interestingly, 
four developmental genes were identified as the most prominent DEGs between SAT depots 
(DMRT2, DMRT3 and HOXA5 higher, and CSN1S1 lower expressed in aSAT compared to 
gSAT) that were unaffected by exercise training.  
Adipose depots have been proposed to arise from different mesodermal layers during 
embryonic development, directed through epigenetic-programmed mechanisms (432, 434). 
Homeobox family (HOX) is among the most studied families of developmental genes in AT 
and has been widely identified as fundamental in controlling the body plan along the anterior-
posterior axis (432, 435). HOX genes have also been suggested as determinants of early 
regional differentiation by directing the evolution and differentiation from mesoderm layers to 
different AT depots (78). Additionally, it has been previously shown in both mice and humans, 
that multiple HOX genes are involved in embryonic development and pattern specification (e.g. 
HOXA5, HOXC8, HOXC9), and play a role in obesity and body fat distribution, with potential 
functional differences between distinct AT depots (81). In the present study, the following HOX 
genes were found with higher expression levels in aSAT than in gSAT: HOXA5 (at both time 
points), IRX2, HOXB8 and IRX5 (at baseline), and IRX2, HOPX, HOXA3, HOXB5 and HOXA9 
(after exercise training). Previous studies in Europeans also showed higher expression of 
HOXA5 in aSAT compared to gSAT as well as higher expression of this gene in the stromal 
fraction of aSAT (78) and VAT (81, 430). Furthermore, high levels of HOXA5 have been 
closely related to BMI and body fat distribution (72, 78, 81, 84, 430). In addition, several 
homeobox genes were showed to be upregulated in aSAT and VAT (e.g. HOXA3, HOXA9, 
HOXB5, HOXB8, IRX5, IRX2 and HOPX) (59, 78, 79, 81, 431, 436), suggesting a similar 
developmental origin of aSAT and VAT, rather than aSAT and gSAT (432). Notably, IRX genes 
(Iroquois homeobox) are potentially involved in the mechanisms underlying the genetic 
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association between FTO and obesity (437). The causal variant (rs1421085) of this association 
eliminates IRX3 and IRX5 repression, leading to a cell-autonomous shift from browning and 
thermogenesis of white adipocytes to lipid storage, increased fat stores and body-weight gain 
(437). Higher expression of IRX genes in aSAT could therefore be one of the causal factors in 
the detrimental central fat accumulation (aSAT) in obese individuals. However, this should be 
further investigated in a cohort of African women characterized with a low central and high 
gynoid fat accumulation. 
Unlike the homeobox family, DMRT (doublesex- and mab-3-related transcription factor) 
family has been less studied in the context of obesity and body fat distribution. Mostly involved 
in sex differentiation and gonadal development during embryogenesis in a wide range of species 
(438-440), the expression of DMRT genes has also been reported in aSAT of individuals with 
obesity (440). Higher expression of DMRT2 and DMRT3 were found in aSAT vs gSAT at 
baseline and post-exercise training in the present study, similar to findings from Passaro et al. 
in healthy men at rest (432). Additionally, a recent study has identified DMRT3 expression in 
omental vs aSAT as a novel marker for the development of IR (441). DMRT2 and DMRT3 
might, therefore, be novel candidate genes involved in “unhealthy” central fat accumulation. 
However, their functional role in AT development and function remains to be elucidated.  
This study showed a higher expression of CSN1S1 in gSAT compared to aSAT at baseline 
and post-exercise training. Previously known as a functionally unreported adipose-specific 
gene, CSN1S1 expression was recently found to be significantly higher expressed in SAT 
(abdominal) of obese compared to lean individuals (442). Moreover, this gene is downregulated 
in aSAT after weight loss in morbidly obese individuals (443). Increased CSN1S1 is involved 
in immune/inflammatory responses (444) and may also play a key role in adipogenesis and lipid 
metabolism (442). Indeed, higher expression of CSN1S1 has been shown in mature adipocytes 
compared to preadipocytes and its expression was high during adipose-derived stem cell 
differentiation (442). Based on these findings, higher expression of CSN1S1 may be reflective 
of higher storage capacity in gSAT.  
Taken together, the unique gene expression signatures of aSAT and gSAT suggest 
differences in developmental processes regulating AT distribution and expandability of distinct 
depots. These data add to the notion that there are intrinsic morphological and functional 
differences between central and lower-body fat (59, 78, 430). Interestingly, from the 
comparison of these depots at baseline and after exercise training, 18 of the DEGs were 
overlapping and were enriched for anatomical structure morphogenesis. These findings 
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therefore postulate that the expression of developmental genes is not affected by 
external/environmental stimuli (such as exercise training) once they have been set during the 
early life stage. Rather, these differences are maintained across the depots as previously shown 
in cell culture studies (78, 79, 81, 82). Moreover, developmental genes might be actively 
involved in AT function, distribution and remodelling (193). GWAS and meta-analyses on 
European individuals identified several genes within the WHR-associated loci with differential 
transcription between aSAT and gSAT (76). However, except for RSPO3, the DEGs emerging 
from the present study did not overlap with these previous reports (76, 445), most probably 
explained by the difference of ethnicities.  
Given the lower number of DEGs between SAT depots at baseline (15 genes) compared 
to the number after exercise training (318 genes), I propose that these major depot-specific 
differences reflect the heterogeneous capacity of SAT to adapt to behavioural (or 
environmental) changes, such as exercise training. This hypothesis is supported by a recent 
study showing that fat depots (e.g. SAT, VAT, liver, perirenal) respond with a highly variable 
alteration in fat mass during a weight loss intervention (dietary and physical activity) (446). 
The depot-specific AT response to exercise training could provide insight on metabolic and 
signalling pathways implicating fat distribution in the development of metabolic disorders. The 
specific response of each SAT depot to exercise training was therefore investigated in the 
present study. The expression of different sets of genes (and associated biological processes) 
was altered in SAT depots in response to exercise training, with only six genes commonly 
changed in both depots. This suggests differential regulatory mechanisms involved in cellular 
and endocrine function in these depots. Specifically, the DEGs in gSAT were mostly enriched 
for immune and inflammatory responses, suggesting increased inflammation after exercise 
training as previously shown in Chapter 5 of this thesis. Exercise training has been shown to 
activate macrophage production of cytokines, leading to the modulation of monocyte 
chemotaxis, differentiation into macrophages and activation (447). In addition, adipocytes 
readily respond to exercise training by modulating the transcriptomic response of pro-
inflammatory genes (447). Therefore, an increased inflammatory response is likely to originate 
both from adipocytes and AT immune cell signalling. In line with this, both cell types can 
display similar transcriptomic profiles especially when the macrophages engulf lipids (448). 
However, our experimental design did not allow dissecting the cell types and their contribution 
to whole AT transcriptome.  
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The increased inflammatory response seems to be contradictory, given the extensively 
reported association between AT inflammation and the development of metabolic diseases 
(161, 448, 449) and decreased AT inflammation after exercise training (450). However, 
elevated immune response and activation of inflammatory pathways have been shown in SAT 
after acute exercise sessions (447, 451); and no studies have investigated the specific 
adaptations in gSAT in response to a long-term exercise training in Africans. The upregulation 
of inflammatory-related response could reflect structural changes of AT and adaptations in the 
early phase of the training, which is downregulated once structural changes are established 
(447). However, the beneficial effect of exercise training on AT physiology is the product of 
continuous changes induced by repeated transient acute exercise bouts (286). Hence the 
observed upregulation of immune and inflammatory responses after the present exercise 
training program mirrors a cumulative response of single exercise bouts. Notably, the sample 
analyzed in the present study were collected at least 3 days after the last exercise training session 
to exclude the potential acute effects of the last bout of exercise training. Furthermore, the 
participants of this study have never completed structured exercise training before participating 
in this program, supporting the hypothesis that sustained inflammatory activation after 12-week 
exercise training is associated with AT reorganization and remodeling. Consistently, the 
identified DEGs in gSAT were also involved in biological processes regulating lipid 
metabolism and plasma lipoprotein particle levels and remodelling (e.g. MMP9, SPP1, APOC1, 
ITGAX and PLA2G7). Changes in metabolic homeostasis such as improved body composition 
or reduced adiposity can trigger immune and inflammatory processes (451). For instance, the 
stimulation of lipolysis and enhanced fat mobilization in AT after exercise training (452, 453) 
was shown to be promoted by enhanced production of pro-inflammatory cytokines, such as IL-
6 (453, 454). Furthermore, pro-inflammatory signalling in adipocytes mediates angiogenesis 
and ECM remodelling (147, 419). Additionally, the overall reduction of stored TGs in response 
to exercise training has been shown to precede an extensive remodelling of AT (420, 455). On 
the other hand, FFA released and the reduction of stored TGs in adipocytes in negative energy 
balance (e.g. in response to fasting, weight loss or exercise training) not only increase the 
activation and migration of immune cells into AT but also increase the expression of lipolysis-
associated M2 macrophage markers, which are involved in tissue repair and remodelling (424, 
425). Therefore, in contrast to the negative effects assigned to inflammatory processes,  the 
observed upregulation of inflammation in response to exercise training is suggested to reflect 
SAT adaptation and remodelling in these women. 
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Surprisingly, in aSAT, most of the DEGs were enriched for muscle-associated processes 
(e.g. ACAT1, TCAP, MYL2, MYH7, MYBPC). Similar muscle-related gene expression profiles 
were found for the first time in brown AT of high fat diet-induced obesity-resistant rats (e.g. 
TNNT3, ACTA1, ACTN3, MYLPF), but their functional role in AT has not been clarified (456). 
As whole AT was used in the present study, the possibility that these genes were expressed 
from non-adipocytes/non-immune cells cannot be excluded. Nevertheless, twist-related protein 
(TWIST1) was down-regulated in aSAT following this exercise intervention. TWIST1 is a 
transcription factor first identified in Drosophila melanogaster as a gene regulating mesoderm 
development; and subsequently reported to be expressed in human AT, mostly from adipocytes, 
and also from other cells in the AT such as macrophages, endothelial and T cells (457). TWIST1 
silencing in adipocytes results in the down-regulation of the expression and secretion of 
inflammatory cytokines such as TNFα, IL-6 and MCP1 (457) and attenuates IR (458). Besides, 
these cytokines are well established to play a major role in promoting IR locally and 
peripherally via the effects on insulin signaling, and FA and adipokine release, as well as gene 
transcription (459). In the present study, the down-regulation of TWIST1 in aSAT in response 
to exercise training is concomitant with the reduction in inflammatory proteins levels (NFĸB, 
TLR4, MCP1) in this depot only and not in gSAT, as reported in Chapter 5 (Figure 5.1). These 
results suggest the beneficial role of exercise training in aSAT, which might have contributed 
to the improvement of insulin sensitivity reported in Chapter 4. It could therefore be interesting 
to further measure the mRNA expression of TWIST1 and to evaluate the association with 
systemic inflammation and SI in these women. Moreover, subsequent investigations on isolated 
cell fractions, or single-cell RNA sequencing approaches, as well as cell culture experiments 
are required to further elucidate the mechanistic link between exercise training and signature 
changes of aSAT.   
It is important to note that these analyses were limited by the amount of material obtained 
from the SAT biopsies. Histological, as well as extensive proteome analyses could not be 
performed, and whether gene expression differences were translated at the protein level could 
not be concluded. Moreover, the lack of a normal-weight control as a comparison group 
prevented me from concluding as to whether these findings are relevant pathways related to 
obesity and exercise training rather than an adaptation to the obese state. As the detection of 
DEGs was based on statistical methods, further validation is needed to rule out the possibility 
of false positives. Nevertheless, records on AT transcriptome of African populations are rare 
and this is one of the first studies providing unique data on SAT depot-specific gene expression 
profiles and adaptation to exercise training in black African women with obesity. This research 
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work generated hypotheses about novel candidate genes potentially implicated in the 
relationship between body fat distribution, AT adaptations and metabolic status.  
In conclusion, the current study showed differential gene expression profiles of SAT 
depots (gluteal and abdominal) in obese black SA women. While the differences at baseline 
suggest dissimilar developmental origin, exercise training unmasked a heterogeneous response 
of different SAT depots to a physical challenge. The specific functional and metabolic 
responses could be related to intrinsic differences in the expression of developmental genes set 
at an early-life stage in each adipose depot. These were represented by an upregulation of the 
immune response and inflammatory processes, lipid metabolism and tissue remodelling in 
gSAT and surprisingly, mainly muscle-related processes in aSAT. Importantly, four genes 
(CSN1S1, DMRT2, DMRT3 and HOXA5) were identified as potential novel candidates of body 
fat distribution pattern in Africans, whose biological function and implication in the 




CHAPTER SEVEN  





7.1. Summary discussion 
Body fat distribution rather than total adiposity is a major determinant of the development 
of metabolic diseases (38-40). Central body fat (VAT and aSAT) is associated with an increased 
risk for T2D, while lower-body fat (gSAT) is proposed to be protective against the development 
of obesity-associated metabolic disorders (39, 40, 58, 59). It is well established that the 
susceptibility to an adverse metabolic status varies with ethnicity, and for the same level of 
adiposity, African descendants are at greater risk for cardio-metabolic diseases than Europeans 
descendants (25, 33, 69, 217). These differences may be partly explained by the difference in 
the pattern of body fat distribution, and most importantly, the depot-specific AT function within 
each ethnic group. In black SA women, higher SAT is associated with lower insulin sensitivity 
(25, 32). Indeed, increased in AT mass may negatively affect systemic and whole-body 
metabolism via several mechanisms (52, 101, 111, 134, 139). Among these mechanisms, the 
increased release of FFAs in the circulation may contribute to the development of low-grade 
inflammation and affect the function of peripheral tissues (134, 155, 357). Moreover, SAT 
dysregulated production and secretion of adipocytokines, oxidative stress and ectopic fat 
deposition are also suggested to be mainly involved in the association between increased SAT 
mass and impairment of insulin sensitivity in the obese state (52, 101, 111, 134, 139, 155, 357). 
However, these associations have not been previously explored in African women, who present 
with a different phenotype to their European counterparts and at a higher risk for IR and T2D 
(31-33). This represents an area of interest which might help to decipher this higher prevalence 
of metabolic diseases in Africans. 
 Physical activity, including exercise training, is an essential component in the 
management of obesity and is inversely correlated with the incidence of NCDs (1, 277). 
Exercise training has been shown to improve glucose metabolism and whole-body insulin 
sensitivity (287-289). Although the favourable exercise-induced changes to the metabolic 
profile have been principally attributed to physiological adaptations within skeletal muscle, 
exercise training-induced improvements in insulin sensitivity in obese individuals may also be 
exerted by changes in AT mass and function (87, 292), and consequently changes in systemic 
metabolism. Indeed, exercise training may partly improve the metabolic risk via an increase in 
energy demand and the utilization of excess calories stored in the fat depots, resulting in the 
reduction of body fat accumulation. Exercise training therefore represents a suitable model to 
investigate the relationship between SAT function and metabolic risk in obese black SA 
women, which to my knowledge has not been previously undertaken. This thesis aimed to i) 
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explore the associations between circulating and depot-specific SAT (aSAT and gSAT) FA 
profile, SAT lipid metabolism and body composition and insulin sensitivity; ii) evaluate the 
depot-specific changes in SAT metabolism and function in response to 12 weeks of supervised 
combined aerobic and resistance training and iii) evaluate the relationship between these 
changes and modifications in metabolic risk in previously sedentary obese black SA women. 
The main findings are summarized below and are presented in Table 7.1. 
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Table 7.1. Summary, implication and novelty of each study and conclusion 
Chapter Summary/Highlights Implications Novelty 
Three  FA profile of RBC-TPL differed from the FA profile of 
SAT depots with higher proportions of SFAs and 
PUFAs and lower MUFA in RBC-TPL than SAT. 
Estimated activities of D5D, D6D and SCD1-18 were 
higher and SCD1-16 was lower in RBC-TPL compared 
to SAT depots. 
 
 Higher RBC-TPL SFA was associated with lower SI but 
did not correlate with VAT/SAT. 
 
 The FA profile of aSAT and gSAT differed, with higher 
SFAs and lower MUFAs, SCD1-16 and SCD1-18 
activity in aSAT compared to gSAT. 
 
 The associations between the FA profiles and VAT/SAT 
and SI did not differ between SAT depots, despite the 
difference in FA profile. In both SAT depots, 1) Lower 
SFAs and higher n-3 and n-6 PUFAs correlated with 
higher VAT/SAT ratio; 2) Lower n-3 and n-6 PUFAs 
and higher total MUFA correlated with higher SI; 3) 
Lower SCD1-18 was associated with lower VAT/SAT 
and higher D6D correlated to lower SI. 
 
These findings showed that the 
associations between the FA profiles 
and metabolic status in obese black SA 
women are not only dependent on the 
class of FA, but most importantly on 
the tissue type where they are stored. 
This was the first study that has 
comprehensively measured and 
compared the FA composition of 
RBC-TPL and two distinct SAT 
depots in humans with obesity; and 
evaluating the tissue-specific 
relationships between FA 
composition, desaturase activities 
and measures of central fat 








Table 7.1 continued. 
Chapter Summary/Highlights Implications Novelty 
Four  Twelve-weeks of combined aerobic and resistance 
exercise training improved SI, cardiorespiratory fitness 
and body composition. 
 
 Exercise training altered RBC-TPL FA composition 
and estimated desaturase activity by reducing SCD1-
16 and D6D (tendency), and increasing D5D, along 
with a reduction of SFAs (18:0 and 20:0) and DGLA 
(20:3n-6). 
 
 These changes corresponded to a decrease in liver fat 
and circulating concentrations of leptin and TNFα. 
 
 Exercise training resulted in SAT depot-specific 
change in FA composition, mostly in aSAT. Within 
aSAT, individual SFAs 12:0 and 14:0 decreased and 
individual PUFAs 20:2n-6 and 22:4n-6 increased. 
Within gSAT only GLA (18:3n-6) decreased.  
 
 There was no association between these changes in 
SAT FAs and changes in liver fat, systemic 
inflammation or SI. 
 
 Exercise training did not alter the expression of genes 
involved in lipid metabolism and insulin signalling in 
both SAT depots. 
These findings suggested that exercise 
training stimulates tissue-specific 
changes in FA classes. Changes in 
RBC-TPL FA profiles were not 
reflective of the changes in FA profile 
and lipid metabolism in SAT. 
 
This study also showed that the 
exercise-induced improvement in SI 
was not directly mediated by the 
changes in FA composition in the 
circulation and SAT, or by the changes 
in SAT lipid metabolism.   
This was the first study evaluating 
the effects of exercise training on FA 
composition of RBC-TPL, aSAT and 
gSAT; however, these adaptations 
were not directly related to the 
exercise-induced improvements in SI, 
but rather to lower systemic 






Table 7.1 continued. 
Chapter Summary/Highlights Implications Novelty 
Five  The cross-sectional analysis comparing gene and 
protein expression between aSAT and gSAT showed 
that gSAT had a higher leptin mRNA expression, but 
the aSAT had a higher inflammatory protein 
expression than gSAT.  
 
 Exercise training improved systemic oxidative stress in 
obese black women (reduction in TBARs 
concentration and an increase in catalase activity) with 
no changes in circulating concentration of 
inflammatory markers. 
 
 Exercise training-induced changes in inflammatory 
mRNA levels were depot-specific, showing increased 
inflammatory gene expression (IL-10, TNFα, NFĸB1 
and MIF mRNA) in gSAT, with no changes in aSAT. 
 
 In response to exercise training, inflammatory protein 
levels (MCP1, NFĸBp65 and TLR4) decreased in 
aSAT only. 
 
 These changes in systemic (oxidative stress) and SAT 
depots (inflammatory markers) were associated with 
the reduction in gynoid fat, but not with the 
improvement in SI. 
 
This study showed that exercise 
training stimulated a depot-specific 
effect on the SAT inflammatory profile 
and importantly, suggested that the 
increase of inflammatory state in 
gSAT was reflective of tissue 
remodelling. This was consecutive to 
the reduction of gynoid fat but was not 
associated with the improvement in 
whole-body SI in obese black SA 
women. 
 
This was the first study in women of 
African ancestry evaluating changes in 
SAT depots and systemic 
inflammatory and oxidative stress 






Table 7.1 continued. 
Chapter Summary/Highlights Implications Novelty 
Six  Transcriptomic profiles differed between aSAT and 
gSAT at baseline with 15 DEGs, which were 
mostly associated with embryonic development 
and anatomical structure morphogenesis. 
 
 Depot-specific differences in SAT transcriptome 
greatly increased with exercise training, with 318 
DEGs, and only 3 genes (COL1A1, HP and CILP) 
commonly changed in aSAT and gSAT. 
 
 The most prominent DEGs between SAT depots 
were four developmental genes, with expression 
unaffected by the exercise training (DMRT2, 
DMRT3 and HOXA5 higher, and CSN1S1, for 
which the expressed was lower in aSAT compared 
to gSAT). 
 
 Exercise training resulted in changes in different 
sets of genes in the SAT depots. In gSAT DEGs 
were mostly enriched for immune and 
inflammatory responses, while aSAT DEGs 
reflected mostly muscle-associated processes.  
This study demonstrated differential gene 
expression profiles of gluteal and 
abdominal SAT depots at baseline and 
after 12-weeks of exercise training. 
 
This study generated hypotheses on novel 
candidate genes potentially implicated in 
the relationship between body fat 
distribution, SAT function and metabolic 
status in black SA women with obesity. 
Reports on the AT transcriptome 
of African populations are 
scarce. This is one of the first 
studies providing unique data on 
abdominal and gluteal SAT 
transcriptomic signatures and the 
depot-specific adaptation to an 
external stimulus such as 
exercise training in black African 
women with obesity. 
FA: fatty acids; SAT: subcutaneous adipose tissue; SFA: saturated fatty acid; MUFA: mono-saturated fatty acid; PUFA: poly-saturated fatty acid;  D5D: delta-5 
desaturase; D6D: delta-6 desaturase; SCD1: stearoyl-CoA desaturase 1; SI: Insulin sensitivity; RBC-TPL: red blood cell total phospholipids aSAT: Abdominal 
subcutaneous adipose tissue; gSAT: gluteal subcutaneous adipose tissue; SA: South African; DGLA: dihomo gamma-linolenic acid; GLA: gamma-linolenic acid; 
TBARS: thiobarbituric reactive acid substances; IL-10: Interleukin 10; TNFα: tumor necrosis factor-alpha; NFkB: nuclear factor-kappa B; MIF: macrophage 
migration inhibitory factor; MCP1: monocyte chemoattractant protein 1; TLR4: toll-like receptor 4; DEGs: differentially expressed genes. 
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One of the principal characteristics of obesity is the excessive accumulation of TGs in AT 
depots, mainly SAT, which serves to protect other tissues against lipotoxicity. However, if the 
SAT expansion limit is reached, progressive energy intake results in the spillover of the excess 
lipids to non-adipose organs, including VAT (134). This limited storage capacity of the SAT is 
characterized by impaired lipogenesis, high lipolytic rates (basal and stimulated), and 
consequently increased FFA release into the bloodstream. FFAs interfere with glucose 
metabolism and phosphorylation activity in peripheral tissues, contributing to IR (250, 357). 
Further, this increased release of FFAs, in addition to high dietary fat intake, may alter 
circulating FA profiles. Alterations in the FA composition of RBC-TPL membrane have been 
associated with IR in obese individuals (358). Therefore, the dysregulation in SAT lipogenesis 
and lipolysis, as well as circulating and SAT FA composition might explain the higher 
susceptibility to metabolic risk in obese black SA women. No studies have investigated the 
association between both circulating FA profile and SAT lipid metabolism and metabolic risk 
in this population.  
The first study of this thesis (Chapter 3) aimed to examine and compare the FA 
composition of RBC-TPL, aSAT and gSAT and to evaluate the tissue-specific associations of 
the differential FA profiles with VAT/SAT ratio and SI in obese black SA women. The main 
findings were the distinct different FAs composition between circulating (RBC-TPL) and SAT. 
Specifically, SFA and PUFA contents were higher, and MUFA content lower in RBC-TPL 
compared to SAT depots. High dietary intake of PUFAs and endogenous synthesis of SFAs 
from energy sources such as carbohydrates may explain the high concentration of these FA 
classes in the circulation (365). This study further showed a tissue-specificity in FA 
composition within SAT depots, with higher SFAs and lower MUFA contents in aSAT 
compared to gSAT. Furthermore, this study showed that not only the metabolic effects of FAs 
vary between different FA classes, but more importantly these effects are dependent on the 
blood compartment/ fraction where they occur or tissue type where they are stored. 
Surprisingly, despite the differences in FA composition between SAT depots, these were 
similarly associated with VAT/SAT ratio and SI. Specifically, lower SFAs content was 
inversely associated with higher VAT/SAT ratio, whereas higher total MUFA and lower PUFA 
were associated with higher SI. Conversely, there were only a few associations between these 
variables and circulating FA profiles, with higher RBC-TPL SFA and 20:2n-6, and lower 22:4n-
6 correlating with lower SI. The variance in VAT/SAT ratio and SI were mainly explained by 
the FA composition of SAT depots. This suggests a stronger influence of SAT lipid metabolism 
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and consequently SAT FA composition, than dietary FA intake (reflected by RBC-TPL) on the 
metabolic risk in obese black SA women. 
Inflammation is one of the main factors linking obesity to increased risk for IR and T2D. 
In addition to ectopic fat deposition, increased basal lipolysis in the obese state and the resultant 
increase of FA in the circulation may induce systemic inflammation (155). In Chapter 3 of this 
thesis, the correlations between circulating individual PUFAs and SI showed no consistent 
pattern. In addition, because of the cross-sectional design of this study, a causative relationship 
between SAT FA composition with VAT/SAT ratio and SI could not be established. Since 
physical activity increases AT catabolism and can therefore modify SAT lipid and FA 
metabolism independently of dietary intake (138), an exercise training intervention was used 
as a model to further understand the tissue-specific metabolic effects of individuals FAs and 
desaturase activities on systemic inflammation, liver fat content and insulin sensitivity in these 
women. The changes in RBC-TPL and SAT FA composition and estimated desaturase activity 
in response to a 12-week (supervised) combined aerobic and resistance exercise training in 
obese and previously sedentary black SA women was therefore evaluated in Chapter 4 of this 
thesis. Moreover, the associations between these changes and alterations in SAT lipid 
metabolism, systemic inflammatory markers, liver fat and SI were also explored.  
Twelve weeks of supervised, combined aerobic and resistance training resulted in 
improvements in SI, VO2peak and body composition, including a reduction in body weight, BMI, 
WC and gynoid fat %. This study further showed FA class- and tissue-specific effects of 
exercise training, with decreased RBC-TPL SFAs (18:0 and 20:0), DGLA (20:3n-6), SCD1-16 
and D6D, and increased in D5D activity. Remarkably, these changes were associated with 
decreased liver fat and lower circulating leptin and TNFα concentrations, and not with the 
improvement of SI. Given the implication of ectopic fat deposition and systemic inflammation 
in the development of IR in obese state (61, 134), the changes in RBC-TPL associated with a 
reduction of liver fat content, circulating leptin and TNFα could represent an indirect 
mechanism by which exercise training improved SI in these women. Conversely, the changes 
of individual FA levels mainly in aSAT with decreased SFAs (12:0 and 14:0) and increased 
PUFAs (20:2n-6 and 22:4n-6) did not correlate with the measured metabolic parameters, 
including SI.  
This is the first study showing positive effects of exercise training on the circulating FA 
profile, with decreased proportions of SFAs, and associations with an improved metabolic 
profile (lower inflammation and liver fat accumulation) in black SA women. The possibility 
147 
 
that these changes may have indirectly contributed to the reported improvement in SI cannot be 
ruled out. However, the unaltered desaturase activities, unchanged expression of genes involved 
in adipogenesis, lipogenesis, lipolysis and insulin signalling in both SAT depots following this 
intervention suggests that these factors are not involved in the exercise-induced improvement 
in SI, but further investigations are required. Indeed, given the hypothesis that there would be 
significant involvement of SAT function in the whole-body metabolic profile of obese 
individuals, what could be the mechanism/potential pathways linking SAT function with IR in 
obese black SA women?  
To address this question, Chapter 5 of this thesis aimed to evaluate the effects of 12-week 
exercise training on systemic and aSAT vs gSAT inflammatory and oxidative status in black 
SA women. Indeed, unrestrained lipolysis is associated with increased inflammation in SAT 
and dysregulated secretion of adipo-cytokines into the circulation (134). Inflammation and 
oxidative stress are also interrelated during obesity and together, are major contributors to IR 
and development of T2D (171, 174). The main findings of this chapter were the improvement 
in systemic oxidative stress, characterized by a reduction of TBARS and an increase in catalase 
and SOD (tendency). Further, exercise training resulted in depot-specific changes in SAT 
inflammatory profile, characterized by an increase of inflammatory gene expression in gSAT 
and decrease trend of inflammatory protein expression in aSAT. Notably, these changes 
correlated with the reduction in gynoid fat % and not with the improvement in SI. Similarly, a 
cross-sectional study in black SA women showed that high SAT (abdominal and gluteal) 
inflammatory gene expression did not explain the variance in SI (213). However, the novel 
aspect of the finding from Chapter 5 of this thesis was the relationship between the depot-
specific changes in SAT inflammation, the improvement of systemic oxidative stress and the 
reduction of gynoid fat.  
This study showed for the first time in black African women that higher inflammation in 
gSAT could be reflective of remodelling of this tissue associated the decrease of fat mass, rather 
than increased inflammation described during pathological SAT expansion. This hypothesis is 
supported by data showing that fat mass reduction requires extensive tissue remodelling, and 
an adequate ECM and angiogenesis necessitates inflammation in the adipocyte 
microenvironment (147, 419-421). Therefore, I hypothesize that the reduction of gynoid fat in 
response to exercise training induced a positive metabolic profile in these women, characterized 
by lower systemic oxidative stress and lower inflammation in aSAT. Gynoid fat or lower-body 
fat accumulation is the preferential/major site of fat storage in women of African ancestry (31-
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33). Therefore, I further hypothesize that the reduction of gynoid fat in response to exercise 
training may be interpreted as increasing the depot storage capacity, by making “extra room” 
to accommodate future TGs accumulation in periods of excess calorie intake and sedentary 
behaviour. This would consequently protect against the spillover of excess lipids to VAT (and 
other organs) and subsequently reduce or prevent inflammation in these tissues, as well as 
systemic oxidative stress. Therefore, although not directly associated with these changes, the 
exercise-induced improvement in SI may be the indirect consequence of the reduction of gynoid 
fat mass and changes in systemic oxidative stress and SAT inflammatory status. However, this 
hypothesis should be verified in future studies. Nevertheless, these findings add to the concept 
of the protective nature of lower-body fat in obesity-associated metabolic disorders and 
highlight the need for further research exploring specific pathways in SAT function that may 
directly affect or regulate peripheral/whole-body insulin sensitivity. The identification of such 
pathways may be informative for future therapeutic targets in the management of obesity in this 
high-risk population in Africa. 
The mechanisms underlying SAT depot-specific associations with metabolic risks are not 
fully understood. In addition to the evidence showing differences in metabolism (e.g. FA 
composition in Chapter 3 and Chapter 4) and function (e.g. inflammatory profile in Chapter 5), 
the differential metabolic effects of SAT depots may also be driven by distinctive gene 
expression profiles, which may be controlled by environmental and genetic factors (46, 78). 
Indeed, given the preferential expansion of AT depots largely determined by heritable factors 
(144), the specific response of AT to calorie intake and/or energy demand may be influenced 
by site-specific developmental processes. The embryonic origins of SAT depots remain under-
studied and have not been investigated in black SA women. Understanding the developmental 
origins of this tissue may help to understand the differences in fat accumulation patterns in these 
women, as well as the specific response to external stimuli such as exercise training. 
Therefore, Chapter 6 of this thesis used an untargeted gene expression analysis approach 
(unbiased microarray analysis) to explore the transcriptome signatures of SAT depots. This 
study aimed to differentiate aSAT and gSAT gene expression profiles in obese black SA women 
and to examine whether the gene expression patterns of these depots were also altered in a 
depot-specific manner by 12-week exercise training. This was the first study, to the best of my 
knowledge that has demonstrated differential gene expression profiles of aSAT and gSAT in 
non-stimulated (baseline) and stimulated (exercise training) states, using an untargeted analysis 
approach. The difference between the number of DEGs at baseline (15) and after the exercise 
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training intervention (318) was outstanding. These findings suggested that except for their 
differential developmental origin (showed here by the differences in sets of developmental 
genes mainly involved in embryonic development and anatomical structure at baseline), SAT 
depots are relatively similar in their functional pathways until an external stimulus (which could 
be comparable to environmental factors) is applied. These depots therefore exhibit highly 
divergent responses under different environmental/behavioural stimuli, illustrated in this study 
by exercise training. While the changes in aSAT transcriptome in response to exercise training 
requires further investigation in terms of the cell types involved, this study showed an 
upregulation of the immune response and inflammatory processes, lipid metabolism and tissue 
remodelling in gSAT, as per the findings of the previous chapter (Chapter 5). Another novel 
aspect of this study was the identification of four developmental genes, including higher 
expression of DMRT2, DMRT3 and HOXA5, and lower expression of CSN1S1 in aSAT 
compared to gSAT. I hypothesise that these genes may represent novel candidate genes in the 
body fat distribution pattern of black women of African ancestry, and could potentially be 
implicated in the development of IR. However, their biological function and implication in the 
pathogenesis of obesity-associated metabolic diseases remain to be revealed. 
In summary, this thesis was the first research, to my knowledge, to investigate depot-
specific SAT metabolism and function on systemic and whole-body metabolism, with the use 
of exercise training as an additional investigation model. This thesis explored depot-specific 
differences in SAT metabolism and function in obese black SA women at baseline and in 
response to exercise training, examining differential pathways. These pathways included FA 
composition, lipogenesis, lipolysis, adipogenesis, insulin signalling, oxidative stress and 
inflammatory profiles, as well as whole transcriptome signatures. Notably, SAT response to an 
external stimulus such as exercise training differs, with depot-specific modifications in FA 
composition, inflammatory profiles and transcriptomic signatures. However, the depot-specific 
differences in FA composition could not explain the differential association of SAT depots with 
insulin sensitivity/IR proposed in the literature. Moreover, the improvement in SI with exercise 
training could not be accounted for by the changes in RBC-TPL and SAT FA composition, 
SAT inflammation or systemic oxidative stress. The reduction in gynoid fat in response to 
exercise training supported the proposed protective nature of gSAT over central body fat 
(aSAT) in these women, which was associated with an improved metabolic profile, including 
lower systemic oxidative stress and aSAT inflammatory profile. This thesis proposed that the 
protective nature of gSAT is exerted by its potential for increased storage capacity during 
periods of positive energy intake and sedentary lifestyle, thereby avoiding lipid spillover to 
150 
 
peripheral tissues. This is hypothesized to be a mechanism linking gSAT function to the 
improvement of SI in response to long-term exercise training. However, it is more likely that 
the improvement in SI in response to this intervention could have been derived from 
modifications in skeletal muscle physiology; for example, increased mitochondria oxidative 
capacity and FA oxidation, reduced inflammation or higher glucose uptake and insulin 
signalling. Further research is required to address this hypothesis.   
 The increased inflammatory profile in gSAT in response to exercise training reported 
in the Chapters 5 and 6 of this thesis might not be ‘detrimental’, as observed during the 
impairment of SAT expandability capacity during fat accumulation (61, 134). Rather, this thesis 
proposed that higher inflammatory profile after exercise training in black SA women is the 
response to the reduction in fat mass, specifically gSAT. It is therefore hypothesized that 
increased AT inflammation in the obese state (61, 134) may also be representative of the 
remodelling of this tissue to accommodate more fat. Noteworthy, most studies investigating the 
causality of inflammation in the development of obesity-associated IR have focused on central 
fat, especially VAT and aSAT, with very few studies focusing on gSAT function, particularly 
in African women. Further studies should therefore explore the inflammatory status of gSAT 
in the context of excess energy intake and its influence on whole-body insulin sensitivity, 
principally in African women, who accumulate a large amount of fat in this depot. Furthermore, 
GWAS or whole-genome profiling studies, have investigated the developmental origin of AT 
depots to understand the genetics of obesity and have identified several loci associated with 
BMI, body fat distribution and body fat percentage, as well as several genetic variants 
associated with the development of IR and T2D (39, 46, 52, 76, 190). Given that these studies 
were mostly conducted in European ancestry populations, this thesis is unique in that it reported 
for the first time, differences in transcriptomic signatures between aSAT and gSAT in women 
from African ancestry, with the identification of potential novel developmental genes. Future 
studies should explore these genes as candidate genes associated with body fat distribution and 
obesity-associated IR.  
7.2. Strengths and limitations 
Strengths of this thesis include the objective measurements of FA composition both in 
the circulation (RBC) and major AT reservoirs, detailed measures of systemic and depot-
specific SAT oxidative stress and inflammatory markers, expression of genes involved in 
adipogenesis, lipolysis, lipogenesis and insulin signalling, as well as untargeted depot-specific 
gene expression profiling.  In combination with these data, the measures of body fatness and 
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distribution, liver fat and whole-body insulin sensitivity, using state-of-the-art techniques, make 
the findings of this thesis novel and of clinical relevance in a context of obesity and associated 
metabolic risks in obese black SA women. Moreover, the exclusion of potential confounders 
such as inflammatory-related diseases and medication during participant recruitment represents 
additional strengths of this research work. African women have shown to be more insulin 
resistant than their white counterparts, despite their greater SAT accumulation mainly in the 
lower-body region, with less VAT. This makes the studied population unique, representing a 
major strength of this thesis. Notably, the specific effects of exercise training were evaluated in 
this thesis rather than the acute response of exercise, as measures of insulin sensitivity and 
biopsies were performed at least 72 hours after the last exercise session. Additionally, this 
exercise training intervention was supervised and well monitored by a trained exercise 
physiologist, who ensured that the prescribed exercise intensity was achieved by using heart 
rate monitoring and ratings of perceived exertion. The attendance was monitored throughout 
the 12 weeks, and this intervention had good overall participant adherence (range: 52-100 %), 
which is most likely because the exercise training program was based on prior focus group 
discussions in the same community (460). 
Some limitations of this thesis should be stated. Firstly, the lack of different ethnic 
comparator group represents a major limitation of this research work. This makes it difficult to 
attribute the findings of this thesis specifically to black South African woman only. Moreover, 
this thesis did not include male participants. The data may therefore not be representative of the 
black SA population and cannot be directly translated to other groups of individuals with 
different phenotypes and/or age, sex, socioeconomic and health status. Moreover, the lack of a 
normal-weight control as a comparison group prevented conclusions as to whether these 
findings were specific pathways related to obesity and exercise training rather than an 
adaptation to the obese state. These results need to be verified in more representative samples 
of black Africans, including normal-weight groups. Besides, only whole-body insulin 
sensitivity was measured using the FSIGT. Accordingly, changes in hepatic and muscle insulin 
sensitivity could not be determined, which would have been of particular interest. However, the 
FSIGT method was chosen for this study as it provided a measure of both insulin sensitivity 
and secretion. Black SA women hyper-secrete insulin and it is not clear whether this is a cause 
or a consequence of insulin resistance. Hence this was a focus of the parent study.  
The cross-sectional associations presented in Chapter 3 prevented me from concluding 
causality. For the determination of tissue-specific FA composition and metabolism in the 
Chapters 3 and 4, the desaturase enzyme activities were estimated based on product to precursor 
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FA ratios and may indicate the higher proportion of product than precursor in this tissue and 
not necessarily a higher desaturation level. Future studies may therefore measure the direct 
activity of the main desaturases as well as elongases involved in FA metabolism (e.g. FASN, 
ACC). The lack of detailed information on the dietary FA intake may also represent a limitation. 
However, the robust measure of the FA composition of RBC membrane and AT is regarded as 
more accurate than estimations from dietary self-reporting. Furthermore, the small sample of 
selected participants for the sub-study of protein analysis (due to tissue availability and related 
costs) in Chapter 5 represents a major limitation. It is important to note that the results from this 
analysis were presented as a pilot study monitoring the changes of the selected genes at the 
translational level in response to exercise training. Similarly, Chapter 5 was limited by the 
number of genes evaluated using a candidate genes approach. Unfortunately, due to limitations 
with tissue availability and cost, additional protein and mRNA analyses could not be completed. 
I acknowledge that there may be other genes and proteins involved in the evaluated pathways 
that were not measured. However, this issue was partly addressed in Chapter 6 of this thesis 
with the untargeted gene expression profiling of a sub-sample of women; although the small 
sample size also represents a limitation of this microarray analysis. Further, histological as well 
as extensive proteome analyses could not be performed, and it is difficult to conclude whether 
gene expression differences in the microarray analyses were translated at the protein level. The 
findings of this study need to be confirmed in a larger sample. As the detection of DEGs was 
based on statistical methods, further validation is needed to rule out the possibility of false 
positives. 
7.3. Future research directions 
Based on the results generated from this thesis, SAT metabolism and depot-specific 
changes in SAT function in response to exercise training do not directly explain the variations 
in whole-body insulin sensitivity in black SA women; although AT expansion has been 
generally associated with the development of IR and T2D in some individuals with obesity. 
Many questions therefore remained unanswered, particularly relating to the influence of SAT 
function on metabolic status and the main determinations of the exercise training-related 
improvement in SI in black SA women. This underlies the complexity of obesity-associated IR 
in women of African ancestry. Further studies should focus on other organs/tissues that affect 
metabolic risk factors, such as skeletal muscle, liver or pancreas, with a specific focus on the 
effect of exercise training on ectopic fat deposition and function of these tissues, which may 
also contribute to disease risk. Furthermore, future research must unravel the molecular 
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mechanisms that direct the endogenous metabolism of circulating FA, the influence of RBC-
TPL FA composition and desaturase activities on liver fat accumulation and systemic 
inflammation, as well as the clinical relevance of the changes in SAT FA composition in 
response to exercise training.  
This thesis provided unique data on SAT depot-specific gene expression profiles and the 
adaptation to exercise training in black African women with obesity. This research work 
generated hypotheses about novel candidate genes potentially implicated in the relationship 
between body fat distribution, AT adaptation and metabolic status. Subsequent studies should 
investigate the biological function of these genes and explore their involvement in metabolic 
risk associated with body fat distribution in this population. Furthermore, future investigations 
on isolated cell fractions, or single-cell RNA sequencing approaches, as well as cell culture 
experiments should also be undertaken to further elucidate the mechanistic link between 
exercise training and changes of AT transcriptomic signatures. 
The practical implication of these findings is that exercise training interventions provide 
an effective therapy for the management of IR and T2D risks in black SA women, with the 
improvement of cardiorespiratory fitness, body composition and insulin sensitivity. These 
women characterized with a poor cardiorespiratory fitness should be continuously encouraged 
to engage in moderate-to-high intensity PA. However, socio-economic issues related to 
adequate exercise practice in SA (e.g. lack of time and facilities, safety issues, cultural 
differences in body image and body size satisfaction or lack of community resources)  are 
barriers to the uptake of PA (279, 460). Although the focus of this thesis was PA and the 
improvement of the metabolic risk in black SA women, this intervention did not extensively 
reduce obesity. Dietary interventions have been shown to stimulate body fat reduction and 
improvement of body composition to a greater extent than PA (270-272). Other studies should 
therefore focus on dietary interventions in this population, as more profound changes in body 
weight and body composition might have amplified the improvement of metabolic profile in 
these women. Finally, South Africans, both at the individual and governmental level, need to 
work together to improve conditions promoting sufficient physical activity and improve dietary 
quality, in order to tackle the epidemics of obesity and T2D in this country.  
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Supplementary Table 2.1. List of genes Taqman IDs 
Gene ID Gene names Probe ID 
RPLPo  Ribosomal protein lateral stalk subunit PO Hs99999902_m1 
LRP10  Low-density lipoprotein receptor-related 
protein 10 
Hs00204094_m1 
ADIPOQ Adiponectin Hs00605917_m1 
MCP1 Monocyte chemoattractant protein 1 Hs00234140_m1 
IL10  Interleukin 10 Hs00961622_m1 
LEP Leptin Hs00174877_m1 
MIF  Macrophage migration inhibitory factor Hs00236988_g1 
NFκB1 Nuclear factor-kappa B1 Hs00765730_m1 
TLR4  Toll like receptor 4 Hs01060206_m1 
TNFα Tumor necrosis factor-alpha Hs00174128_m1 
PPARγ Peroxisome proliferator activator receptor 
gamma 
Hs01115513_m1 
LPL Lipoprotein lipase Hs00173425_m1 
DGAT2 Diacylglycerol acyltransferase 2 Hs01045913_m1 
PLIN1 Perilipin 1 Hs00160173_m1 
ATGL Adipose triglyceride lipase Hs00386101_m1 
IRS1 Insulin receptor substrate 1 Hs00178563_m1 
GLUT4 Glucose transporter 4 Hs00168966_m1 
SMG1 Serine/threonine-protein kinase Hs00979691_m1 
CAT  Catalase Hs00156308_m1 
SOD1 Superoxide dismutase Hs00533490_m1 

























Supplementary Figure 5.1. Effect of exercise training on gluteal (gSAT) and 
abdominal subcutaneous adipose tissue (aSAT) expression of leptin, adiponectin, 
catalase (CAT), superoxide dismutase (SOD1) and nitric oxide synthase (NOS3).  
#P<0.1 and *P <0.05: pre vs post within groups following the intervention (time effect). Control 
group n=15, both depots and exercise group n=20 in aSAT and n=18 in gSAT at post-training.  
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Supplementary Figure 5. 2.  Effect of exercise training on gluteal (gSAT) and 
abdominal subcutaneous adipose tissue (aSAT) inflammatory protein expression: 
representative.  
IL-10: interleukin-10; MCP1: monocyte chemoattractant protein 1; MIF: Macrophage 
migration inhibitory factor; NFκB: nuclear factor kappa B; TLR4: toll-like receptor 4; TNFα: 
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Supplementary Figure 6.1. GO term enrichment of differentially expressed genes 
between abdominal and gluteal subcutaneous adipose tissue after exercise training 
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Supplementary figure 6.1. continued  
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Supplementary Table 6.1. List of all differentially expressed genes between SAT 
depots after exercise training based on log2 fold change > 0.58  
(up and down-regulated; aSAT: abdominal subcutaneous adipose tissue; gSAT: gluteal 
subcutaneous adipose tissue) 
 
SYMBOL SEARCH_KEY logFC DEFINITION 
Higher in aSAT than gSAT 
HOXA5 NM_019102.2 -1.44 Homo sapiens homeobox A5 (HOXA5), mRNA. 
DMRT2 NM_181872.1 -1.41 Homo sapiens doublesex and mab-3 related transcription factor 2 
(DMRT2), transcript variant 1, mRNA. 
DMRT3 NM_021240.2 -1.35 Homo sapiens doublesex and mab-3 related transcription factor 3 
(DMRT3), mRNA. 
MYL2 NM_000432.2 -1.15 Homo sapiens myosin, light chain 2, regulatory, cardiac, slow (MYL2), 
mRNA. 
CDKN1B NM_004064.2 -1.10 Homo sapiens cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
(CDKN1B), mRNA. 
MYH11 NM_002474.1 -1.07 Homo sapiens myosin, heavy chain 11, smooth muscle (MYH11), 
transcript variant SM1A, mRNA. 
ANGPT2 NM_001118888.1 -1.06 Homo sapiens angiopoietin 2 (ANGPT2), transcript variant 3, mRNA. 
LOC649841 XM_938906.1 -1.05 PREDICTED: Homo sapiens similar to protein immuno-reactive with 
anti-PTH polyclonal antibodies (LOC649841), mRNA. 
PARM1 NM_015393.2 -1.05 Homo sapiens prostate androgen-regulated mucin-like protein 1 
(PARM1), mRNA. 
MYH7 NM_000257.1 -1.05 Homo sapiens myosin, heavy chain 7, cardiac muscle, beta (MYH7), 
mRNA. 
FLNC NM_001458.2 -1.02 Homo sapiens filamin C, gamma (actin-binding protein 280) (FLNC), 
mRNA. 
FNDC1 NM_032532.1 -0.97 Homo sapiens fibronectin type III domain containing 1 (FNDC1), 
mRNA. 
HSPA1B NM_005346.3 -0.96 Homo sapiens heat shock 70kDa protein 1B (HSPA1B), mRNA. 
FAM129A NM_022083.1 -0.94 Homo sapiens family with sequence similarity 129, member A 
(FAM129A), transcript variant 2, mRNA. 
CLDN11 NM_005602.4 -0.93 Homo sapiens claudin 11 (oligodendrocyte transmembrane protein) 
(CLDN11), mRNA. 
MYADM NM_138373.3 -0.91 Homo sapiens myeloid-associated differentiation marker (MYADM), 
transcript variant 2, mRNA. 
PER2 NM_022817.1 -0.89 Homo sapiens period homolog 2 (Drosophila) (PER2), mRNA. 
LEPR NM_001003679.1 -0.88 Homo sapiens leptin receptor (LEPR), transcript variant 2, mRNA. 
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NR5A2 NM_003822.3 -0.88 Homo sapiens nuclear receptor subfamily 5, group A, member 2 
(NR5A2), transcript variant 2, mRNA. 
NRGN NM_006176.1 -0.88 Homo sapiens neurogranin (protein kinase C substrate, RC3) (NRGN), 
mRNA. 
RECK NM_021111.1 -0.87 Homo sapiens reversion-inducing-cysteine-rich protein with kazal 
motifs (RECK), mRNA. 
RSPO3 NM_032784.3 -0.87 Homo sapiens R-spondin 3 homolog (Xenopus laevis) (RSPO3), mRNA. 
MSL3 NM_078629.2 -0.85 Homo sapiens male-specific lethal 3 homolog (Drosophila) (MSL3), 
transcript variant 1, mRNA. 
ALDH1A1 NM_000689.3 -0.84 Homo sapiens aldehyde dehydrogenase 1 family, member A1 
(ALDH1A1), mRNA. 
MUC6 XM_932177.1 -0.84 Homo sapiens mucin 6, oligomeric mucus/gel-forming (MUC6), mRNA. 
ATP6V1B1 NM_001692.2 -0.84 Homo sapiens ATPase, H+ transporting, lysosomal 56/58kDa, V1 
subunit B1 (ATP6V1B1), mRNA. 
AFAP1L2 NM_001001936.1 -0.84 Homo sapiens actin filament associated protein 1-like 2 (AFAP1L2), 
transcript variant 1, mRNA. 
LOC100134648 XM_001724681.1 -0.83 PREDICTED: Homo sapiens similar to hCG2024106, transcript variant 
2 (LOC100134648), mRNA. 
TUBB1 NM_030773.2 -0.83 Homo sapiens tubulin, beta 1 (TUBB1), mRNA. 
CXCL12 NM_001033886.1 -0.83 Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) (CXCL12), transcript variant 2, mRNA. 
ARID4B NM_016374.5 -0.83 Homo sapiens AT rich interactive domain 4B (RBP1-like) (ARID4B), 
transcript variant 1, mRNA. 
MEF2C NM_002397.2 -0.82 Homo sapiens myocyte enhancer factor 2C (MEF2C), mRNA. 
SYT7 NM_004200.2 -0.81 Homo sapiens synaptotagmin VII (SYT7), mRNA. 
ATP8B2 NM_020452.2 -0.80 Homo sapiens ATPase, class I, type 8B, member 2 (ATP8B2), transcript 
variant 1, mRNA. 
C1QTNF9 NM_178540.3 -0.80 Homo sapiens C1q and tumor necrosis factor related protein 9 
(C1QTNF9), mRNA. 
RFX7 NM_022841.5 -0.80 Homo sapiens regulatory factor X, 7 (RFX7), mRNA. 
LOC644852 XM_934213.1 -0.79 PREDICTED: Homo sapiens hypothetical protein LOC644852, 
transcript variant 1 (LOC644852), mRNA. 
HOPX NM_139212.2 -0.79 Homo sapiens HOP homeobox (HOPX), transcript variant 3, mRNA. 
MYOM1 NM_003803.2 -0.79 Homo sapiens myomesin 1, 185kDa (MYOM1), transcript variant 1, 
mRNA. 
C7 NM_000587.2 -0.79 Homo sapiens complement component 7 (C7), mRNA. 
EFNA1 NM_004428.2 -0.79 Homo sapiens ephrin-A1 (EFNA1), transcript variant 1, mRNA. 
TAOK1 NM_020791.1 -0.78 Homo sapiens TAO kinase 1 (TAOK1), mRNA. 
RERGL NM_024730.2 -0.78 Homo sapiens RERG/RAS-like (RERGL), mRNA. 
TMEM178 NM_152390.1 -0.77 Homo sapiens transmembrane protein 178 (TMEM178), mRNA. 
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ZDHHC11 NM_024786.1 -0.77 Homo sapiens zinc finger, DHHC-type containing 11 (ZDHHC11), 
mRNA. 
SLCO3A1 NM_013272.2 -0.77 Homo sapiens solute carrier organic anion transporter family, member 
3A1 (SLCO3A1), mRNA. 
RUNX1T1 NM_175636.1 -0.77 Homo sapiens runt-related transcription factor 1; translocated to, 1 
(cyclin D-related) (RUNX1T1), transcript variant 1, mRNA. 
PHACTR2 NM_014721.1 -0.77 Homo sapiens phosphatase and actin regulator 2 (PHACTR2), transcript 
variant 1, mRNA. 
PAK2 NM_002577.3 -0.76 PREDICTED: Homo sapiens p21 (CDKN1A)-activated kinase 2 
(PAK2), mRNA. 
TMEM154 NM_152680.1 -0.76 Homo sapiens transmembrane protein 154 (TMEM154), mRNA. 
HOXA3 NM_153631.1 -0.76 Homo sapiens homeobox A3 (HOXA3), transcript variant 2, mRNA. 
HOXB5 NM_002147.2 -0.76 Homo sapiens homeobox B5 (HOXB5), mRNA. 
PRMT2 NM_206962.1 -0.76 Homo sapiens protein arginine methyltransferase 2 (PRMT2), transcript 
variant 1, mRNA. 
LOC730525 NM_199327.1 -0.76 PREDICTED: Homo sapiens hypothetical protein LOC730525 
(LOC730525), mRNA. 
MSL3L1 NM_078630.1 -0.75 Homo sapiens male-specific lethal 3-like 1 (Drosophila) (MSL3L1), 
transcript variant 1, mRNA. 
SEPT5 NM_000407.3 -0.75 Homo sapiens septin 5 (SEPT5), mRNA. 
LOC400986 NM_001010914.1 -0.75 PREDICTED: Homo sapiens protein immuno-reactive with anti-PTH 
polyclonal antibodies (LOC400986), mRNA. 
COL4A5 NM_033381.1 -0.75 Homo sapiens collagen, type IV, alpha 5 (COL4A5), transcript variant 1, 
mRNA. 
MAP3K1 XM_042066.10 -0.74 Homo sapiens mitogen-activated protein kinase kinase kinase 1 
(MAP3K1), mRNA. 
NBPF8 XM_001726946.1 -0.74 PREDICTED: Homo sapiens neuroblastoma breakpoint family, member 
8 (NBPF8), mRNA. 
C1orf24 NM_052966.1 -0.74 Homo sapiens chromosome 1 open reading frame 24 (C1orf24), 
transcript variant 2, mRNA. 
FEM1C NM_020177.2 -0.73 Homo sapiens fem-1 homolog c (C. elegans) (FEM1C), mRNA. 
 
Hs.436134 -0.73 ta96c03.x1 NCI_CGAP_Lu26 Homo sapiens cDNA clone 
IMAGE:2051908 3, mRNA sequence 
CAST NM_001750.4 -0.73 Homo sapiens calpastatin (CAST), transcript variant 9, mRNA. 
LOC440928 XM_942885.1 -0.73 PREDICTED: Homo sapiens hypothetical LOC440928 (LOC440928), 
mRNA. 
ZNF462 NM_021224.3 -0.72 Homo sapiens zinc finger protein 462 (ZNF462), mRNA. 
PLCB1 NM_182734.1 -0.72 Homo sapiens phospholipase C, beta 1 (phosphoinositide-specific) 
(PLCB1), transcript variant 1, mRNA. 
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LOC644162 XM_933956.1 -0.72 PREDICTED: Homo sapiens similar to septin 7, transcript variant 4 
(LOC644162), mRNA. 
DKK3 NM_013253.4 -0.71 Homo sapiens dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript 
variant 2, mRNA. 
SAPS2 XM_942540.1 -0.71 PREDICTED: Homo sapiens SAPS domain family, member 2, transcript 
variant 2 (SAPS2), mRNA. 
VPS13C NM_018080.2 -0.71 Homo sapiens vacuolar protein sorting 13 homolog C (S. cerevisiae) 
(VPS13C), transcript variant 1B, mRNA. 
BRD3 NM_007371.2 -0.71 Homo sapiens bromodomain containing 3 (BRD3), mRNA. 
SMARCA1 NM_003069.2 -0.71 Homo sapiens SWI/SNF related matrix associated, actin-dependent 
regulator of chromatin, subfamily a, member 1 (SMARCA1), transcript 
variant 1, mRNA. 
TM4SF18 NM_138786.1 -0.71 Homo sapiens transmembrane 4 L six family member 18 (TM4SF18), 
mRNA. 
MPZL2 NM_005797.2 -0.71 Homo sapiens myelin protein zero-like 2 (MPZL2), transcript variant 1, 
mRNA. 
C1orf71 NM_152609.1 -0.71 Homo sapiens chromosome 1 open reading frame 71 (C1orf71), mRNA. 
SNTB2 NM_006750.2 -0.71 Homo sapiens syntrophin, beta 2 (dystrophin-associated protein A1, 
59kDa, basic component 2) (SNTB2), transcript variant 1, mRNA. 
IRX2 NM_033267.2 -0.70 Homo sapiens iroquois homeobox 2 (IRX2), mRNA. 
MYADM NM_001020820.1 -0.70 Homo sapiens myeloid-associated differentiation marker (MYADM), 
transcript variant 4, mRNA. 
LBH NM_030915.1 -0.70 Homo sapiens limb bud and heart development homolog (mouse) (LBH), 
mRNA. 
ETS1 NM_005238.2 -0.70 Homo sapiens v-ets erythroblastosis virus E26 oncogene homolog 1 
(avian) (ETS1), mRNA. 
FNDC1 NM_032532.1 -0.69 Homo sapiens fibronectin type III domain containing 1 (FNDC1), 
mRNA. 
MTF2 NM_007358.1 -0.69 Homo sapiens metal response element binding transcription factor 2 
(MTF2), mRNA. 
APCDD1L NM_153360.1 -0.69 Homo sapiens adenomatosis polyposis coli down-regulated 1-like 
(APCDD1L), mRNA. 
CPNE8 NM_153634.2 -0.69 Homo sapiens copine VIII (CPNE8), mRNA. 
STXBP6 NM_014178.6 -0.68 Homo sapiens syntaxin binding protein 6 (amisyn) (STXBP6), mRNA. 
ANGPT2 NM_001147.1 -0.68 Homo sapiens angiopoietin 2 (ANGPT2), mRNA. 
SMARCC2 NM_003075.2 -0.67 Homo sapiens SWI/SNF related matrix associated, actin-dependent 
regulator of chromatin, subfamily c, member 2 (SMARCC2), transcript 
variant 2, mRNA. 
C4orf31 NM_024574.2 -0.67 Homo sapiens chromosome 4 open reading frame 31 (C4orf31), mRNA. 
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ADO NM_032804.5 -0.67 Homo sapiens 2-aminoethanethiol (cysteamine) dioxygenase (ADO), 
mRNA. 
DACH1 NM_080759.3 -0.67 Homo sapiens dachshund homolog 1 (Drosophila) (DACH1), transcript 
variant 2, mRNA. 
ALDH1A1 NM_000689.3 -0.67 Homo sapiens aldehyde dehydrogenase 1 family, member A1 
(ALDH1A1), mRNA. 
FRMD3 NM_174938.3 -0.67 Homo sapiens FERM domain containing 3 (FRMD3), mRNA. 
NAP1L1 NM_139207.1 -0.66 Homo sapiens nucleosome assembly protein 1-like 1 (NAP1L1), 
transcript variant 1, mRNA. 
TMEM47 NM_031442.2 -0.66 Homo sapiens transmembrane protein 47 (TMEM47), mRNA. 
PSMC1 XM_928629.1 -0.66 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 
1 (PSMC1), mRNA. 
GALNTL1 NM_020692.1 -0.66 Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 1 (GALNTL1), mRNA. 
CHD1 NM_001270.2 -0.66 Homo sapiens chromodomain helicase DNA binding protein 1 (CHD1), 
mRNA. 
EIF2C2 NM_012154.2 -0.66 Homo sapiens eukaryotic translation initiation factor 2C, 2 (EIF2C2), 
mRNA. 
BAT2D1 NM_015172.2 -0.66 Homo sapiens BAT2 domain containing 1 (BAT2D1), mRNA. 
SAFB2 NM_014649.2 -0.65 Homo sapiens scaffold attachment factor B2 (SAFB2), mRNA. 
CNN3 NM_001839.2 -0.65 Homo sapiens calponin 3, acidic (CNN3), mRNA. 
ARID4B NM_016374.5 -0.65 Homo sapiens AT rich interactive domain 4B (RBP1-like) (ARID4B), 
transcript variant 1, mRNA. 
TSHZ3 NM_020856.1 -0.65 Homo sapiens tea shirt zinc finger homeobox 3 (TSHZ3), mRNA. 
PTRF NM_012232.2 -0.65 Homo sapiens polymerase I and transcript release factor (PTRF), mRNA. 
ULK1 XM_942125.1 -0.65 Homo sapiens unc-51-like kinase 1 (C. elegans) (ULK1), mRNA. 
SULF1 NM_015170.1 -0.65 Homo sapiens sulfatase 1 (SULF1), mRNA. 
TNRC6B NM_001024843.1 -0.65 Homo sapiens trinucleotide repeat containing 6B (TNRC6B), transcript 
variant 2, mRNA. 
HELZ NM_014877.2 -0.64 Homo sapiens helicase with zinc finger (HELZ), mRNA. 
CXCR7 NM_020311.1 -0.64 Homo sapiens chemokine (C-X-C motif) receptor 7 (CXCR7), mRNA. 
SERPINI1 NM_005025.2 -0.64 Homo sapiens serpin peptidase inhibitor, clade I (neuroserpin), member 
1 (SERPINI1), mRNA. 
 
Hs.388347 -0.64 Homo sapiens mRNA; cDNA DKFZp686J0156 (from clone 
DKFZp686J0156) 
ULK1 NM_003565.1 -0.64 Homo sapiens unc-51-like kinase 1 (C. elegans) (ULK1), mRNA. 
ZBTB20 NM_015642.2 -0.64 Homo sapiens zinc finger and BTB domain containing 20 (ZBTB20), 
mRNA. 
PTGDS NM_000954.5 -0.64 Homo sapiens prostaglandin D2 synthase 21kDa (brain) (PTGDS), 
mRNA. 
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LOC651309 XM_942586.1 -0.64 PREDICTED: Homo sapiens hypothetical protein LOC651309 
(LOC651309), mRNA. 
PCDH17 NM_014459.2 -0.64 Homo sapiens protocadherin 17 (PCDH17), mRNA. 
 
Hs.555252 -0.64 DA371742 BRTHA2 Homo sapiens cDNA clone BRTHA2001741 5, 
mRNA sequence 
PLS3 NM_005032.3 -0.64 Homo sapiens plastin 3 (T isoform) (PLS3), mRNA. 
RAD21 NM_006265.1 -0.64 Homo sapiens RAD21 homolog (S. pombe) (RAD21), mRNA. 
 
Hs.379253 -0.64 Homo sapiens mRNA; cDNA DKFZp686J23256 (from clone 
DKFZp686J23256) 
LOC441155 XM_930970.1 -0.64 PREDICTED: Homo sapiens similar to Zinc finger CCCH-type domain-
containing protein 11A, transcript variant 2 (LOC441155), mRNA. 
C10orf140 NM_207371.3 -0.63 Homo sapiens chromosome 10 open reading frame 140 (C10orf140), 
mRNA. 
FAM179B NM_015091.1 -0.63 Homo sapiens family with sequence similarity 179, member B 
(FAM179B), mRNA. 
CFI NM_000204.1 -0.63 Homo sapiens complement factor I (CFI), mRNA. 
NFAT5 NM_173215.1 -0.63 Homo sapiens nuclear factor of activated T-cells 5, tonicity-responsive 
(NFAT5), transcript variant 5, mRNA. 
SENP7 NM_001077203.1 -0.63 Homo sapiens SUMO1/sentrin specific peptidase 7 (SENP7), transcript 
variant 2, mRNA. 
RIPK5 NM_199462.1 -0.62 Homo sapiens receptor interacting protein kinase 5 (RIPK5), transcript 
variant 2, mRNA. 
DMWD NM_004943.1 -0.62 Homo sapiens dystrophia myotonica, WD repeat-containing (DMWD), 
mRNA. 
NFKBIA NM_020529.1 -0.62 Homo sapiens nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha (NFKBIA), mRNA. 
PDE5A NM_033437.2 -0.62 Homo sapiens phosphodiesterase 5A, cGMP-specific (PDE5A), 
transcript variant 1, mRNA. 
C4orf32 NM_152400.1 -0.62 Homo sapiens chromosome 4 open reading frame 32 (C4orf32), mRNA. 
LRRC17 NM_001031692.1 -0.62 Homo sapiens leucine-rich repeat-containing 17 (LRRC17), transcript 
variant 2, mRNA. 
FAM13B NM_001101800.1 -0.62 Homo sapiens family with sequence similarity 13, member B 
(FAM13B), transcript variant 2, mRNA. 
CPE NM_001873.1 -0.62 Homo sapiens carboxypeptidase E (CPE), mRNA. 
C21orf7 NM_020152.2 -0.62 Homo sapiens chromosome 21 open reading frame 7 (C21orf7), mRNA. 
COL8A1 NM_020351.2 -0.61 Homo sapiens collagen, type VIII, alpha 1 (COL8A1), transcript variant 
2, mRNA. 
ABTB1 NM_172027.1 -0.61 Homo sapiens ankyrin repeat and BTB (POZ) domain containing 1 
(ABTB1), transcript variant 1, mRNA. 
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SERPINE2 NM_006216.2 -0.61 Homo sapiens serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2 (SERPINE2), mRNA. 
PDCD10 NM_145860.1 -0.61 Homo sapiens programmed cell death 10 (PDCD10), transcript variant 
2, mRNA. 
EDN1 NM_001955.2 -0.61 Homo sapiens endothelin 1 (EDN1), mRNA. 
 
Hs.184721 -0.61 EST366269 MAGE resequences, MAGC Homo sapiens cDNA, mRNA 
sequence 
KLHL28 NM_017658.2 -0.61 Homo sapiens kelch-like 28 (Drosophila) (KLHL28), mRNA. 
BST2 NM_004335.2 -0.61 Homo sapiens bone marrow stromal cell antigen 2 (BST2), mRNA. 
VCAN NM_004385.2 -0.61 Homo sapiens versican (VCAN), mRNA. 
 
Hs.571887 -0.61 Homo sapiens cDNA: FLJ21429 fis, clone COL04205 
RNF19A NM_183419.1 -0.61 Homo sapiens ring finger protein 19A (RNF19A), transcript variant 1, 
mRNA. 
LRRC1 NM_018214.3 -0.60 Homo sapiens leucine-rich repeat-containing 1 (LRRC1), mRNA. 
DOCK10 NM_014689.1 -0.60 Homo sapiens dedicator of cytokinesis 10 (DOCK10), mRNA. 
MBNL3 NM_133486.1 -0.60 Homo sapiens muscleblind-like 3 (Drosophila) (MBNL3), transcript 
variant R, mRNA. 
ISM1 XM_939699.1 -0.60 Homo sapiens isthmin 1 homolog (zebrafish) (ISM1), mRNA. 
KIAA1600 NM_020940.2 -0.60 Homo sapiens KIAA1600 (KIAA1600), mRNA. 
CDCA7 NM_145810.1 -0.60 Homo sapiens cell division cycle associated 7 (CDCA7), transcript 
variant 1, mRNA. 
C6 NM_000065.1 -0.59 Homo sapiens complement component 6 (C6), mRNA. 
DPYSL5 NM_020134.2 -0.59 Homo sapiens dihydropyrimidinase-like 5 (DPYSL5), mRNA. 
MLLT10 NM_004641.2 -0.59 Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 10 (MLLT10), transcript variant 
1, mRNA. 
HOXA9 NM_152739.2 -0.59 Homo sapiens homeobox A9 (HOXA9), mRNA. 
PGM5 XM_936702.1 -0.59 Homo sapiens phosphoglucomutase 5 (PGM5), mRNA. 
KIAA1267 NM_015443.2 -0.59 Homo sapiens KIAA1267 (KIAA1267), mRNA. 
TMEM200A NM_052913.2 -0.59 Homo sapiens transmembrane protein 200A (TMEM200A), mRNA. 
C17orf58 NM_181656.1 -0.59 Homo sapiens chromosome 17 open reading frame 58 (C17orf58), 
transcript variant 2, mRNA. 
PDPN NM_001006625.1 -0.59 Homo sapiens podoplanin (PDPN), transcript variant 4, mRNA. 
SORBS2 NM_003603.4 -0.59 Homo sapiens sorbin and SH3 domain containing 2 (SORBS2), 
transcript variant 1, mRNA. 
SORL1 NM_003105.3 -0.59 Homo sapiens sortilin-related receptor, L(DLR class) A repeats-
containing (SORL1), mRNA. 
ZNF385D NM_024697.1 -0.59 Homo sapiens zinc finger protein 385D (ZNF385D), mRNA. 
CBX6 NM_014292.3 -0.59 Homo sapiens chromobox homolog 6 (CBX6), mRNA. 
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Lower in aSAT than gSAT 
CSN1S1 NM_001025104.1 1.37 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, mRNA. 
SPP1 NM_001040058.1 1.25 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript variant 1, 
mRNA. 
LOC644936 NR_004845.1 1.22 Homo sapiens cytoplasmic beta-actin pseudogene (LOC644936), non-
coding RNA. 
IFI30 NM_006332.3 1.17 Homo sapiens interferon, gamma-inducible protein 30 (IFI30), mRNA. 
LAPTM5 NM_006762.1 1.17 Homo sapiens lysosomal multispanning membrane protein 5 
(LAPTM5), mRNA. 
SPP1 NM_000582.2 1.16 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript variant 2, 
mRNA. 
FCGBP NM_003890.1 1.15 Homo sapiens Fc fragment of IgG binding protein (FCGBP), mRNA. 
TM4SF19 NM_138461.1 1.13 PREDICTED: Homo sapiens transmembrane 4 L six family member 
19, transcript variant 2 (TM4SF19), mRNA. 
CSN1S1 NM_001890.1 1.12 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, mRNA. 
FOSB NM_006732.1 1.10 Homo sapiens FBJ murine osteosarcoma viral oncogene homolog B 
(FOSB), mRNA. 
LOC55908 NM_018687.3 1.10 Homo sapiens hepatocellular carcinoma-associated gene TD26 
(LOC55908), mRNA. 
LOC645313 XR_017585.2 1.09 PREDICTED: Homo sapiens misc_RNA (LOC645313), miscRNA. 
CD163 NM_203416.1 1.06 Homo sapiens CD163 molecule (CD163), transcript variant 2, mRNA. 
APOC1 NM_001645.3 1.02 Homo sapiens apolipoprotein C-I (APOC1), mRNA. 
G0S2 NM_015714.2 1.01 Homo sapiens G0/G1switch 2 (G0S2), mRNA. 
LOC649679 XM_945045.1 1.00 PREDICTED: Homo sapiens similar to Tubulin beta-4q chain, 
transcript variant 2 (LOC649679), mRNA. 
TUBB4Q NM_020040.3 0.98 Homo sapiens tubulin, beta polypeptide 4, member Q (TUBB4Q), 
mRNA. 
CD163 NM_203416.1 0.98 Homo sapiens CD163 molecule (CD163), transcript variant 2, mRNA. 
FCER1G NM_004106.1 0.96 Homo sapiens Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide (FCER1G), mRNA. 
FCGBP XM_940656.1 0.95 PREDICTED: Homo sapiens Fc fragment of IgG binding protein 
(FCGBP), mRNA. 
MYOC NM_000261.1 0.95 Homo sapiens myocilin, trabecular meshwork inducible glucocorticoid 
response (MYOC), mRNA. 
LAMB3 NM_000228.2 0.94 Homo sapiens laminin, beta 3 (LAMB3), transcript variant 1, mRNA. 
CYR61 NM_001554.3 0.93 Homo sapiens cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA. 
MYOC NM_000261.1 0.92 Homo sapiens myocilin, trabecular meshwork inducible glucocorticoid 
response (MYOC), mRNA. 
PLIN2 NM_001122.2 0.92 Homo sapiens perilipin 2 (PLIN2), mRNA. 
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TNMD NM_022144.1 0.91 Homo sapiens tenomodulin (TNMD), mRNA. 
ITGAX NM_000887.3 0.91 Homo sapiens integrin, alpha X (complement component 3 receptor 4 
subunit) (ITGAX), mRNA. 
FPR3 NM_002030.3 0.90 Homo sapiens formyl peptide receptor 3 (FPR3), mRNA. 
PEMT NM_148173.1 0.87 Homo sapiens phosphatidylethanolamine N-methyltransferase 
(PEMT), nuclear gene encoding mitochondrial protein, transcript 
variant 1, mRNA. 
HLA-DQA1 XM_936120.1 0.86 PREDICTED: Homo sapiens major histocompatibility complex, class 
II, DQ alpha 1, transcript variant 10 (HLA-DQA1), mRNA. 
CHI3L1 NM_001276.2 0.86 Homo sapiens chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), 
mRNA. 
FBP1 NM_000507.2 0.86 Homo sapiens fructose-1,6-bisphosphatase 1 (FBP1), mRNA. 
CAPG NM_001747.2 0.86 Homo sapiens capping protein (actin filament), gelsolin-like (CAPG), 
mRNA. 
VSIG4 NM_007268.1 0.84 Homo sapiens V-set and immunoglobulin domain containing 4 
(VSIG4), transcript variant 1, mRNA. 
VEGFB NM_003377.3 0.84 Homo sapiens vascular endothelial growth factor B (VEGFB), mRNA. 
LOC644237 XR_039184.1 0.84 PREDICTED: Homo sapiens misc_RNA (LOC644237), miscRNA. 
PLA2G7 NM_005084.2 0.82 Homo sapiens phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma) (PLA2G7), mRNA. 
TUBB NM_178014.2 0.82 Homo sapiens tubulin, beta (TUBB), mRNA. 
C1QC NM_172369.2 0.81 Homo sapiens complement component 1, q subcomponent, C chain 
(C1QC), mRNA. 
ACP5 NM_001611.2 0.80 Homo sapiens acid phosphatase 5, tartrate resistant (ACP5), mRNA. 
C1QB NM_000491.2 0.80 Homo sapiens complement component 1, q subcomponent, B chain 
(C1QB), mRNA. 
ANKRD33 NM_182608.2 0.80 Homo sapiens ankyrin repeat domain 33 (ANKRD33), mRNA. 
TREM2 NM_018965.1 0.77 Homo sapiens triggering receptor expressed on myeloid cells 2 
(TREM2), mRNA. 
IDH2 NM_002168.2 0.77 Homo sapiens isocitrate dehydrogenase 2 (NADP+), mitochondrial 
(IDH2), nuclear gene encoding mitochondrial protein, mRNA. 
CISH NM_145071.1 0.77 Homo sapiens cytokine-inducible SH2-containing protein (CISH), 
mRNA. 
RBP4 NM_006744.3 0.75 Homo sapiens retinol binding protein 4, plasma (RBP4), mRNA. 
CPVL NM_031311.3 0.75 Homo sapiens carboxypeptidase, vitellogenic-like (CPVL), transcript 
variant 1, mRNA. 
SRPR NM_003139.2 0.74 Homo sapiens signal recognition particle receptor (docking protein) 
(SRPR), mRNA. 
TM7SF4 NM_030788.2 0.74 Homo sapiens transmembrane 7 superfamily member 4 (TM7SF4), 
mRNA. 
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MRAS NM_012219.2 0.73 Homo sapiens muscle RAS oncogene homolog (MRAS), transcript 
variant 1, mRNA. 
CYP4B1 NM_000779.2 0.73 Homo sapiens cytochrome P450, family 4, subfamily B, polypeptide 1 
(CYP4B1), transcript variant 2, mRNA. 
LOC100133678 XM_001719804.1 0.72 PREDICTED: Homo sapiens similar to hCG2042724 
(LOC100133678), partial mRNA. 
TUBB2C NM_006088.5 0.72 Homo sapiens tubulin, beta 2C (TUBB2C), mRNA. 
CARS NM_001751.4 0.71 Homo sapiens cysteinyl-tRNA synthetase (CARS), transcript variant 4, 
mRNA. 
ALCAM NM_001627.2 0.71 Homo sapiens activated leukocyte cell adhesion molecule (ALCAM), 
mRNA. 
FTHL3 NR_002201.1 0.71 Homo sapiens ferritin, heavy polypeptide-like 3 (FTHL3), non-coding 
RNA. 
DPP7 NM_013379.2 0.71 Homo sapiens dipeptidyl-peptidase 7 (DPP7), mRNA. 
KIAA1598 NM_018330.3 0.70 Homo sapiens KIAA1598 (KIAA1598), mRNA. 
ABCC6 XM_936351.1 0.70 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), 
member 6 (ABCC6), transcript variant 1, mRNA. 
CXCL9 NM_002416.1 0.70 Homo sapiens chemokine (C-X-C motif) ligand 9 (CXCL9), mRNA. 
SLC6A8 NM_005629.1 0.70 Homo sapiens solute carrier family 6 (neurotransmitter transporter, 
creatine), member 8 (SLC6A8), mRNA. 
AHNAK NM_024060.2 0.69 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 2, 
mRNA. 
DECR1 NM_001359.1 0.69 Homo sapiens 2,4-dienoyl CoA reductase 1, mitochondrial (DECR1), 
nuclear gene encoding mitochondrial protein, mRNA. 
MS4A6E NM_139249.2 0.69 Homo sapiens membrane-spanning 4-domains, subfamily A, member 
6E (MS4A6E), mRNA. 
RASSF4 NM_178145.1 0.68 Homo sapiens Ras association (RalGDS/AF-6) domain family member 
4 (RASSF4), mRNA. 
CCL22 NM_002990.3 0.68 Homo sapiens chemokine (C-C motif) ligand 22 (CCL22), mRNA. 
MAL2 NM_052886.1 0.68 Homo sapiens mal, T-cell differentiation protein 2 (MAL2), mRNA. 
NNMT NM_006169.2 0.68 Homo sapiens nicotinamide N-methyltransferase (NNMT), mRNA. 
FASN NM_004104.4 0.68 Homo sapiens fatty acid synthase (FASN), mRNA. 




0.68 Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
mRNA. 
IRF8 NM_002163.2 0.67 Homo sapiens interferon regulatory factor 8 (IRF8), mRNA. 
C1QA NM_015991.1 0.67 Homo sapiens complement component 1, q subcomponent, alpha 
polypeptide (C1QA), mRNA. 
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LGALS12 NM_033101.2 0.67 Homo sapiens lectin, galactoside-binding, soluble, 12 (LGALS12), 
mRNA. 
NCKAP1L NM_005337.2 0.67 Homo sapiens NCK-associated protein 1-like (NCKAP1L), mRNA. 
INDO NM_002164.3 0.67 Homo sapiens indoleamine-pyrrole 2,3 dioxygenase (INDO), mRNA. 
ATP6V0C NM_001694.2 0.67 PREDICTED: Homo sapiens ATPase, H+ transporting, lysosomal 
16kDa, V0 subunit c (ATP6V0C), mRNA. 
REEP6 NM_138393.1 0.67 Homo sapiens receptor accessory protein 6 (REEP6), mRNA. 
FOLR2 NM_000803.2 0.67 Homo sapiens folate receptor 2 (fetal) (FOLR2), mRNA. 
CRYBB2 NM_000496.1 0.67 Homo sapiens crystallin, beta B2 (CRYBB2), mRNA. 
CD74 NM_004355.2 0.67 Homo sapiens CD74 molecule, major histocompatibility complex, class 
II invariant chain (CD74), transcript variant 2, mRNA. 
CLMN NM_024734.2 0.66 Homo sapiens calmin (calponin-like, transmembrane) (CLMN), 
mRNA. 
SAA1 NM_199161.1 0.66 Homo sapiens serum amyloid A1 (SAA1), transcript variant 2, mRNA. 
ME3 NM_006680.2 0.66 Homo sapiens malic enzyme 3, NADP(+)-dependent, mitochondrial 
(ME3), nuclear gene encoding mitochondrial protein, transcript variant 
2, mRNA. 
PTPLA NM_014241.2 0.66 Homo sapiens protein tyrosine phosphatase-like (proline instead of 
catalytic arginine), member A (PTPLA), mRNA. 
CTSA NM_000308.1 0.66 Homo sapiens cathepsin A (CTSA), transcript variant 1, mRNA. 
LY86 NM_004271.3 0.66 Homo sapiens lymphocyte antigen 86 (LY86), mRNA. 
AP1B1 NM_145730.1 0.66 Homo sapiens adaptor-related protein complex 1, beta 1 subunit 
(AP1B1), transcript variant 2, mRNA. 
GPC1 NM_002081.1 0.66 Homo sapiens glypican 1 (GPC1), mRNA. 
DMPK NM_004409.2 0.66 Homo sapiens dystrophia myotonica-protein kinase (DMPK), transcript 
variant 4, mRNA. 
DAP NM_004394.1 0.65 Homo sapiens death-associated protein (DAP), mRNA. 
GAPDH NM_002046.2 0.65 Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
mRNA. 
ITPK1 NM_014216.3 0.65 Homo sapiens inositol 1,3,4-triphosphate 5/6 kinase (ITPK1), mRNA. 
IDH1 NM_005896.2 0.65 Homo sapiens isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), 
mRNA. 
PPP1R1A NM_006741.2 0.65 Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 1A 
(PPP1R1A), mRNA. 
ITGB5 NM_002213.3 0.64 Homo sapiens integrin, beta 5 (ITGB5), mRNA. XM_944688 
XM_944693 
LIPA NM_000235.2 0.64 Homo sapiens lipase A, lysosomal acid, cholesterol esterase (LIPA), 
transcript variant 2, mRNA. 
C6orf145 NM_183373.2 0.64 PREDICTED: Homo sapiens chromosome 6 open reading frame 145 
(C6orf145), mRNA. 
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HSD11B1 NM_181755.1 0.64 Homo sapiens hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), 
transcript variant 2, mRNA. 
NPLOC4 NM_017921.1 0.64 Homo sapiens nuclear protein localization 4 homolog (S. cerevisiae) 
(NPLOC4), mRNA. 
LOC92755 XR_018705.2 0.64 PREDICTED: Homo sapiens misc_RNA (LOC92755), miscRNA. 
LGALS8 NM_201545.1 0.64 Homo sapiens lectin, galactoside-binding, soluble, 8 (LGALS8), 
transcript variant 4, mRNA. 
GDE1 NM_016641.3 0.63 Homo sapiens glycerophosphodiester phosphodiesterase 1 (GDE1), 
mRNA. 
KLC1 NM_182923.2 0.63 Homo sapiens kinesin light chain 1 (KLC1), transcript variant 1, 
mRNA. 
PGD NM_002631.2 0.63 Homo sapiens phosphogluconate dehydrogenase (PGD), mRNA. 
RARRES1 NM_206963.1 0.63 Homo sapiens retinoic acid receptor responder (tazarotene induced) 1 
(RARRES1), transcript variant 1, mRNA. 
CD74 NM_001025158.1 0.63 Homo sapiens CD74 molecule, major histocompatibility complex, class 
II invariant chain (CD74), transcript variant 1, mRNA. 
PCK1 NM_002591.2 0.63 Homo sapiens phosphoenolpyruvate carboxykinase 1 (soluble) (PCK1), 
mRNA. 
AADACL1 NM_020792.3 0.62 Homo sapiens arylacetamide deacetylase-like 1 (AADACL1), mRNA. 
VAC14 NM_018052.3 0.62 Homo sapiens Vac14 homolog (S. cerevisiae) (VAC14), mRNA. 
ELAC2 NM_018127.4 0.62 Homo sapiens elaC homolog 2 (E. coli) (ELAC2), mRNA. 
CD52 NM_001803.2 0.62 Homo sapiens CD52 molecule (CD52), mRNA. 
PLCD4 NM_032726.2 0.62 Homo sapiens phospholipase C, delta 4 (PLCD4), mRNA. 
FMO3 NM_006894.4 0.62 Homo sapiens flavin-containing monooxygenase 3 (FMO3), transcript 
variant 1, mRNA. 
MED8 NM_001001653.1 0.62 Homo sapiens mediator of RNA polymerase II transcription, subunit 8 
homolog (S. cerevisiae) (MED8), transcript variant 5, mRNA. 
P8 NM_012385.1 0.62 Homo sapiens p8 protein (candidate of metastasis 1) (P8), mRNA. 
MATK NM_139354.2 0.62 Homo sapiens megakaryocyte-associated tyrosine kinase (MATK), 
transcript variant 3, mRNA. 
PAK1 NM_002576.3 0.62 Homo sapiens p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, 
yeast) (PAK1), mRNA. 
ERGIC3 NM_198398.1 0.62 Homo sapiens ERGIC and golgi 3 (ERGIC3), transcript variant 1, 
mRNA. 
ALDOC NM_005165.2 0.62 Homo sapiens aldolase C, fructose-bisphosphate (ALDOC), mRNA. 
FADS3 NM_021727.3 0.62 Homo sapiens fatty acid desaturase 3 (FADS3), mRNA. 
SH3GLB1 NM_016009.2 0.61 Homo sapiens SH3-domain GRB2-like endophilin B1 (SH3GLB1), 
mRNA. 
CBR1 NM_001757.2 0.61 Homo sapiens carbonyl reductase 1 (CBR1), mRNA. 
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SLC6A10P NM_198857.1 0.61 Homo sapiens solute carrier family 6 (neurotransmitter transporter, 
creatine), member 10 (pseudogene) (SLC6A10P) on chromosome 16. 
RRAS2 NM_012250.3 0.61 Homo sapiens related RAS viral (r-ras) oncogene homolog 2 (RRAS2), 
mRNA. 
OLFM2 NM_058164.1 0.61 Homo sapiens olfactomedin 2 (OLFM2), mRNA. 
TFRC NM_003234.1 0.61 Homo sapiens transferrin receptor (p90, CD71) (TFRC), mRNA. 
CIDEC NM_022094.2 0.61 Homo sapiens cell death-inducing DFFA-like effector c (CIDEC), 
mRNA. 
ACO2 NM_001098.2 0.61 Homo sapiens aconitase 2, mitochondrial (ACO2), nuclear gene 
encoding mitochondrial protein, mRNA. 
CALB2 NM_001740.2 0.61 Homo sapiens calbindin 2 (CALB2), transcript variant CALB2c, 
mRNA. 
TENC1 NM_198316.1 0.61 Homo sapiens tensin like C1 domain containing phosphatase (tensin 2) 
(TENC1), transcript variant 3, mRNA. 
DYNLL2 NM_080677.1 0.60 Homo sapiens dynein, light chain, LC8-type 2 (DYNLL2), mRNA. 
NMB NM_021077.3 0.60 Homo sapiens neuromedin B (NMB), transcript variant 1, mRNA. 
CS NM_004077.2 0.60 Homo sapiens citrate synthase (CS), nuclear gene encoding 
mitochondrial protein, mRNA. 
CPVL NM_031311.2 0.60 Homo sapiens carboxypeptidase, vitellogenic-like (CPVL), transcript 
variant 2, mRNA. 
SPOCD1 NM_144569.3 0.60 Homo sapiens SPOC domain containing 1 (SPOCD1), mRNA. 
MOCOS NM_017947.1 0.60 Homo sapiens molybdenum cofactor sulfurase (MOCOS), mRNA. 
MAGED2 NM_201222.1 0.60 Homo sapiens melanoma antigen family D, 2 (MAGED2), transcript 
variant 3, mRNA. 
MS4A7 NM_206938.1 0.60 Homo sapiens membrane-spanning 4-domains, subfamily A, member 7 
(MS4A7), transcript variant 2, mRNA. 
ALDH3B1 NM_001030010.1 0.60 Homo sapiens aldehyde dehydrogenase 3 family, member B1 
(ALDH3B1), transcript variant 1, mRNA. 
CD151 NM_139030.2 0.60 Homo sapiens CD151 molecule (Raph blood group) (CD151), 
transcript variant 5, mRNA. 
RBPMS NM_001008712.1 0.60 Homo sapiens RNA binding protein with multiple splicing (RBPMS), 
transcript variant 3, mRNA. 
RGS20 NM_170587.1 0.60 Homo sapiens regulator of G-protein signaling 20 (RGS20), transcript 
variant 1, mRNA. 
LOC730908 XM_001717941.1 0.60 PREDICTED: Homo sapiens hypothetical LOC730908, transcript 
variant 2 (LOC730908), mRNA. 
HSPB7 NM_014424.3 0.59 Homo sapiens heat shock 27kDa protein family, member 7 
(cardiovascular) (HSPB7), mRNA. 
LOC731486 NM_198277.1 0.59 PREDICTED: Homo sapiens hypothetical protein LOC731486 
(LOC731486), mRNA. 
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CRYAB NM_001885.1 0.59 Homo sapiens crystallin, alpha B (CRYAB), mRNA. 
RETSAT NM_017750.2 0.59 Homo sapiens retinol saturase (all-trans-retinol 13,14-reductase) 
(RETSAT), mRNA. 
MEGF9 NM_001080497.1 0.59 Homo sapiens multiple EGF-like-domains 9 (MEGF9), mRNA. 
NEU1 NM_000434.2 0.59 Homo sapiens sialidase 1 (lysosomal sialidase) (NEU1), mRNA. 
DNASE2B NM_021233.2 0.59 Homo sapiens deoxyribonuclease II beta (DNASE2B), transcript 
variant 1, mRNA. 




Supplementary Table 6.2. List of all differentially expressed genes in gluteal 
subcutaneous adipose tissue (gSAT) in response to exercise training based on log2 
fold change > 0.58 (up and down-regulated) 
 
SYMBOL SEARCH_KEY logFC DEFINITION 
Up-regulated genes in gSAT after exercise training 
MMP9 NM_004994.2 -1.44 Homo sapiens matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) (MMP9), mRNA. 
SPP1 NM_001040058.1 -1.24 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript variant 1, 
mRNA. 
SPP1 NM_000582.2 -1.20 Homo sapiens secreted phosphoprotein 1 (SPP1), transcript variant 2, 
mRNA. 
APOC1 NM_001645.3 -1.14 Homo sapiens apolipoprotein C-I (APOC1), mRNA. 
ITGAX NM_000887.3 -1.04 Homo sapiens integrin, alpha X (complement component 3 receptor 4 
subunit) (ITGAX), mRNA. 
TM4SF19 NM_138461.2 -1.04 Homo sapiens transmembrane 4 L six family member 19 (TM4SF19), 
mRNA. 
IFI30 NM_006332.3 -1.02 Homo sapiens interferon, gamma-inducible protein 30 (IFI30), 
mRNA. 
PLA2G7 NM_005084.2 -0.94 Homo sapiens phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma) (PLA2G7), mRNA. 
LAPTM5 NM_006762.1 -0.93 Homo sapiens lysosomal multispanning membrane protein 5 
(LAPTM5), mRNA. 
CISH NM_145071.1 -0.89 Homo sapiens cytokine-inducible SH2-containing protein (CISH), 
mRNA. 
TM4SF19 NM_138461.1 -0.85 PREDICTED: Homo sapiens transmembrane 4 L six family member 
19, transcript variant 2 (TM4SF19), mRNA. 
DHRS9 NM_005771.3 -0.84 Homo sapiens dehydrogenase/reductase (SDR family) member 9 
(DHRS9), transcript variant 1, mRNA. 
COL1A1 NM_000088.2 -0.83 Homo sapiens collagen, type I, alpha 1 (COL1A1), mRNA. 
FCER1G NM_004106.1 -0.82 Homo sapiens Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide (FCER1G), mRNA. 
CCL22 NM_002990.3 -0.80 Homo sapiens chemokine (C-C motif) ligand 22 (CCL22), mRNA. 
FCGBP NM_003890.1 -0.79 Homo sapiens Fc fragment of IgG binding protein (FCGBP), mRNA. 
APOE NM_000041.2 -0.79 Homo sapiens apolipoprotein E (APOE), mRNA. 
HP NM_005143.2 -0.78 Homo sapiens haptoglobin (HP), mRNA. 
CHI3L1 NM_001276.2 -0.77 Homo sapiens chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), 
mRNA. 
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LOC653879 XM_936226.1 -0.77 PREDICTED: Homo sapiens similar to Complement C3 precursor 
(LOC653879), mRNA. 
SREBF1 NM_004176.3 -0.76 Homo sapiens sterol regulatory element binding transcription factor 1 
(SREBF1), transcript variant 2, mRNA. 
MATK NM_139354.2 -0.74 Homo sapiens megakaryocyte-associated tyrosine kinase (MATK), 
transcript variant 3, mRNA. 
NNMT NM_006169.2 -0.74 Homo sapiens nicotinamide N-methyltransferase (NNMT), mRNA. 
CAPG NM_001747.2 -0.73 Homo sapiens capping protein (actin filament), gelsolin-like (CAPG), 
mRNA. 
ERGIC3 NM_198398.1 -0.73 Homo sapiens ERGIC and golgi 3 (ERGIC3), transcript variant 1, 
mRNA. 
F13A1 NM_000129.2 -0.72 Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1), 
mRNA. 
ACP5 NM_001611.2 -0.72 Homo sapiens acid phosphatase 5, tartrate resistant (ACP5), mRNA. 
FAIM3 NM_005449.3 -0.71 Homo sapiens Fas apoptotic inhibitory molecule 3 (FAIM3), mRNA. 
PLTP NM_006227.2 -0.69 Homo sapiens phospholipid transfer protein (PLTP), transcript variant 
2, mRNA. 
SLC43A3 NM_017611.2 -0.69 Homo sapiens solute carrier family 43, member 3 (SLC43A3), mRNA. 
LIPA NM_000235.2 -0.69 Homo sapiens lipase A, lysosomal acid, cholesterol esterase (LIPA), 
transcript variant 2, mRNA. 
GRN NM_002087.2 -0.68 Homo sapiens granulin (GRN), mRNA. 
FCGBP XM_940656.1 -0.68 PREDICTED: Homo sapiens Fc fragment of IgG binding protein 
(FCGBP), mRNA. 
TM7SF4 NM_030788.2 -0.66 Homo sapiens transmembrane 7 superfamily member 4 (TM7SF4), 
mRNA. 
TYROBP NM_003332.2 -0.66 Homo sapiens TYRO protein tyrosine kinase binding protein 
(TYROBP), transcript variant 1, mRNA. 
FBP1 NM_000507.2 -0.66 Homo sapiens fructose-1,6-bisphosphatase 1 (FBP1), mRNA. 
COL6A2 NM_058174.1 -0.65 Homo sapiens collagen, type VI, alpha 2 (COL6A2), transcript variant 
2C2, mRNA. 
NPL NM_030769.1 -0.64 Homo sapiens N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) (NPL), mRNA. 
RABGGTA NM_182836.1 -0.64 Homo sapiens Rab geranylgeranyltransferase, alpha subunit 
(RABGGTA), transcript variant 1, mRNA. 
NPL NM_030769.1 -0.64 Homo sapiens N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) (NPL), mRNA. 
RNH1 NM_203385.1 -0.61 Homo sapiens ribonuclease/angiogenin inhibitor 1 (RNH1), transcript 
variant 4, mRNA. 
C3 NM_000064.1 -0.61 Homo sapiens complement component 3 (C3), mRNA. 
LGMN NM_001008530.1 -0.61 Homo sapiens legumain (LGMN), transcript variant 2, mRNA. 
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MVP NM_005115.3 -0.61 Homo sapiens major vault protein (MVP), transcript variant 2, mRNA. 
CILP NM_003613.2 -0.60 Homo sapiens cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase (CILP), mRNA. 
CYP27A1 NM_000784.2 -0.60 Homo sapiens cytochrome P450, family 27, subfamily A, polypeptide 
1 (CYP27A1), nuclear gene encoding mitochondrial protein, mRNA. 
GFPT2 NM_005110.1 -0.60 Homo sapiens glutamine-fructose-6-phosphate transaminase 2 
(GFPT2), mRNA. 
LOC92755 XR_018705.2 -0.59 PREDICTED: Homo sapiens misc_RNA (LOC92755), miscRNA. 
CD163 NM_203416.1 -0.59 Homo sapiens CD163 molecule (CD163), transcript variant 2, mRNA. 
LOC646294 XR_019565.2 -0.59 PREDICTED: Homo sapiens misc_RNA (LOC646294), miscRNA. 
EMILIN2 NM_032048.2 -0.59 Homo sapiens elastin microfibril interfacer 2 (EMILIN2), mRNA. 
ALCAM NM_001627.2 -0.59 Homo sapiens activated leukocyte cell adhesion molecule (ALCAM), 
mRNA. 
LOC649679 XM_945045.1 -0.59 PREDICTED: Homo sapiens similar to Tubulin beta-4q chain, 
transcript variant 2 (LOC649679), mRNA. 
CLDN7 NM_001307.3 -0.59 Homo sapiens claudin 7 (CLDN7), mRNA. 
Down-regulated genes in gSAT after exercise training 
LOC651309 XM_942586.1 0.64 PREDICTED: Homo sapiens hypothetical protein LOC651309 
(LOC651309), mRNA. 
PCDH9 NM_020403.3 0.64 Homo sapiens protocadherin 9 (PCDH9), transcript variant 1, mRNA. 
NTM NM_016522.2 0.63 Homo sapiens neurotrimin (NTM), transcript variant 2, mRNA. 
SLIT2 NM_004787.1 0.62 Homo sapiens slit homolog 2 (Drosophila) (SLIT2), mRNA. 
NUTF2 NM_005796.1 0.61 Homo sapiens nuclear transport factor 2 (NUTF2), mRNA. 
 
Hs.99472 0.60 Homo sapiens mRNA; cDNA DKFZp564O0862 (from clone 
DKFZp564O0862) 
FAM13A NM_014883.2 0.59 Homo sapiens family with sequence similarity 13, member A 




Supplementary Table 6.3. List of all differentially expressed genes in abdominal 
subcutaneous adipose tissue (aSAT) in response to exercise training based on log2 
fold change > 0.58 (up and down-regulated) 
 
SYMBOL SEARCH_KEY logFC DEFINITION 
Up-regulated genes in aSAT after exercise training 
ACTA1 NM_001100.3 -1.59 Homo sapiens actin, alpha 1, skeletal muscle (ACTA1), mRNA. 
FOLR3 NM_000804.2 -1.23 Homo sapiens folate receptor 3 (gamma) (FOLR3), mRNA. 
MYL2 NM_000432.2 -1.15 Homo sapiens myosin, light chain 2, regulatory, cardiac, slow 
(MYL2), mRNA. 
CHI3L2 NM_004000.2 -1.13 Homo sapiens chitinase 3-like 2 (CHI3L2), transcript variant 1, 
mRNA. 
MYH7 NM_000257.1 -1.09 Homo sapiens myosin, heavy chain 7, cardiac muscle, beta (MYH7), 
mRNA. 
COL1A1 NM_000088.2 -1.02 Homo sapiens collagen, type I, alpha 1 (COL1A1), mRNA. 
FLNC NM_001458.2 -0.98 Homo sapiens filamin C, gamma (actin-binding protein 280) 
(FLNC), mRNA. 
CKM NM_001824.2 -0.96 Homo sapiens creatine kinase, muscle (CKM), mRNA. 
LTB NM_002341.1 -0.93 Homo sapiens lymphotoxin beta (TNF superfamily, member 3) 
(LTB), transcript variant 1, mRNA. 
FNDC1 NM_032532.1 -0.90 Homo sapiens fibronectin type III domain containing 1 (FNDC1), 
mRNA. 
CFB NM_001710.4 -0.89 Homo sapiens complement factor B (CFB), mRNA. 
HOPX NM_139212.2 -0.88 Homo sapiens HOP homeobox (HOPX), transcript variant 3, 
mRNA. 
SLN NM_003063.1 -0.84 Homo sapiens sarcolipin (SLN), mRNA. 
CXCL12 NM_000609.4 -0.82 Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) (CXCL12), transcript variant 2, mRNA. 
ALPL NM_000478.2 -0.82 Homo sapiens alkaline phosphatase, liver/bone/kidney (ALPL), 
transcript variant 1, mRNA. 
MB NM_005368.2 -0.81 Homo sapiens myoglobin (MB), transcript variant 1, mRNA. 
MYBPC1 NM_002465.2 -0.80 Homo sapiens myosin binding protein C, slow type (MYBPC1), 
transcript variant 2, mRNA. 
PTGDS NM_000954.5 -0.80 Homo sapiens prostaglandin D2 synthase 21kDa (brain) (PTGDS), 
mRNA. 
C1QTNF9 NM_178540.3 -0.79 Homo sapiens C1q and tumor necrosis factor related protein 9 
(C1QTNF9), mRNA. 
CXCL12 NM_001033886.1 -0.79 Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) (CXCL12), transcript variant 2, mRNA. 
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CPXM1 NM_019609.3 -0.75 Homo sapiens carboxypeptidase X (M14 family), member 1 
(CPXM1), mRNA. 
IGDCC4 NM_020962.1 -0.74 Homo sapiens immunoglobulin superfamily, DCC subclass, 
member 4 (IGDCC4), mRNA. 
BASP1 NM_006317.3 -0.71 Homo sapiens brain abundant, membrane attached signal protein 1 
(BASP1), mRNA. 
FNDC1 NM_032532.1 -0.69 Homo sapiens fibronectin type III domain containing 1 (FNDC1), 
mRNA. 
SMOC2 NM_022138.1 -0.69 Homo sapiens SPARC related modular calcium binding 2 
(SMOC2), mRNA. 
ISLR NM_005545.3 -0.69 Homo sapiens immunoglobulin superfamily containing leucine-rich 
repeat (ISLR), transcript variant 1, mRNA. 
IL7R NM_002185.2 -0.68 Homo sapiens interleukin 7 receptor (IL7R), mRNA. 
IL7R XM_937367.1 -0.68 PREDICTED: Homo sapiens interleukin 7 receptor (IL7R), mRNA. 
PDPN NM_001006625.1 -0.67 Homo sapiens podoplanin (PDPN), transcript variant 4, mRNA. 
HP NM_005143.2 -0.67 Homo sapiens haptoglobin (HP), mRNA. 
GNLY NM_012483.1 -0.66 Homo sapiens granulysin (GNLY), transcript variant 519, mRNA. 
ATP8B2 NM_020452.2 -0.66 Homo sapiens ATPase, class I, type 8B, member 2 (ATP8B2), 
transcript variant 1, mRNA. 
CTSG NM_001911.2 -0.66 Homo sapiens cathepsin G (CTSG), mRNA. 
HRC NM_002152.2 -0.64 Homo sapiens histidine-rich calcium-binding protein (HRC), 
mRNA. 
FAM129A NM_022083.1 -0.64 Homo sapiens family with sequence similarity 129, member A 
(FAM129A), transcript variant 2, mRNA. 
F10 NM_000504.2 -0.64 Homo sapiens coagulation factor X (F10), mRNA. 
APCDD1L NM_153360.1 -0.64 Homo sapiens adenomatosis polyposis coli down-regulated 1-like 
(APCDD1L), mRNA. 
GZMA NM_006144.2 -0.63 Homo sapiens granzyme A (granzyme 1, cytotoxic T-lymphocyte-
associated serine esterase 3) (GZMA), mRNA. 
C7 NM_000587.2 -0.63 Homo sapiens complement component 7 (C7), mRNA. 
CD3D NM_001040651.1 -0.63 Homo sapiens CD3d molecule, delta (CD3-TCR complex) (CD3D), 
transcript variant 2, mRNA. 
TCAP NM_003673.2 -0.63 Homo sapiens titin-cap (telethonin) (TCAP), mRNA. 
TMEM154 NM_152680.1 -0.62 Homo sapiens transmembrane protein 154 (TMEM154), mRNA. 
KBTBD10 NM_006063.2 -0.62 Homo sapiens kelch repeat and BTB (POZ) domain containing 10 
(KBTBD10), mRNA. 
CHST15 NM_015892.2 -0.61 Homo sapiens carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulfotransferase 15 (CHST15), mRNA. 
CD48 NM_001778.2 -0.61 Homo sapiens CD48 molecule (CD48), mRNA. 
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KLRB1 NM_002258.2 -0.61 Homo sapiens killer cell lectin-like receptor subfamily B, member 1 
(KLRB1), mRNA. 
MYOZ1 NM_021245.2 -0.61 Homo sapiens myozenin 1 (MYOZ1), mRNA. 
GALNTL1 NM_020692.1 -0.61 Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase-like 1 (GALNTL1), mRNA. 
LTB NM_002341.1 -0.60 Homo sapiens lymphotoxin beta (TNF superfamily, member 3) 
(LTB), transcript variant 1, mRNA. 
C1orf54 NM_024579.1 -0.60 Homo sapiens chromosome 1 open reading frame 54 (C1orf54), 
mRNA. 
CILP NM_003613.2 -0.59 Homo sapiens cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase (CILP), mRNA. 
LILRB3 NM_006864.1 -0.59 Homo sapiens leukocyte immunoglobulin-like receptor, subfamily 
B (with TM and ITIM domains), member 3 (LILRB3), transcript 
variant 2, mRNA. 
SEMA4D NM_006378.2 -0.59 Homo sapiens sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 4D (SEMA4D), mRNA. 
TPSAB1 NM_003294.3 -0.59 Homo sapiens tryptase alpha/beta 1 (TPSAB1), mRNA. 
CD79A NM_001783.2 -0.59 Homo sapiens CD79a molecule, immunoglobulin-associated alpha 
(CD79A), transcript variant 2, mRNA. 
Down-regulated genes in aSAT after exercise training 
FOS NM_005252.2 1.05 Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene 
homolog (FOS), mRNA. 
FOSB NM_006732.1 0.89 Homo sapiens FBJ murine osteosarcoma viral oncogene homolog B 
(FOSB), mRNA. 
CSN1S1 NM_001025104.1 0.87 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 
MYOC NM_000261.1 0.82 Homo sapiens myocilin, trabecular meshwork inducible 
glucocorticoid response (MYOC), mRNA. 
TWIST1 NM_000474.3 0.77 Homo sapiens twist homolog 1 (Drosophila) (TWIST1), mRNA. 
LOC643911 XR_042101.1 0.76 PREDICTED: Homo sapiens hCG1815491 (LOC643911), 
miscRNA. 
CSN1S1 NM_001890.1 0.76 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, 
mRNA. 
MYOC NM_000261.1 0.75 Homo sapiens myocilin, trabecular meshwork inducible 
glucocorticoid response (MYOC), mRNA. 
THBS4 NM_003248.3 0.75 Homo sapiens thrombospondin 4 (THBS4), mRNA. 
LOC643911 XM_931911.1 0.72 PREDICTED: Homo sapiens hypothetical LOC643911 
(LOC643911), mRNA. 
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TSTD1 NM_001113206.1 0.71 Homo sapiens thiosulfate sulfurtransferase (rhodanese)-like domain 
containing 1 (TSTD1), transcript variant 2, mRNA. 
GLDN NM_181789.1 0.65 Homo sapiens gliomedin (GLDN), mRNA. 
TMEM100 NM_018286.1 0.65 Homo sapiens transmembrane protein 100 (TMEM100), transcript 
variant 2, mRNA. 
IRX5 NM_005853.4 0.64 Homo sapiens iroquois homeobox protein 5 (IRX5), mRNA. 
TNMD NM_022144.1 0.64 Homo sapiens tenomodulin (TNMD), mRNA. 
SYN2 NM_133625.2 0.63 Homo sapiens synapsin II (SYN2), transcript variant IIa, mRNA. 
IRX5 NM_005853.4 0.63 Homo sapiens iroquois homeobox 5 (IRX5), mRNA. 
AHNAK NM_024060.2 0.61 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 
2, mRNA. 
AHNAK NM_024060.2 0.60 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 
1, mRNA. 
NPY5R NM_006174.2 0.60 Homo sapiens neuropeptide Y receptor Y5 (NPY5R), mRNA. 
CALB2 NM_001740.2 0.59 Homo sapiens calbindin 2 (CALB2), transcript variant CALB2c, 
mRNA. 









RNA Extraction from adipose tissue samples  
- Weigh   ̴ 70 mg of the frozen samples. Do not allow the thawing of the tissue, 
work on dry ice. 
- Place the tissue in a suitably sized vessel containing 1 ml QIAzol lysis reagent 
and place the tip of the probe into the vessel. Operate the TissueRuptor at full 
speed until the lysate is uniformly homogeneous (20-40 s). 
- Place the tube containing the homogenate on the benchtop at room temperature 
(15-25ºC) for 5 min.  
- Centrifuge a 2 ml tube at 12,000-16,000 x g for 20-30 s and transfer the 
homogenate to the tube. 
- Add 200 μL of chloroform to the tube, securely cap the tube, and shake it 
vigorously for 15 s. Do not vortex. 
- Place the tube on the benchtop at room temperature for 2-3 min 
- Centrifuge at 12,000 x g for 15 min at 4ºC 
- Transfer the upper, aqueous phase to another 2mL tube. Add 1 volume of 70% 
ethanol and mix thoroughly by vortexing. Do not centrifuge.  
- Transfer up to 700 μl of the sample to an RNeasy Mini spin column placed in a 2 
ml collection tube. Close the lid gently, and centrifuge for 15 s at ≥8000 x g 
(≥10,000 rpm) at room temperature (15-25ºC). Discard the flow-through. 
- Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at ≥8000 x g (≥10,000 rpm) to wash the membrane. Discard 
the flow-through. 
- Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at ≥8000 x g (≥10,000 rpm) to wash the membrane. Discard 
the flow-through. 
- Place the RNeasy spin column in a new 2 ml collection tube and discard the old 
collection tube with the flow-through. Close the lid gently, and centrifuge at full 
speed for 1 min.  
- Place the RNeasy spin column in a new 1.5 ml collection tube. Add 30-50 μl 
RNase-free water directly to the spin column membrane. Close the lid gently and 
centrifuge for 1 min at ≥8000 x g (≥10,000 rpm) to elute the RNA. 
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RNA dilution and cDNA synthesis - workflow 
- Calculate the amount of RNA that contains 1200 ng and the amount of Rnase free 
water to add for the final volume of 30 uL per sample. 
- Thaw RNA on ice, gently vortex and quick microfuge each tube/sample. 
- Pipette the volume of RNA per sample in the plate, for all samples (work on ice)  
- Pipette the corresponding volume of water to make up to 30 uL of solution for each 
sample. 
- Add 30 uL of RT master mix to each well and insert the plate in the machine to 
perform reverse transcription in a thermal cycler. 
Note: Work on the ice during the whole process, put samples in a randomized manner 
on the plate. 
 
RT master mix preparation (for 30 µL reaction) 
                                                           RT master mix sol   RT buffer 
10xRT-buffer     960 µl                             6 µl 
25x dNTP     384 µl                    2.4 µl 
10 x RT Random primers   960 µl                             6 µl 
Multiscribe Reverse Transcriptase  480 µl                    0 µl 
RNAse inhibitor    480 µl                              3 µl 
Nuclease free water    1536 µl                   12.6 µl 
Total                4800 µl                    30 µl 
 
 
- Pipette 30 µL of RT master mix solution and add to each well (containing 30uL of 
RNA diluted with Rnase free water). 










Gene Expression Analysis workflow 
-  Storage: Store TaqMan Gene Expression Assay products at -15 to -25 °C and 
keep them protected from light. To minimize freeze-thaw cycles, consider 
diluting 60x assays to 20x working stocks and dividing the solutions into smaller 
aliquots. 
- Prepare the PCR reaction mix before transferring it to the reaction plate for 
thermal cycling and fluorescence analysis. 
- Add 2 µl from each sample to one tube and mix well. Dilute the cDNA mixture 
to 5 different concentrations between 1-40 ng (eg: 2,5 ng, 5ng, 10 ng, 20 ng, and 
40 ng). 
- Add in triplicates the five different concentrations of cDNA standards (1-40 ng) 
for each gene (including the endogenous controls). The concentration that signals 
between (Ct) 16-30 is suitable to use.  
- Thaw the reagents on ice, completely re-suspend by gentle vortex, and briefly 
centrifuge to bring the liquid to the bottom of the tube: 
• TaqMan Gene Expression Assays (20x) 
• cDNA samples 
- Mix the master mix reagent by gently swirling the bottle  
-  Calculate the number of reactions (for 20uL volume) 
 
PCR reaction mix component              single reaction               Triplicate            
20x Taqman gene expression Assay                  1.0 µl                             3.0 µl                              
2X Taqman gene expression master mix          10.0 µl                             30 µl                              
RNase-free water                                                5.0 µl                             15 µl                               
cDNA template (1 to 100 ng)                             4.0 µl                              12 µl                                
 
- Cap the tube and invert it several times to mix the reaction components. 
- Centrifuge the tube briefly. 
- Transfer 16 μL of PCR reaction mix into each well of the reaction plate 
- Transfer 4 uL of each cDNA standard, control, and sample in triplicate 
- Seal the plate and centrifuge briefly 
- Load the plate into the instrument and run the plate 
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REAL-TIME PCR Amplification Plots 
Real-Time PCR (RT-PCR) was performed in triplicate for each sample using Applied 
Biosystems QuantStudioTM3 Real-Time PCR system with predesigned Taqman assays 
from Applied Biosystems (Warrington, UK). The evaluated genes were selected based 
on the physiological pathways involved in adipogenesis (PPARγ), lipid metabolism 
(LPL, DGAT2, PLIN1, ATGL), insulin signalling (IRS1, GLUT4, serine/threonine-
protein kinase; SMG1), inflammation (adiponectin, leptin, MIF, CCL2 (orMCP1), IL-
10, TLR4, NFκB1 and TNFα) and oxidative stress (nitric oxide synthase 3 (NOS3), CAT, 
SOD1). The amplification plots show the variation of log (ΔRn) with PCR cycle 
number. This indicates the level of expression of each gene for a given set of samples 





































































































The numbers below each plot represent the different samples loaded on each plate; B: Blank; S1-S4: 
standard samples with different concentrations. Ct: cycle threshold;  IL-10: interleukin-10; MCP1: 
monocyte chemoattractant protein 1; MIF: Macrophage migration inhibitory factor; NFκB: nuclear 
factor kappa B; TLR4: toll-like receptor 4; TNFα: tumor necrosis factor-alpha; PPARγ: Peroxisome 
proliferator activator receptor gamma; LPL: Lipoprotein lipase; DGAT2: Diacylglycerol 
acyltransferase 2; PLIN1: Perilipin 1; ATGL: Adipose triglyceride lipase; IRS1: Insulin receptor 
substrate 1; GLUT4: Glucose transporter 4; SMG1: Serine/threonine-protein kinase; SOD1: 
Superoxide dismutase; NOS3: Nitric oxide synthase; RPLPo: Ribosomal protein lateral stalk subunit 








Western blot Bench Protocol 
- Preparation of Radio Immuno Precipitation Assay buffer (RIPA II) 
150 mM (0.15M) NaCl, 5M (3 mL) 
1.0% NP40 (Triton X-100) (10 mL of 10% NP40) 
0.5 % Sodium deoxycholate (10 mL of 5% SOD stored at -20°C) 
0.1% SDS – sodium dodecyl sulfate (1mL of 10% SDS) 
50 mM Tris pH 8.0 (5 mL of 1M Tris) 
5 mM EDTA (1ml 0.5 M EDTA) 
70 mL distillate water 
Total volume 100 mL 
 
- Aliquot the prepared RIPA buffer in 10mL tubes. 
- Add 1 tablet of proteinase inhibitor in one of the aliquots (working solution). 
- Cut the frozen tissue, place it into the rupture-tube, add 200 µL of RIPA buffer 
(working solution) and disrupt the tissue.  
- Pipette the lysate in a new labelled tube and centrifuge at 10 000rpm at 4°C for 15 
min 
- Pipette the supernatant in a new tube, add 200 uL of RIPA buffer and centrifuge at 
10 000rpm at 4°C for 15 min 
- Keep the protein lysate at -20°C for later use or prepare for loading ton to gel. 
 




0.004% bromophenol blue 
0.125 M tris HCL 
pH ≈ 6. 
 
- Sample preparation 
Protein lysate + Laemmli buffer 6:1 (6X Laemmli) 





- Assemble the chamber and check if it is tight (fill the tank with running buffer to 
approx. 1/3). 
- Load 3 µL ladder, and 20 µg of total protein per lane for each sample on the precast 
gel. 
- Run the gel at 100 V and 10 mA for 15 min, and 200 V and 20 mA for approx. 1-
1.5 h. 
- Place/rinse the PVDF-membrane first in methanol and equilibrate in transfer buffer 
(for about 1h). 
 
Blotting and staining  
- After running, wash the gel in transfer buffer 
- Build the blot: Filter paper- membrane- gel (all layers should be well moisturized 
with transfer buffer and free of air bubbles). 
- Blot for 60 min (6x8 cm membrane 100 mA). 
- Prepare the blocking buffer (5% BSA in TBST buffer). 
- Place the membrane in ponceau S and incubate for 1 min. 
- Wash the membrane 2 times in distillate water. 
 
Antibody coloring/catching 
- Shortly rinse the membrane with TBST buffer. 
- Incubate 60 min in blocking buffer. 
- Incubate with the primary antibody (dilute antibody with fresh blocking buffer) 
overnight at approx. 4°C. 
- The next day, rinse the membrane with distillate water, 3 x for 10 min with TBST 
buffer.  
- Incubate with the secondary antibody (dilute the antibody with blocking buffer) for 
approx. 1 h. 
- Rinse with distillate water and wash the membrane 3x for 10 min each with TBST. 
- Prepare the membrane for visualization. 
 230 
Western Blot Buffers 
 
10% SDS 
10 g SDS 
100 ml H2O 
 
Upper Gel Buffer (Collection) 
30.3 g Tris -> 0,5 M 
20 ml 10% SDS -> 0,4% 
pH = 6.8 
add 500 ml H2O 
 
Lower Gel Buffer (Separation) 
90.85 g Tris -> 1.5 M 
20 ml 10% SDS -> 0.4% 
pH = 8.8 
add 500 ml H2O 
 
10% APS 
0.5 g APS 
5 ml H2O  
14 d at 4°C 
 
10 x Glycine Buffer 
30 g Tris 
144 g Glycine 
ad 1000 ml H2O 
 
1 x Running Buffer 
20 ml 10% SDS 
200 ml 10 x Glycine Buffer 
ad 2000 ml H2O 
 
Transfer Buffer 
100 ml Glycine Buffer 
200 ml Methanol  
ad 1000 ml H2O 
 
10 x TBS-Wash-Buffer 
24 g Tris (HCL) 
80 g NaCl 
pH = 7.6 
ad 1000 ml H2O 
 
1 x TBST-Wash-Buffer 
100 ml 10 x TBS-Wash-Buffer 
10 ml 10% Tween 





10 ml Tween 
90 ml H2O 
 
Blocking Buffer 
2.5 g BSA -> 5% 
50 ml TBST-Wash-Buffer 
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Oxidative stress markers analyses 
Thiobarbituric reactive substance (TBARS) assay 
Assay principle:  
Malonic dialdehyde (MDA) is a reactive compound formed during lipid 
peroxidation caused by ROS and can be measured by the thiobarbituric acid reactive 
substances (TBARS) assay. During this assay, blood samples (serum) are mixed with 
thiobarbituric acid and malonic dialdehyde resulting from the lipid peroxidation within 
the sample form a pink colour, indicating the levels of TBARS. These last were 
measured spectrophotometrically and absorbance was recorded at 532 nm. 
Assay procedure: 
- Add 50 µL serum + 6.25 µL butylated hydroxytoluene (BHT; 4nM in absolute 
ethanol) + 50µL ortho-phosphoric acid (0.2M) in 2 mL tubes 
- Vortex 10 s 
- Add 6.25 uL thiobarbituric  acid reagent (TBA; 0.793g in 50 mL 0.1M NaOH) 
- Vortex 10s 
- Microfuge for 2 min at 3000 rpm, 4°C (to collect volumes at the bottom) 
- Place tubes in heating bock for 45 min, 90°C (color should change to pink) 
- Place tube on ice for 5 min 
- Add 500 uL of n-butanol + 50uL saturated NaCl  
- Vortex for 10 s 
- Microfuge for 2 min at 12000rpm, 4°C (two phases will be formed, top butanol  
phase and bottom protein phase) 
- Pipette 300 uL of top butanol phase into the wells of the UV readable plate  
- Read at 532 nm at room temperature 
- Calculate the concentrations of malonic dialdehyde using the Beer-Lamberts 
Law with an extinction coefficient of 1.54x105 M-1/cm-1.  
 
 Jentzsch AM, Heinin B, H., Furst P, Biesalski HK. Improved analysis of 





Oxygen radical absorbance capacity assay 
Assay Principle 
Oxygen radical capacity absorbance (ORAC) measures the total antioxidant 
capacity a sample by determining the ability of this last to scavenge free radicals.  
This assay is based on the principle that free radicals are generated from the 
thermal decomposition of 2, 2’-azobis-2-methyl-propanimidamide dihydrochloride 
(AAPH), on the signal intensity from the fluorescent probe in the presence of an oxygen 
radical absorbing substance. Strong absorbance capacity indicates more free radicals 
scavenged, which maintain the intensity of the fluorescent signal observed. The area 
under the curve of the fluorescence intensity versus time is subtracted from that of the 
blank, to determine the antioxidant capacity of the sample, in Trolox equivalents. 
Trolox is a vitamin-E analog used as the standard measure of antioxidant capacity. 
Assay Protocol 
Phosphate buffer: mix K2HPO4·3H2O (0.75M) and NaH2PO4·H2O (0.75M) to a final 
concentration of 0.75M and pH of 7.4. 
Standard curve:  
- Dilute 0.0050g of trolox (6-OH-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid) 
in 200 µL ethanol (100M) (“Solution 1”) 
- Add 100 µL of “Solution 1” to 9.9mL of phosphate buffer (1000 µM) (“Solution 
2”). 
- Take 1mL of “Solution 2” to 9 mL of phosphate buffer (5nmol/L) (“Solution 3”). 
- Add 300 µL of “Solution 3” to 300 µL of phosphate buffer (2.5nmo/L).  
- Add 300 μL of the previous solution to 300 μL of phosphate buffer (1.25nmol/L) 
and prepare further dilution (0.625nmol/L, 0.313nmol/L, 0.156nmol/L and 
0.078nmol/L).  
Fluorescein solutions:  
- Add 0.0225g fluorescein to 50mL of phosphate buffer (0.0012 mol/L) for Stock 1 
solution.  
- Add 50 μL of stock 1 to 10mL of phosphate buffer (5.98 μmol/L) for the Stock 2 
solution.  
- Add 320 μL of the Stock 2 solution to 20mL of phosphate buffer (95.7 nmol/L) to 
prepare the working solution. 
AAPH solution: Add 0.087g of AAPH to 980 μL of pre-warm (37°C) phosphate 
buffer, to a final concentration of 0.33M.  
Sample dilution: 
- Pipette 100 µL of serum in a 2 mL tubes, add 500 μL of phosphate buffer (0.075M, 
pH 7.4) and vortex (dilution A).  
- Pipette 160 μL of dilution A in a tube, add 840 μL of phosphate buffer and vortex 
for 10 seconds (dilution B).  
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- Add 100 μL of dilution B to 700 μL of phosphate buffer (dilution C)  
- Pipette 200μL of the previous dilution C and add 200 μL of phosphate buffer. This 
formed the final sample to use for the experiment (726x dilution). 
 
Assay protocol plate setting 
- Add 300 μL of phosphate buffer to the wells A1 and A2 (blank), 200 μL of 
phosphate buffer in A3 and A4 plus 100 μL of fluorescein.  
- To well A5 and A6, add 100 μL of phosphate buffer and 100 μL of fluorescein, 
into wells A7 and A8, add 50 μL of phosphate buffer and 100μL of fluorescein.  
- Add 50 μL of phosphate buffer in in wells A7 to B8, and 100μL of fluorescein and 
50μL of trolox (0.078nmol/L, 0.156nmol/L, 0.313nmol/L, 0.625nmol/L, 
1.25nmol/L, 2.5nmol/L and 0.078nmol/L respectively). 
- Into the rest of the wells (C1 to H12), add 50μL of phosphate buffer, 100μL of 
fluorescein and 50μL of samples (duplicated).  
- After the plate is set, quickly add 100 μL of APPH all the wells (except blank: A1-
A4) and insert the 96-well plate into the plate reader.  
- Read the plate at an excitation wavelength of 485nm and an emission wavelength 
of 520nm, with a microplate data acquisition program. 
 
 Prior R.L. HH, Gu L., Wu X., Bacchiocca M.,  Howard L., Hampsch-Woodill M., 
Huang D., Ou B., Jacob R. Assays for Hydrophilic and Lipophilic Antioxidant 
Capacity (oxygen radical absorbance capacity (ORACFL)) of Plasma and Other 
Biological and Food Samples. J Agric Food Chem 2003;51:3273-9. 
 Huang D, Ou B, Hampsch-Woodill M, Flanagan JA, Prior RL. High-throughput 
assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid 
handling system coupled with a microplate fluorescence reader in 96-well format.  
2002;50:4437-44. J Agric Food Chem. 2002;50: 4437-44. 
 Maarman GJ. Melatonin as a novel cardioprotective therapy in pulmonary 




Catalase activity assay 
- Catalase is an antioxidant enzyme that catalyzes the reduction of hydrogen 
peroxide into water.   
- Dilute serum samples with phosphate buffer (K2HPO4.3H2O/NaH2-PO4.H2O, 
0.075 mol/L, pH 7.4) (1:10 dilution). 
- Dilute 30% hydrogen peroxide to the concentration of 12nM (150uL of hydrogen 
peroxide into 100mL phosphate buffer).  
- On a UV-readable 96-well plate, pipette 10μL of phosphate buffer into the first two 
wells (A1 and A2). 
- Add 10μL of phosphate buffer + 290μL of hydrogen peroxide solution into the 
wells A3 and A4. 
- Insert the plate into the plate reader and read at 240nm to ascertain that the 
absorbance of the diluted hydrogen peroxide is approximately 0.523 ± 0.025. 
- Pipette 10μL of diluted samples into the empty wells and add 290μL of diluted 
hydrogen peroxide to each of the samples well. 
- Read at time point zero and one minute after point zero.  
- Calculate catalase activity by the difference between the values recorded at this 
two time-point. 
 




Superoxide dismutase activity (SOD) assay  
Assay principle 
The superoxide radical is produced enzymatically by the reaction catalyzed by 
Xanthine Oxidase (XOD): Oxidation of xanthine to uric acid with production of 
superoxide: 
 Xanthine + O2 + H2O 
   XOD    > Uric acid + O2
¯∙ + H+ 
Oxidized cytochrome C is reduced by superoxide radical and the rate of reduction 
is measurable spectrophotometrically at 550nm. 
Cytochrome3+ c + O2
¯∙       > Cytochrome2+ c + O2  
SOD inhibits/diminishes the reduction of cytochrome c by competing for the 
superoxide radicals. 
2 O2
¯∙ + 2 H+    SOD   > O2 + H2O2 
Reagents and Solution preparation 
- Potassium phosphate buffer (216 mM; pH 7.8; 25°C): Add 49.3 g of Potassium 
phosphate dibasic trihydrate (HK2PO4) to 500 ml of purified water (H2O) and 
adjust the pH to 7.8 before completion to the final volume of 1L. 
- Ethylenediaminetetraacetic Acid Solution (EDTA, 10.7mM): Add 0.02 g of EDTA 
to 5 mL of H2O. 
- Cytochrome C solution (1.1mM): Dilute 14.6mg in 1mL of H2O. 
-  Xanthine solution (0.108 mM): Dissolve 1.64 mg of xanthine in 90 mL of purified 
H2O and adjust the pH to 7.7 with 1 N KOH. Transfer the solution to a 100ml 
volumetric flask and complete it to a final volume of 100 mL with purified H2O. 
- Cocktail reaction solution: Add 25 mL of phosphate buffer, 1 mL of EDTA, 1 mL 
of Cytochrome C, 50 mL of Xanthine solution and 28 mL of purified H2O for a 
final volume of 100 mL in a container. Mix the solution and adjust the pH to 7.8 at 
25°C. 
- Immediately before use, prepare the SOD stock solution (5000U/mL) to make the 
standards as follows: 
Standard 1 (10U/mL): 2uL SOD stock in 998 µL of ice H2O 
Standard 2 (20U/mL): 4uL SOD stock in 996 µL of ice H2O 
Standard 3 (40U/mL): 8uL SOD stock in 992 µL of ice H2O 
Standard 4 (80U/mL): 16uL SOD stock in 984 µL of ice H2O 
- Xanthine oxidase stock solution (5U/ml): Add 490 µL of Xanthine Oxidase to 510 
µL of cold purified water and place on ice. Immediately before use, prepare 
0.05U/mL XOD working solution from the stock solution (10 µL of stock XOD to 
990 µL cold water).  
- Check the XOD working solution by pipetting 280uL of cocktail solution in 4 wells 
of the 96 well-plate followed by 20 µL of H2O in the 2 first wells (Blank) and 10 
 237 
µL of H2O + 10 µL XOD in the remaining wells (uninhibited reaction) and read 
the absorbance read at 550nm (A550) every minutes during 5 min.  
- Subtract the A550 of XOD by that of the blank. Values must be in the range 0.025 
± 0.005, otherwise, adjust the XOD concentration.  
- Pipette the prepared reagents solution in suitable wells in duplicate: 
A1 – A2: Blank (280 µL cocktail solution + 20 µL H2O) 
B1 – B2: XOD (280 µL cocktail solution + 16 µL H2O + 4 µL XOD) 
C1 – C2 to F1 - F2: Standards (280 µL cocktail solution + 16 µL H2O + 4 µL 
XOD + 10 µL SOD standards 1-4) 
H1 – H2 …: Samples (280 µL cocktail solution + 16 µL H2O + 4 µL XOD + 10 
µL serum) 
- Read the plate using a microplate reader and record values for approx. 5 min. 
- Calculate the fastest linear rate over the one-minute interval for the inhibited 
reaction and use this time interval to obtain the rates for each test (standards or 
samples) and blank.  
- Calculate the final serum SOD activity using the SOD standard curve. 
 
 McCord, J. M., and Fridovich, I. Superoxide dismutase. An enzymic function for 







Age: ……… Occupation: …………………………………………….. 
 






Country of Birth …………………….  Xhosa ……………………... 
 
Weight: …………………  Height: ………………………… 
 
BMI: ……………  Weight stability last 6 months ………………. 
 
Do you know your BP …………. Glucose ………  Cholesterol ………. 
 






Alcohol consumption drinks per week? …………….. 
 
Smoking…………… Contraception ………………….. 
 
Are you pregnant or breastfeeding? ................................. 
 
Menstrual cycle Regular …… Normal …..    Last start date …………. 
 
Disease info:  HIV Status …………..  
   Hepatitis ………………. 
   Anemic………………….. 
    
Availability   1 full day and when? ……………………………… 
   Morning and when? …………………………………. 
   Afternoon and when ………………………… 








Exercise Intervention - Participant recruitment




IDENTIFICATION AND CONTACT DETAILS 
 
Name   
 
 
ID number:  _______________________________________________________ 
 
 
Date of Birth _______________________     Age:   __________   
 
 
















Tel No’s:  ____________________ (h)  ___________________ (w)  _______________________ (Cel)  
 
 
























Date screened              __________________________________________ 
 
Informed consent:        _________ Subject info sheet        ______ 
 
Pregnancy test:        ________________ 
 
BP      ________________ 
 
Fasting bloods:    _________________________ 
 
OGTT:         ______________________________ 
 
Basic Anthropometry:    _______________________ 
 
PAR Questionnaire:   ______________________ 
 
FITNESS TEST   ____________________________ 
 
HIV Test:   ________________________________ 
 
DXA:   ____________________________ 
 
CT:   ________________________________ 
 
 





MOLECULAR CHANGES OF ADIPOSE TISSUE IN RELATION TO 
INSULIN SENSITIVITY IN BLACK SA WOMEN IN RESPONSE TO AN 
EXERCISE INTERVENTION. 
Why is the study being done? 
Within South Africa, there are many people living with diabetes (sugar 
disease), with black women being the most affected, especially those who are 
carrying extra body weight (obese). Many studies in other countries have 
shown that exercise training reduces the risk for diabetes. However, there are 
no studies in South Africa that have studied this. This study will help us 
understand the various factors that may cause diabetes in obese black women, 
including factors within the muscle, fat and blood, as well as lifestyle factors 
including food intake, activity levels and family history. Therefore, the aim of the 
study is to measure changes in the risk for diabetes in response to a 12-week 
exercise-training programme in obese black South African women, and to 
examine specific factors linked to the changes in diabetes risk. This study is 
important, as it will help us understand if exercise training does reduce the risk 
of diabetes in obese black South African women, and help us understand how 
this is done.  
Who can participate? 
If you fulfil the following criteria you will be able to take part in the study:  
I. Aged 20-35 years;  
II. Obese (weight in kg divided by height in metres squared: 30-35 kg/m2) 
III. No known diseases or not taking medication for any diseases; 
IV. Not smoking or taking recreational drugs; 
V. Not currently pregnant or breast feeding; 
VI. Self-reported race or ethnicity as black South African 
VII. No muscle or joint pains or medical problems that prevent you from 
exercising;  
VIII. Able to attend four exercise sessions per week for the 12 week study 
period; 
IX. Weight stable (weight not changed more than 5 kg or no change in your 
clothes size over the past 6 months); 
X. Are using injectable contraceptives to prevent pregnancy, for a minimum 
of 1 month prior to testing; 
XI. Not currently taking part in organized physical activity (exercise training); 
XII. No previous adverse reactions to an anaesthetic (e.g. at the dentist). 
XIII. No surgical procedures in the last 6 months. 
 
How do we decide if you are eligible to take part in the study? 
If you meet all the criteria listed above, you will then be asked to 
completesome tests on one day at David Flude Memorial Church hall in 
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Khayelitsha to check that you meet the inclusion criteria of the study. You will 
be asked to complete the following tests/measurements: 
 Complete a questionnaire including information on your age, medication 
use, ancestry, medical history, exercise and diet history, physical activity 
readiness; 
 Weight and height will be measured using a scale and a height measure; 
 Blood pressure: After a 5 minute relaxation period, blood pressure will be 
measured 3 times in a row, separated by 5 minutes between readings using 
a standard blood pressure monitor.  
 Glycated haemoglobin (red blood cells that joined with blood glucose 
(sugar)) – A measure of the average blood glucose over a period of time:  
A blood sample will be obtained; 
 HIV screening will be performed. You will receive pre- and post-test 
counselling from a trained counsellor and a referral will be made to an 
appropriate HIV clinicif you are found to be HIV positive. If you test negative, 
you will be able to participate in the trial. 
 A urine pregnancy test will be performed. If you are not pregnant you will 
be able to participate in the trial. 
How many people will take part in the study? 
Forty (40) obese women, who meet all the criteria above, can take part in 
the study.  
How long will the study last? 
The study will last 14 weeks in total. The first week (week 1) and last week 
(week 14) will include testing at the Sports Science Institute in Newlands. 
Weeks 2-13 (12 weeks) will include exercise training (4 times per week)in 
Khayeltisha.  
What will happen if you decide to take part in the study? 
If you meet all the criteria listed above and decide to take part in the study, 
you will be asked to complete all the testing and training procedures outlined 
below.  
You will be randomly assigned to either an exercise group or a control 
group. Neither you nor the investigators will be able to choose which group you 
will be assigned to. If you are assigned to the exercise group, you will be 
required to complete 12 weeks of supervised aerobic training (training that 
increases your heart rate and breathing rate) for 1 hour on 4 days/week by a 
trained facilitator at David Flude Memorial Church hall in Khayelitsha. We 
request that you do not participate in any new additional training outside of this 
study. If you are assigned to the control group, you can continue with your 
normal life activities, and we request that you do not start a new exercise-
training programme somewhere else for the 12 weeks.  
You are under no obligation to take part in the study and are not required 
to give a reason if you do not wish to participate. If you decide to take part in 
the study, you are free to withdraw at any time and without giving a reason and 
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without prejudice. If you decide to withdraw from the study, we will discuss with 
you what will happen to any information or samples that you have provided. If 
the incomplete samples and information can usefully contribute to the study, 
we will ask your permission to store them and use them in our analysis. 
Alternatively, on your request all your information and samples will be 
destroyed.  
Procedures : 
If you meet all the criteria above and are in the control OR experimental group, 
you will be required to complete 3 testing sessions before and another 3 
sessions at the end of the 12 week study, as summarised in Table 1 and 
explained in detail below. All testing will be undertaken either at the Division of 
Exercise Science and Sports Medicine, based at the Sports Science Institute 
of South Africa (SSISA) in Newlands, at the Academy of Plastic Surgery, 
Claremont, or CUBIC at Groote Schuur Hospital. Appropriately trained medical 
personnel will carry out all procedures. 
Table 1. Summary of testing schedule the week before and after the 12 week 
exercise/control intervention 






Testing session 2 
Testing session 
3 
Location: David Flude Memorial 
Church hall, 
Khayelitsha 
SSISA CUBIC Academy of 
Plastic Surgery 
Time of day: Any 8 am 8 am 8 am 
Preparation: None Overnight fast 
and no exercise 
training for 72 hrs 
prior 
Overnight fast and 
no exercise training 
for 72 hrs prior 
Overnight fast 
and no exercise 
training for 72 hrs 
prior 
Duration: 2 hrs 4 hrs 2 hrs 1 hr 
Procedure: -Trial information 
-Informed consent 

















Testing Session 1: Early morning before breakfast - At SSISA - 4 hours 
You will be requested to come to the laboratory at the Sports Science Institute in 
the morning after an overnight fast. In other words, you must not eat or drink anything, 
except water, from 10pm the night before (at least 10 hours). You cannot take part in 
any exercise training for 72hours (3 days) before this test.  
Insulin test – a measure of insulin secretion and insulin sensitivity: 
A small plastic tube will be placed into a vein in each arm. You will then be 
required to undergo a test that will measure how much insulin your body produces and 
how sensitive your body is to insulin. We will inject a concentrated glucose solution (~ 
30-100 ml, depending on your weight) into one vein over a 1-minute period. Small 
amounts of blood (1 teaspoon) will be withdrawn from the other arm at regular intervals 
(1-2 minutes) for 20 min.  After 20 min, insulin will be infused into your arm, which will 
assist your body to take up the glucose into the cells. Further blood samples (1 
teaspoon each) will be drawn from your other arm for a further 3.5 hrs. During this test, 
a maximum of 200 ml of blood will be drawn (1/3rd of the amount drawn when you 
donate blood). During the tests, you will be required to sit or lie quietly and DVDs will 
be provided for entertainment.   
Questionnaires: 
You will be asked questions on various measures of social and economic status 
(including your education, where you live and how many people share your home, the 
work that you do, how you spend your spare time), as well as questions on food 
security (access to food), family history, your personal health and reproductive history, 
including the number of children you have, medications that you use and how much 
physical activity you do.  You will also be interviewed by a dietician who will ask you 
questions about your diet and the foods that you normally eat.  
Body composition: 
After your insulin test, we will take measurements of your body, including weight, 
height, waist and hip circumference. In addition, you will be asked to undergo a scan, 
which will accurately measure your fat mass. This is called a dual x-ray absorptiometry 
(DXA) scan. The scan will take approximately 20 minutes to perform during which you 
will lie quietly on the scanning table in a medical gown provided.  
Physical activity: 
You will be given motion sensors to wear (accelerometer, which measures how fast 
you move and an Actipal that measures how little you move) for 7 days. Both devices are 
the size of a small match box and will be attached to your waist with a lightweight belt. You 
should wear the monitors at all times, except when swimming, bathing, showering and 
sleeping.  
Testing Session 2: Early morning before breakfast - CUBIC at Groote Schuur 
Hospital - 2 hours 
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Magnetic resonance spectroscopy (MRS) scans 
The MRS scans will be performed at CUBIC at Groote Schuur Hospital, and will 
take approximately 1 hour. It will be used to measure the fat content of your calf 
muscle, liver and pancreas. MRS uses magnetic and radio waves, and will be used to 
generate a picture of your calf,liver and pancreas. You will be required to lie on a bed, 
which is moved into a wide-bore tubular structure. This is open at both ends. You will 
be required to lie still for 15 minutes while being in constant voice contact with the 
Radiographer.   
If you have any of the following conditions, you may not have an MRS scan:  
implanted medical devices such as aneurysm clips in the brain, heart pacemakers, 
and cochlear (inner ear) implants; lead-based tattoos; or pieces of metal close to or in 
an important organ (such as the eye); claustrophobia or fear of being confined in a 
small space.   
Session 3: Early morning before breakfast – at the Academy of Plastic Surgery - 1 
hour 
You will be requested to go to the Academy of Plastic Surgery in Claremont in 
the morning after an overnight fast. In other words, you must not eat or drink anything, 
except water from 10 pm the night before (at least 10 hours). You may not take part in 
any exercise training for 72 hours (3 days) before this test: 
Fat biopsy: 
You will be requested to undergo a fat biopsy from your buttocks (bum) and your 
abdominal area (tummy). The samples will be used to analyse the proteins and 
hormones produced by the fat cells, which may influence your disease risk. A medical 
doctor (plastic surgeon) will perform the biopsy. A local anaesthetic will be 
administered prior to the procedure. Please inform us if you have had any previous 
reactions to any other anaesthetics, for example at the dentist. After the anaesthetic 
has taken effect, a small incision (0.5-1 cm) will be made in the skin, and fat samples 
(1.5 cm3) will be removed using a needle connected to a syringe. After this procedure, 
a waterproof sterile dressing will be applied. 
12-week exercise/control intervention 
If you are assigned to the control group we will request that you do not start any 
new exercise training programs during the 12-week study period, and continue with 
your normal daily activities and diet as usual. When you have completed the 14-week 
trial, you will be offered the opportunity to undergo the same exercise training as the 
exercise group, as described below. This is totally voluntary.  
If you are assigned to the exercise group, you will be required to perform 12-
weeks of supervised aerobic training at a moderate-vigorous intensity for one hour, 
four times per week. The exercise training will include cardiovascular exercises in the 
form of aerobic dance, boxing, running, skipping, stepping, and strengthening 
exercises using your own body weight or minimal equipment for resistance training 
(e.g. bands and weights). The frequency, duration and intensity of the exercise 
intervention are based on the recommendations from the British Association of Sport 
and Exercise Sciences (BASES), to ensure the prevention of injuries. The 60 min 
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classes will include moderate exercise (70-75% of your maximum heart rate) and at 
least 30 min of vigorous activity (75-85% of your maximum heart rate), which will be 
monitored using heart rate monitors. The exercise classes will be supervised by a 
trained biokineticist, who will monitor your progress (using heart rate data) and adjust 
the classes accordingly to ensure adequate improvement in cardiorespiratory fitness 
throughout the 12-week programme. We request that you do not participate in any 
new additional training outside of this study and maintain your normal diet during the 
12-week trial.  
Monitoring in the control and exercise groups:  
You will be asked to wear the accelerometer and Actipal for 7 days at the beginning 
and every 4 weeks during the 12-week trial (week -1, 4, 8 and 12) (as described above). 
Accelerometers will be used to provide a more accurate assessment of the intensity of your 
activity, and Actipals provide more information on sedentary time. You should wear the 
monitors at all times, except when swimming, bathing, showering and sleeping. At the same 
time that you wear the monitors (week -1, 4, 8 and 12), we will request that you record your 
dietary intake for three days, as explained in the first session. Attendance at each session, 
and the compliance to the exercise training will be monitored by the biokineticist.  
What are the risks and discomforts of this study? 
Insulin test – a measure of insulin secretion and insulin sensitivity: 
There are no appreciable risks for this test, other than those associated with 
routine blood sampling. All procedures will be supervised and carried out by a medical 
doctor and appropriately trained medical personnel using sterile techniques to 
minimise any risks of infection. These tests are used routinely in research to accurately 
determine insulin secretion and insulin sensitivity. A maximum of 200 ml of blood will 
be drawn during the entire study, which is less than half that drawn during standard 
blood donation.  
Body composition: 
The only risk associated with the DXA scan is exposure to radiation. However, 
the radiation exposure with a DXA scan is less than half that of a chest x-ray (11.3 
microSieverts).  
Physical activity monitors: 
There are no risks or side-effects from wearing the physical activity monitors. 
Magnetic resonance spectroscopy (MRS) scans 
You will not experience any pain or discomfort when having the MRS scan, and 
there are no known harmful long-term effects of the magnetic fields used in this study. 
When the scanner takes the pictures, the bed may shake, and you will hear loud 
banging noises. You will be given earplugs or headphones to protect your ears. Also, 
some people feel nervous in a small closed space, such as when they are in the 
scanner. You will be able to see out of the scanner at all times, and we will not start 
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until you tell us that you are comfortable. You will be able to stop at any time by 
squeezing a ball that you will hold in one hand and can talk to us using an intercom 
that is built into the scanner. If you have any of the following conditions, you may not 
have an MRS scan:  implanted medical devices such as aneurysm clips in the brain, 
heart pacemakers, and cochlear (inner ear) implants; lead-based tattoos; or pieces of 
metal close to or in an important organ (such as the eye); claustrophobia or fear of 
being confined in a small space.   
Fat biopsy: 
For the fat biopsies, you may feel some local stinging for a few seconds after the 
local anaesthetic is given.You will experience some discomfort during the biopsies, 
and after the biopsies you may experience some bruising, which will generally feel 
better within 2-3 days. We have performed many fat biopsies and have had very few 
adverse events. These included the temporary loss of feeling in the area around the 
biopsy site, which resolved on its own after a short while; and local infection, which 
healed without any problem after treatment. Rarely there may be an allergic reaction 
to the local anaesthetic or to the preservative in it, methylparaben, which could cause 
itching and if severe, wheezing or low blood pressure that are symptoms of 
anaphylactic shock. Severe reactions will be treated with adrenaline, which will be 
available during the procedure.  
12-week exercise/control intervention 
The training program is designed for exercise progression to ensure minimal 
physical discomfort and associated soreness. In the unlikely event that you sustain an 
injury due to the exercise intervention, you will be referred to the appropriate clinic for 
treatment at no expense to yourself. However, you might experience some physical 
discomfort and associated muscle soreness following the first session (and in some 
cases the first week) of training. All efforts will be made to ensure a suitable training 
environment, including safe setting up and provision of equipment, sufficient lighting, 
suitable temperature, suitable ventilation, and convenient access to toilets, etc. The 
researchers are trained in first aid and basic life support, and a phone will be carried 
at all times should medical assistance be required. 
Are there any benefits to you for being in the study? 
You will receive your own results, including body composition (weight, height, 
waist circumference and fat mass), blood pressure, risk for diabetes, physical fitness 
and dietary analysis, with some recommendations made by a dietician on how to adapt 
your dietary intake to improve your health. If you are in the control group, after the 
completion of the study, you will have the opportunity to participate in the same 
exercise training as the exercise group. This is completely voluntary. Following the 
training (if you were in the exercise or control group), you will receive guidelines and 
recommendations on how to continue your exercise training. If you have any abnormal 
results, you will be given a referral letter and directed to the appropriate health 
practitioner or local clinic.  
What will happen when the study is over? 
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As mentioned above, when the testing of all the women has been completed, 
you will receive your individual results and the provisional findings of the study will be 
presented. Detailed analysis of the tissues samples will take more time. However, 
once these analyses have been completed, the final results of the study will be shared 
with you. This information will assist in our understanding of the effect of exercising 
training on the risk for diabetes, and therefore help us to prevent and/or manage the 
problem of diabetes in South African women.   
 
Will any of your blood and fat samples be stored and used for research in the 
future? 
The researchers will ask your permission to store your blood and fat samples for 
future research. All samples will be kept in a freezer in a secure facility with access 
limited to research personnel. Future research analyses will be based on new research 
that we are at present not aware of, but may be important in our understanding of the 
risk for type 2 diabetes. Any research done on your blood or tissue in the future must 
be approved by the Faculty of Health Sciences Research Ethics Committee at the 
University of Cape Town that is set up to determine that the research is done according 
to accepted standards. You will not be penalized in any way for not allowing the use 
of your blood or tissue for future research. If you decide not to donate blood or tissue 
for future research, it will be destroyed on completion of this trial. Strict confidentiality 
of results will be maintained.  
Will you receive reimbursement for transport, time and inconvenience? 
All transport required to get to the training and testing facilities will be arranged 
by the researchers and be at no cost to you. You will receive R30/day to cover their 
transport costs to the training venue in Khayelitsha (4 x training sessions per week for 
12 weeks + 3 monthly monitoring visits). In addition, either transport will be provided 
or you will receive R60/day for transport to the testing facilities at UCT (R50 x 8 testing 
sessions). The transport money will be paid to you at the end of each session. 
To compensate you for your time and inconvenience, you will be reimbursed 
R20/hr for the training session (48 hrs), and R50/hr for the testing sessions (18 hrs of 
testing and monitoring). Payment for time and inconvenience will be paid on a pro-rata 
basis at the end of the 12-week study period.  
Who will see the information that is collected about you during the study? 
Strict confidentiality of results will be maintained. Your name will be removed 
from all data, and you will be assigned a number, which will be used to identify data 
relating to you.  All records will be kept in a locked room and in a secure computer 
database in the research unit.  Your name will not be used in any publication of the 
results. 
What if Something Goes Wrong? 
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The University of Cape Town (UCT) has insurance cover for the event that 
research-related injury or harm results from your participation in the trial. The insurer 
will pay all reasonable medical expenses in accordance with the South African Good 
Clinical Practice Guidelines (DoH 2006), based on the Association of the British 
Pharmaceutical Industry Guidelines (ABPI) in the event of an injury or side effect 
resulting directly from your participation in the trial. You will not be required to prove 
fault on the part of the University. 
The University will not be liable for any loss, injuries and/or harm that you may 
sustain where the loss is caused by 
 The use of unauthorised medicine or substances during the study 
 Any injury that results from you not following the protocol requirements or the 
instructions that the study doctor may give you 
 Any injury that arises from inadequate action or lack of action to deal adequately 
with a side effect or reaction to the intervention 
 An injury that results from negligence on your part 
By agreeing to participate in this study, you do not give up your right to claim 
compensation for injury where you can prove negligence, in separate litigation. In 
particular, your right to pursue such a claim in a South African court in terms of South 
African law must be ensured. Note, however, that you will usually be requested to 
accept that payment made by the University under the SA GCP guideline 4.11 is in full 
settlement of the claim relating to the medical expenses.  
An injury is considered trial-related if, and to the extent that, it is caused by study 
activities. You must notify the study doctor immediately of any side effects and/or 
injuries during the trial, whether they are research-related or other related 
complications. 
UCT reserves the right not to provide compensation if, and to the extent that, 
your injury came about because you chose not to follow the instructions that you were 
given while you were taking part in the study. Your right in law to claim compensation 
for injury where you prove negligence is not affected. Copies of these guidelines are 
available on request. 
Who do I contact if I have any questions about the study? 
If you have any questions or you experience any problems during or after the 
tests, please contact Professor Julia Goedecke or Dr Amy Mendham: 
Associate Professor Julia Goedecke (PhD)  
Principal Investigator 
Division of Exercise Science and Sports Medicine 
Department of Human Biology 
3rd Floor, Sports Science Institute of South Africa 
Boundary Road, Newlands, 7725 
Cape Town 
Tel:  021-6504570(w) 0828255616 (cell) 
Email:julia.goedecke@uct.ac.za 
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Dr Amy Mendham (PhD) 
Project coordinator 
Division of Exercise Science and Sports Medicine 
Department of Human Biology 
3rd Floor, Sports Science Institute of South Africa 
Boundary Road, Newlands, 7725 
Cape Town 
Tel:  021-6504567 (w) 0729 255 347 (cell) 
Email:Amy.Mendham@uct.ac.za 
Should you have any concerns about this study, you are also free to contact the 
head of the University Of Cape Town Faculty Of Health Sciences Human Research 
Ethics Committee, Professor Marc Blockman. 
Professor Marc Blockman 
Head, Human Research Ethics Committee 
Faculty of Health Sciences 
Room E52-24 Groote Schuur Hospital Old Main Building, Observatory 7925 







Subject code:  
 
 
MOLECULAR CHANGES OF ADIPOSE TISSUE IN RELATION TO INSULIN 
SENSITIVITY IN OBESE BLACK SOUTH AFRICAN WOMEN IN RESPONSE TO 
AN EXERCISE INTERVENTION 
 
Consent to participate in the study: 
 
“I, _________________________, hereby give consent to participate in this research 
trial to be conducted by the Division of Exercise Science and Sports Medicine, within 
the Department of Human Biology at the University of Cape Town. 
I understand that I will undergo preliminary testing to determine if I am eligible for the 
study. I understand that I will be randomly assigned to the exercise or the control 
group. If I am assigned to the exercise group, I understand that I will be required to 
complete 12 weeks of exercise training, consisting of 40-60 min of aerobic exercise 
training 4 days/week by a trained facilitator in David Flude Church in Khayelitsha. If I 
am assigned to the control group, I understand that I will be required to continue with 
my normal daily living and not start a new exercise-training programme during the 
study period, but can be part of the same exercise-training programme once I have 
completed the study. I understand that irrespective of the group that I am assigned to, 
I will be required to complete 3 testing sessions before and at the end of the 12-week 
study. In addition, I understand that I will be required to visit the community centre to 
have my weight, dietary intake and physical activity measured every month. I 
understand that the testing sessions will be performed at the Sports Science Institute, 
CUBIC at Groote Schuur Hospital and the Academy of Plastic Surgery in Claremont, 
and will include completion of a demographic and lifestyle questionnaire, the 
measurement of blood pressure, body composition including whole body scans and 
MRS scans of my calf muscle, liver and pancreas, as well as a test to measure insulin 
secretion and sensitivity.  I also understand that fat samples (~1.5 cm3) will be taken 
from the fat stores in my abdominal (belly) and gluteal (bottom) area. 
I have read and have had explained to me the procedures described. I have had an 
opportunity to ask questions and my questions have been answered in a satisfactory 
way. I understand the nature of the trial and the risks and benefits associated with my 
participation and that I am free to withdraw from this study at any time. 
I understand that all the information collected during the study will be treated with the 
strictest confidentiality and will only be used for scientific research purposes. All 
samples will be kept in a freezer in a secure facility with access limited to research 
personnel. All records will be kept in a locked room and in a secure computer database 
in the research unit. My name will not be used in any publication of the results. I 
understand that for data verification and quality control purposes regulatory authorities 
and/or members of the University of Cape Town, Faculty of Health Sciences, Human 
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Research Ethics Committee may be allowed access to my personal data under 
conditions of strict confidentiality.  
I have read the information, or it has been read to me. I have had the opportunity 
to ask questions about it and my questions have been answered to my 
satisfaction. I consent voluntarily and understand that I have the right to 
withdraw my consent without this affecting the current research study or my 
medical care.  
 
Print Name of Participant _________________________  
 
Signature of Participant ___________________________  
 
Date ___________________________  
 
 
I have fully and carefully explained the study to the person named above and 
confirm that to the best of my knowledge, they clearly understand the nature, 
risks and benefits of taking part in the study. I confirm that I have given them 
an opportunity to ask questions and answered their questions to the best of 
my ability. 
 
Print Name of Researcher________________________  
Signature of Researcher _________________________  
Date ___________________________  
 
Copy provided to participant _______ (initialled by researcher) 
 
For illiterate participants (If possible the witness should be selected by the 
participant and not be part of the research team) 
 
I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I 
confirm that the individual has given consent freely.  
 
Print name of witness_____________________  AND Thumb print of participant  
Signature of witness ______________________  






Subject code:  
 
 
CONSENT FOR HIV TESTING: 
 
Additional consent to: Molecular changes of adipose tissue in relation to insulin 
sensitivity in obese black South African women in response to an exercise 
intervention. 
I ______________________________ agree to provide a blood sample for the 
purposes of confidential HIV testing. I understand that it is necessary for me to have 
this test to participate in the research study. If I test positive, I cannot participate in the 
study entitled “Molecular changes of adipose tissue in relation to insulin sensitivity in 
obese black South African women in response to an exercise intervention”, conducted 
by the Division of Exercise Science and Sports Medicine, within the Department of 
Human Biology at the University of Cape Town.I am aware that I will receive pre and 
post-test counselling from a qualified HIV counsellor, and will be referred to an 
appropriate health care clinic if necessary. I understand the implications of performing 
the test. 
I have read the information, or it has been read to me. I have had the opportunity 
to ask questions about it and my questions have been answered to my 
satisfaction. I consent voluntarily and understand that I have the right to 
withdraw my consent without this affecting the current research study or my 
medical care.  
 
Print Name of Participant _________________________  
 
Signature of Participant ___________________________  
Date ___________________________  
 
I have fully and carefully explained the study to the person named above and 
confirm that to the best of my knowledge, they clearly understand the nature, 
risks and benefits of taking part in the study. I confirm that I have given them 
an opportunity to ask questions and answered their questions to the best of 
my ability. 
 
Print Name of Researcher________________________  






Subject code:  
 
 
CONSENT FOR STORAGE AND FUTURE USE OF UNUSED SAMPLES: 
 
Additional consent to: Molecular changes of adipose tissue in relation to insulin 




We are seeking permission to store your unused blood and fat samples for possible 
future in either our own research or collaborators’ research studies. After we have 
analysed your blood and fat samples for the current study we might want to do 
additional analyses on these samples. However, we require your permission before 
we can do any additional analyses on your blood and fat samples. The reasons why 
we might need to do additional analyses not specified at the start of the study could 
be due to new research that we are at present not aware of, but may be important in 
our understanding of the risk for type 2 diabetes. You can inform us if you do not want 
us to use your stored samples for any further analyses or only for certain types of 
testing such as genetic testing. Before the samples can be used for future research, 
approval by the University of Cape Town Faculty Of Health Sciences Human Research 
Ethics Committee will be obtained. Please be aware that the samples will not be sold 
for profit.  
When entering into the study, you will receive a unique code that will be used for 
sample and data analysis, which serves to maintain your confidentiality. When storing 
samples, you may choose that we keep the unique code on the sample so that we can 
link any new results to your existing data. If any clinically relevant information relating 
to this sample is found, we will inform you of the results. Alternatively, you can remove 
the identifying number, so that your information will not be linked to the sample and 
you will not be informed of any clinical results relating to the new analyses.  
You may also refuse to allow future analyses of samples without being penalised, and 
your results relating to the current study will not be compromised in any way. If you 
refuse to allow future analyses of samples, your samples will be destroyed on 
completion of this trial. Furthermore, you may withdraw permission to use your 
samples at any time. If you wish to do this, please contact: 
Associate Professor Julia Goedecke (PhD) 
Principal Investigator 
Division of Exercise Science and Sports Medicine 
Department of Human Biology 
3rd Floor, Sports Science Institute of South Africa 
Boundary Road, Newlands, 7725 
Cape Town 
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Tel:  021-6504570 (w) 0828255616 (cell) 
Email:julia.goedecke@uct.ac.za 
All information collected during the study will be treated with the strictest confidentiality 
and will only be used for scientific research purposes. All samples will be kept in a 
freezer in a secure facility with access limited to research personnel; all records will 
be kept in a locked room and in a secure computer database in the research unit. Your 
name will not be used in any publication of the results. For data verification and quality 
control purposes regulatory authorities and/or members of the University of Cape 
Town Faculty of Health Sciences Human Research Ethics Committeemay be allowed 
access to my personal data under conditions of strict confidentiality.  
Certificate of Consent: 
1) If any of the BLOOD that I have provided for this research project is unused or leftover 
when the project is completed (Tick one choice from each of the following boxes)  
☐ I wish my blood sample to be destroyed immediately.  
☐ I want my blood sample to be destroyed after ____ years.  
☐ I give permission for my blood sample to be stored indefinitely  
 
AND if my blood sample is to be stored: 
􀂆 I give permission for my blood sample to be stored and used in future research but 
only on the same subject as the current research project:“Molecular changes of 
adipose tissue in relation to insulin sensitivity in obese black South African women in 
response to an exercise intervention”. 
􀂆 I give my permission for my blood sample to be stored and used in future 
research of any type, which has been properly approved  
􀂆 I give permission for my blood sample to be stored and used in future research 
except for research about __________________________ 
 
AND 
􀂆 I want my identity to be removed from my blood sample.  
􀂆 I want my identity to be kept with my blood sample. 
 
 
2) If any of the fat that I have provided for this research project is unused or leftover when 
the project is completed (Tick one choice from each of the following boxes)  
☐ I wish my fat sample to be destroyed immediately.  
☐ I want my fat sample to be destroyed after ____ years.  
☐ I give permission for my fat sample to be stored indefinitely  
 
AND if my fat sample is to be stored: 
􀂆 I give permission for my fat sample to be stored and used in future research but 
only on the same subject as the current research project: “Molecular changes 
of adipose tissue in relation to insulin sensitivity in obese black South African 
women in response to an exercise intervention”. 
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􀂆 I give my permission for my fat sample to be stored and used in future research 
of any type, which has been properly approved  
􀂆 I give permission for my fat sample to be stored and used in future research 
except for research about __________________________ 
AND 
􀂆 I want my identity to be removed from my fat sample. 
􀂆 I want my identity to be kept with my fat sample.  
I have read the information, or it has been read to me. I have had the opportunity 
to ask questions about it and my questions have been answered to my 
satisfaction. I consent voluntarily and understand that I have the right to 
withdraw my consent without this affecting the current research study or my 
medical care. 
Print Name of Participant _________________________ 
Signature of Participant ___________________________ 
Date ___________________________  
For illiterate participants (If possible the witness should be selected by the 
participant and not be part of the research team) 
I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I 
confirm that the individual has given consent freely. 
Print name of witness_____________________ AND Thumb print of participant 
Signature of witness ______________________ 
Date ________________________ 
Day/month/year 
I have accurately read or witnessed the accurate reading of the consent form 
to the potential participant, and the individual has had the opportunity to ask 
questions. I confirm that the individual has given consent freely.  
Print Name of Researcher________________________ 
Signature of Researcher _________________________ 
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Date ___________________________  
Day/month/year  







Signature removed to avoid exposure online
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